<SEC-DOCUMENT>0001654954-17-011928.txt : 20171229
<SEC-HEADER>0001654954-17-011928.hdr.sgml : 20171229
<ACCEPTANCE-DATETIME>20171229161225
ACCESSION NUMBER:		0001654954-17-011928
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171229
DATE AS OF CHANGE:		20171229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		171282078

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cvm_10k.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 10-K</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">SECURITIES AND
EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Washington, D.C.
20549</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Mark
One)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(X)&#xA0;&#xA0;</font><font style="font-size: 13px; font-family: Times New Roman">ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">For the fiscal year
ended September 30, 2017.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">OR</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(&#xA0;&#xA0;)</font>
<font style="font-size: 13px; font-family: Times New Roman">TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">For the transition
period from _________ to __________.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Commission file
number 1-11889</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: auto; margin-right: auto;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; margin-left: auto; margin-right: auto; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td colspan="3" style="text-indent: 0px; width: 95%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CEL-SCI
CORPORATION</font></div>
</td>
</tr><tr>
<td colspan="3" style="text-indent: 0px; width: 95%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Exact name of
registrant as specified in its charter)</font></div>
</td>
</tr><tr>
<td colspan="3" style="width: 95%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">COLORADO</font></div>
</td>
<td style="width: 5%; padding-bottom: 2px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">84-0916344<font id="TAB2" style="letter-spacing: 3pt; color: black">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(State or other
jurisdiction of incorporation or organization)</font></div>
</td>
<td style="width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(I.R.S. Employer
Identification No.)</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 45%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">8229 Boone Blvd.,
Suite 802</font></div>
</td>
<td style="width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Vienna,
Virginia</font></div>
</td>
<td style="width: 5%; padding-bottom: 2px">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px; border-bottom: 2px solid black">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">22182</font></div>
</td>
</tr><tr>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Address of
principal executive offices)</font></div>
</td>
<td style="width: 5%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="text-indent: 0px; width: 45%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Zip
Code)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Registrant's
telephone number, including area code: (703) 506-9460</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities
registered pursuant to Section 12(b) of the Act: None</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Securities
registered pursuant to Section 12(g) of the Act:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Common Stock, $.01 par
value</font></font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="text-decoration: underline">Series S Warrants</font></font></div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">(Title of
Class)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark if the registrant is a well-known seasoned issuer, as defined
in Rule 405 of the Securities
Act.&#xA0;&#xA0;[&#xA0;&#xA0;]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark if the registrant is not required to file reports pursuant to
Section 13 or Section 15(d) of the Act. [&#xA0;&#xA0;]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90
days.&#xA0;&#xA0;&#xA0;&#xA0;Yes
[X]&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;No
[&#xA0;&#xA0;&#xA0;]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (&#xA7;232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was
required to submit and post such
files).&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Yes&#xA0;&#xA0;[X]
No&#xA0;&#xA0;[ ]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Indicate by check
mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein,&#xA0;&#xA0;and will not be
contained,&#xA0;&#xA0;to the best of
Registrant's&#xA0;&#xA0;knowledge,&#xA0;&#xA0;in definitive proxy
or information&#xA0;&#xA0;statements incorporated by reference in
Part III of this Form 10-K or any amendment to this Form 10-K.
[X]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of
&#x201C;large accelerated filer,&#x201D; &#x201C;accelerated
filer&#x201D;, &#x201C;smaller reporting company&#x201D; and "emerging
growth company" in Rule 12b-2 of the Exchange Act. (Check
one):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: bottom; width: 21%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Large&#xA0;accelerated&#xA0;filer</font></div>
</td>
<td style="vertical-align: bottom; width: 48%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">[
]<br></font></div>
</td>
<td style="vertical-align: bottom; width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Accelerated&#xA0;filer</font></div>
</td>
<td style="vertical-align: bottom; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">[
]</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 21%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Non-accelerated
filer</font></div>
</td>
<td style="vertical-align: bottom; width: 48%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">[ ]
<font style="font-family: Times New Roman; font-size: 13px">(Do not check if a smaller
reporting company)</font></div>
</td>
<td style="vertical-align: bottom; width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Smaller&#xA0;reporting&#xA0;company</font></div>
</td>
<td style="vertical-align: bottom; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">[X]</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 21%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company</font></div>
</td>
<td style="vertical-align: bottom; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">[
]</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. <font style="font-family: Times New Roman">[ ]<br></font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Act):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -8px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Yes [
]&#xA0; No [X]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -8px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
aggregate market value of the voting stock held by non-affiliates
of the Registrant, based upon the closing sale price of the
registrant&#x2019;s common stock on March 31, 2017, as quoted on the
NYSE American, was $17,625,571.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: -8px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As of
December 21, 2017, the Registrant had 13,206,316 issued and
outstanding shares of common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Documents
Incorporated by Reference: None</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PART I</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
ITEM 1. BUSINESS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
is focused on finding the best way to activate the immune system to
fight cancer and infectious diseases. Its lead investigational
therapy Multikine&#xAE; (Leukocyte Interleukin, Injection) is
currently in a pivotal Phase 3 clinical trial involving head and
neck cancer, for which CEL-SCI has received Orphan Drug Status from
the U.S. FDA. If the primary endpoint of this global study is
achieved, the results will be used to support applications to
regulatory agencies around the world for worldwide commercial
marketing approvals as a first line cancer therapy.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
immune therapy, Multikine, is being used in a different way than
immune therapy is usually used. It is given before any other
therapy has been administered because that is when the immune
system is thought to be strongest.<font style="color: #404040">&#xA0;</font>It is also administered locally to
treat tumors or infections.<font style="color: #404040">&#xA0;</font>For example, <font style="color: #404040">i</font>n the Phase 3 clinical trial, Multikine is
given locally at the site of the tumor as a first line treatment
before surgery, radiation and/or chemotherapy. The goal is to help
the intact immune system kill the micro metastases that usually
cause recurrence of the cancer. In short, CEL-SCI believes that
local administration and administration before weakening of the
immune system by chemotherapy and radiation will result in higher
efficacy with less or no toxicity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
is also investigating a different peptide-based immunotherapy
(LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized
patients and as a vaccine (CEL-2000 and CEL-4000) for Rheumatoid
Arthritis (currently in preclinical testing) using its LEAPS
technology platform. CEL-SCI was recently awarded a Phase 2 Small
Business Innovation Research (SBIR) grant in the amount of $1.5
million from the National Institutes of Health (NIH). This grant
will provide funding to allow CEL-SCI to advance its first LEAPS
product candidate, CEL-4000, towards an Investigational New Drug
(IND) application, by funding GMP manufacturing, IND enabling
studies, and additional mechanism of action studies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
was formed as a Colorado corporation in 1983. CEL-SCI&#x2019;s
principal office is located at 8229 Boone Boulevard, Suite 802,
Vienna, VA 22182. CEL-SCI&#x2019;s telephone number is 703-506-9460
and its website is www.cel-sci.com. CEL-SCI does not incorporate
the information on its website into this report, and you should not
consider it part of this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
makes its electronic filings with the Securities and Exchange
Commission (SEC), including its annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K and
amendments to these reports available on its website free of charge
as soon as practicable after they are filed or furnished to the
SEC.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On June
25, 2017 a 1-for-25 reverse stock split of CEL-SCI&#x2019;s common
stock became effective on the NYSE American. Unless otherwise
indicated, all per share amounts have been adjusted for this
reverse stock split.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI&#x2019;S PRODUCTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
is dedicated to research and development directed at improving the
treatment of cancer and other diseases by using the immune system,
the body&#x2019;s natural defense system. CEL-SCI is currently
focused on the development of the following product candidates and
technologies:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 49px">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">1)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Multikine,
an<font style="color: #57575B">&#xA0;</font>investigational<font style="color: #57575B">&#xA0;</font>immunotherapy under development for
the potential treatment of certain head and neck
cancers;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table; margin-left: 49px">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">2)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">L.E.A.P.S. (Ligand
Epitope Antigen Presentation System) technology, or LEAPS, with two
investigational therapies, LEAPS-H1N1-DC, a product candidate under
development for the potential treatment of pandemic influenza in
hospitalized patients, and CEL-2000 and CEL-4000, vaccine product
candidates under development for the potential treatment of
rheumatoid arthritis.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
MULTIKINE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
lead investigational therapy, Multikine, is currently being
developed as a potential therapeutic agent directed at using the
immune system to produce an anti-tumor immune response. Data from
Phase 1 and Phase 2 clinical trials suggest that Multikine may help
the immune system &#x201C;see&#x201D; the tumor and then attack it,
enabling the body&#x2019;s own anti-tumor immune response to fight
the tumor. Multikine is the trademark that CEL-SCI has registered
for this investigational therapy, and this proprietary name is
subject to review by the U.S. Food and Drug Administration, or FDA,
in connection with CEL-SCI&#x2019;s future anticipated regulatory
submission for approval. Multikine has not been licensed or
approved for sale, barter or exchange by the FDA or any other
regulatory agency, such as the European Medicine Agency, or EMA.
Neither has its safety or efficacy been established for any
use.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Multikine is an
immunotherapy product candidate comprised of a patented defined
mixture of 14 human natural cytokines and is manufactured in a
proprietary manner in CEL-SCI&#x2019;s manufacturing facility.
CEL-SCI spent over 10 years and more than $80 million developing
and validating the manufacturing process for Multikine. The
pro-inflammatory cytokine mixture includes interleukins,
interferons, chemokines and colony-stimulating factors, which
contain elements of the body&#x2019;s natural mix of defenses
against cancer.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Multikine is
designed to be used in a different way than immune therapy is
generally being used. Generally immunotherapy is given to patients
who have already failed other treatments <font style="text-decoration: line-through">of</font> such as surgery,
radiation and/or chemotherapy and most of the time it is
administered systemically.&#xA0; Multikine on the other hand is
administered locally to treat tumors and their microenvironment
before any other therapy has been administered because it is
believed that this is the time when the immune system is thought to
be most amenable to activation against the tumor.&#xA0; For
example, in the Phase 3 clinical trial, Multikine is injected
locally at the site of the tumor and near the adjacent draining
lymph nodes as a first line of treatment before surgery, radiation
and/or chemotherapy because that is when the immune system is
thought to be strongest. The goal is to help the intact immune
system recognize and kill the tumor micro metastases that usually
cause recurrence of the cancer. In short, CEL-SCI believes that the
local administration and administration of Multikine and its
administration before weakening of the immune system by
chemotherapy and radiation will result in better anti-tumor
response than if Multikine were administered as a second- or
later-line therapy. In clinical studies of Multikine,
administration of the investigational therapy to head and neck
cancer patients has demonstrated the potential for lesser or no
appreciable toxicity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="cvm_10k000.jpg"></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Source: Adapted from Timar et al., Journal of Clinical Oncology
23(15) May 20, 2005</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
first indication CEL-SCI is pursuing for its investigational drug
product candidate Multikine is an indication for the neoadjuvant
therapy in patients with squamous cell carcinoma of the head and
neck, or SCCHN (hereafter also referred to as advanced primary head
and neck cancer).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">SCCHN
is a type of head and neck cancer, and CEL-SCI believes that, in
the aggregate, there is a large, unmet medical need among head and
neck cancer patients. CEL-SCI believes the last FDA approval of a
therapy indicated for the treatment of advanced primary head and
neck cancer was over 50 years ago. In the aggregate, head and neck
cancer represents about 6% of the world&#x2019;s cancer cases, with
approximately over 650,000 patients diagnosed worldwide each year,
and nearly 60,000 patients diagnosed annually in the United States.
Multikine investigational immunotherapy was granted Orphan Drug
designation for neoadjuvant therapy in patients with SCCHN by the
FDA in the United States.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">This
trial is currently primarily under the management of two clinical
research organizations, or CROs: ICON Inc., or ICON, and Ergomed
Clinical Research Limited, or Ergomed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Phase 3 study was designed with the objective that, if the study
endpoint, which is an improvement in overall survival of the
subjects treated with the Multikine treatment regimen plus the
current standard of care (SOC) as compared to subjects treated with
the current SOC only, is satisfied, the study results are expected
to be used to support applications that CEL-SCI plans to submit to
regulatory agencies in order to seek commercial marketing approvals
for Multikine in major markets around the world. This assessment
can only be made when a certain number of deaths have occurred in
these two main comparator groups of the study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
primary endpoint for the protocol for this Phase 3 head and neck
cancer study required that a 10% increase in overall survival be
obtained in the Multikine group which also is administered CIZ (CIZ
= low dose (non-chemotherapeutic) of cyclophosphamide, indomethacin
and Zinc-multivitamins) all of which are thought to enhance
Multikine activity), plus Standard of Care (Surgery + Radiotherapy
or Chemoradiotherapy) arm of the study over the Control comparator
(Standard of Care alone) arm. As the study was designed, the final
determination of whether this endpoint had been successfully
reached could only be determined when 298 events (deaths) had
occurred in the combined comparator arms of the study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">4</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Nine
hundred twenty-eight (928) newly diagnosed head and neck cancer
patients have been enrolled in this Phase 3 cancer study and all
the patients who have completed treatment continue to be followed
for protocol-specific outcomes in accordance with the Study
Protocol. The last patient was enrolled in the study in September
2016. Approximately 135 patients were enrolled in the study from
2011 to 2013, about 195 were enrolled in 2014, about 340 in 2015,
and about 260 in 2016. The study protocol assumed an overall
survival rate of about 55% at 3 years for the SOC treatment group
alone. At this point in the study the 928 patients enrolled in the
study are being followed-up as required by the study
protocol.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Since
CEL-SCI launched its Phase 3 clinical trial for Multikine, CEL-SCI
has incurred expenses of approximately $45.9 million as of
September 30, 2017 on direct costs for the Phase 3 clinical trial.
CEL-SCI estimates it will incur additional expenses of
approximately $13.0 million for the remainder of the Phase 3
clinical trial. It should be noted that this estimate is based only
on the information currently available in CEL-SCI&#x2019;s contracts
with the Clinical Research Organizations responsible for managing
the Phase 3 clinical trial and does not include other related
costs, e.g., the manufacturing of the drug. This number may be
affected by the rate of death accumulation in the study, foreign
currency exchange rates, and many other factors, some of which
cannot be foreseen today. It is therefore possible that the cost of
the Phase 3 clinical trial will be higher than currently
estimated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Throughout the
course of the Phase 3 study, an Independent Data Monitoring
Committee, or IDMC, has met periodically to review safety data from
the Phase 3 study, and the IDMC is expected to continue doing so
throughout the remainder of the Phase 3 study. At various points in
the study at which the IDMC has completed review of the safety data
and has issued recommendations, it has recommended that the Phase 3
study may continue. However, on one occasion, in the spring of
2014, the IDMC made a recommendation that the study be closed. This
recommendation by the IDMC was reversed following review of
additional information submitted by CEL-SCI, and the IDMC
recommended that the study continue. In the spring of 2016, with
close to 800 patients enrolled, the IDMC made a recommendation that
enrollment in the Phase 3 study should stop, but that patients
already enrolled in the study should continue treatment and
follow-up. CEL-SCI responded to this letter and indicated it would
address the remaining three requests, generally relating to study
design considerations that were not part of the IDMC recommendation
in follow-up correspondence. Subsequent to this correspondence,
CEL-SCI submitted a complete response to the IDMC addressing all of
their requests, as well as providing to them a copy of the
suggested protocol amendment which was sent to the FDA for review
and comment, as was requested by the IDMC. The IDMC did not provide
any additional response following the additional submission to
them.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
September 26, 2016, CEL-SCI received notice from the FDA that the
Phase 3 clinical trial in advanced primary head and neck cancer has
been placed on partial clinical hold. In August 2017, FDA removed
the clinical hold on the Phase 3 study and informed CEL-SCI that
all clinical trial activities under this Investigational New Drug
application (IND) may resume.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
September 2016, the last patient was accrued to the study. A total
of 928 randomized patients were enrolled in the study as of that
date. In December 2016, and again in February 2017 the IDMC
reviewed the data from the Study, but offered no recommendation as
they awaited the outcome of discussions with the FDA regarding the
clinical hold, which was subsequently removed by the FDA on August
10, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">5</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 7, 2017 CEL-SCI announced that the IDMC had completed its
most recent review of the Phase 3 study data. The data from all 928
enrolled patients were provided to the IDMC by the clinical
research organization (CRO) responsible for data management of this
Phase 3 study. The IDMC made the following observation and
recommendation, a) the IDMC saw no evidence of any significant
safety questions and b) the IDMC recommends continuing the
study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 11, 2017 CEL-SCI announced that the Phase 3 clinical study
is fully enrolled and will not need to enroll more
patients.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Ultimately, the
decision as to whether CEL-SCI&#x2019;s drug product candidate is
safe and effective can only be made by FDA and/or by other
regulatory authorities based upon an assessment of all of the data
from an entire drug development program submitted as part of an
application for marketing approval. As detailed elsewhere in this
report the current Phase 3 clinical study for CEL-SCI&#x2019;s
investigational drug may or may not be able to be used as the
pivotal study supporting a marketing application in the United
States, and, if not, at least one entirely new Phase 3 pivotal
study would need to be conducted to support a marketing application
in the United States.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Follow-Up Analysis of Overall Survival in Phase 2
Patients</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">Prior
to starting the Phase 3 study, CEL-SCI had tested Multikine in over
200 patients. The following is a summary of results from
CEL-SCI&#x2019;s last Phase 2 study conducted with Multikine. This
study employed the same treatment protocol as is being followed in
CEL-SCI&#x2019;s Phase 3 study:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Reported potential for improved
survival:</font> In a follow-up analysis of the Phase 2 clinical
study population, which used the same dosage and treatment regimen
as is being used in the Phase 3 study, head and neck cancer
patients with locally advanced primary disease who received the
investigational therapy Multikine as first-line investigational
therapy, followed by surgery and radiotherapy, were reported by the
clinical investigators to have had a 63.2% overall survival, or OS,
rate at a median of 3.33 years from surgery. This percentage of OS
was arrived at as follows: of the 21 subjects enrolled in the Phase
2 study, the consent for the survival follow-up portion of the
study was received from 19 subjects. OS was calculated using the
entire treatment population that consented to the follow-up portion
of the study (19 subjects), including two subjects who, as later
determined by three pathologists blinded to the study, did not have
oral squamous cell carcinoma, or OSCC. These two subjects were thus
not evaluable per the protocol and were not included in the
pathology portion of the study for purposes of calculating complete
response rate, as described below, but were included in the OS
calculation. The overall survival rate of subjects receiving the
investigational therapy in this study was compared to the overall
survival rate that was calculated based upon a review of 55
clinical trials conducted in the same cancer population (with a
total of 7,294 patients studied), and reported in the peer reviewed
scientific literature between 1987 and 2007. Review of this
literature showed an approximate survival rate of 47.5% at 3.5
years from treatment. Therefore, the results of CEL-SCI's final
Phase 2 study were considered to be potentially favorable in terms
of overall survival, recognizing the limitations of this
early-phase study. It should be noted that an earlier
investigational therapy Multikine study appears to lend support to
the overall survival findings described above - Feinmesser et al
Arch Otolaryngol. Surg. 2003. However, no definitive conclusions
can be drawn from these data about the potential efficacy or safety
profile of this investigational therapy. Moreover, further research
is required, and these results must be confirmed in the Phase 3
clinical trial of this investigational therapy that is currently in
progress. Subject to completion of that Phase 3 clinical trial and
the FDA&#x2019;s review and acceptance of CEL-SCI's entire data set
on this investigational therapy, CEL-SCI believes that these
early-stage clinical trial results indicate the potential for the
Multikine product candidate to become a treatment for advanced
primary head and neck cancer, if approved.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">6</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Reported average of 50% reduction in tumor
cells in Phase 2 trials (based on 19 patients evaluable by
pathology, having OSCC):</font> The clinical investigators who
administered the three week Multikine treatment regimen used in the
Phase 2 study reported that, as was determined in a controlled
pathology study, Multikine administration appeared to have caused,
on average, the disappearance of about half of the cancer cells
present at surgery (as determined by histopathology assessing the
area of Stroma/Tumor (Mean+/- Standard Error of the Mean of the
number of cells counted per filed)) even before the start of
standard therapy, which normally includes surgery, radiation and
chemotherapy (Timar et al JCO 2005).</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Reported 10.5% complete response in the final
Phase 2 trial (based on 19 patients evaluable by pathology, having
OSCC):</font> The clinical investigators who administered the
three-week Multikine investigational treatment regimen used in the
Phase 2 study reported that, as was determined in a controlled
pathology study, the tumor apparently was no longer present (as
determined by histopathology) in approximately 10.5% of evaluable
patients with OSCC (Timar et al JCO 2005). In the original study,
21 subjects received Multikine, two of which were later excluded,
as subsequent analysis by three pathologists blinded to the study
revealed that these two patients did not have OSCC. Two subjects in
this study had a complete response, leaving a reported complete
response rate of two out of 19 assessable subjects with OSCC (or
10.5%) (Timar et al JCO 2005).</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Adverse events reported in clinical
trials:</font> In clinical trials conducted to date with the
Multikine investigational therapy, adverse events which have been
reported by the clinical investigators as possibly or probably
related to Multikine administration included pain at the injection
site, local minor bleeding and edema at the injection site,
diarrhea, headache, nausea, and constipation<font style="font-weight: bold">.</font></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Subsequently, an
analysis on the 21 subjects originally treated with Multikine in
the study to evaluate overall survival was conducted, as described
above. In connection with the follow-up portion of the study for
overall survival, <font style="color: #000000">CEL-SCI</font> also
conducted an unreported post-hoc analysis of complete response rate
in the study population, which included subjects who provided
consent for the follow-up and who also had OSCC. Two of the 21
subjects did not re-consent for follow-up, and two of the remaining
19 subjects were excluded from the post-hoc complete response rate
analysis as they had previously been determined by pathology
analysis to not have OSCC. The two complete responders with OSCC
both consented to the follow-up study. Therefore, the post-hoc
analysis of complete response was based on a calculation of the two
complete responders out of 17 evaluable subjects who consented to
the follow-up analysis and who also had OSCC (or
11.8%).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Furthermore,
CEL-SCI reported an overall response rate of 42.1% based on the
number of evaluable patients who experienced a favorable response
to the treatment, including those who experienced minor, major and
complete responses. Out of the 19 evaluable patients, two
experienced a complete response, two experienced a major response,
and four experienced a minor response to treatment. Thus,
<font style="color: #000000">CEL-SCI</font> calculated the number
of patients experiencing a favorable response as eight patients out
of 19 (or 42.1%) (Timar et al, JCO 2005).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
clinical significance of these and other data, to date, from the
multiple Multikine clinical trials, is not yet known. These
preliminary clinical data do suggest the potential to demonstrate a
possible improvement in the clinical outcome for patients treated
with Multikine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">7</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Peri-Anal Warts and Cervical Dysplasia in HIV/HPV Co-Infected
Patients</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">HPV is
a very common sexually transmitted disease in the United States and
other parts of the world. It can lead to cancer of the cervix,
penis, anus, esophagus and head and neck. CEL-SCI&#x2019;s focus in
HPV, however, is not on developing an antiviral for the potential
treatment or prevention of HPV in the general population. Instead,
the focus is on developing an immunotherapy product candidate
designed to be administered to patients who are immune-suppressed
by other diseases, such as HIV, and who are therefore less able or
unable to control HPV and its resultant or co-morbid diseases. Such
patients have limited treatment options available to
them.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">One
condition that is commonly associated with both HIV and HPV is the
occurrence of anal intraepithelial dysplasia, or AIN, and anal and
genital warts. The incidence of AIN in HIV-infected people is
estimated to be about 25%. The incidence of anal HPV infection in
HIV-infected men who have sex with men, or MSM, is estimated to be
as high as 95%. In the aggregate, the United States and Europe have
about 875,000 HIV-infected patients with AIN (assuming AIN
prevalence of approximately 25% of the aggregate HIV-infected
population). Persistent HPV infection in the anal region is thought
to be responsible for up to 80% of anal cancers, and men and women
who are HIV positive have a 30-fold increase in their risk of anal
cancer. Persistent HPV infection can also be a precursor to
cervical cancer, as well as certain head and neck
cancers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2013, <font style="color: #000000">CEL-SCI</font> signed a
cooperative research and development agreement, or CRADA, with the
U.S. Naval Medical Center, San Diego, or the USNMC. Pursuant to
this agreement, the USNMC was to conduct a Phase 1 study, approved
by the Human Subjects Institutional Review Board, of
CEL-SCI&#x2019;s investigational immunotherapy, Multikine, in
HIV/HPV co-infected men and women with peri-anal warts. The purpose
of this study was to evaluate the safety and clinical impact of
Multikine as a potential treatment of peri-anal warts and assess
its effect on AIN in HIV/HPV co-infected men and
women.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In July
2015, CEL-SCI added a clinical site at the University of
California, San Francisco, or UCSF, and Key Opinion Leader, or KOL,
to the ongoing Phase 1 study. In August 2016, the U.S. Navy
discontinued this Phase 1 study because of difficulties in
enrolling patients. UCSF is continuing with the study. The Company
will not continue with this indication because 1) the patient
enrollment is extremely slow and 2) it needs to focus its resources
on the Phase 3 study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2013, <font style="color: #000000">CEL-SCI</font> entered
into a co-development and profit sharing agreement with Ergomed for
development of Multikine as a potential treatment of HIV/HPV
co-infected men and women with peri-anal warts. This agreement is
supporting the development of Multikine with UCSF.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
treatment regimen for this Phase 1 study of up to 15 HIV/HPV
co-infected patient volunteers with peri-anal warts is identical to
the regimen that was used in an earlier Institutional Review
Board-approved Multikine Phase 1 study in HIV/HPV co-infected
patients, which was conducted at the University of Maryland. In
that study, the Multikine investigational therapy was administered
to HIV/HPV co-infected women with cervical dysplasia, resulting in
visual and histological evidence of clearance of lesions in three
out of the eight subjects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">8</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Furthermore, in
this cervical dysplasia Phase 1 study, the number of HPV viral
sub-types in three volunteer subjects tested were reduced
post-treatment with Multikine, as opposed to pre-treatment, as
determined by in situ polymerase chain reaction performed on tissue
biopsy collected before and after Multikine treatment. As reported
by the investigators in the earlier study, the study volunteers,
except one subject volunteer, all appeared to tolerate the
treatment with no reported serious adverse events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Development Agreements for Multikine</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">In
August 2008, CEL-SCI signed an agreement with Teva Pharmaceutical
Industries Ltd., or Teva, that gives Teva the exclusive right and
license to market, distribute and sell Multikine in Israel and
Turkey for treatment of head and neck cancer, if approved. The
agreement terminates on a country-by-country basis 10 years after
the product launch in each country or upon a material breach or
upon bankruptcy of either party. The agreement will automatically
extend for additional two year terms unless either party gives
notice of its intent not to extend the agreement. If CEL-SCI
develops Multikine for other oncology indications and Teva
indicates a desire to participate, the parties have agreed to
negotiate in good faith with respect to Teva&#x2019;s participation
and contribution in future clinical trials.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">Teva
has agreed to use all reasonable efforts to obtain regulatory
approval to market and sell Multikine in its territory at its own
cost and expense. Pursuant to the agreement, it is CEL-SCI&#x2019;s
responsibility to supply Multikine and Teva&#x2019;s responsibility
to sell Multikine, if approved. Net sales will be divided 50/50
between the two parties. Teva also initially agreed to fund certain
activities relating to the conduct of a clinical trial in Israel as
part of the global Phase 3 trial for Multikine. In January 2012,
pursuant to an assignment and assumption agreement between CEL-SCI,
Teva and GCP Clinical Studies Ltd., or GCP, Teva transferred all of
its rights and obligations concerning the Phase III trial in Israel
to GCP. GCP is now operating the Phase 3 trial in Israel pursuant
to a service agreement with CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">In July
2011, Serbia and Croatia were added to Teva&#x2019;s territory,
pursuant to a joinder agreement between CEL-SCI and PLIVA Hrvatska
d.o.o., or PLIVA, an affiliate of Teva&#x2019;s, subject to similar
terms as described above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">In
consideration for the rights granted by CEL-SCI to PLIVA under the
joinder agreement, CEL-SCI will be paid by PLIVA (in U.S.
dollars):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$100,000 upon EMA
grant of Marketing Authorization for Multikine;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$50,000 upon
Croatia&#x2019;s grant of reimbursement status for Multikine in
Croatia; and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$50,000 upon
Serbia&#x2019;s grant of reimbursement status for Multikine in
Serbia.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px">
<font style="font-family: Times New Roman; font-size: 13px">In
November 2000, CEL-SCI signed an agreement with Orient Europharma
Co., Ltd., or Orient Europharma, of Taiwan, which agreement was
amended in October 2008 and again in June 2010. Pursuant to this
agreement, as amended, Orient Europharma has the exclusive
marketing and distribution rights to Multikine, if approved, for
head and neck cancer, naso-pharyngeal cancer and potentially
cervical cancer indications in Taiwan, Singapore, Malaysia, Hong
Kong, the Philippines, South Korea, Australia and New Zealand.
CEL-SCI has granted Orient Europharma the first right of
negotiation with respect to Thailand and China.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">9</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">The
agreement requires Orient Europharma to fund 10% of the cost of the
clinical trials needed to obtain marketing approvals in these
countries for head and neck cancer, naso-pharyngeal cancer and
potentially cervical cancer. Orient Europharma has signed ten
centers in Taiwan, four centers in Malaysia, three centers in
Philippines and one center in Thailand to enroll patients as part
of the Phase 3 Multikine clinical trial and has made further
financial contributions towards the cost of the Phase 3 clinical
trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; text-indent: 48px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">If Multikine is
approved for sale, Orient Europharma will purchase Multikine from
CEL-SCI for 35% of the gross selling price in each
country.<font style="font-weight: bold">&#xA0;</font>Orient
Europharma is obligated to use the same diligent efforts to
develop, register, market, sell and distribute Multikine in the
territory as with its own products or other licensed
products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">The
agreement will terminate on a country-by-country basis 15 years
after the product approval for Multikine in each country, at which
point the agreement will be automatically extended for successive
two year periods, unless either party gives notice of its intent
not to extend the agreement. The agreement may also be terminated
upon bankruptcy of either party or material misrepresentations that
are not cured within 60 days. If the agreement ends before the 15
year term through no fault of either party, CEL-SCI will reimburse
Orient Europharma for a prorated part of Orient Europhorma&#x2019;s
costs towards the clinical trials of Multikine. If Orient
Europharma fails to make certain minimum purchases of Multikine
during the term of the agreement, Orient Europhorma&#x2019;s rights
to the territory will become non-exclusive.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
has a licensing agreement with Byron Biopharma LLC, or Byron, under
which CEL-SCI granted Byron an exclusive license to market and
distribute Multikine in the Republic of South Africa, if approved.
This license will terminate 20 years after marketing approval in
South Africa or after bankruptcy or uncured material breach. After
the 20-year period has expired, the agreement will be automatically
extended for successive two year periods, unless either party gives
notice of its intent not to extend the agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
agreement, Byron will be responsible for registering Multikine in
South Africa. If Multikine is approved for sale in South Africa,
CEL-SCI will be responsible for manufacturing the product, while
Byron will be responsible for sales in South Africa. Sales revenues
will be divided between CEL-SCI and Byron. CEL-SCI will be paid
fifty (50%) percent of the net sales of Multikine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
MANUFACTURING FACILITY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Before
starting the Phase 3 clinical trial, for reasons related to
regulatory considerations, CEL-SCI needed to build a dedicated
manufacturing facility to produce Multikine. This facility has been
completed and validated, and has produced multiple clinical lots
for the Phase 3 clinical trial. The facility has also passed review
by a European Union Qualified Person on several
occasions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">10</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
lease on the manufacturing facility expires on October 31,
2028.<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>CEL-SCI
completed validation of its new manufacturing facility in January
2010. The state-of-the-art facility is being used to manufacture
Multikine for CEL-SCI&#x2019;s Phase 3 clinical trial. In addition
to using this facility to manufacture Multikine, CEL-SCI, only if
the facility is not being used for Multikine, may offer the use of
the facility as a service to pharmaceutical companies and others,
particularly those that need to &#x201C;fill and finish&#x201D; their
drugs in a cold environment (4 degrees Celsius, or approximately 39
degrees Fahrenheit). Fill and finish is the process of filling
injectable drugs in a sterile manner and is a key part of the
manufacturing process for many medicines. However, priority will
always be given to Multikine as management considers the Multikine
supply to the clinical studies and preparation for a final
marketing approval to be more important than offering fill and
finish services. See Item 2 of this report for more information
concerning the terms of this lease.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
LEAPS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
patented T-cell Modulation Process, referred to as LEAPS (Ligand
Epitope Antigen Presentation System), uses
&#x201C;heteroconjugates&#x201D; to direct the body to choose a
specific immune response. LEAPS is designed to stimulate the human
immune system to more effectively fight bacterial, viral and
parasitic infections as well as autoimmune, allergies,
transplantation rejection and cancer, when it cannot do so on its
own. Administered like a vaccine, LEAPS combines T-cell binding
ligands with small, disease associated, peptide antigens and may
provide a new method to treat and prevent certain
diseases.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
ability to generate a specific immune response is important because
many diseases are often not combated effectively due to the
body&#x2019;s selection of the &#x201C;inappropriate&#x201D; immune
response. The capability to specifically reprogram an immune
response may offer a more effective approach than existing vaccines
and drugs in attacking an underlying disease.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
September 19, 2017, CEL-SCI announced that it has been awarded a
Phase 2 Small Business Innovation Research (SBIR) grant in the
amount of $1.5 million from the National Institute of Arthritis
Muscoskeletal and Skin Diseases, which is part of the National
Institutes of Health (NIH). This grant will provide funding to
allow CEL-SCI to advance its first LEAPS product candidate,
CEL-4000, towards an Investigational New Drug (IND) application, by
funding GMP manufacturing, IND enabling studies, and additional
mechanism of action studies. The work is being conducted at
CEL-SCI&#x2019;s research laboratory and Rush University Medical
Center in Chicago, Illinois in the laboratories of Tibor Glant, MD,
Ph.D., The Jorge O. Galante Professor of Orthopedic Surgery and
Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery &amp;
Biochemistry. The grant was awarded based on published data
described below by Dr. Glant's team in collaboration with CEL-SCI
showing that the administration of a proprietary peptide using
CEL-SCI's LEAPS technology prevented the development, and lessened
the severity, including inflammation, of experimental proteoglycan
induced arthritis (PGIA or GIA) when it was administered after the
disease was induced in the animals.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">11</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In July
2014, CEL-SCI announced that it has been awarded a Phase 1 Small
Business Innovation Research (SBIR) grant in the amount of $225,000
from the National Institute of Arthritis Muscoskeletal and Skin
Diseases, which is part of the National Institutes of Health. The
grant funded the development of CEL-SCI&#x2019;s LEAPS technology as
a potential treatment for rheumatoid arthritis, an autoimmune
disease of the joints. The work was conducted at Rush University
Medical Center in Chicago, Illinois in the laboratories of Tibor
Glant, MD, Ph.D., The Jorge O. Galante Professor of Orthopedic
Surgery; Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery
&amp; Biochemistry; and Allison Finnegan, Ph.D. Professor of
Medicine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">With
the support of the SBIR grant, CEL-SCI is developing two new drug
candidates, CEL-2000 and CEL-4000, as potential rheumatoid
arthritis therapeutic vaccines. The data from animal studies using
the CEL-2000 treatment vaccine demonstrated that it could be used
as an effective treatment against rheumatoid arthritis with fewer
administrations than those required by other anti-rheumatoid
arthritis treatments currently on the market for arthritic
conditions associated with the Th17 signature cytokine
TNF-<font style="font-size: 13px">&#xA0;</font> . The data for
CEL-4000 indicates it could be effective against rheumatoid
arthritis cases where a Th1 signature cytokine (IFN-c) is dominant.
CEL-2000 and CEL-4000 have the potential to be a more
disease-specific therapy, significantly less expensive, act at an
earlier step in the disease process than current therapies and may
be useful in patients not responding to existing rheumatoid
arthritis therapies. CEL-SCI believes this represents a large unmet
medical need in the rheumatoid arthritis market.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
February 2017 and November 2016, CEL-SCI announced new preclinical
data that demonstrate its investigational new drug candidate
CEL-4000 has the potential for use as a therapeutic vaccine to
treat rheumatoid arthritis. This efficacy study was supported in
part by the SBIR Phase I Grant and was conducted in collaboration
with Drs. Katalin Mikecz and Tibor Glant, and their research team
at Rush University Medical Center in Chicago, IL.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
March 2015, CEL-SCI and its collaborators published a review
article on vaccine therapies for rheumatoid arthritis based in part
on work supported by the SBIR grant. The article is entitled
&#x201C;Rheumatoid arthritis vaccine therapies: perspectives and
lessons from therapeutic Ligand Epitope Antigen Presentation System
vaccines for models of rheumatoid arthritis&#x201D; and was
published in Expert Rev. Vaccines 1 - 18 and can be found at
http://www.ncbi.nlm.nih.gov/ pubmed/25787143.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
August 2012, Dr. Zimmerman, CEL-SCI&#x2019;s Senior Vice President
of Research, Cellular Immunology, gave a Keynote presentation at
the OMICS 2nd International Conference on Vaccines and Vaccinations
in Chicago. This presentation showed how the LEAPS peptides
administered altered only select cytokines specific for each
disease model, thereby improving the status of the test animals and
even preventing death and morbidity. These results support the
growing body of evidence that provides for its mode of action by a
common format in these unrelated conditions by regulation of Th1
(e.g., IL12 and IFN-c) and their action on reducing
TNF-<font style="font-size: 13px">&#xA0;</font> and other
inflammatory cytokines as well as regulation of antibodies to these
disease associated antigens. This was also illustrated by a
schematic model showing how these pathways interact and result in
the overall effect of protection and regulation of cytokines in a
beneficial manner.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">12</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
February 2010, CEL-SCI announced that its CEL-2000 vaccine
demonstrated that it was able to block the progression of
rheumatoid arthritis in a mouse model, where a Th17 signature
cytokine (TNF-<font style="font-size: 13px">&#xA0;</font> ) is
dominant. The results were published in the scientific
peer-reviewed Journal of International Immunopharmacology (online
edition) in an article titled &#x201C;CEL-2000: A Therapeutic
Vaccine for Rheumatoid Arthritis Arrests Disease Development and
Alters Serum Cytokine / Chemokine Patterns in the Bovine Collagen
Type II Induced Arthritis in the DBA Mouse Model&#x201D; Int
Immunopharmacol. 2010 Apr; 10(4):412-21 http://www.
ncbi.nlm.nih.gov/pubmed/20074669.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Using
the LEAPS technology, CEL-SCI has created a potential peptide
treatment for H1N1 (swine flu) hospitalized patients.&#xA0; This
LEAPS flu treatment is designed to focus on the conserved,
non-changing epitopes of the different strains of Type A Influenza
viruses (H1N1, H5N1, H3N1, etc.), including &#x201C;swine&#x201D;,
&#x201C;avian or bird&#x201D;, and &#x201C;Spanish Influenza&#x201D;,
in order to minimize the chance of viral &#x201C;escape by
mutations&#x201D; from immune recognition. Therefore one should
think of this treatment not really as an H1N1 treatment, but as a
potential pandemic flu treatment. CEL-SCI&#x2019;s LEAPS flu
treatment contains epitopes known to be associated with immune
protection against influenza in animal models.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
September 2009, the U.S. FDA advised CEL-SCI that it could proceed
with its first clinical trial to evaluate the effect of LEAPS-H1N1
treatment on the white blood cells of hospitalized H1N1 patients.
This followed an expedited initial review of CEL-SCI's regulatory
submission for this study proposal.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
November 2009, CEL-SCI announced that The Johns Hopkins University
School of Medicine had given clearance for CEL-SCI&#x2019;s first
clinical study to proceed using LEAPS-H1N1.&#xA0;&#xA0; Soon after
the start of the study, the number of hospitalized H1N1 patients
dramatically declined and the study was unable to complete the
enrollment of patients.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Additional work on
this treatment for the pandemic flu is being pursued in
collaboration with the National Institute of Allergy and Infectious
Diseases (NIAID), part of the National Institutes of Health, USA.
In May 2011 NIAID scientists presented data at the Keystone
Conference on &#x201C;Pathogenesis of Influenza: Virus-Host
Interactions&#x201D; in Hong Kong, China, showing the positive
results of efficacy studies in mice of LEAPS H1N1 activated
dendritic cells (DCs) to treat the H1N1 virus. Scientists at the
NIAID found that H1N1-infected mice treated with LEAPS-H1N1 DCs
showed a survival advantage over mice treated with control DCs. The
work was performed in collaboration with scientists led by Kanta
Subbarao, M.D., Chief of the Emerging Respiratory Diseases Section
in NIAID&#x2019;s Division of Intramural Research, part of the
National Institutes of Health, USA.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In July
2013, CEL-SCI announced the publication of the results of influenza
studies by researchers from the NIAID in the Journal of Clinical
Investigation (<font style="text-decoration: underline; color: #0000FF">www.jci.org/articles/view/67550</font>).
The studies described in the publication show that when
CEL-SCI&#x2019;s investigational J-LEAPS Influenza Virus treatments
were used &#x201C;in vitro&#x201D; to activate DCs, these activated
DCs, when injected into influenza infected mice, arrested the
progression of lethal influenza virus infection in these mice. The
work was performed in the laboratory of Dr. Subbarao.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">13</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Even
though the various LEAPS drug candidates have not yet been given to
humans, they have been tested in vitro with human cells. They have
induced similar cytokine responses that were seen in these animal
models, which may indicate that the LEAPS technology might
translate to humans. The LEAPS candidates have demonstrated
protection against lethal herpes simplex virus (HSV1) and H1N1
influenza infection, as a prophylactic or therapeutic agent in
animals. They have also shown some level of efficacy in animals in
two autoimmune conditions, curtailing and sometimes preventing
disease progression in arthritis and myocarditis animal models.
CEL-SCI&#x2019;s belief is that the LEAPS technology may be a
significant alternative to the vaccines currently available on the
market for these diseases.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">None of
the LEAPS investigational products have been approved for sale,
barter or exchange by the FDA or any other regulatory agency for
any use to treat disease in animals or humans. The safety or
efficacy of these products has not been established for any use.
Lastly, no definitive conclusions can be drawn from the
early-phase, preclinical-trials data involving these
investigational products. Before obtaining marketing approval from
the FDA in the United States, and by comparable agencies in most
foreign countries, these product candidates must undergo rigorous
preclinical and clinical testing which is costly and time consuming
and subject to unanticipated delays. There can be no assurance that
these approvals will be granted.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
INTELLECTUAL PROPERTY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">Patents
and other proprietary rights are essential to CEL-SCI&#x2019;s
business. CEL-SCI files patent applications to protect its
technologies, inventions and improvements to its inventions that
CEL-SCI considers important to the development of its business.
CEL-SCI&#x2019;S intellectual property portfolio covers its
proprietary technologies, including Multikine and LEAPS, by
multiple issued patents and pending patent applications in the
United States and in key foreign markets.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Multikine is
protected by a US patent, which is a composition-of-matter patent
issued in May 2005 that, in its current format, expires in 2023.
Additional composition-of-matter patents for Multikine have been
issued in Germany (issued in June 2011 and currently set to expire
in 2025), China (issued in May 2011 and currently set to expire in
2024), Japan (issued in November 2012 and currently set to expire
in 2025), and three in Europe (issued in September 2015, May 2016
and October 4, 2017, currently set to expire in 2025 and 2026). In
September 2017 CEL-SCI announced that the European Patent Office
has issued a new patent to CEL-SCI for Multikine. Patent # EP 1 879
618 B1, titled &#x201C;A Method for Modulating HLA Class II Tumor
Cell Surface Expression With A Cytokine Mixture,&#x201D; addresses
Multikine&#x2019;s mechanism of action to make tumors more visible
to the immune system. This new patent is important because, along
with the other Multikine issued patents, it addresses how Multikine
enables the immune system to recognize and attack the tumor. One
way tumor cells evade the immune system is by expressing human
leukocyte antigens (HLA) on the tumor cell surface, thus appearing
as &#x2018;self&#x2019; to the immune cells and therefore the tumor
cells are not attacked. It is important to note that the tumors of
the Multikine-treated responders in CEL-SCI&#x2019;s prior Phase 2
studies had no HLA Class II expressed on the cell surface following
Multikine treatment as compared to controls. This points to
Multikine&#x2019;s ability to modulate HLA expression on the tumor
cell surface, thereby allowing the immune system to recognize and
attack the tumor.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">14</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition to the patents that offer certain protections for
Multikine, the method of manufacture for Multikine, a complex
biological product, is held by CEL-SCI as trade
secret.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">LEAPS
is protected by patents in the United States issued in February
2006, April 2007, and August 2007. The LEAPS patents, which expire
in 2021, 2022 and 2021, respectively, include overlapping claims,
with composition of both matter (new chemical entity), process and
methods-of-use, to maximize and extend the coverage in their
current format. In October 2017, a patent was issued in Europe for
LEAPS, which expires in 2029. Additional patent applications are
pending in the United States and Europe that could offer protection
through 2034.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
has six patent applications pending in the United States and one in
Europe for LEAPS, which, if issued, would extend protection through
2034, subject to any potential patent term extensions. One pending
U.S. application is a joint application with Northeast Ohio Medical
University (&#x201C;Neoucom&#x201D;). If granted, CEL-SCI will share
the ability to use the patent, unless CEL-SCI licenses the rights
to the patent application and any ensuing patent from
Neoucom.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">As of
December 21, 2017, there were no contested proceedings and/or third
party claims with respect to CEL-SCI&#x2019;s patents or patent
applications.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM
1B. RISK FACTORS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
risks described below could adversely affect the price of
CEL-SCI&#x2019;s common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Risks Related to CEL-SCI</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI has identified material weaknesses in its internal control
over financial reporting which could, if not remediated, result in
material misstatements in CEL-SCI&#x2019;s financial
statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
management is responsible for establishing and maintaining adequate
internal control over its financial reporting, as defined in Rule
13a-15(f) under the Exchange Act. CEL-SCI&#x2019;s management
identified material weaknesses in the internal control over
financial reporting as of September 30, 2016. A material weakness
is a deficiency, or a combination of deficiencies, in internal
control over financial reporting, such that there is a reasonable
possibility that a material misstatement of CEL-SCI&#x2019;s annual
or interim financial statements will not be prevented or detected
on a timely basis.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
discovered an error in the way it accounted for the lease for its
manufacturing facility. The accounting error was determined to be a
material weakness in CEL-SCI&#x2019;s internal control over
financial reporting as of September 30, 2016 relating to
CEL-SCI&#x2019;s financial close process for non-routine
transactions including the accounting for leases and the assessment
of impairment of long-lived assets. The errors were identified
during the course of the preparation of its financial statements
and other financial data for its fiscal year ended September 30,
2017, as well as its assessment of its disclosure controls and
procedures and internal control over financial reporting as of that
date. This resulted in CEL-SCI filing an amended 10-K/A for the
year ended September 30, 2016, that disclosed these material
weaknesses and the impact of the restatement to the previously
issued financial statements. These material weaknesses continue to
exist at September 30, 2017 and CEL-SCI is in the process of
remediating these material weaknesses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">15</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">If the
remedial measures CEL-SCI has begun implementing that are designed
to address these material weaknesses are insufficient to address
these material weaknesses, or if additional material weaknesses or
significant deficiencies in CEL-SCI&#x2019;s internal control are
discovered or occur in the future, the financial statements may
contain material misstatements and CEL-SCI could be required to
restate its financial results.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI has incurred significant losses since inception, and
CEL-SCI anticipates that it will continue to incur significant
losses for the foreseeable future and may never achieve or maintain
profitability.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
has a history of net losses, expects to incur substantial losses
and have negative operating cash flow for the foreseeable future,
and may never achieve or maintain profitability.&#xA0;&#xA0;Since
the date of its formation and through September 30, 2017, CEL-SCI
incurred net losses of approximately $300 million. CEL-SCI has
relied principally upon the proceeds from the public and private
sales of its securities to finance its activities to date. To date,
CEL-SCI has not commercialized any products or generated any
revenue from the sale of products, and CEL-SCI does not expect to
generate any product revenue for the foreseeable future. CEL-SCI
does not know whether or when it will generate product revenue or
become profitable.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
is heavily dependent on the success of Multikine which is under
clinical development. CEL-SCI cannot be certain that Multikine will
receive regulatory approval or be successfully commercialized even
if CEL-SCI receives regulatory approval. Multikine is the only
product candidate in late-stage clinical development, and
CEL-SCI&#x2019;s business currently depends heavily on its
successful development, regulatory approval and commercialization.
CEL-SCI has no drug products for sale currently and may never be
able to develop approved and marketable drug products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Even
if CEL-SCI succeeds in developing and commercializing one or more
of its product candidates, CEL-SCI expects to continue to incur
significant operating and capital expenditures as
CEL-SCI:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">continues
to undertake preclinical development and clinical trials for
product candidates;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">seeks
regulatory approvals for product candidates; and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">implements
additional internal systems and infrastructure.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">To
become and remain profitable, CEL-SCI must succeed in developing
and commercializing product candidates which must generate
significant revenue. This will require CEL-SCI to be successful in
a range of challenging activities, including completing preclinical
testing and clinical trials of its product candidates, discovering
or acquiring additional product candidates, obtaining regulatory
approval for these product candidates and manufacturing, marketing
and selling any products for which CEL-SCI may obtain regulatory
approval. CEL-SCI is only in the preliminary stages of most of
these activities. CEL-SCI may never succeed in these activities
and, even if CEL-SCI does, may never generate revenue that is
significant enough to achieve profitability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">16</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Even
if CEL-SCI does achieve profitability, it may not be able to
sustain or increase profitability on a quarterly or annual basis.
The failure to become and remain profitable could depress the value
of CEL-SCI and could impair its ability to raise capital, expand
its business, maintain research and development efforts, diversify
product offerings or even continue in operation. A decline in the
value of CEL-SCI could cause its stockholders to lose all or part
of their investment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI will require substantial additional capital to remain in
operation. A failure to obtain this necessary capital when needed
could force CEL-SCI to delay, limit, reduce or terminate the
product candidates&#x2019; development or commercialization
efforts.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
of September 30, 2017, CEL-SCI had cash and cash equivalents of
approximately $2.4 million.&#xA0;&#xA0;CEL-SCI believes that it
will continue to expend substantial resources for the foreseeable
future developing Multikine, LEAPS and any other product candidates
or technologies that it may develop or acquire. These expenditures
will include costs associated with research and development,
potentially obtaining regulatory approvals and having the products
manufactured, as well as marketing and selling products approved
for sale, if any. In addition, other unanticipated costs may arise.
Because the outcome of the current and anticipated clinical trials
is highly uncertain, CEL-SCI cannot reasonably estimate the actual
amounts necessary to successfully complete the development and
commercialization of the product candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
future capital requirements depend on many factors,
including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
rate of progress of, results of and cost of completing Phase 3
clinical development of Multikine for the treatment of certain head
and neck cancers;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
results of the applications to and meetings with the FDA, the EMA
and other regulatory authorities and the consequential effect on
operating costs;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">assuming
favorable Phase 3 clinical results, the cost, timing and outcome of
the efforts to obtain marketing approval for Multikine in the
United States, Europe and in other jurisdictions, including the
preparation and filing of regulatory submissions for Multikine with
the FDA, the EMA and other regulatory authorities;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
scope, progress, results and costs of additional preclinical,
clinical, or other studies for additional indications for
Multikine, LEAPS and other product candidates and technologies that
CEL-SCI may develop or acquire;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
timing of, and the costs involved in, obtaining regulatory
approvals for LEAPS if clinical studies are
successful;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
cost and timing of future commercialization activities for the
products, if any of the product candidates are approved for
marketing, including product manufacturing, marketing, sales and
distribution costs;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
revenue, if any, received from commercial sales of the product
candidates for which CEL-SCI receives marketing
approval;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
cost of having the product candidates manufactured for clinical
trials and in preparation for commercialization;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">17</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
ability to establish and maintain strategic collaborations,
licensing or other arrangements and the financial terms of such
agreements;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
costs involved in preparing, filing and prosecuting patent
applications and maintaining, defending and enforcing its
intellectual property rights, including litigation costs, and the
outcome of such litigation; and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
extent to which CEL-SCI acquires or in-licenses other products or
technologies.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Based
on the current operating plan, and absent any future financings or
strategic partnerships, CEL-SCI believes that its existing cash and
cash equivalents and investments will be sufficient to fund its
projected operating expenses and capital expenditure requirements
into March 2018. However, CEL-SCI&#x2019;s operating plan may change
as a result of many factors currently unknown to CEL-SCI, and
CEL-SCI may need additional funds sooner than planned. Additional
funds may not be available when CEL-SCI needs them on terms that
are acceptable to CEL-SCI, or at all. If adequate funds are not
available to CEL-SCI on a timely basis, CEL-SCI may be required to
delay, limit, reduce or terminate preclinical studies, clinical
trials or other development activities for Multikine, LEAPS, or any
other product candidates or technologies that CEL-SCI develops or
acquires, or delay, limit, reduce or terminate its sales and
marketing capabilities or other activities that may be necessary to
commercialize its product candidates. Due to recurring losses from
operations and future liquidity needs, there is substantial doubt
about CEL-SCI&#x2019;s ability to continue as a going concern
without additional capital becoming available. The doubt about
CEL-SCI&#x2019;s ability to continue as a going concern could have
an adverse impact on CEL-SCI&#x2019;s ability to execute its
business plan, result in the reluctance on the part of certain
suppliers to do business with CEL-SCI, or adversely affect
CEL-SCI&#x2019;s ability to raise additional debt or equity
capital.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
The costs of the product candidates development and clinical trials
are difficult to estimate and will be very high for many years,
preventing CEL-SCI from making a profit for the foreseeable future,
if ever.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Clinical
and other studies necessary to obtain approval of a new drug can be
time consuming and costly, especially in the United States, but
also in foreign countries. The estimates of the costs associated
with future clinical trials and research may be substantially lower
than what CEL-SCI actually experiences. It is impossible to predict
what CEL-SCI will face in the development of a product candidate,
such as Multikine. The purpose of clinical trials is to provide
both CEL-SCI and regulatory authorities with safety and efficacy
data in humans. It is relatively common to revise a trial or add
subjects to a trial in progress. The difficult and often complex
steps necessary to obtain regulatory approval, especially that of
the FDA and the EMA, involve significant costs and may require
several years to complete. CEL-SCI expects that it will need
substantial additional financing over an extended period of time in
order to fund the costs of future clinical trials, related
research, and general and administrative expenses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
extent of the clinical trials and research programs are primarily
based upon the amount of capital available to CEL-SCI and the
extent to which CEL-SCI receives regulatory approvals for clinical
trials. CEL-SCI has established estimates of the future costs of
the Phase 3 clinical trial for Multikine, but, as explained above,
the estimates may not prove correct.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">18</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
An adverse determination in any current or future lawsuits or
arbitration proceedings to which CEL-SCI is a party could have a
material adverse effect on CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">CEL-SCI is currently involved in a pending
arbitration proceeding,&#xA0;</font><font style="font-style: italic; color: #000000">CEL-SCI Corporation v.
inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet
GmbH (f/k/a PharmaNet AG)</font><font style="color: #000000">.
CEL-SCI initiated the proceedings against inVentiv Health Clinical,
LLC, or inVentiv, the former third-party CRO, and is seeking
payment for damages related to inVentiv&#x2019;s prior involvement
in the Phase 3 clinical trial of Multikine. The arbitration claim,
initiated under the Commercial Rules of the American Arbitration
Association, alleges (i) breach of contract, (ii) fraud in the
inducement, and (iii) common law fraud. Currently, CEL-SCI is
seeking at least $50 million in damages in its amended statement of
claim.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
an amended statement of claim, CEL-SCI asserted the claims set
forth above as well as an additional claim for professional
malpractice.&#xA0;&#xA0;The arbitrator subsequently granted
inVentiv&#x2019;s motion to dismiss the professional malpractice
claim based on the &#x201C;economic loss doctrine&#x201D; which,
under New Jersey law, is a legal doctrine that, under certain
circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#xA0;&#xA0;The arbitrator
denied the remainder of inVentiv&#x2019;s motion, which had sought
to dismiss certain other aspects of the amended statement of
claim.&#xA0;&#xA0;In particular, the arbitrator rejected
inVentiv&#x2019;s argument that several aspects of the amended
statement of claim were beyond the arbitrator&#x2019;s
jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
connection with the pending arbitration proceedings, inVentiv has
asserted counterclaims against CEL-SCI for (i) breach of contract,
seeking at least $2 million in damages for services allegedly
performed by inVentiv; (ii) breach of contract, seeking at least $1
million in damages for the alleged use of inVentiv&#x2019;s name in
connection with publications and promotions in violation of the
parties&#x2019; contract; (iii) opportunistic breach, restitution
and unjust enrichment, seeking at least $20 million in disgorgement
of alleged unjust profits allegedly made by CEL-SCI as a result of
the purported breaches referenced in subsection (ii); and (iv)
defamation, seeking at least $1 million in damages for allegedly
defamatory statements made about inVentiv. CEL-SCI believes
inVentiv&#x2019;s counterclaims are meritless and intends to
vigorously defend against them. However, if such defense is
unsuccessful, and inVentiv successfully asserts any of its
counterclaims, such an adverse determination could have a material
adverse effect on CEL-SCI&#x2019;s business, results, financial
condition and liquidity.&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2015 CEL-SCI signed an arbitration funding agreement with a
company established by Lake Whillans Litigation Finance, LLC, a
firm specializing in funding litigation expenses. Pursuant to the
agreement, an affiliate of Lake Whillans provides CEL-SCI with up
to $5 million in funding for litigation expenses to support its
arbitration claims against inVentiv. The funding is available to
CEL-SCI to fund the expenses of the ongoing arbitration and will
only be repaid if CEL-SCI receives proceeds from the
arbitration.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
hearing (the &#x201C;trial&#x201D;) started on September 26, 2016 and
was originally scheduled to end in November/December of 2016. On
November 13, 2017, CEL-SCI announced that the last witness in the
arbitration hearing testified on November 8, 2017, and no further
witnesses or testimony are expected. With that final witness, the
testimony phase of the arbitration concluded. All that remains at
the trial level are closing statements and post-trial
submissions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Additionally,
CEL-SCI may also be the target of claims asserting violations of
securities fraud and derivative actions, or other litigation or
arbitration proceedings in the future. Any future litigation could
result in substantial costs and divert management&#x2019;s attention
and resources. These lawsuits or arbitration proceedings may result
in large judgments or settlements against CEL-SCI, any of which
could have a material adverse effect on its business, operating
results, financial condition and liquidity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Compliance with changing regulations concerning corporate
governance and public disclosure may result in additional
expenses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Changing
laws, regulations and standards relating to corporate governance
and public disclosure may create uncertainty regarding compliance
matters. New or changed laws, regulations and standards are subject
to varying interpretations in many cases. As a result, their
application in practice may evolve over time. CEL-SCI is committed
to maintaining high standards of corporate governance and public
disclosure. Complying with evolving interpretations of new or
changing legal requirements may cause CEL-SCI to incur higher costs
as CEL-SCI revises current practices, policies and procedures, and
may divert management time and attention from potential
revenue-generating activities to compliance matters. If the efforts
to comply with new or changed laws, regulations and standards
differ from the activities intended by regulatory or governing
bodies due to ambiguities related to practice, CEL-SCI&#x2019;s
reputation may also be harmed. Further, CEL-SCI&#x2019;s board
members, chief executive officer, and other executive officers
could face an increased risk of personal liability in connection
with the performance of their duties. As a result, CEL-SCI may have
difficulty attracting and retaining qualified board members and
executive officers, which could harm its business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI has not established a definite plan for the marketing of
Multikine, if approved.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
has not established a definitive plan for marketing nor has CEL-SCI
established a price structure for any of its product candidates, if
approved. However, CEL-SCI intends, if it is in a position to do
so, to sell Multikine itself in certain markets where it is
approved, and or to enter into written marketing agreements with
various third parties with established sales forces in such
markets.&#xA0;&#xA0;The sales forces in turn would, CEL-SCI
believes, focus on selling Multikine to targeted cancer centers,
physicians and clinics involved in the treatment of head and neck
cancer. CEL-SCI has already licensed future sales of Multikine, if
approved, to three companies: Teva Pharmaceuticals in Israel,
Turkey, Serbia and Croatia; Orient Europharma in Taiwan, Singapore,
Hong Kong, Malaysia, South Korea, the Philippines, Australia and
New Zealand; and Byron BioPharma, LLC in South
Africa.&#xA0;&#xA0;CEL-SCI believes that these companies will have
the resources to market Multikine appropriately in their respective
territories, if approved, but there is no guarantee that they
will.&#xA0;&#xA0;There is no assurance that CEL-SCI will be able to
find qualified third-party partners to market its products in other
areas, on terms that are favorable to CEL-SCI, or at
all.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
may encounter problems, delays and additional expenses in
developing marketing plans with third parties. In addition, even if
Multikine, if approved, is cost-effective and demonstrated to
increase overall patient survival, CEL-SCI may experience other
limitations involving the proposed sale of Multikine, such as
uncertainty of third-party coverage and reimbursement. There is no
assurance that CEL-SCI can successfully market Multikine, if
approved, or any other product candidates it may
develop.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI hopes to expand its clinical development capabilities in
the future, and any difficulties hiring or retaining key personnel
or managing this growth could disrupt its operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
is highly dependent on the principal members of its management and
development staff. If the Phase 3 Multikine clinical trial is
successful, CEL-SCI expects to expand its clinical development and
manufacturing capabilities, which will involve hiring additional
employees. Future growth will require CEL-SCI to continue to
implement and improve its managerial, operational and financial
systems and continue to retain, recruit and train additional
qualified personnel, which may impose a strain on its
administrative and its operational infrastructure. The competition
for qualified personnel in the biopharmaceutical field is intense.
CEL-SCI is highly dependent on its ability to attract, retain and
motivate highly qualified management and specialized personnel
required for clinical development. Due to limited resources,
CEL-SCI may not be able to manage effectively the expansion of its
operations or recruit and train additional qualified
personnel.&#xA0;&#xA0;If CEL-SCI is unable to retain key personnel
or manage its future growth effectively, CEL-SCI may not be able to
implement its business plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
If product liability or patient injury lawsuits are brought against
CEL-SCI, CEL-SCI may incur substantial liabilities and may be
required to limit clinical testing or future commercialization of
Multikine or its other product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
faces an inherent risk of product liability as a result of the
clinical testing of Multikine and other product candidates, and
will face an even greater risk if CEL-SCI commercializes any of its
product candidates. For example, CEL-SCI may be sued if its
Multikine or LEAPS product candidates, or any other future product
candidates, allegedly cause injury or are found to be otherwise
unsuitable during clinical testing, manufacturing or, if approved,
marketing or sale. Any such product liability claims may include
allegations of defects in manufacturing, defects in design, a
failure to warn of dangers inherent in the product candidate,
negligence, strict liability and a breach of warranties. Claims
could also be asserted under state consumer protection
acts.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Furthermore,
Multikine is made, in part, from components of human blood. There
are inherent risks associated with products that involve human
blood such as possible contamination with viruses, including
hepatitis or HIV. Any possible contamination could cause injuries
to patients who receive contaminated Multikine, or could require
CEL-SCI to destroy batches of Multikine, thereby subjecting CEL-SCI
to possible financial losses, lawsuits and harm to its
business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
CEL-SCI cannot successfully defend itself against product liability
claims, CEL-SCI may incur substantial liabilities or be required to
limit or cease the clinical testing or commercialization of its
product candidates, if approved. Even a successful defense would
require significant financial and management resources. Regardless
of the merits or eventual outcome, liability claims may result
in:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">decreased
demand for Multikine or other product candidates, if
approved;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">injury
to CEL-SCI&#x2019;s reputation;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">withdrawal
of existing, or failure to enroll additional, clinical trial
participants;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">21</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">costs
to defend any related litigation;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">a
diversion of management&#x2019;s time and resources;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">substantial
monetary awards to trial participants or patients;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">product
candidate recalls, withdrawals or labeling, marketing or
promotional restrictions;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">loss
of revenue;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">inability
to commercialize Multikine or other product candidates;
and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">a
decline in the price of CEL-SCI&#x2019;s common stock.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Although
CEL-SCI has product liability insurance for Multikine in the amount
of $5.0 million, the successful prosecution of a product liability
case against CEL-SCI could have a materially adverse effect upon
its business if the amount of any judgment exceeds the insurance
coverage. Any claim that may be brought against CEL-SCI could
result in a court judgment or settlement in an amount that is not
covered, in whole or in part, by CEL-SCI&#x2019;s insurance or that
is in excess of the limits of the insurance coverage.
CEL-SCI&#x2019;s insurance policies also have various exclusions,
and CEL-SCI may be subject to a claim for which CEL-SCI has no
coverage. CEL-SCI may have to pay any amounts awarded by a court or
negotiated in a settlement that exceed the coverage limitations or
that are not covered by its insurance, and CEL-SCI may not have, or
be able to obtain, sufficient capital to pay such
amounts.&#xA0;&#xA0;CEL-SCI commenced the Phase 3 clinical trial
for Multikine in December 2010. Although no claims have been
brought to date, participants in the clinical trials could bring
civil actions against CEL-SCI for any unanticipated harmful effects
allegedly arising from the use of Multikine or any other product
candidate that CEL-SCI may attempt to develop.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI&#x2019;s commercial success depends, in part, upon attaining
significant market acceptance of its product candidates, if
approved, among physicians, patients, healthcare payors and major
operators of cancer clinics.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Even
if CEL-SCI obtains regulatory approval for its product candidates,
any resulting product may not gain market acceptance among
physicians, healthcare payors, patients and the medical community,
which are critical to commercial success. Market acceptance of any
product candidate for which CEL-SCI receives approval depends on a
number of factors, including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
efficacy and safety as demonstrated in clinical
trials;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
timing of market introduction of such product candidate as well as
competitive products;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
clinical indications for which the drug is approved;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
approval, availability, market acceptance and reimbursement for the
companion diagnostic;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">acceptance
by physicians, major operators of cancer clinics and patients of
the drug as a safe and effective treatment;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
potential and perceived advantages of such product candidate over
alternative treatments, especially with respect to patient subsets
that are targeted with such product candidate;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">22</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
safety of such product candidate seen in a broader patient group,
including its use outside the approved indications;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
cost of treatment in relation to alternative
treatments;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
availability of adequate reimbursement and pricing by third-party
payors and government authorities;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">relative
convenience and ease of administration;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
prevalence and severity of adverse side effects; and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
effectiveness of sales and marketing efforts.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
CEL-SCI&#x2019;s product candidates are approved but fail to achieve
an adequate level of acceptance by physicians, healthcare payors
and patients, CEL-SCI will not be able to generate significant
revenues, and CEL-SCI may not become or remain
profitable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Our Independent Registered Public Accountants have included in
their report on our financial statements a paragraph stating that
we may be unable to continue as a going concern.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
a result of our recurring losses from operations, our independent
registered public accounting firm, BDO USA, LLP, has issued a
report in connection with their audit of our financial statements
for the year ended September 30, 2017, that included an explanatory
paragraph referring to our recurring losses from operations and
expressing substantial doubt in our ability to continue as a going
concern without additional capital becoming available. The doubt
about our ability to continue as a going concern could have an
adverse impact on our ability to execute our business plan, result
in the reluctance on the part of certain suppliers to do business
with us, or adversely affect our ability to raise additional debt
or equity capital.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Risks Related to Government Approvals</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI&#x2019;s product candidates must undergo rigorous
preclinical and clinical testing and regulatory approvals, which
could be costly and time-consuming and subject CEL-SCI to
unanticipated delays or prevent CEL-SCI from marketing any
products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
product candidates are subject to premarket approval from the FDA
in the United States, the EMA in the European Union, and by
comparable agencies in most foreign countries before they can be
sold. Before obtaining marketing approval, these product candidates
must undergo costly and time consuming preclinical and clinical
testing which could subject CEL-SCI to unanticipated delays and may
prevent CEL-SCI from marketing the product candidates. There can be
no assurance that such approvals will be granted on a timely basis,
if at all.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Clinical
testing is expensive and can take many years to complete, and its
outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. The results of preclinical
studies and early clinical trials of the product candidates may not
be predictive of the results of later-stage clinical trials. A
number of companies in the biopharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of
efficacy or adverse safety profiles, notwithstanding promising
results in earlier trials. CEL-SCI&#x2019;s current and future
clinical trials may not be successful.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">23</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Although
CEL-SCI is involved in Phase 1 and Phase 3 clinical trials for
Multikine, CEL-SCI may experience delays in the clinical trials and
CEL-SCI does not know whether the clinical trials will need to be
redesigned, enroll patients on a timely basis or be completed on
schedule, if at all. Clinical trials can be delayed for a variety
of reasons, including delays related to:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
availability of financial resources needed to commence and complete
the planned trials;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">obtaining
regulatory approval to commence a trial;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">reaching
agreement on acceptable terms with prospective contract research
organizations, or CROs, and clinical trial sites, the terms of
which can be subject to extensive negotiation and may vary
significantly among different CROs and trial sites;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">obtaining
Institutional Review Board, or IRB, approval at each clinical trial
site;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">recruiting
suitable patients to participate in a trial;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">having
patients complete a trial or return for post-treatment
follow-up;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">clinical
trial sites deviating from trial protocol or dropping out of a
trial;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">adding
new clinical trial sites; or</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">manufacturing
sufficient quantities of the product candidate for use in clinical
trials.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patient
enrollment, a significant factor in the timing of clinical trials,
is affected by many factors including the competence of the CRO
running the study, size and nature of the patient population, the
proximity of patients to clinical sites, the eligibility criteria
for the trial, the design of the clinical trial, competing clinical
trials and clinicians' and patients' perceptions as to the
potential advantages of the drug being studied in relation to other
available therapies, including any new drugs that may be approved
for the indications CEL-SCI is investigating. Furthermore, CEL-SCI
relies on CROs and clinical trial sites to ensure the proper and
timely conduct of the clinical trials and while CEL-SCI has
agreements governing their committed activities, CEL-SCI has
limited influence over their actual performance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
October 31, 2013, CEL-SCI commenced arbitration proceedings against
inVentiv Health Clinical, LLC, or inVentiv, its former clinical
research organization (CRO). The arbitration claim, initiated under
the Commercial Rules of the American Arbitration Association,
alleges (i) breach of contract, (ii) fraud in the inducement, and
(iii) common law fraud. Currently, CEL-SCI is seeking at least $50
million in damages in its amended statement of claim.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
connection with the pending arbitration proceedings, inVentiv has
asserted counterclaims against CEL-SCI for (i) breach of contract,
seeking at least $2 million in damages for services allegedly
performed by inVentiv; (ii) breach of contract, seeking at least $1
million in damages for CEL-SCI&#x2019;s alleged use of
inVentiv&#x2019;s name in connection with publications and
promotions in violation of the parties&#x2019; contract; (iii)
opportunistic breach, restitution and unjust enrichment, seeking at
least $20 million in disgorgement of alleged unjust profits
allegedly made by CEL-SCI as a result of the purported breaches
referenced in subsection (ii); and (iv) defamation, seeking at
least $1 million in damages for allegedly defamatory statements
made about inVentiv.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">24</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">It
remains possible that the regulatory authorities could determine
that the Phase 3 study is not sufficient to support a marketing
application in the United States. Under this circumstance, at least
one entirely new Phase 3 clinical trial would need to be conducted
to support a marketing application in the United States. If there
is a need to conduct an additional Phase 3 clinical trial, any such
requirement would have significant and severe material consequences
for CEL-SCI and could impact CEL-SCI&#x2019;s ability to continue as
a going concern.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">CEL-SCI could also encounter significant delays
and/or need to terminate a development program for a product
candidate if physicians encounter unresolved ethical issues
associated with enrolling patients in clinical trials of the
product candidates in addition to existing treatments that have
established safety and efficacy profiles. Further, a clinical trial
may be suspended or terminated by CEL-SCI, one or more of the IRBs
for the institutions in which such trials are being conducted, by
CEL-SCI upon a final recommendation by the Independent Data
Monitoring Committee, or IDMC, with which CEL-SCI agrees for such
trial, or by FDA or other regulatory authorities due to a number of
factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or the clinical protocols,
as a result of inspection of the clinical trial operations or trial
site(s) by FDA or other regulatory authorities, the imposition of a
clinical hold</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="color: #000000">or
partial clinical hold, unforeseen safety issues or adverse side
effects, failure to demonstrate a benefit from using a product
candidate, changes in governmental regulations or administrative
actions or lack of adequate funding to continue the clinical trial.
The occurrence of any one or more of these events would have
significant and severe material consequences for CEL-SCI and could
impact CEL-SCI&#x2019;s ability to continue as a going
concern.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
CEL-SCI experiences termination of, or delays in the completion of,
any clinical trial of its product candidates, the commercial
prospects for the product candidates will be harmed, and the
ability to generate product revenues will be delayed. In addition,
any delays in completing the clinical trials will increase the
costs, slow the product development and approval process and
jeopardize the ability to commence product sales and generate
revenues. Any of these occurrences may harm CEL-SCI&#x2019;s
business, prospects, financial condition and results of operations
significantly. Many of the factors that cause, or lead to, a delay
in the commencement or completion of clinical trials may also
ultimately lead to a delay or the denial of regulatory approval for
the product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
cannot be certain when or under what conditions it will undertake
future clinical trials.&#xA0;&#xA0;A variety of issues may delay
the Phase 3 clinical trial for Multikine. Early trials for the
other product candidates, or the plans for later trials, may not
satisfy the requirements of regulatory authorities, such as the
FDA. CEL-SCI may fail to find subjects willing to enroll in the
trials. CEL-SCI manufactures Multikine in its manufacturing
facility, but relies on third-party vendors to manage the trial
process and other activities, and these vendors may fail to meet
appropriate standards.&#xA0;&#xA0;Accordingly, the clinical trials
relating to the product candidates may not be completed on
schedule, the FDA or foreign regulatory agencies may order CEL-SCI
to stop or modify research, or these agencies may not ultimately
approve any of the product candidates for commercial sale. Varying
interpretations of the data obtained from pre-clinical and clinical
testing could delay, limit or prevent regulatory approval of the
product candidates. The data collected from the clinical trials may
not be sufficient to support regulatory approval of the various
product candidates, including Multikine. The failure to adequately
demonstrate the safety and efficacy of any of the product
candidates would delay or prevent regulatory approval of the
product candidates in the United States, which could prevent
CEL-SCI from achieving profitability. Although CEL-SCI had positive
results in the Phase 2 trials for Multikine, those results were for
a very small sample set, and CEL-SCI will not know how Multikine
will perform in a larger set of subjects until CEL-SCI is well
into, or completes, the Phase 3 clinical trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">25</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
development and testing of product candidates and the process of
obtaining regulatory approvals and the subsequent compliance with
appropriate federal, state, local and foreign statutes and
regulations require the expenditure of substantial time and
financial resources.&#xA0;&#xA0;Failure to comply with the
applicable U.S. requirements at any time during the product
development process, approval process or after approval, may
subject an applicant to administrative or judicial sanctions. FDA
sanctions could include, among other actions, refusal to approve
pending applications, withdrawal of an approval, a clinical hold,
termination of the Phase 3 study, warning letters, product recalls
or withdrawals from the market, product seizures, total or partial
suspension of production or distribution, injunctions, fines,
refusals of government contracts, restitution, disgorgement or
civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on
CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
requirements governing the conduct of clinical trials,
manufacturing and marketing of the product candidates, including
Multikine, outside the United States vary from country to country.
Foreign approvals may take longer to obtain than FDA approvals and
can require, among other things, additional testing and different
trial designs. Foreign regulatory approval processes include all of
the risks associated with the FDA approval process. Some of those
agencies also must approve prices for products approved for
marketing. Approval of a product by the FDA or the EMA does not
ensure approval of the same product by the health authorities of
other countries. In addition, changes in regulatory requirements
for product approval in any country during the clinical trial
process and regulatory agency review of each submitted new
application may cause delays or rejections.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
has only limited experience in filing and pursuing applications
necessary to gain regulatory approvals.&#xA0;&#xA0;The lack of
experience may impede its ability to obtain timely approvals from
regulatory agencies, if at all. CEL-SCI will not be able to
commercialize Multikine and other product candidates until CEL-SCI
has obtained regulatory approval.&#xA0;&#xA0;In addition,
regulatory authorities may also limit the types of patients to
which CEL-SCI or its third-party partners may market Multikine or
the other product candidates. Any failure to obtain or any delay in
obtaining required regulatory approvals may adversely affect
CEL-SCI&#x2019;s or its third-party partners&#x2019; ability to
successfully market the product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Even if CEL-SCI obtains regulatory approval for its investigational
products, CEL-SCI will be subject to stringent, ongoing government
regulation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
CEL-SCI&#x2019;s investigational products receive regulatory
approval, either in the United States or internationally, those
products will be subject to limitations on the approved indicated
uses for which the product may be marketed or to the conditions of
approval, and may contain requirements for potentially costly
post-marketing testing, including Phase&#xA0;4 clinical trials, and
surveillance of the safety and efficacy of the investigational
products.&#xA0;&#xA0;CEL-SCI will continue to be subject to
extensive regulatory requirements. These regulations are
wide-ranging and govern, among other things:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">product
design, development and manufacture;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">product
application and use</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">adverse
drug experience;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">product
advertising and promotion;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">26</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">product
manufacturing, including good manufacturing practices</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">record
keeping requirements;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">registration
and listing of the establishments and products with the FDA, EMA
and other state and national agencies;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">product
storage and shipping;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">drug
sampling and distribution requirements;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">electronic
record and signature requirements; and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">labeling
changes or modifications.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
and any of its third-party manufacturers or suppliers must
continually adhere to federal regulations setting forth
requirements, known as current Good Manufacturing Practices, or
cGMPs, and their foreign equivalents, which are enforced by the
FDA, the EMA and other national regulatory bodies through their
facilities inspection programs. If the facilities, or the
facilities of the contract manufacturers or suppliers, cannot pass
a pre-approval plant inspection or fail such inspections in the
future, the FDA, EMA or other national regulators will not approve
the marketing applications for the product candidates, or may
withdraw any prior approval. In complying with cGMP and foreign
regulatory requirements, CEL-SCI and any of its potential
third-party manufacturers or suppliers will be obligated to expend
time, money and effort in production, record-keeping and quality
control to ensure that the product candidates meet applicable
specifications and other requirements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
CEL-SCI does not comply with regulatory requirements at any stage,
whether before or after marketing approval is obtained, CEL-SCI may
be subject to, among other things, license suspension or
revocation, criminal prosecution, seizure, injunction, fines, be
forced to remove a product from the market or experience other
adverse consequences, including restrictions or delays in obtaining
regulatory marketing approval for such products or for other
product candidates for which CEL-SCI seeks
approval.&#xA0;&#xA0;This could materially harm CEL-SCI&#x2019;s
financial results, reputation and stock price. Additionally,
CEL-SCI may not be able to obtain the labeling claims necessary or
desirable for product promotion. If CEL-SCI or other parties
identify adverse effects after any of the products are on the
market, or if manufacturing problems occur, regulatory approval may
be suspended or withdrawn. CEL-SCI may be required to reformulate
products, conduct additional clinical trials, make changes in
product labeling or indications of use, or submit additional
marketing applications to support any changes.&#xA0;&#xA0;If
CEL-SCI encounters any of the foregoing problems, its business and
results of operations will be harmed and the market price of its
common stock may decline.<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
FDA and other governmental authorities&#x2019; policies may change
and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of CEL-SCI&#x2019;s
product candidates. If CEL-SCI is slow or unable to adapt to
changes in existing requirements or the adoption of new
requirements or policies, or if CEL-SCI is not able to maintain
regulatory compliance, CEL-SCI may lose any marketing approval that
it may have obtained, which would adversely affect its business,
prospects and ability to achieve or sustain
profitability.&#xA0;&#xA0;CEL-SCI cannot predict the extent of
adverse government regulations which might arise from future
legislative or administrative action. Without government approval,
CEL-SCI will be unable to sell any of its product
candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">27</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI&#x2019;s product candidates may cause undesirable side
effects or have other properties that could delay or prevent their
regulatory approval, limit the commercial profile of an approved
label, or result in significant negative consequences following
marketing approval, if any.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Undesirable
side effects caused by its product candidates could cause CEL-SCI
or regulatory authorities to interrupt, delay or halt clinical
trials and could result in a more restrictive label or the delay or
denial of regulatory approval by the FDA or other comparable
foreign authorities. Results of the clinical trials could reveal a
high and unacceptable severity and/or prevalence of these or other
side effects. In such an event, the trials could be suspended or
terminated and the FDA or comparable foreign regulatory authorities
could order CEL-SCI to cease further development of, or deny
approval of, the product candidates for any or all targeted
indications. The drug-related side effects could affect patient
recruitment or the ability of enrolled patients to complete the
trial or result in potential product liability claims. Any of these
occurrences may harm CEL-SCI&#x2019;s business, financial condition
and prospects significantly.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Additionally,
if one or more of the product candidates receives marketing
approval, and CEL-SCI or others later identify undesirable side
effects caused by such products, a number of potentially
significant negative consequences could result,
including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">regulatory
authorities may withdraw approvals of such product;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">regulatory
authorities may require additional warnings on the
label;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
may be required to create a medication guide outlining the risks of
such side effects for distribution to patients;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
could be sued and held liable for harm caused to patients;
and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
reputation may suffer.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Any
of these events could prevent CEL-SCI from achieving or maintaining
market acceptance of a particular product candidate, if approved,
and could significantly harm its business, results of operations
and prospects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">28</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI relies on third parties to conduct its preclinical and
clinical trials. If these third parties do not successfully carry
out their contractual duties and meet regulatory requirements, or
meet expected deadlines, CEL-SCI may not be able to obtain
regulatory approval for or commercialize the product candidates and
its business could be substantially harmed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
has relied upon and plans to continue to rely upon third-party CROs
to prepare for, conduct, monitor and manage data for its ongoing
preclinical and clinical programs. CEL-SCI relies on these parties
for all aspects of the execution of its preclinical studies and
clinical trials, and although CEL-SCI diligently oversees and
carefully manages the CROs, CEL-SCI directly controls only certain
aspects of their activities and relies upon them to provide timely,
complete, and accurate reports on the conduct of the studies.
Although such third parties provide support and represent CEL-SCI
for regulatory purposes in the context of the clinical trials,
ultimately CEL-SCI is responsible for ensuring that each of the
studies is conducted in accordance with the applicable protocol,
legal, regulatory, and scientific standards, and the reliance on
the CROs does not relieve CEL-SCI of its regulatory
responsibilities. CEL-SCI and the CROs acting on CEL-SCI&#x2019;s
behalf, as well as principal investigators and trial sites, are
required to comply with Good Clinical Practice, or GCP, and other
applicable requirements, which are implemented through regulations
and guidelines enforced by the FDA, the Competent Authorities of
the Member States of the European Economic Area, or EEA, and
comparable foreign regulatory authorities for all of the products
in clinical development. Regulatory authorities enforce these GCPs
through periodic inspections of trial sponsors, principal
investigators, and trial sites. If CEL-SCI or any of the CROs fail
to comply with applicable GCPs or other applicable regulations, the
clinical data generated in the clinical trials may be determined to
be unreliable and CEL-SCI may therefore need to enroll additional
subjects in the clinical trials, or the FDA, EMA or comparable
foreign regulatory authorities may require CEL-SCI to perform an
additional clinical trial or trials before approving the marketing
applications. Moreover, if CEL-SCI or any of the CROs, principal
investigators, or trial sites, fail to comply with applicable
regulatory and GCP requirements, CEL-SCI, the CROs, principal
investigators, or trial sites may be subject to enforcement
actions, such as fines, warning letters, untitled letters, clinical
holds, civil or criminal penalties, and/or injunctions. CEL-SCI
cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of the
clinical trials comply with GCP regulations. In addition, the
clinical trials must be conducted with product produced under GMP
regulations. The failure to comply with these regulations may
require CEL-SCI to delay or repeat clinical trials, which would
delay the regulatory approval process.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">For
example, CEL-SCI is currently involved in a dispute with the former
CRO relating to the conduct of the Phase 3 study where CEL-SCI
alleges (i) breach of contract, (ii) fraud in the inducement and
(iii) fraud. In connection with this dispute, CEL-SCI has alleged
that the CRO failed to properly select, monitor and supervise the
study sites and principal investigators, ensure proper enrollment
of subjects, and ensure strict compliance with the Phase 3 trial
protocol and GCP and other applicable regulatory
requirements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">29</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
any of the relationships with the third-party CROs terminate,
CEL-SCI may not be able to enter into arrangements with alternative
CROs or to do so on commercially reasonable terms. In addition, the
CROs are not CEL-SCI&#x2019;s employees, and except for remedies
available to CEL-SCI under the agreements with such CROs, CEL-SCI
cannot control whether or not they devote sufficient time and
resources to the on-going clinical, nonclinical and preclinical
programs. If CROs do not successfully fulfill their regulatory
obligations, carry out their contractual duties or obligations or
meet expected deadlines, if they need to be replaced or if the
quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to the clinical protocols, regulatory
requirements or for other reasons, the clinical trials may be
extended, delayed or terminated, and CEL-SCI may not be able to
obtain regulatory approval for or successfully commercialize the
product candidates. As a result, CEL-SCI&#x2019;s results of
operations and the commercial prospects for the product candidates
would be harmed, the costs could increase and the ability to
generate revenues could be delayed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Switching
or adding additional CROs involves additional cost and requires
management time and focus. In addition, there is a natural
transition period when a new CRO commences work. As a result,
delays may occur, which can materially impact CEL-SCI&#x2019;s
ability to meet the desired clinical development timelines. Though
CEL-SCI diligently oversees and carefully manages its relationships
with the CROs, there can be no assurance that CEL-SCI will not
encounter similar challenges or delays in clinical development in
the future or that these delays or challenges will not have a
material adverse impact on CEL-SCI&#x2019;s business, financial
condition and prospects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI has obtained orphan drug designation from the FDA for
Multikine for neoadjuvant, or primary, therapy in patients with
squamous cell carcinoma of the head and neck, but CEL-SCI may be
unable to maintain the benefits associated with orphan drug
designation, including the potential for market
exclusivity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a
drug or biologic intended to treat a rare disease or condition,
which is defined as one occurring in a patient population of fewer
than 200,000 in the United States, or a patient population greater
than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug or biologic will
be recovered from sales in the United States. In the United States,
orphan drug designation entitles a party to financial incentives
such as opportunities for grant funding towards clinical trial
costs, tax advantages and user-fee waivers. In addition, if a
product that has orphan drug designation subsequently receives the
first FDA approval for the disease for which it has such
designation, the product is entitled to orphan drug exclusivity,
which means that the FDA may not approve any other applications,
including a full Biologics License Application, or BLA, to market
the same biologic for the same indication for seven years, except
in limited circumstances, such as a showing of clinical superiority
to the product with orphan drug exclusivity or where the
manufacturer is unable to assure sufficient product
quantity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">30</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Even
though CEL-SCI has received orphan drug designation for Multikine
for the treatment of squamous cell carcinoma of the head and neck,
CEL-SCI may not be the first to obtain marketing approval of a
product for the orphan-designated indication due to the
uncertainties associated with developing pharmaceutical products.
In addition, exclusive marketing rights in the United States may be
limited if CEL-SCI seeks approval for an indication broader than
the orphan-designated indication, or may be lost if the FDA later
determines that the request for designation was materially
defective or if CEL-SCI is unable to assure sufficient quantities
of the product to meet the needs of patients with the rare disease
or condition. Further, even if CEL-SCI obtains orphan drug
exclusivity for a product candidate, that exclusivity may not
effectively protect the product candidate from competition because
different drugs with different active moieties can be approved for
the same condition. Even after an orphan product is approved, the
FDA can subsequently approve another drug with the same active
moiety for the same condition if the FDA concludes that the later
drug is safer, more effective, or makes a major contribution to
patient care. Orphan drug designation neither shortens the
development time or regulatory review time of a drug nor gives the
drug any advantage in the regulatory review or approval
process.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
The current and future relationships with healthcare professionals,
principal investigators, consultants, potential customers and
third-party payors in the United States and elsewhere may be
subject, directly or indirectly, to applicable healthcare laws and
regulations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Healthcare
providers, physicians and third-party payors in the United States
and elsewhere will play a primary role in the recommendation and
prescription of any drug candidates for which CEL-SCI obtains
marketing approval. The current and future arrangements with
healthcare professionals, principal investigators, consultants,
potential customers and third-party payors may expose CEL-SCI to
broadly applicable healthcare laws, including, without
limitation:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
federal Anti-Kickback Statute, which prohibits, among other things,
persons from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in
cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, lease, order or
recommendation of, any good, facility, item or service, for which
payment may be made, in whole or in part, under federal and state
healthcare programs such as Medicare and Medicaid. A person or
entity does not need to have actual knowledge of the statute or
specific intent to violate it to have committed a violation. In
addition, the Affordable Care Act provides that the government may
assert that a claim including items or services resulting from a
violation of the federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the False Claims
Act;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">federal
civil and criminal false claims laws, including the federal False
Claims Act, which impose criminal and civil penalties, including
civil whistleblower actions, against individuals or entities for,
among other things, knowingly presenting, or causing to be
presented, to the federal government, including the Medicare and
Medicaid programs, claims for payment that are false or fraudulent
or making a false statement to avoid, decrease or conceal an
obligation to pay money to the federal government;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">31</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
civil monetary penalties statute, which imposes penalties against
any person or entity who, among other things, is determined to have
presented or caused to be presented a claim to a federal health
program that the person knows or should know is for an item or
service that was not provided as claimed or is false or
fraudulent;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
federal Health Insurance Portability and Accountability Act of
1996, or HIPAA, which created new federal criminal statutes that
prohibit knowingly and willfully executing, or attempting to
execute, a scheme to defraud any healthcare benefit program or
obtain, by means of false or fraudulent pretenses, representations
or promises, any of the money or property owned by, or under the
custody or control of, any healthcare benefit program, regardless
of the payor (e.g., public or private), knowingly and willfully
embezzling or stealing from a health care benefit program,
willfully obstructing a criminal investigation of a healthcare
offense and knowingly and willfully falsifying, concealing or
covering up by any trick or device a material fact or making any
materially false statements in connection with the delivery of, or
payment for, healthcare benefits, items or services relating to
healthcare matters. A person or entity does not need to have actual
knowledge of the statute or specific intent to violate it to have
committed a violation;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">HIPAA,
as amended by the Health Information Technology for Economic and
Clinical Health Act of 2009, or HITECH, and their respective
implementing regulations, which impose obligations on covered
entities, including healthcare providers, health plans, and
healthcare clearinghouses, as well as their respective business
associates that create, receive, maintain or transmit individually
identifiable health information for or on behalf of a covered
entity, with respect to safeguarding the privacy, security and
transmission of individually identifiable health
information;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
federal Physician Payments Sunshine Act and its implementing
regulations, which imposed annual reporting requirements for
certain manufacturers of drugs, devices, biologicals and medical
supplies for payments and &#x201C;transfers of value&#x201D; provided
to physicians and teaching hospitals, as well as ownership and
investment interests held by physicians and their immediate family
members; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">analogous
state and foreign laws, such as state anti-kickback and false
claims laws, which may apply to sales or marketing arrangements and
claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers;
state laws that require pharmaceutical companies to comply with the
pharmaceutical industry&#x2019;s voluntary compliance guidelines and
the relevant compliance guidance promulgated by the federal
government or otherwise restrict payments that may be made to
healthcare providers; state and foreign laws that require drug
manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers or
marketing expenditures; and state and foreign laws governing the
privacy and security of health information in certain
circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating
compliance efforts.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">32</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Efforts
to ensure that the future business arrangements with third parties
will comply with applicable healthcare laws and regulations may
involve substantial costs. It is possible that governmental
authorities will conclude that the business practices may not
comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws. If
CEL-SCI&#x2019;s operations are found to be in violation of any of
these laws or any other governmental regulations, CEL-SCI may be
subject to significant civil, criminal and administrative
penalties, including, without limitation, damages, fines,
imprisonment, exclusion from participation in government healthcare
programs, such as Medicare and Medicaid, and the curtailment or
restructuring of the operations, all of which could significantly
harm CEL-SCI&#x2019;s business. If any of the physicians or other
healthcare providers or entities with whom CEL-SCI expects to do
business, including current and future collaborators, are found not
to be in compliance with applicable laws, they may be subject to
criminal, civil or administrative sanctions, including exclusions
from participation in government healthcare programs, which could
also adversely affect CEL-SCI&#x2019;s business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Failure to obtain or maintain adequate coverage and reimbursement
for the product candidates, if approved, could limit the ability to
market those products and decrease CEL-SCI&#x2019;s ability to
generate revenue.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Sales
of CEL-SCI&#x2019;s product candidates will depend substantially,
both domestically and abroad, on the extent to which the costs of
the product candidates will be paid by health maintenance, managed
care, pharmacy benefit, and similar healthcare management
organizations, or reimbursed by government authorities, private
health insurers and other third-party payors. CEL-SCI anticipates
that government authorities and other third-party payors will
continue efforts to contain healthcare costs by limiting the
coverage and reimbursement levels for new drugs. If coverage and
reimbursement are not available, or are available only to limited
levels, CEL-SCI may not be able to successfully commercialize its
product candidates. Even if coverage is provided, the approved
reimbursement amount may not be high enough to allow CEL-SCI to
establish or maintain pricing sufficient to realize a return on its
investment. It is difficult to predict at this time what
third-party payors will decide with respect to the coverage and
reimbursement for CEL-SCI&#x2019;s product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Healthcare legislative reform measures may have a material adverse
effect on CEL-SCI&#x2019;s business and results of
operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
the United States, there have been and continue to be a number of
legislative initiatives to contain healthcare costs that may result
in more limited coverage or downward pressure on the price CEL-SCI
may otherwise receive for its product candidates. For example, in
March 2010, the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act, or
collectively, the Affordable Care Act, was passed, which
substantially changes the way health care is financed by both
governmental and private insurers, and significantly impacts the
U.S. pharmaceutical industry. The Affordable Care Act, among other
things, addressed a new methodology by which rebates owed by
manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or
injected, increased the minimum Medicaid rebates owed by
manufacturers under the Medicaid Drug Rebate Program and extended
the rebate program to individuals enrolled in Medicaid managed care
organizations, established annual fees and taxes on manufacturers
of certain branded prescription drugs, and established the Center
for Medicare and Medicaid Innovation with broad authority to test
and implement new payment models under Medicare and Medicaid, which
are designed to reduce expenditures while preserving and enhancing
quality of care.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">33</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
addition, other legislative changes have been proposed and adopted
in the United States since the Affordable Care Act was enacted. On
August 2, 2011, the Budget Control Act of 2011 among other things,
created measures for spending reductions by Congress. A Joint
Select Committee on Deficit Reduction, tasked with recommending a
targeted deficit reduction of at least $1.2 trillion for the years
2013 through 2021, was unable to reach required goals, thereby
triggering the legislation's automatic reduction to several
government programs. This includes aggregate reductions of Medicare
payments to providers of 2% per fiscal year, which went into effect
in April 2013 and, due to subsequent legislative amendments to the
statute, will remain in effect through 2024 unless additional
Congressional action is taken. On January 2, 2013, former President
Obama signed into law the American Taxpayer Relief Act of 2012,
which, among other things, further reduced Medicare payments to
several providers, including hospitals, imaging centers and cancer
treatment centers. On April 16, 2015, former President Obama signed
into law the Medicare Access and CHIP Reauthorization Act of 2015,
or MACRA. Among other things, MACRA creates incentives for
physicians to participate in alternative payment models under
Medicare that emphasize quality and value in place of the
traditional, volume-based fee-for-service program. CEL-SCI expects
that additional state and federal healthcare reform measures will
be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and
services, which could result in reduced demand for its product
candidates or additional pricing pressures.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Foreign governments often impose strict price controls, which may
adversely affect CEL-SCI&#x2019;s future profitability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
intends to seek approval to market Multikine in both the United
States and foreign jurisdictions. If CEL-SCI obtains approval in
one or more foreign jurisdictions, CEL-SCI will be subject to rules
and regulations in those jurisdictions relating to Multikine. In
some foreign countries, particularly in the European Union,
prescription drug pricing is subject to governmental control. In
these countries, pricing negotiations with governmental authorities
can take considerable time after the receipt of marketing approval
for a drug candidate. Coverage and reimbursement decisions in one
foreign jurisdiction may impact decisions in other countries. To
obtain reimbursement or pricing approval in some countries, CEL-SCI
may be required to conduct clinical trials that demonstrate the
product candidate is more effective than current treatments and
that compare the cost-effectiveness of Multikine to other available
therapies. If reimbursement of Multikine is unavailable or limited
in scope or amount, or if pricing is set at unsatisfactory levels,
CEL-SCI may be unable to achieve or sustain
profitability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Risks Related to Intellectual Property</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI may not be able to achieve or maintain a competitive
position, and other technological developments may result in its
proprietary technologies becoming uneconomical or
obsolete.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
is involved in a biomedical field that is undergoing rapid and
significant technological change. The pace of change continues to
accelerate.&#xA0;&#xA0;The successful development of product
candidates from the compounds, compositions and processes, through
research financed by CEL-SCI, or as a result of possible
third-party licensing arrangements with pharmaceutical or other
companies, is not assured.&#xA0;&#xA0;CEL-SCI may fail to apply for
patents on important technologies or product candidates in a timely
fashion, or at all.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">34</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Many
companies are working on drugs designed to cure or treat cancer or
cure and treat viruses, such as HPV or H1N1.&#xA0;&#xA0;Many of
these companies have financial, research and development, and
marketing resources, which are much greater than CEL-SCI&#x2019;s,
and are capable of providing significant long-term competition
either by establishing in-house research groups or by forming
collaborative ventures with other entities. In addition, smaller
companies and non-profit institutions are active in research
relating to cancer and infectious diseases.&#xA0;&#xA0;The future
market share of Multikine or the other product candidates, if
approved, will be reduced or eliminated if the competitors develop
and obtain approval for products that are safer or more effective
than CEL-SCI&#x2019;S product candidates.&#xA0;&#xA0;Moreover, the
patent positions of pharmaceutical companies are highly uncertain
and involve complex legal and factual questions for which important
legal principles are often evolving and remain unresolved. As a
result, the validity and enforceability of patents cannot be
predicted with certainty. In addition, CEL-SCI does not know
whether:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
was the first to make the inventions covered by each of its issued
patents and pending patent applications;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
was the first to file patent applications for these
inventions;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">others
will independently develop similar or alternative technologies or
duplicate any of the technologies;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">any
of the pending patent applications will result in issued
patents;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">any
of the patents will be valid or enforceable;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">any
patents issued to CEL-SCI or the collaboration partners will
provide CEL-SCI with any competitive advantages, or will be
challenged by third parties;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
will be able to develop additional proprietary technologies that
are patentable;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
U.S. government will exercise any of its statutory rights to
CEL-SCI&#x2019;s intellectual property that was developed with
government funding; or</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">its
business may infringe the patents or other proprietary rights of
others.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI&#x2019;s patents might not protect its technology from
competitors, in which case CEL-SCI may not have any advantage over
competitors in selling any products that CEL-SCI may
develop.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
commercial success will depend in part on its ability to obtain
additional patents and protect its existing patent position, as
well as its ability to maintain adequate intellectual property
protection for the technologies, product candidates, and any future
products in the United States and other countries. If CEL-SCI does
not adequately protect its technology, product candidates and
future products, competitors may be able to use or practice them
and erode or negate any competitive advantage CEL-SCI may have,
which could harm CEL-SCI&#x2019;s business and its ability to
achieve profitability. The laws of some foreign countries do not
protect the proprietary rights to the same extent or in the same
manner as U.S. laws, and CEL-SCI may encounter significant problems
in protecting and defending its proprietary rights in these
countries. CEL-SCI will be able to protect its proprietary rights
from unauthorized use by third parties only to the extent that its
proprietary technologies, product candidates and any future
products are covered by valid and enforceable patents or are
effectively maintained as trade secrets.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">35</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Certain
aspects of CEL-SCI&#x2019;s technologies are covered by U.S. and
foreign patents. In addition, CEL-SCI has a number of new patent
applications pending. There is no assurance that the applications
still pending or which may be filed in the future will result in
the issuance of any patents. Furthermore, there is no assurance as
to the breadth and degree of protection any issued patents might
afford CEL-SCI. Disputes may arise between CEL-SCI and others as to
the scope and validity of these or other patents. Any defense of
the patents could prove costly and time consuming and there can be
no assurance that CEL-SCI will be in a position, or will deem it
advisable, to carry on such a defense.&#xA0;&#xA0;A suit for patent
infringement could result in increasing costs, delaying or halting
development, or even forcing CEL-SCI to abandon a product
candidate.&#xA0;&#xA0;Other private and public concerns, including
universities, may have filed applications for, may have been
issued, or may obtain additional patents and other proprietary
rights to technology potentially useful or necessary to CEL-SCI.
CEL-SCI is not currently aware of any such patents, but the scope
and validity of such patents, if any, and the cost and availability
of such rights are impossible to predict.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Much of CEL-SCI&#x2019;s intellectual property is protected as trade
secrets or confidential know-how, not as a patent.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
considers proprietary trade secrets and/or confidential know-how
and unpatented know-how to be important to its
business.&#xA0;&#xA0;Much of the intellectual property pertains to
CEL-SCI&#x2019;S manufacturing system, certain aspects of which may
not be suitable for patent filings and must be protected as trade
secrets and/or confidential know-how.&#xA0;&#xA0;This type of
information must be protected diligently by CEL-SCI to protect its
disclosure to competitors, since legal protections after disclosure
may be minimal or non-existent.&#xA0;&#xA0;Accordingly, much of the
value of this intellectual property is dependent upon the ability
of CEL-SCI to keep its trade secrets and know-how
confidential.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">To
protect this type of information against disclosure or
appropriation by competitors, CEL-SCI&#x2019;s policy is to require
its employees, consultants, contractors and advisors to enter into
confidentiality agreements with CEL-SCI. However, current or former
employees, consultants, contractors and advisers may
unintentionally or willfully disclose the confidential information
to competitors, and confidentiality agreements may not provide an
adequate remedy in the event of unauthorized disclosure of
confidential information. Enforcing a claim that a third party
obtained illegally, and is using, trade secrets and/or confidential
know-how is expensive, time consuming and unpredictable. The
enforceability of confidentiality agreements may vary from
jurisdiction to jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
addition, in some cases a regulator considering the application for
product candidate approval may require the disclosure of some or
all of the proprietary information.&#xA0;&#xA0;In such a case,
CEL-SCI must decide whether to disclose the information or forego
approval in a particular country.&#xA0;&#xA0;If CEL-SCI is unable
to market its product candidates in key countries, CEL-SCI&#x2019;s
opportunities and value may suffer.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Failure
to obtain or maintain trade secrets and/or confidential know-how
trade protection could adversely affect CEL-SCI&#x2019;S competitive
position. Moreover, competitors may independently develop
substantially equivalent proprietary information and may even apply
for patent protection in respect of the same. If successful in
obtaining such patent protection, competitors could limit the use
of such trade secrets and/or confidential know-how.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">36</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI may be subject to claims challenging the inventorship or
ownership of its patents and other intellectual
property.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
may also be subject to claims that former employees, collaborators
or other third parties have an ownership interest in its patents or
other intellectual property. CEL-SCI may be subject to ownership
disputes in the future arising, for example, from conflicting
obligations of consultants or others who are involved in developing
the product candidates. Litigation may be necessary to defend
against these and other claims challenging inventorship or
ownership. If CEL-SCI fails in defending any such claims, in
addition to paying monetary damages, CEL-SCI may lose valuable
intellectual property rights, such as exclusive ownership of, or
right to use, valuable intellectual property. Such an outcome could
have a material adverse effect on its business. Even if CEL-SCI is
successful in defending against such claims, litigation could
result in substantial costs and be a distraction to CEL-SCI&#x2019;s
management and employees.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Risks Related to CEL-SCI&#x2019;s common stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
You may experience future dilution as a result of future equity
offerings or other equity issuances.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
expects that significant additional capital will be needed in the
future to continue its planned operations. To raise additional
capital, CEL-SCI may in the future offer additional shares of its
common stock or other securities convertible into or exchangeable
for its common stock.&#xA0;&#xA0;&#xA0;&#xA0;To the extent CEL-SCI
raises additional capital by issuing equity securities,
CEL-SCI&#x2019;s stockholders may experience substantial dilution.
These sales may result in material dilution to CEL-SCI&#x2019;s
existing stockholders and new investors could gain rights superior
to existing stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI&#x2019;s outstanding options, warrants and convertible notes
may adversely affect the trading price of its common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
of September 30, 2017, there were outstanding warrants, convertible
notes and options which allow the holders to purchase 11,558,444
shares of common stock that may be issued upon the exercise of
outstanding warrants, with a weighted average exercise price of
$8.40 per share, 1,166,106 shares that may be issued upon the
conversion of outstanding notes, with a weighted average conversion
price of $1.97 per share and 1,239,844 shares that may be issued
upon the exercise of outstanding options, with a weighted average
exercise price of $16.44 per share. The outstanding options, notes
and warrants could adversely affect the ability of CEL-SCI to
obtain future financing or engage in certain mergers or other
transactions, since the holders of options and warrants can be
expected to exercise them at a time when CEL-SCI may be able to
obtain additional capital through a new offering of securities on
terms more favorable to CEL-SCI than the terms of the outstanding
options and warrants.&#xA0; For the life of the options, notes and
warrants, the holders have the opportunity to profit from a rise in
the market price of its common stock without assuming the risk of
ownership.&#xA0; The issuance of shares upon the exercise or
conversion of outstanding options, notes and warrants will also
dilute the ownership interests of CEL-SCI&#x2019;s existing
stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">37</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI&#x2019;s ability to utilize its net operating loss
carryforwards and certain other tax attributes may be
limited.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Under Section 382 of the Internal Revenue Code of
1986, as amended, if a corporation undergoes an &#x201C;ownership
change&#x201D; (generally defined as a greater than 50% change (by
value) in its equity ownership over a three-year period), the
corporation&#x2019;s ability to use its pre-change net operating
loss carryforwards and other pre-change tax attributes to offset
its post-change income may be limited. As a result of public
offerings and other transactions, CEL-SCI may experience ownership
changes in the future based on subsequent shifts in CEL-SCI&#x2019;s
stock ownership, some of which are outside its control. As a
result, the ability to use the pre-change net operating loss
carryforwards and other pre-change tax attributes to offset U.S.
federal taxable income may be subject to limitations, which could
result in increased tax liability to CEL-SCI</font><font style="font-weight: bold; color: #000000">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Since CEL-SCI does not intend to pay dividends on its common stock,
any potential return to investors will result only from any
increases in the price of its common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 48px; margin-right: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">At
the present time, CEL-SCI intends to use available funds to finance
its operations. Accordingly, while payment of dividends rests
within the discretion of its board of directors, no common stock
dividends have been declared or paid by CEL-SCI and CEL-SCI has no
intention of paying any common stock dividends in the foreseeable
future. Additionally, any future debt financing arrangement may
contain terms prohibiting or limiting the amount of dividends that
may be declared or paid on CEL-SCI&#x2019;s common
stock.&#xA0;&#xA0;Any return to CEL-SCI&#x2019;s shareholders will
therefore be limited to appreciation in the price of its common
stock, which may never occur.&#xA0;&#xA0;If CEL-SCI&#x2019;s stock
price does not increase, CEL-SCI&#x2019;S shareholders are unlikely
to receive any return on their investments in CEL-SCI&#x2019;s
common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
The price of CEL-SCI&#x2019;s common stock has been volatile and is
likely to continue to be volatile, which could result in
substantial losses for CEL-SCI&#x2019;s shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
stock price has been, and is likely to continue to be, volatile. As
a result of this volatility, CEL-SCI&#x2019;s shareholders may not
be able to sell their shares at or above its current market price.
The market price for CEL-SCI&#x2019;s common stock may be influenced
by many factors, including:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">actual
or anticipated fluctuations in CEL-SCI&#x2019;s financial condition
and operating results;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">actual
or anticipated changes in CEL-SCI&#x2019;s growth rate relative to
competitors;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">competition
from existing products or new products or product candidates that
may emerge;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">development
of new technologies that may make CEL-SCI&#x2019;s technology less
attractive;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">changes
in physician, hospital or healthcare provider practices that may
make CEL-SCI&#x2019;s product candidates less useful;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">announcements
by CEL-SCI, its partners or competitors of significant
acquisitions, strategic partnerships, joint ventures,
collaborations or capital commitments;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">developments
or disputes concerning patent applications, issued patents or other
proprietary rights;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">38</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
recruitment or departure of key personnel;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">failure
to meet or exceed financial estimates and projections of the
investment community or that CEL-SCI provides to the
public;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">actual
or anticipated changes in estimates as to financial results,
development timelines or recommendations by securities
analysts;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">variations
in its financial results or those of companies that are perceived
to be similar to CEL-SCI;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">changes
to coverage and reimbursement levels by commercial third-party
payors and government payors, including Medicare, and any
announcements relating to reimbursement levels;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">general
economic, industry and market conditions; and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
other factors described in this &#x201C;Risk Factors&#x201D;
section.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI has been advised that it is not in compliance with certain
continued listing standards of the NYSE American.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 9, 2016, CEL-SCI received a letter from the NYSE American,
its current listing exchange, which advised CEL-SCI that, based
upon its quarterly report for the quarter ended June 30, 2016,
CEL-SCI was noncompliant with certain continued listing standards
of the NYSE American. CEL-SCI can maintain its listing by
submitting a plan of compliance by January 9, 2017. This plan must
advise of actions CEL-SCI has taken or will take to regain
compliance with the continued listing standards by June 11, 2018.
CEL-SCI submitted such a plan on January 9, 2017. On February 24,
2017, the NYSE American accepted CEL-SCI&#x2019;s plan of compliance
and granted CEL-SCI until June 11, 2018 to regain compliance with
the continued listing standards. Although, the NYSE American will
not normally remove the securities if an issuer has a market
capitalization of at least $50 million if CEL-SCI does not make
sufficient progress under the plan to reestablish compliance by
June 11, 2018, the staff of the exchange may initiate proceedings
to delist CEL-SCI&#x2019;s securities from the NYSE American.
CEL-SCI may appeal a delisting determination in accordance with the
rules of the exchange.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
letter from the NYSE American has no immediate effect on the
listing of CEL-SCI&#x2019;s securities on the exchange.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">39</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Under its amended bylaws, stockholders that initiate certain
proceedings may be obligated to reimburse CEL-SCI and its officers
and directors for all fees, costs and expenses incurred in
connection with such proceedings if the claim proves
unsuccessful.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
February 18, 2015, CEL-SCI adopted new bylaws which include a
fee-shifting provision in Article X for stockholder claims. Article
X provides that in the event any stockholder initiates or asserts a
claim against CEL-SCI, or any of its officers or directors,
including any derivative claim or claim purportedly filed on
CEL-SCI&#x2019;s behalf, and the stockholder does not obtain a
judgment on the merits that substantially achieves, in substance
and amount, the full remedy sought, then the stockholder will be
obligated to reimburse CEL-SCI and any of its officers or directors
named in the action, for all fees, costs and expenses of every kind
and description that CEL-SCI or its officers or directors may incur
in connection with the claim.&#xA0;&#xA0;In adopting Article X, it
is the intent that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">all
actions, including federal securities law claims, would be subject
to Article X;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
phrase &#x201C;a judgment on the merits&#x201D; means the
determination by a court of competent jurisdiction on the matters
submitted to the court;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
phrase &#x201C;substantially achieves, in both substance and
amount&#x201D; means the plaintiffs in the action would be awarded
at least 90% of the relief sought;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">only
persons who were stockholders at the time an action was brought
would be subject to Article X; and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">only
the directors or officers named in the action would be allowed to
recover.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
fee-shifting provision contained in Article X of the bylaws is not
limited to specific types of actions, but is rather potentially
applicable to the fullest extent permitted by law. Fee-shifting
bylaws are relatively new and untested. The case law and potential
legislative action on fee-shifting bylaws are evolving and there
exists considerable uncertainty regarding the validity of, and
potential judicial and legislative responses to, such bylaws. For
example, it is unclear whether the ability to invoke the
fee-shifting bylaw in connection with claims under the federal
securities laws would be pre-empted by federal law. Similarly, it
is unclear how courts might apply the standard that a claiming
stockholder must obtain a judgment that substantially achieves, in
substance and amount, the full remedy sought. The application of
the fee-shifting bylaw in connection with such claims, if any, will
depend in part on future developments of the law. CEL-SCI cannot
assure its shareholders that CEL-SCI will or will not invoke the
fee-shifting bylaw in any particular dispute In addition, given the
unsettled state of the law related to fee-shifting bylaws, such as
CEL-SCI&#x2019;s, CEL-SCI may incur significant additional costs
associated with resolving disputes with respect to such bylaw,
which could adversely affect its business and financial
condition.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
a stockholder that brings any such claim, suit, action or
proceeding is unable to obtain the required judgment, the
attorneys&#x2019; fees and other litigation expenses that might be
shifted to a claiming stockholder are potentially significant. This
fee-shifting bylaw, therefore, may dissuade or discourage
stockholders (and their attorneys) from initiating lawsuits or
claims against CEL-SCI or its directors and officers.&#xA0;In
addition, it may impact the fees, contingency or otherwise,
required by potential plaintiffs&#x2019; attorneys to represent the
stockholders or otherwise discourage plaintiffs&#x2019; attorneys
from representing the stockholders at all. As a result, this bylaw
may limit the ability of stockholders to affect the management and
direction of CEL-SCI, particularly through litigation or the threat
of litigation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">40</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
The provision of the amended bylaws requiring exclusive venue in
the U.S. District Court for Delaware for certain types of lawsuits
may have the effect of discouraging lawsuits against CEL-SCI and
its directors and officers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Article
X of CEL-SCI&#x2019;s amended bylaws provides that stockholder
claims brought against CEL-SCI, or its officers or directors,
including any derivative claim or claim purportedly filed on
CEL-SCI&#x2019;s behalf, must be brought in the U.S. District Court
for the district of Delaware and that with respect to any such
claim, the laws of Delaware will apply.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
exclusive forum provision may limit a stockholder&#x2019;s ability
to bring a claim in a judicial forum the stockholder finds
favorable for disputes with CEL-SCI or its directors or officers,
and may have the effect of discouraging lawsuits with respect to
claims that may benefit CEL-SCI or the stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
1B.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
UNRESOLVED SEC COMMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">None</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
2.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
PROPERTIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
leases office space at 8229 Boone Blvd., Suite 802, Vienna,
Virginia at a monthly rental of approximately $8,000. The lease on
the office space expires on June 30, 2020. CEL-SCI believes this
arrangement is adequate for the conduct of its present
business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
has a 17,900 square foot laboratory located in Baltimore, Maryland.
The laboratory is leased by CEL-SCI at a cost of approximately
$13,000 per month. The laboratory lease expires on February 28,
2022.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
August 2007, CEL-SCI leased a building near Baltimore, Maryland
(the San Tomas lease). The building, which consists of
approximately 73,000 square feet, has been remodeled in accordance
with CEL-SCI&#x2019;s specifications so that it can be used by
CEL-SCI to manufacture Multikine for CEL-SCI&#x2019;s Phase 3
clinical trial and sales of the drug if approved by the FDA. The
lease expires on October 31, 2028 and required annual base rent
payments of approximately $1.7 million during the twelve months
ended September 30, 2017. The annual base rent escalates each year
at 3% beginning on November 1st. CEL-SCI is also required to pay
all real and personal property taxes, insurance premiums,
maintenance expenses, repair costs and utilities, which were
approximately $46,000 per month as of September 30, 2017. The lease
allows CEL-SCI, at its election, to extend the lease for two
ten-year periods or to purchase the building at the end of the
20-year lease. The Company is not the legal owner of the
manufacturing building, but is deemed to be the owner for the
accounting purposes based on the accounting guidance for
build-to-suit leases under ASC 840-40-55.The lease required CEL-SCI
to pay $3,150,000 towards the remodeling costs, which is being
recouped by reductions in the annual base rent of $303,228
beginning in fiscal year 2014. In August 2011, CEL-SCI was required
to deposit $1,670,917, the equivalent of one year of base rent. The
$1,670,917 was required to be deposited when the amount of
CEL-SCI&#x2019;s cash had dropped below the amount stipulated in the
lease and is included in non-current assets at September 30,
2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">41</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
3.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
LEGAL PROCEEDINGS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;CEL-SCI is
currently involved in a pending arbitration proceeding, CEL-SCI
Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC)
and PharmaNet GmbH (f/k/a PharmaNet AG). CEL-SCI initiated the
proceedings against inVentiv Health Clinical LLC, or inVentiv,
CEL-SCI&#x2019;s former third-party CRO, and is seeking payment for
damages related to inVentiv&#x2019;s prior involvement in the Phase
3 clinical trial of Multikine. The arbitration claim, initiated
under the Commercial Rules of the American Arbitration Association,
alleges (i) breach of contract, (ii) fraud in the inducement, and
(iii) common law fraud. <font style="color: #000000">Currently,
CEL-SCI seeks at least $50 million in damages in its amended
statement of claim.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In an
amended statement of claim, CEL-SCI asserted the claims set forth
above as well as an additional claim for professional
malpractice.&#xA0;&#xA0;The arbitrator subsequently granted
inVentiv&#x2019;s motion to dismiss the professional malpractice
claim based on the &#x201C;economic loss doctrine&#x201D; which,
under New Jersey law, is a legal doctrine that, under certain
circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#xA0;&#xA0;The arbitrator
denied the remainder of inVentiv&#x2019;s motion, which had sought
to dismiss certain other aspects of the amended statement of
claim.&#xA0;&#xA0;In particular, the arbitrator rejected
inVentiv&#x2019;s argument that several aspects of the amended
statement of claim were beyond the arbitrator&#x2019;s
jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the pending arbitration proceedings, inVentiv has
asserted counterclaims against CEL-SCI for (i) breach of contract,
seeking at least $2 million in damages for services allegedly
performed by inVentiv; (ii) breach of contract, seeking at least $1
million in damages for CEL-SCI&#x2019;s alleged use of
inVentiv&#x2019;s name in connection with publications and
promotions in violation of the parties&#x2019; contract; (iii)
opportunistic breach, restitution and unjust enrichment, seeking at
least $20 million in disgorgement of alleged unjust profits
allegedly made by CEL-SCI as a result of the purported breaches
referenced in subsection (ii); and (iv) defamation, seeking at
least $1 million in damages for allegedly defamatory statements
made about inVentiv. CEL-SCI believes inVentiv&#x2019;s
counterclaims are meritless. However, if inVentiv successfully
asserts any of its counterclaims, such an adverse determination
could have a material adverse effect on CEL-SCI&#x2019;s business,
results, financial condition and liquidity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2015, CEL-SCI signed an arbitration funding agreement with
a company established by Lake Whillans Litigation Finance, LLC, a
firm specializing in funding litigation expenses. Pursuant to the
agreement, an affiliate of Lake Whillans provides CEL-SCI with
funding for litigation expenses to support its arbitration claims
against inVentiv. The funding is available to CEL-SCI to fund the
expenses of the ongoing arbitration and will only be repaid when
CEL-SCI receives proceeds from the arbitration.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
arbitration hearing on the merits (the &#x201C;trial&#x201D;) started
on September 26, 2016 and was originally scheduled to end in
November/December of 2016. <font style="color: #000000">On November
13, 2017, CEL-SCI announced that the last witness in the
arbitration hearing testified on November 8, 2017, and no further
witnesses or testimony are expected. With that final witness, the
testimony phase of the arbitration concluded. All that remains at
the trial level are closing statements and post-trial
submissions.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">42</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ITEM 4.<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="text-decoration: underline">MINE
SAFETY DISCLOSURES</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">Not
applicable.&#xA0;<br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
5.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
MARKET FOR CEL-SCI'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">As of
September 30, 2017, there were approximately 800 record holders of
CEL-SCI&#x2019;s common stock. CEL-SCI&#x2019;s common stock is
traded on the NYSE American under the symbol
&#x201C;CVM&#x201D;.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On June
12, 2017, CEL-SCI&#x2019;s shareholders approved a reverse split of
CEL-SCI&#x2019;s common stock. The reverse split became effective on
the NYSE American on June 15, 2017. On that date, every twenty-five
issued and outstanding shares of CEL-SCI&#x2019;s common stock
automatically converted into one outstanding share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">As a
result of the reverse stock split, the number of CEL-SCI&#x2019;s
outstanding shares of common stock decreased from 230,127,331
(pre-split) shares to 9,214,645 (post-split) shares.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Shown
below are the post-split range of high and low quotations for
CEL-SCI&#x2019;s common stock for the periods indicated as reported
on the NYSE American. The market quotations reflect inter-dealer
prices, without retail mark-up, mark-down or commissions and may
not necessarily represent actual transactions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="font-family: Times New Roman; font-weight: bold;">Quarter
Ending</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">High</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Low</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">12/31/2015</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">18.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">3/31/2016</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16.50</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">6/30/2016</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">11.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">9/30/2016</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.50</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">12/31/16</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">7.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1.50</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">3/31/2017</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4.50</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">6/30/2017</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4.00</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1.46</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">9/30/2017</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3.69</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1.57</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Holders
of common stock are entitled to receive dividends as may be
declared by CEL-SCI&#x2019;s Board of Directors out of legally
available funds and, in the event of liquidation, to share pro rata
in any distribution of CEL-SCI&#x2019;s assets after payment of
liabilities. CEL-SCI&#x2019;s Board of Directors is not obligated to
declare a dividend. CEL-SCI has not paid any dividends on its
common stock and CEL-SCI does not have any current plans to pay any
common stock dividends.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">43</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
provisions in CEL-SCI&#x2019;s Articles of Incorporation relating to
CEL-SCI&#x2019;s preferred stock allow CEL-SCI&#x2019;s directors to
issue preferred stock with rights to multiple votes per share and
dividend rights which would have priority over any dividends paid
with respect to CEL-SCI&#x2019;s common stock. The issuance of
preferred stock with such rights may make more difficult the
removal of management even if such removal would be considered
beneficial to shareholders generally, and will have the effect of
limiting shareholder participation in certain transactions such as
mergers or tender offers if such transactions are not favored by
incumbent management.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
market price of CEL-SCI&#x2019;s common stock, as well as the
securities of other biopharmaceutical and biotechnology companies,
have historically been highly volatile, and the market has from
time to time experienced significant price and volume fluctuations
that are unrelated to the operating performance of particular
companies. Factors such as fluctuations in CEL-SCI&#x2019;s
operating results, announcements of technological innovations or
new therapeutic products by CEL-SCI or its competitors,
governmental regulation, developments in patent or other
proprietary rights, public concern as to the safety of products
which may be developed by CEL-SCI or other biotechnology and
pharmaceutical companies, and general market conditions may have a
significant effect on the market price of CEL-SCI&#x2019;s common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
graph below matches the cumulative 5-year total return of holders
of CEL-SCI&#x2019;s common stock with the cumulative total returns
of the NYSE American Composite index and the RDG MicroCap
Biotechnology index. The graph assumes that the value of an
investment in CEL-SCI's common stock and in each of the indexes
(including reinvestment of dividends) was $100 on September 30,
2012 and tracks it through September 30, 2017.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center"><img src="img001.jpg" alt=""></div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">44</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
stock price performance included in this graph is not necessarily
indicative of future stock price performance.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr style="">
<td rowspan="1" style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; font-size: 11px;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; font-size: 11px;">9/12</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; font-size: 11px;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; font-size: 11px;">9/13</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; font-size: 11px;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; font-size: 11px;">9/14</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; font-size: 11px;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; font-size: 11px;">9/15</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; font-size: 11px;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; font-size: 11px;">9/16</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; font-size: 11px;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; font-size: 11px;">9/17</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI Corporation</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">100.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">49.28</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">26.43</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">17.39</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">8.84</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">1.92</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
NYSE American</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">100.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">92.32</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">105.61</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">75.60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">83.69</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">87.12</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
RDG MicroCap Biotechnology</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">100.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">91.20</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">74.12</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">58.64</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">30.77</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">21.86</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
ITEM 6. SELECTED FINANCIAL DATA</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">We are
a smaller reporting company as defined by Rule 12b-2 of the
Securities Exchange Act of 1934 and are not required to provide the
information required under this item.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">45</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 84px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM
7.&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
following discussion should be read in conjunction with the
financial statements and the related notes thereto appearing
elsewhere in this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
lead investigational therapy, Multikine, is cleared for a Phase 3
clinical trial in advanced primary head and neck cancer. It has
received a go-ahead by the U.S. FDA as well as twenty-three other
countries.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
September 26, 2016, CEL-SCI received verbal notice from the FDA
that the Phase 3 clinical trial in advanced primary head and neck
cancer has been placed on clinical hold. Pursuant to this
communication from FDA, patients currently receiving study
treatments could continue to receive treatment, and patients
already enrolled in the study continued to be
followed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
August 10, 2017, CEL-SCI received a letter from the FDA stating
that the clinical hold that had been imposed on the Phase 3 cancer
study with Multikine has been removed and that all clinical trial
activities under this IND may resume.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
also owns and is developing a pre-clinical technology called
LEAPS.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">All of
CEL-SCI&#x2019;s projects are under development. As a result,
CEL-SCI cannot predict when it will be able to generate any revenue
from the sale of any of its products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Since
inception, CEL-SCI has financed its operations through the issuance
of equity securities, convertible notes, loans and certain research
grants. CEL-SCI&#x2019;s expenses will likely exceed its revenues as
it continues the development of Multikine and brings other drug
candidates into clinical trials. Until such time as CEL-SCI becomes
profitable, any or all of these financing vehicles or others may be
utilized to assist CEL-SCI&#x2019;s capital
requirements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Results of Operations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Fiscal 2017</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the year ended September 30, 2017, grant and other income decreased
by approximately $216,000 compared to the year ended September 30,
2016. The decrease is primarily due to the timing of drug shipments
to supply the Company&#x2019;s partner in Taiwan during fiscal year
2017 compared to fiscal year 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the year ended September 30, 2017, research and development
expenses decreased by approximately $1.8 million compared to the
year ended September 30, 2016. The Company is continuing the Phase
3 clinical trial and research and development fluctuates based on
the activity level of the clinical trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">46</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the year ended September 30, 2017, general and administrative
expenses decreased by approximately $686,000, compared to the year
ended September 30, 2016. Major components of the decrease are an
approximate $839,000 decrease in compensation costs, of which
approximately $733,000 relates to stock compensation, and an
approximate decrease of $915,000 related to non-employee
compensation costs for consultants, of which approximately $519,000
relates to stock compensation, and a net decrease of other general
and administrative expenses of approximately $32,000. These
decreases are offset by an approximate $1.1 million gain on
de-recognition of legal fees recorded during the year ended
September 30, 2016 due to the transfer of the liability that
existed prior to the execution of the Lake Whillians financing
agreement from the Company to Lake Whillans. The gain on
de-recognition of legal fees is recorded as a reduction of general
and administrative expenses for the year ended September 30,
2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the years ended September 30, 2017 and 2016, the Company recorded a
derivative gain of approximately $11.0 million and $14.0 million,
respectively. This variation was the result of the change in fair
value of the derivative liabilities during the period which was
caused by fluctuations in the share price of CEL-SCI&#x2019;s common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Net
interest expense increased approximately $2.2 million during the
year ended September 30, 2017 compared to the year ended September
30, 2016, primarily due to an approximate $1.34 million in interest
expense recorded on a stock financing transaction with Ergomed and
$0.9 million interest expense relating to the amortization of debt
discounts and accrued interest on convertible notes payable issued
during fiscal 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Research and Development Expenses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the five years ended September 30, 2017, CEL-SCI&#x2019;s research
and development efforts involved Multikine and LEAPS. The table
below shows the research and development expenses associated with
each project during this five-year period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:50%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 11px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 11px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 11px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%;">2015</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 11px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%;">2014</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 11px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%;">2013</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:50%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:50%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">MULTIKINE</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,253,190</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,054,474</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18,697,940</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,891,411</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,650,239</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:50%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LEAPS</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">353,795</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">390,908</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">493,810</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">374,778</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">377,485</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:50%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">15,606,985</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">17,445,382</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">19,191,750</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">15,266,189</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">11,027,724</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
January 2007, CEL-SCI received a &#x201C;no objection&#x201D; letter
from the FDA indicating that it could proceed with Phase 3 trials
with Multikine in head and neck cancer patients.&#xA0;&#xA0;CEL-SCI
had previously received a &#x201C;no objection&#x201D; letter from
the Canadian Biologics and Genetic Therapies Directorate which
enabled CEL-SCI to begin its Phase 3 clinical trial in
Canada.&#xA0;&#xA0;Subsequently, CEL-SCI received similar
authorizations from twenty-three other
regulators.</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
Phase 3 clinical trial began in December 2010 after the completion
and validation of CEL-SCI&#x2019;s dedicated manufacturing
facility.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">47</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">As
explained in Item 1 of this report, as of November 30, 2017,
CEL-SCI was involved in pre-clinical studies with respect to its
LEAPS technology. As with Multikine, CEL-SCI does not know what
obstacles it will encounter in future pre-clinical and clinical
studies involving its LEAPS technology. Consequently, CEL-SCI
cannot predict with any certainty the funds required for future
research and clinical trials and the timing of future research and
development projects.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Liquidity and Capital Resources</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
has had only limited revenues from operations since its inception
in March 1983.&#xA0;&#xA0;CEL-SCI has relied upon capital generated
from the public and private offerings of its common stock and
convertible notes.&#xA0;&#xA0;In addition, CEL-SCI has utilized
short-term loans to meet its capital
requirements.&#xA0;&#xA0;Capital raised by CEL-SCI has been used to
acquire an exclusive worldwide license to use, and later purchase,
certain patented and unpatented proprietary technology and know-how
relating to the human immunological defense system and for clinical
trials.&#xA0;&#xA0;Capital has also been used for patent
applications, debt repayment, research and development,
administrative costs, and the construction of CEL-SCI&#x2019;s
laboratory facilities.&#xA0;&#xA0;CEL-SCI does not anticipate
realizing significant revenues until it enters into licensing
arrangements regarding its technology and know-how or until it
receives regulatory approval to sell its products (which could take
a number of years). As a result, CEL-SCI has been dependent upon
the proceeds from the sale of its securities to meet all of its
liquidity and capital requirements and anticipates having to do so
in the future. During fiscal year 2017 and 2016, CEL-SCI raised net
proceeds of approximately $13.3 million and $21.4 million,
respectively, through the sale of stock and the issuance of
convertible notes.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
August 2007, CEL-SCI leased a building near Baltimore, Maryland.
The building, which consists of approximately 73,000 square feet,
has been remodeled in accordance with CEL-SCI&#x2019;s
specifications so that it can be used by CEL-SCI to manufacture
Multikine for CEL-SCI&#x2019;s Phase III clinical trials and sales
of the drug if approved by the FDA. The lease expires on October
31, 2028, and required annual base rent payments of approximately
$1.7 million during the twelve months ended September 30, 2017. See
Item 2 of this report for more information concerning the terms of
this lease.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 28, 2015, CEL-SCI closed an underwritten public offering of
688,930 shares of common stock and 688,930 Series W warrants to
purchase shares of common stock. The common stock and warrants were
sold at a combined per unit price of $16.75 for net proceeds of
approximately $10.5 million, net of underwriting discounts and
commissions and offering expenses. The Series W warrants are
immediately exercisable at a price of $16.75 and expire on October
28, 2020. As of September 30, 2017, none of the Series W warrants
had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
January 2016, CEL-SCI repaid the note payable to the de Clara
Trust, the balance of which was approximately $1.1 million,
including principal and interest At the same time, the Company sold
120,000 shares of its common stock and 120,000 Series X warrants to
the de Clara Trust for approximately $1.1 million, as noted above.
Geert Kersten, the Company's Chief Executive Officer and a
director, is a beneficiary of the de Clara Trust. Each Series X
warrant allows the de Clara Trust to purchase one share of the
CEL-SCI&#x2019;s common stock at a price of $9.25 per share at any
time on or before January 13, 2021. As of September 30, 2017, none
of the Series X warrants had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">48</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
February 2016, CEL-SCI sold 52,000 shares of its common stock and
26,000 Series Y warrants to a private investor for $624,000. Each
Series Y warrant allows the holder to purchase one share of
CEL-SCI&#x2019;s common stock at a price of $12.00 per share at any
time on or before February 15, 2021. As of September 30, 2017, none
of the Series Y warrants had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On May
23, 2016, CEL-SCI closed a registered direct offering of 400,000
shares of common stock and 264,000 Series Z warrants to purchase
shares of common stock. The common stock and warrants were sold at
a combined per unit price of $12.50 for net proceeds of
approximately $4.6 million, net of placement agent&#x2019;s
commissions and offering expenses. The Series Z warrants may be
exercised at any time on or before November 23, 2021 at a price of
$13.75 per share. CEL-SCI also issued 20,000 Series ZZ warrants to
the placement agent as part of its compensation. The Series ZZ
warrants may be exercised at any time on or before May 18, 2021 at
a price of $13.75 per share. As of September 30, 2017, none of the
Series Z and ZZ warrants had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On August 26, 2016, CEL-SCI closed a registered
direct offering of&#xA0;400,000 shares of common stock and Series
AA warrants to purchase up to 200,000 shares of common stock. Each
share of common stock was sold together with a Series AA warrant to
purchase one-half of a share of common stock for the combined
purchase price of $12.50. Each warrant can be exercised at any time
on or before February 22, 2022 at a price of $13.75 per
share.</font> CEL-SCI also issued 16,000 Series BB warrants to the
placement agent as part of its compensation. The Series BB warrants
may be exercised at any time on or before August 22, 2021 at a
price of $13.75 per share. The Company received proceeds from the
sale of Series AA and Series BB shares and warrants of
approximately $4.5 million, net of placement agent&#x2019;s
commissions and offering expenses. As of September 30, 2017, none
of the Series AA and BB warrants had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 8, 2016, the Company sold 1,360,960 shares of common stock
and warrants to purchase common stock at a price of $3.13 in a
public offering. The warrants consist of 680,480 Series CC warrants
to purchase 680,480 shares of common stock, 1,360,960 Series DD
warrants to purchase 1,360,960 shares of common stock and 1,360,960
Series EE warrants to purchase 1,360,960 shares of common stock.
The Series CC warrants are immediately exercisable, expire in
five-years and have an exercise price of $5.00 per share. The
Series DD warrants are immediately exercisable, expire on December
1, 2017 and have an exercise price of $4.50 per share. The Series
EE warrants are immediately exercisable, expire on December 1, 2017
and have an exercise price of $4.50 per share. In addition, the
Company issued 68,048 Series FF warrants to purchase 68,048 shares
of common stock to the placement agent. The FF warrants are
exercisable at any time on or before December 1, 2021 and have an
exercise price $3.91. The net proceeds to CEL-SCI from this
offering was approximately $3.7 million, excluding any future
proceeds that may be received from the exercise of the warrants. As
of September 30, 2017, none of the Series CC, DD and EE warrants
had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">49</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
February 23, 2017, CEL-SCI sold 400,000 registered shares of common
stock and 400,000 Series GG warrants to purchase 400,000
unregistered shares of common stock at a combined price of $2.50
per share. The Series GG warrants have an exercise price of $3.00
per share are exercisable on or before August 23, 2022. In
addition, CEL-SCI issued 20,000 Series HH warrants to purchase
20,000 shares of unregistered common stock to the placement agent.
The Series HH warrants have an exercise price $3.13 and are
exercisable on or before February 16, 2022. The net proceeds from
this offering were approximately $0.8 million. As of September 30,
2017, none of the Series GG and HH warrants had been
exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
March 14, 2017, CEL-SCI sold 600,000 registered shares of common
stock and 600,000 Series II warrants to purchase 600,000
unregistered shares of common stock at combined offering price of
$2.50 per share. The Series II warrants have an exercise price of
$3.00 per share and are exercisable on or before September 14,
2022. In addition, CEL-SCI issued 30,000 Series JJ warrants to
purchase 30,000 shares of unregistered common stock to the
placement agent. The Series JJ warrants have an exercise price
$3.13 and are exercisable on or before March 8, 2022. The net
proceeds from this offering were approximately $1.3 million. As of
September 30, 2017, none of the Series II and JJ warrants had been
exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
April 30, 2017, CEL-SCI sold 527,960 registered shares of common
stock and 395,970 Series KK warrants to purchase 395,970
unregistered shares of common stock at combined offering price of
$2.88 per share. The Series KK warrants have an exercise price of
$3.04 per share, are exercisable on November 3, 2017 and expire on
November 3, 2022. In addition, CEL-SCI issued 26,398 Series LL
warrants to purchase 26,398 shares of unregistered common stock to
the placement agent. The Series LL warrants have an exercise price
$3.59, are exercisable on October 30, 2017 and expire on April 30,
2022. The net proceeds from this offering were approximately $1.4
million. As of September 30, 2017, none of the Series KK and LL
warrants had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On June
22, 2017, CEL-SCI issued Series MM warrants in connection with the
issuance of convertible notes in the aggregate principal amount of
$1.5 million to six individual investors. Geert Kersten,
CEL-SCI&#x2019;s Chief Executive Officer, participated in the
offering and purchased notes in the principal amount of $250,000.
The notes bear interest at 4% per year and are due and payable on
December 22, 2017. At the option of the note holders, the notes can
be converted into shares of the Company&#x2019;s common stock at a
fixed conversion rate of $1.69. The Series MM warrants entitle the
purchasers to acquire 893,491 shares of CEL-SCI&#x2019;s common
stock. The Series MM warrants are exercisable at $1.86 per share
and expire on June 22, 2022. Shares issuable upon the exercise of
the notes and warrants were registered subsequently. As of
September 30, 2017, $450,700 of the notes had been converted into
266,686 shares of CEL-SCI&#x2019;s common stock and none of the
Series MM warrants had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On July
17, 2017, CEL-SCI extended the expiration date of the Series N
warrants to August 18, 2018, reduced the exercise price from $13.18
to $3.00 and reduced the number of warrants outstanding from
113,785 to 85,339. As of September 30, 2017, the remaining 85,339
Series N warrants entitle the holders to purchase one share of
CEL-SCI's common stock at a price of $3.00 per share at any time
prior to August 18, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">50</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On July
24, 2017, CEL-SCI issued Series NN warrants in connection with the
issuance of convertible notes in the aggregate principal amount of
$1.2 million to twelve individual investors. A trust in which Geert
Kersten, CEL-SCI&#x2019;s Chief Executive Officer, holds a
beneficial interest participated in the offering and purchased
notes in the principal amount of $250,000. Patricia B. Prichep,
CEL-SCI&#x2019;s Senior Vice President of Operations, purchased a
note in the principal amount of $25,000. The notes bear interest at
4% per year and are due and payable on December 22, 2017. At the
option of the note holders, the notes can be converted into shares
of the Company&#x2019;s common stock at a fixed conversion rate of
$2.29. The Series NN warrants entitle the purchasers to acquire
539,300 shares of CEL-SCI&#x2019;s common stock. The Series NN
warrants are exercisable at $2.52 per share and expire on July 24,
2022. Shares issuable upon the exercise of the notes and warrants
were registered subsequently. As of September 30, 2017, none of the
notes had been converted and none of the Series NN warrants had
been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
November 2, 2017 holders of convertible notes in the principal
amount of $1,059,300 sold in June 2017 and holders of convertible
notes in the principal amount of $1,235,000 sold in July 2017
agreed to extend the maturity date of these notes to September 21,
2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
consideration for the extension of the maturity date of the
convertible notes, the Company issued a total of 716,400 Series RR
warrants to the convertible note holders that agreed to the
extension. Each Series RR warrant entitles the holder to purchase
one share of the Company&#x2019;s common stock. The Series RR
warrants may be exercised at any time on or before October 30, 2022
at an exercise price of $1.65 per share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On July
26, 2017, CEL-SCI sold 100,000 registered shares of common stock
and 60,000 Series OO warrants to purchase 60,000 unregistered
shares of common stock at a combined price of $2.29 per share. The
Series OO warrants have an exercise price of $2.52 per share are
exercisable on January 31, 2018 and expire on July 31, 2022. The
net proceeds from this offering were approximately $222,000. As of
September 30, 2017, none of the Series OO warrants had been
exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 22, 2017, CEL-SCI sold 1,750,000 registered shares of common
stock and 1,750,000 Series PP warrants to purchase 1,750,000
unregistered shares of common stock at combined offering price of
$2.00 per share. The Series PP warrants have an exercise price of
$2.30 per share, are exercisable on February 28, 2018 and expire on
February 28, 2023. In addition, CEL-SCI issued 87,500 Series QQ
warrants to purchase 87,500 shares of unregistered common stock to
the placement agent. The Series QQ warrants have an exercise price
$2.50, are exercisable on February 22, 2018 and expire on August
22, 2022. The net proceeds from this offering were approximately
$3.2 million. As of September 30, 2017, none of the Series PP and
QQ warrants had been exercised.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Inventory decreased
by approximately $336,000 at September 30, 2017 as compared to
September 30, 2016, due to the timing of supplies purchased and
used in the manufacturing of Multikine for the Phase 3 clinical
trial. In addition, receivables decreased by approximately
$176,000, primarily due to the timing of payments reimbursed under
the litigation funding arrangement noted above and the timing of
shipments of Multikine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">51</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the year ended September 30, 2017, the Company&#x2019;s cash
decreased by approximately $549,000. Significant components of this
decrease include: net cash used in operating activities of
approximately $13.8 million and expenditures for equipment and
patents, as well as payments on capital leases, of approximately
$21,000, offset by proceeds from the sale of common stock and
warrants of approximately $10.5 million and proceeds from the
issuance of notes payable of approximately $2.7
million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Future Capital Requirements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s material capital commitments include funding
operating losses, funding its research and development program,
making required lease payments and repaying convertible notes. As
of September 30, 2017, material contractual obligations are as
follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:30%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="7" rowspan="1" style="vertical-align:bottom;width:70%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 1%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 98%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Years Ending September 30,</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 1%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:30%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Total</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2018</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2019</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2020</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2021</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2022</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2023 &amp; thereafter</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:30%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
Leases</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">979,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">251,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">258,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">238,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">163,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">69,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:30%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Financing Lease</font><font style="font-size: 70%; vertical-align: top; color: #000000">(1)</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">23,126,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,747,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,808,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,872,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,937,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,004,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,758,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:30%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Convertible Notes</font><font style="font-size: 70%; vertical-align: top; color: #000000">(2)</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,407,019</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,407,019</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:30%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Contractual Obligations</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">26,512,019</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">4,405,019</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,066,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,110,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,100,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,073,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">13,758,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td colspan="8" style="vertical-align: bottom; width: 100%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; color: #000000">
(1)</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">The amounts include future
minimum lease payments under the Company's lease of its
manufacturing facility (the San Tomas lease)</font></font></div>
</td>
</tr><tr>
<td colspan="8" style="vertical-align: bottom; width: 100%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; color: #000000">
(2)</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">The amounts include future
interest payments at a fixed rate of 4% and payment of the notes in
full upon maturity in 2018</font></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: -12px; margin-right: 0px; text-indent: 60px">
<font style="font-size: 13px; font-family: Times New Roman">For
information on employment contracts, see Item 11 of this
report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Further, CEL-SCI
has contingent obligations with vendors for work that will be
completed in relation to the Phase 3 trial. The timing of these
obligations cannot be determined at this time. CEL-SCI estimates it
will incur additional expenses of approximately $13.0 million for
the remainder of the Phase 3 clinical trial. It should be noted
that this estimate is based only on the information currently
available in CEL-SCI&#x2019;s contracts with the Clinical Research
Organizations responsible for managing the Phase 3 clinical trial
and does not include other related costs, e.g. the manufacturing of
the drug.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
will need to raise additional funds, either through the exercise of
outstanding warrants/options, through a debt or equity financing or
a partnering arrangement, to complete the Phase 3 trial and bring
Multikine to market. The ability of CEL-SCI to complete the
necessary clinical trials and obtain FDA approval for the sale of
products to be developed on a commercial basis is uncertain.
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>In
general, CEL-SCI believes that it will be able to raise sufficient
capital in fiscal year 2018 to continue operations into March 2018.
However, it is possible that CEL-SCI will not be able to generate
enough cash to continue operations at its current level. CEL-SCI's
registered independent public accounting firm has issued an audit
opinion that includes an explanatory paragraph that expresses
substantial doubt about CEL-SCI&#x2019;s ability to continue as a
going concern mainly due to continued losses from operations and
future liquidity needs of CEL-SCI. CEL-SCI&#x2019;s management has
engaged in fundraising for over 20 years and believes that the
manner in which it is proceeding will produce the best possible
outcome for the shareholders. There can be no assurances that
CEL-SCI will be successful in raising additional
funds.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">52</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Clinical and other
studies necessary to obtain regulatory approval of a new drug
involve significant costs and require several years to complete.
The extent of CEL-SCI&#x2019;s clinical trials and research programs
are primarily based upon the amount of capital available to CEL-SCI
and the extent to which CEL-SCI has received regulatory approvals
for clinical trials. The inability of CEL-SCI to conduct clinical
trials or research, whether due to a lack of capital or regulatory
approval, will prevent CEL-SCI from completing the studies and
research required to obtain regulatory approval for any products
which CEL-SCI is developing. Without regulatory approval, CEL-SCI
will be unable to sell any of its products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In the
absence of revenues, CEL-SCI will be required to raise additional
funds through the sale of securities, debt financing or other
arrangements in order to continue with its research efforts.
However, there can be no assurance that such financing will be
available or be available on favorable terms. Ultimately, CEL-SCI
must complete the development of its products, obtain appropriate
regulatory approvals and obtain sufficient revenues to support its
cost structure.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Since
all of CEL-SCI&#x2019;s projects are under development, CEL-SCI
cannot predict with any certainty the funds required for future
research and clinical trials, the timing of future research and
development projects, or<font style="color: #FF0000">&#xA0;</font>when it will be able to generate any
revenue from the sale of any of its products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI's cash flow
and earnings are subject to fluctuations due to changes in interest
rates on its bank accounts, and, to an immaterial extent, foreign
currency exchange rates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Critical Accounting Policies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI's
significant accounting policies are more fully described in Note 1
to the financial statements included as part of this report.
However, certain accounting policies are particularly important to
the portrayal of CEL-SCI&#x2019;s financial position and results of
operations and require the application of significant judgments by
management. As a result, the financial statements are subject to an
inherent degree of uncertainty. In applying those policies,
management uses its judgment to determine the appropriate
assumptions to be used in the determination of certain estimates.
These estimates are based on CEL-SCI's historical experience, terms
of existing contracts, observance of trends in the industry and
information available from outside sources, as appropriate.
CEL-SCI&#x2019;s critical accounting policies include:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Stock Options and Warrants</font> &#x2013;
Compensation cost is measured at fair value as of the grant date in
accordance with the provisions of ASC 718. The fair value of the
stock options is calculated using the Black-Scholes option pricing
model. The Black-Scholes model requires various judgmental
assumptions including volatility, forfeiture rates and expected
option life. The stock-based compensation cost is recognized on the
accelerated method as expense over the requisite service or vesting
period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Options
to non-employees are accounted for in accordance with ASC 505-50,
&#x201C;<font style="font-style: italic">Equity-Based Payments to
Non-Employees</font>.&#x201D; Accordingly, compensation cost is
recognized when goods or services are received and is measured
using the Black-Scholes valuation model. The Black-Scholes model
requires CEL-SCI&#x2019;s management to make assumptions regarding
the fair value of the options at the date of grant and the expected
life of the options.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">53</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Asset Valuations and Review for Potential
Impairments</font> - CEL-SCI reviews its fixed assets and
intangibles every fiscal quarter. This review requires that CEL-SCI
make assumptions regarding the value of these assets and the
changes in circumstances that would affect the carrying value of
these assets. If such analysis indicates that a possible impairment
may exist, CEL-SCI is then required to estimate the fair value of
the asset and, as deemed appropriate, expense all or a portion of
the asset. The determination of fair value includes numerous
uncertainties, such as the impact of competition on future value.
CEL-SCI believes that it has made reasonable estimates and
judgments in determining whether its long-lived assets have been
impaired; however, if there is a material change in the assumptions
used in its determination of fair values or if there is a material
change in economic conditions or circumstances influencing fair
value, CEL-SCI could be required to recognize certain impairment
charges in the future. As a result of the reviews, no changes in
asset values were required.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Derivative Instruments&#x2014;</font>CEL-SCI
enters into financing arrangements that consist of freestanding
derivative instruments or hybrid instruments that contain embedded
derivative features. CEL-SCI accounts for these arrangements in
accordance with ASC 815, &#x201C;<font style="font-style: italic">Accounting for Derivative Instruments and
Hedging Activities</font>, as well as related interpretations of
these standards. In accordance with accounting principles generally
accepted in the United States (&#x201C;GAAP&#x201D;), derivative
instruments and hybrid instruments are recognized as either assets
or liabilities in the statement of financial position and are
measured at fair value with gains or losses recognized in earnings
or other comprehensive income depending on the nature of the
derivative or hybrid instruments. Embedded derivatives that are not
clearly and closely related to the host contract are bifurcated and
recognized at fair value with changes in fair value recognized as
either a gain or loss in earnings if they can be reliably measured.
When the fair value of embedded derivative features cannot be
reliably measured, CEL-SCI measures and reports the entire hybrid
instrument at fair value with changes in fair value recognized as
either a gain or loss in earnings. CEL-SCI determines the fair
value of derivative instruments and hybrid instruments based on
available market data using appropriate valuation models, giving
consideration to all of the rights and obligations of each
instrument and precluding the use of &#x201C;blockage&#x201D;
discounts or premiums in determining the fair value of a large
block of financial instruments. Fair value under these conditions
does not necessarily represent fair value determined using
valuation standards that give consideration to blockage discounts
and other factors that may be considered by market participants in
establishing fair value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
7A.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET
RISKS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Not
applicable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
8.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">See the
financial statements included with this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
9.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Not
applicable</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">54</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
9A.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CONTROLS AND PROCEDURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Under
the direction and with the participation of CEL-SCI&#x2019;s
management, including CEL-SCI&#x2019;s Chief Executive Officer and
Chief Financial Officer, CEL-SCI carried out an evaluation of the
effectiveness of the design and operation of its disclosure
controls and procedures as of September 30, 2017. CEL-SCI maintains
disclosure controls and procedures that are designed to ensure that
information required to be disclosed in its periodic reports with
the Securities and Exchange Commission is recorded, processed,
summarized and reported within the time periods specified in the
SEC&#x2019;s rules and regulations, and that such information is
accumulated and communicated to CEL-SCI&#x2019;s management,
including its principal executive officer and principal financial
officer, as appropriate, to allow timely decisions regarding
required disclosure. CEL-SCI&#x2019;s disclosure controls and
procedures are designed to provide a reasonable level of assurance
of reaching its desired disclosure control objectives. Due to the
material weaknesses outlined below, CEL-SCI&#x2019;s Chief Executive
and Principal Financial Officer has concluded that CEL-SCI&#x2019;s
disclosure controls were not effective as of September 30,
2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Management&#x2019;s Report on Internal Control over Financial
Reporting</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
management is responsible for establishing and maintaining adequate
internal control over financial reporting and for the assessment of
the effectiveness of internal control over financial reporting. As
defined by the Securities and Exchange Commission, internal control
over financial reporting is a process designed by, or under the
supervision of CEL-SCI&#x2019;s&#xA0;principal executive officer and
principal financial officer&#xA0;and implemented by CEL-SCI&#x2019;s
Board of Directors, management and other personnel, to provide
reasonable assurance regarding the reliability of financial
reporting and the preparation of CEL-SCI&#x2019;s financial
statements in accordance with U.S. generally accepted accounting
principles.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Because
of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten, CEL-SCI&#x2019;s Chief Executive and Principal Financial
Officer, evaluated the effectiveness of CEL-SCI&#x2019;s internal
control over financial reporting as of September 30, 2017 based on
criteria established in Internal Control - Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the
Treadway Commission, or the COSO Framework. Management&#x2019;s
assessment included an evaluation of the design of CEL-SCI&#x2019;s
internal control over financial reporting and testing of the
operational effectiveness of those controls.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
November 2017, CEL-SCI discovered an error in the way it accounted
for the lease for its manufacturing facility. CEL-SCI initially
recorded this lease as an operating lease but later identified that
it should have accounted for it as a financing lease and
capitalized an asset and related liability. Management concluded
that the correction of the error for this lease, the lack of
impairment assessment for the related asset, and the operating
effectiveness of the financial close process are control
deficiencies that constitute material weaknesses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">55</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
order to remediate these material weaknesses, the Company will
change certain control activities over financial reporting to
include the following:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">All facility
leasing activities will be subject to a thorough review of capital
versus operating lease classification. Further, leases that include
construction activity prior to lease inception will be reviewed
against the build-to-suit lease guidance in ASC 840. In addition,
the Company will also engage outside financial reporting
specialists to assist it in the review process.</font></div>
</div>
</div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The Company will
enhance its policy for reviewing long-lived assets for impairments
by incorporating additional triggering event factors for
consideration as part of its control. This review will be carried
out by the Company and also be assisted by an outside financial
reporting specialist.</font></div>
</div>
</div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The financial
reporting process will be enhanced to include the use of monthly,
quarterly and annual closing checklists to capture routine and
non-routine transactions that require additional review. Further,
the Company will also augment its control process by expanding the
use of a financial reporting specialist to assist in the financial
close process.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Based
on this evaluation and the corrective measures CEL-SCI has taken,
Mr. Kersten concluded that CEL-SCI&#x2019;s internal control over
financial reporting was not effective as of September 30,
2017.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">There
was no change in CEL-SCI&#x2019;s internal control over financial
reporting that occurred during the fiscal year ended September 30,
2017 that has materially affected, or is reasonably likely to
materially affect, CEL-SCI&#x2019;s internal control over financial
reporting except as disclosed above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
9B.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
OTHER INFORMATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;None.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
10.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Officers and Directors</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 31%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Name</font></font></font></font></div>
</td>
<td style="vertical-align: top; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Age</font></font></font></font></div>
</td>
<td style="vertical-align: top; width: 59%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Position</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 31%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 59%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 31%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
R. Kersten, Esq.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">59</font></div>
</td>
<td style="vertical-align: top; width: 59%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Director,
Chief Executive Officer and Treasurer</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 31%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Patricia
B. Prichep</font>&#xA0;</div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">66</font></div>
</td>
<td style="vertical-align: top; width: 59%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Senior
Vice President of Operations and Corporate</font> <font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">Secretary</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 31%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Dr.
Eyal Talor</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">61</font></div>
</td>
<td style="vertical-align: top; width: 59%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Scientific Officer</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 31%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Dr.
Daniel H. Zimmerman</font> <font style="font-family: Times New Roman; font-size: 13px">Immunology</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">76</font></div>
</td>
<td style="vertical-align: top; width: 59%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Senior
Vice President of Research, Cellular</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 31%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">75</font></div>
</td>
<td style="vertical-align: top; width: 59%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Senior
Vice President of Regulatory Affairs</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 31%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Dr.
Peter R. Young</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">72</font></div>
</td>
<td style="vertical-align: top; width: 59%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Director</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 31%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">65</font></div>
</td>
<td style="vertical-align: top; width: 59%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Director</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
directors of CEL-SCI serve in such capacity until the next annual
meeting of CEL-SCI's shareholders or until their successors have
been duly elected and qualified. The officers of CEL-SCI serve at
the discretion of CEL-SCI's directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">56</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">All of
CEL-SCI&#x2019;s directors have served as directors for a
significant period of time. Consequently, their long-standing
experience with CEL-SCI benefits both CEL-SCI and its
shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
principal occupations of CEL-SCI's officers and directors, during
the past several years, are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten has served in his current leadership role at CEL-SCI since
1995. Mr. Kersten has been with CEL-SCI since 1987. He has been
involved in the pioneering field of cancer immunotherapy for over
two decades and has successfully steered CEL-SCI through many
challenging cycles in the biotechnology industry. Mr. Kersten also
provides CEL-SCI with significant expertise in the fields of
finance and law and has a unique vision of how CEL-SCI's Multikine
product could potentially change the way cancer is treated.&#xA0;
Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of
Finley &amp; Kumble and worked at Source Capital, an investment
banking firm located in McLean, VA. He is a native of Germany,
graduated from Millfield School in England, and completed his
studies in the US. Mr. Kersten received his Undergraduate Degree in
Accounting and an M.B.A. from George Washington University, and a
law degree (J.D.) from American University in Washington,
DC.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Patricia B. Prichep
joined CEL-SCI in 1992 and has been CEL-SCI's Senior Vice President
of Operations since March 1994. Between December 1992 and March
1994, Ms. Prichep was CEL-SCI's Director of Operations. Ms. Prichep
became CEL-SCI's Corporate Secretary in May 2000. She is
responsible for all day-to-day operations of CEL-SCI, including
human resources and is the liaison with CEL-SCI&#x2019;s independent
registered public accounting firm for financial reporting. From
June 1990 to December 1992, Ms. Prichep was the Manager of Quality
and Productivity for the NASD&#x2019;s Management, Systems and
Support Department and was responsible for the internal auditing
and work flow analysis of operations. Between 1982 and 1990, Ms.
Prichep was Vice President and Operations Manager for Source
Capital, Ltd. She handled all operations and compliance for Source
Capital and was licensed as a securities broker. Ms. Prichep
received her B.A. from the University of Bridgeport in
Connecticut.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Eyal Talor, Ph.D. joined CEL-SCI in October 1993.
In October 2009, Dr. Talor was promoted to Chief Scientific
Officer. Between this promotion and March of 1994 he was the Senior
Vice President of Research and Manufacturing.&#xA0; He is a
clinical immunologist with over 19 years of hands-on management of
clinical research and drug development for immunotherapy
application; pre-clinical to Phase III, in the biopharmaceutical
industry.&#xA0; His expertise includes; biopharmaceutical R&amp;D
and Biologics product development, GMP (Good Manufacturing
Practices) manufacture, Quality Control testing, and the design and
building of GMP manufacturing and testing facilities.&#xA0; He
served as Director of Clinical Laboratories (certified by the State
of Maryland) and has experience in the design of clinical trials
(Phase I &#x2013; III) and GCP (Good Clinical Practices)
requirements.&#xA0; He also has broad experience in the different
aspects of biological assay development, analytical methods
validation, raw material specifications, and QC (Quality Control)
tests development under FDA/GMP, USP, and ICH guidelines.&#xA0; He
has extensive experience in the preparation of documentation for
IND and other regulatory submissions.&#xA0; His scientific area of
expertise encompasses immune response assessment.&#xA0; He is the
author of over 25 publications and has published a number of
reviews on immune regulations in relation to clinical immunology.
Before coming to CEL-SCI, he was Director of R&amp;D and Clinical
Development at CBL, Inc., Principal Scientist - Project Director,
and Clinical Laboratory Director at SRA Technologies, Inc. Prior to
that he was a full time faculty member at The Johns Hopkins
University, Medical Institutions; School of Public Health.&#xA0; He
has invented technologies which are covered by</font> <font style="color: #000000">two US patents; one on Multikine&#x2019;s
composition of matter and method of use in cancer, and one on a
platform Peptide technology (&#x2018;Adapt&#x2019;) for the treatment
of autoimmune diseases, asthma, allergy, and transplantation
rejection.&#xA0; He also</font> is responsible for <font style="color: #000000">numerous product and process inventions as well as
a number of pending US and PCT patent applications.&#xA0; He
received his Ph.D. in Microbiology and Immunology from the
University of Ottawa, Ottawa, Ontario, Canada, and had
post-doctoral training in clinical and cellular immunology at The
John Hopkins University, Baltimore, Maryland, USA.&#xA0; He holds
an Adjunct Associate teaching position at the Johns Hopkins
University Medical Institutions.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">57</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Daniel H. Zimmerman, Ph.D., was CEL-SCI's Senior
Vice President of Cellular Immunology between 1996 and December
2008 and again since November 2009.&#xA0; He joined CEL-SCI in
January 1996 as the Vice President of Research, Cellular
Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its
president from 1987-1995.&#xA0; From 1973-1987, Dr. Zimmerman
served in various positions at Electronucleonics, Inc. His
positions included: Scientist, Senior Scientist, Technical Director
and Program Manager. Dr. Zimmerman held various teaching positions
at Montgomery College between 1987 and 1995. Dr. Zimmerman has
invented technologies which are covered by over a dozen US patents
as well as many foreign equivalent patents. He is the author of
over 40 scientific publications in the area of immunology and
infectious diseases. He has been awarded numerous grants from NIH
and DOD.&#xA0; From 1969-1973, Dr. Zimmerman was a Senior Staff
Fellow at NIH. For the following 25 years, he continued on at NIH
as a&#xA0;guest worker. Dr. Zimmerman received a Ph.D. in
Biochemistry in 1969, and a Masters in Zoology in 1966 from the
University of Florida as well as a B.S. in Biology from Emory and
Henry College in</font> 1963.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">John
Cipriano, was CEL-SCI&#x2019;s Senior Vice President of Regulatory
Affairs between March 2004 and December 2008 and again since
October 2009. Mr. Cipriano brings to CEL-SCI over 30 years of
experience with both biotech and pharmaceutical companies. In
addition, he held positions at the United States Food and Drug
Administration (FDA) as Deputy Director, Division of Biologics
Investigational New Drugs, Office of Biologics Research and Review
and was the Deputy Director, IND Branch, Division of Biologics
Evaluation, Office of Biologics. Mr. Cipriano completed his B.S. in
Pharmacy from the Massachusetts College of Pharmacy in Boston,
Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue
University in West Lafayette, Indiana.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Peter
R. Young, Ph.D. has been a Director of CEL-SCI since August 2002.
Dr. Young has been a senior executive within the pharmaceutical
industry in the United States and Canada for most of his career,
originally in organizations that are now part of Sanofi S.A. Over
the last 20 years he has primarily held positions of Chief
Executive Officer or Chief Financial Officer and has extensive
experience with acquisitions and equity financing. Since November
2001, Dr. Young has been the President of Agnus Dei, LLC, which has
acted as a partner in an organization managing immune system
clinics which treats patients with diseases such as cancer,
multiple sclerosis and hepatitis. Dr. Young was also the President
and Chief Executive Officer of SRL Technology, Inc., a company
involved in the development of pharmaceutical drug delivery
systems. Between 1998 and 2001, Dr. Young was the Chief Financial
Officer of Adams Laboratories, Inc., the developer of
Mucinex&#xAE;. Dr. Young received his Ph.D. in Organic Chemistry
from the University of Bristol, England after obtaining his
Bachelor's degree in Honors Chemistry, Mathematics and Economics.
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>Subsequently,
he qualified as a Fellow of the Chartered Institute of Management
Accountants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">58</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine joined CEL-SCI&#x2019;s board of directors in June 2015.
Since 2010, Mr. Baillavoine has been a partner of Globomass
Holdings Limited, a London, England based developer of renewable
energy projects from concept through final operations. Since 2012
Mr. Baillavoine has been the Executive Chairman of Globomass
Holdings. Globomass Holdings has subsidiaries in Ireland, Bulgaria,
Croatia, Serbia, and has recently acquired a 20% stake in a US
based renewable energy company. Between 1978 and 1982 he was the
marketing manager of Ravenhead Ltd., a manufacturer of glass
tableware, and part of United Distillers Group (later acquired by
Grand Metropolitan). During this time Mr. Baillavoine became the UK
Business Manager where he restored market share and profit for
United Distillers. From 1982 to 1986 Mr. Baillavoine was Group
Corporate Planning and Group Marketing Director for Prontaprint
where he expanded the number of shops to 500 locations in four
years. Mr. Baillavoine joined Grand Metropolitan Plc between
1986-1988 (now Diageo Plc), an FTSE 100 beverage, food, hotel and
leisure company, as director in the Special Operations division. In
this capacity, he developed plans for Grand Met&#x2019;s
trouble-shooting division for over 20,000 Grand Met retail outlets.
From 1988-1991 he was the Managing Director of Nutri Systems (UK)
Ltd., a subsidiary of the US based provider of professionally
supervised weight loss programs. Between 1991 and 1995, Mr.
Baillavoine was Director of BET Group plc, a multinational business
support services group, and in 1992, was promoted to the Managing
Director for the manufacturing businesses. The &#xA3;2.3 billion
turnaround of BET during his tenure is one of the most successful
turnarounds of a top 100 FTSE company. Since 1995, Mr. Baillavoine
has held a number of CEO positions across a wide range of
industries and geographical locations. Mr. Baillavoine has European
and American educations (US high school and University of Wisconsin
Eau Claire 1972-1976).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 30, 2017, Mr. Alexander Esterhazy, a former director, passed
away.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">All of
CEL-SCI's officers devote substantially all of their time to
CEL-SCI's business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
Board of Directors does not have a &#x201C;leadership
structure&#x201D;, as such, since each director is entitled to
introduce resolutions to be considered by the Board and each
director is entitled to one vote on any resolution considered by
the Board. CEL-SCI&#x2019;s Chief Executive Officer is not the
Chairman of CEL-SCI&#x2019;s Board of Directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
Board of Directors has the ultimate responsibility to evaluate and
respond to risks facing CEL-SCI. CEL-SCI&#x2019;s Board of Directors
fulfills its obligations in this regard by meeting on a regular
basis and communicating, when necessary, with CEL-SCI&#x2019;s
officers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Dr.
Peter R. Young and Bruno Baillavoine are independent directors as
that term is defined in section 803 of the listing standards of the
NYSE American.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
has adopted a Code of Ethics which is applicable to CEL-SCI&#x2019;S
principal executive, financial, and accounting officers and persons
performing similar functions. The Code of Ethics is available on
CEL-SCI&#x2019;s website, located at <font style="font-style: italic">www.cel-sci.com.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">59</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">If a
violation of this code of ethics act is discovered or suspected,
any person (anonymously, if desired) may send a detailed note, with
relevant documents, to CEL-SCI&#x2019;s Audit Committee, c/o Dr.
Peter Young, 208 Hewitt Drive, Suite 103-143, Waco, TX
76712<font style="font-weight: bold">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">For
purposes of electing directors at its annual meeting, CEL-SCI has a
nominating committee that is made up of CEL-SCI&#x2019;s two
independent directors. The nominating committee selects the
nominees to the Board of Directors and they are approved by
CEL-SCI&#x2019;s shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
does not have any policy regarding the consideration of director
candidates recommended by shareholders and under Colorado law, any
shareholder can nominate a person for election as a director at the
annual shareholders&#x2019; meeting. However, CEL-SCI&#x2019;s Board
of Directors will consider candidates recommended by shareholders.
To submit a candidate for the Board of Directors the shareholder
should send the name, address and telephone number of the
candidate, together with any relevant background or biographical
information, to CEL-SCI&#x2019;s Chief Executive Officer, at the
address shown on the cover page of this report. The Board has not
established any specific qualifications or skills a nominee must
meet to serve as a director. Although the Board does not have any
process for identifying and evaluating director nominees, the Board
does not believe there would be any differences in the manner in
which the Board evaluates nominees submitted by shareholders as
opposed to nominees submitted by any other person.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
does not have a policy with regard to Board member&#x2019;s
attendance at annual meetings. All Board members, with the
exception of Dr. Young and Mr. Esterhazy, attended the last annual
shareholder&#x2019;s meeting held on June 12, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Holders
of CEL-SCI&#x2019;s common stock can send written communications to
CEL-SCI&#x2019;s entire Board of Directors, or to one or more Board
members, by addressing the communication to &#x201C;the Board of
Directors&#x201D; or to one or more directors, specifying the
director or directors by name, and sending the communication to
CEL-SCI&#x2019;s offices in Vienna, Virginia. Communications
addressed to the Board of Directors as whole will be delivered to
each Board member. Communications addressed to a specific director
(or directors) will be delivered to the director (or directors)
specified.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Security holder
communications not sent to the Board of Directors as a whole are
not relayed to Board members.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ITEM 11. <font style="text-decoration: underline">EXECUTIVE
COMPENSATION</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Compensation Discussion and Analysis</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">This
Compensation Discussion and Analysis (CD&amp;A) outlines
CEL-SCI&#x2019;s compensation philosophy, objectives and process for
its executive officers. <font style="color: #000000">This CD&amp;A
includes information on how compensation decisions are made, the
overall objectives of CEL-SCI&#x2019;s compensation program, a
description of the various components of compensation that are
provided, and additional information pertinent to understanding
CEL-SCI&#x2019;s executive officer compensation
program.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">60</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Compensation Committee determines the compensation of
CEL-SCI&#x2019;s Chief Executive Officer and delegates to the Chief
Executive Officer the responsibility to determine the base salaries
of all other officers, other than himself, under the constraints of
an overall limitation on the total amount of compensation to be
paid to them.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Compensation Philosophy</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
compensation philosophy extends to all employees, including
executive officers, and is designed to align employee and
shareholder interests. The philosophy&#x2019;s objective is to pay
fairly based upon the employee&#x2019;s position, experience and
individual performance. Employees may be rewarded through
additional compensation when CEL-SCI meets or exceeds targeted
business objectives. Generally, under CEL-SCI&#x2019;s compensation
philosophy, as an employee&#x2019;s level of responsibility
increases, a greater portion of his or her total potential
compensation becomes contingent upon annual
performance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">A
substantial portion of an executive's compensation incorporates
performance criteria that support and reward achievement of
CEL-SCI&#x2019;s long term business goals.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">The
fundamental principles of CEL-SCI&#x2019;s compensation philosophy
are described below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Market-driven.</font> Compensation programs
are structured to be competitive both in their design and in the
total compensation that they offer.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Performance-based.</font> Certain officers
have some portion of their incentive compensation linked to
CEL-SCI&#x2019;s performance. The application of performance
measures as well as the form of the reward may vary depending on
the employee&#x2019;s position and responsibilities.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">Based
on a review of its compensation programs, CEL-SCI does not believe
that such programs encourage any of its employees to take risks
that would be likely to have a material adverse effect on
CEL-SCI.&#xA0;&#xA0;CEL-SCI reached this conclusion based on the
following:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The salaries paid
to employees are consistent with the employees&#x2019; duties and
responsibilities.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Employees who have
high impact relative to the expectations of their job duties and
functions are rewarded.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">CEL-SCI retains
employees who have skills critical to its long term
success.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">61</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Review of Executive Officer Compensation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
current policy is that the various elements of the compensation
package are not interrelated in that gains or losses from past
equity incentives are not factored into the determination of other
compensation.&#xA0;&#xA0;For instance, if options that are granted
in a previous year have an exercise price which is above the market
price of CEL-SCI&#x2019;s common stock, the Committee does not take
that circumstance into consideration in determining the amount of
the options or restricted stock to be granted the next
year.&#xA0;&#xA0;Similarly, if the options or restricted shares
granted in a previous year become extremely valuable, the Committee
does not take that into consideration in determining the options or
restricted stock to be awarded for the next
year.&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
does not have a policy with regard to the adjustment or recovery of
awards or payments if relevant performance measures upon which they
are based are restated or otherwise adjusted in a manner that would
reduce the size of an award or payment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Components of Compensation&#x2014;Executive Officers</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
executive officers are compensated through the following three
components:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Base
Salary</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Long-Term
Incentives (&#x201C;LTIs&#x201D;) (stock options and/or grants of
stock)</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Benefits</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">These
components provide a balanced mix of base compensation and
compensation that is contingent upon each executive officer&#x2019;s
individual performance. A goal of the compensation program is to
provide executive officers with a reasonable level of security
through base salary and benefits. CEL-SCI wants to ensure that the
compensation programs are appropriately designed to encourage
executive officer retention and motivation to create shareholder
value. <font style="color: #000000">The Compensation Committee
believes that CEL-SCI&#x2019;s stockholders are best served when
CEL-SCI can attract and retain talented executives by providing
compensation packages that are competitive but
fair.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In past
years, base salaries, benefits and incentive compensation
opportunities were generally targeted near the median of general
survey market data derived from indices covering similar
biotech/pharmaceutical companies.&#xA0;&#xA0;The companies included
Advaxis, Inc., Amicus Therapeutics, Inc., Celsion Corp., CytRx
Corporation, GERON Corp, Idera Pharmaceuticals, Inc., Northwest
Biotherapeutics, Inc., Oragenics, Inc., TG Therapeutics, Inc.,
Venaxis, Inc., Arrowhead Research Corp, CorMedix Inc., Fibrocell
Science, Inc., Hemispherx Biopharma, Inc., Mateon Therapeutics,
Inc., Catalyst Bioscience, Inc., Sorrento Therapeutics, Inc., Tenax
Therapeutics, Inc., Trovagene, Inc. and ZIOPHARM Oncology,
Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Base Salaries</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Base
salaries generally have been targeted to be competitive when
compared to the salary levels of persons holding similar positions
in other pharmaceutical companies and other publicly traded
companies of comparable size. Each executive officer&#x2019;s
respective responsibilities, experience, expertise and individual
performance are considered.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">62</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">A
further consideration in establishing compensation for the senior
employees is their long term history with CEL-SCI. Taken into
consideration are factors that have helped CEL-SCI survive in times
when it was financially weak, such as: willingness to accept salary
cuts, willingness not to be paid at all for extended time periods,
and in general an attitude that helped CEL-SCI survive during
financially difficult times.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Long-Term Incentives</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Stock
grants and option grants help to align the interests of
CEL-SCI&#x2019;s employees with those of its
shareholders.&#xA0;&#xA0;Options and stock grants are made under
CEL-SCI&#x2019;s Stock Option, Incentive Stock Bonus, Stock Bonus
and Stock Compensation Plans.&#xA0;&#xA0;Options are granted with
exercise prices equal to the closing price of CEL-SCI&#x2019;s
common stock on the day immediately preceding the date of grant,
with pro rata vesting at the end of each of the following three
years.&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
believes that grants of equity-based compensation:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Enhance the link
between the creation of shareholder value and long-term executive
incentive compensation;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Provide focus,
motivation and retention incentive; and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Provide competitive
levels of total compensation.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
management believes that the pricing for biotechnology stocks is
highly inefficient until the time of product sales. As such, any
long term compensation tied to progress as measured by share price
is not as efficient as it should be. The plan approved by the
shareholders in July 2014, which covers senior and mid-level
employees, seeks to address this issue by rewarding employees for
meeting major operational milestones and significantly improved
share prices.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Benefits</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition to cash and equity compensation programs, executive
officers participate in the health and welfare benefit programs
available to other employees. In a few limited circumstances,
CEL-SCI provides other benefits to certain executive officers, such
as car allowances.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">All
executive officers are eligible to participate in CEL-SCI&#x2019;s
401(k) plan on the same basis as its other employees. CEL-SCI
matches 100% of each employee&#x2019;s contribution up to 6% of his
or her salary.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">63</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
following table sets forth in summary form the compensation
received by (i) the Chief Executive and Financial Officer of
CEL-SCI and (ii) by each other executive officer of CEL-SCI who
received in excess of $100,000 during the three fiscal years ended
September 30, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 19%; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; font-weight: bold; padding-bottom: 2px;">Name and Principal Position</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font style="font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Fiscal Year</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Salary (1)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Bonus (2)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Restricted Stock Awards (3)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Option Awards (4)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">All Other Compen-sation(5)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Total</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font style="font-weight: bold; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">$</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 13px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Geert R. Kersten,</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div style="text-align: center; margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">2017</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">437,461</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15,900</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">326,961</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">55,631</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">835,953</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Chief Executive</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div style="text-align: center; margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">2016</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">558,432</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15,900</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">54,981</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">629,314</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Officer and Treasurer</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div style="text-align: center; margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">2015</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">514,083</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16,050</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">54,981</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">585,114</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;"><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div style="text-align: center; margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div style="text-align: center; margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Patricia B. Prichep,</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2017</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">171,028</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,704</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">217,974</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">411,737</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Senior Vice President</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2016</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">245,804</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,725</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">269,559</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">of Operations and</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2015</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">235,702</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,128</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,906</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">256,736</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Secretary</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Eyal Talor, Ph.D.,</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2017</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">270,163</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,600</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">217,974</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">503,768</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Chief Scientific Officer</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2016</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">303,597</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,600</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">319,227</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2015</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">290,983</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,600</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">306,613</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Daniel Zimmerman, Ph.D.,</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2017</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">166,320</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,333</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">35,989</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">221,673</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Senior Vice President of</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2016</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">228,413</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,708</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">37,081</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">285,233</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Research, Cellular</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2015</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">219,026</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,148</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">52,003</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">290,209</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Immunology</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font>
<font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">John Cipriano,</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2017</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">185,592</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">163,480</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">31</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">349,103</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Senior Vice President of</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2016</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">211,405</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">31</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">211,437</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 19%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">Regulatory Affairs</font><font style="text-align: left; vertical-align:bottom;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center"><font style="font-size: 13px; font-family: Times New Roman;">2015</font><font style="font-size: 13px; font-family: Times New Roman;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">202,718</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">31</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">202,749</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(1)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The dollar value of
base salary (cash and non-cash) earned. The officers of the Company
received stock in lieu of salary increases in FY 2016 and 2015. On
September 30, 2017, the Company had not paid and owed salaries to
the following employees:</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Name</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Salary</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">125,559</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patricia
Prichep</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">71,648</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Eyal
Talor, Ph.D.</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">33,392</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Daniel
Zimmerman, Ph.D.</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62,088</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31,828</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(2)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The dollar value of
bonus (cash and non-cash) earned.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(3)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The fair value of
the shares of restricted stock issued during the periods covered by
the table is shown as compensation for services to the persons
listed in the table. For all persons listed in the table, the
shares were issued as CEL-SCI's contribution on behalf of the named
officer who participates in CEL-SCI's 401(k) retirement plan. The
value of all stock awarded during the periods covered by the table
is calculated according to ASC 718-10-30-3 which represented the
grant date fair value.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">64</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(4)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The fair value of
all stock options granted during the periods covered by the table
are calculated on the grant date in accordance with ASC 718-10-30-3
which represented the grant date fair value.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(5)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">All other
compensation received that CEL-SCI could not properly report in any
other column of the table including the dollar value of any
insurance premiums paid by, or on behalf of, CEL-SCI with respect
to term life insurance for the benefit of the named executive
officer and car allowances paid by CEL-SCI. Includes board of
directors fees for Mr. Kersten.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Employee Pension, Profit Sharing or Other Retirement
Plans</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
has a defined contribution retirement plan, qualifying under
Section 401(k) of the Internal Revenue Code and covering
substantially all CEL-SCI&#x2019;s employees. CEL-SCI&#x2019;s
contribution to the plan is made in shares of CEL-SCI's common
stock. Each participant's contribution is matched by CEL-SCI with
shares of common stock which have a value equal to 100% of the
participant's contribution, not to exceed the lesser of $1,000 or
6% of the participant's total compensation. CEL-SCI's contribution
of common stock is valued each quarter based upon the closing price
of its common stock. The fiscal 2017 expenses for this plan were
approximately $163,000. Other than the 401(k) Plan, CEL-SCI does
not have a defined benefit, pension plan, profit sharing or other
retirement plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Compensation of Directors During Year Ended September 30,
2017</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="font-family: Times New Roman; font-weight: bold;">Name</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Fees</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Stock Awards (1)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Option Awards (2)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Total</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">40,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">326,961</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">366,961</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Alexander Esterhazy
(3)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">33,750</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15,581</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">49,331</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Peter R.
Young</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">50,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">51,477</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">101,477</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">45,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">51,477</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">96,477</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(1)&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The fair value of
stock issued for services.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(2)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The fair value of
options granted computed in accordance with ASC 718-10-30-3 on the
date of grant which represents their grant date fair
value.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(3)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Mr. Esterhazy
passed away on August 30, 2017.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Directors&#x2019;
fees paid to Geert Kersten are included in the Executive
Compensation table.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Employment Contracts</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Geert Kersten</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 31, 2016, CEL-SCI entered into a three-year employment
agreement with Geert Kersten, CEL-SCI&#x2019;s Chief Executive
Officer. The employment agreement with Mr. Kersten, which is
essentially the same as Mr. Kersten&#x2019;s prior employment
agreement, as amended on August 30, 2013, provided that, during the
term of the agreement, CEL-SCI would pay Mr. Kersten an annual
salary of $559,052, plus any increases in proportion to salary
increases granted to other senior executive officers of CEL-SCI, as
well any increases approved by the Board of Directors during the
period of the employment agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">65</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 12px;">
<font style="font-family: Times New Roman; font-size: 13px">During
the employment term, Mr. Kersten will be entitled to receive any
other benefits which are provided to CEL-SCI's executive officers
or other full time employees in accordance with CEL-SCI's policies
and practices and subject to Mr. Kersten&#x2019;s satisfaction of
any applicable condition of eligibility.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">If Mr.
Kersten resigns within ninety (90) days of the occurrence of any of
the following events: (i) a reduction in Mr. Kersten&#x2019;s salary
(ii) a relocation (or demand for relocation) of Mr. Kersten&#x2019;s
place of employment to a location more than ten (10) miles from his
current place of employment, (iii) a significant and material
reduction in Mr. Kersten&#x2019;s authority, job duties or level of
responsibility or the imposition of significant and material
limitations on the Mr. Kersten&#x2019;s autonomy in his position, or
(iv) a Change in Control, then the employment agreement will be
terminated and Mr. Kersten will be entitled to receive a lump-sum
payment from CEL-SCI equal to 24 months of salary ($1,118,104) and
the unvested portion of any stock options would vest immediately
($690,418). For purposes of the employment agreement a change in
the control of CEL-SCI means: (1) the merger of CEL-SCI with
another entity if after such merger the shareholders of CEL-SCI do
not own at least 50% of voting capital stock of the surviving
corporation; (2) the sale of substantially all of the assets of
CEL-SCI; (3) the acquisition by any person of more than 50% of
CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's
directors which has not been approved by the incumbent
directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
employment agreement will also terminate upon the death of Mr.
Kersten, Mr. Kersten&#x2019;s physical or mental disability, willful
misconduct, an act of fraud against CEL-SCI, or a breach of the
employment agreement by Mr. Kersten. If the employment agreement is
terminated for any of these reasons, Mr. Kersten, or his legal
representatives, as the case may be, will be paid the salary
provided by the employment agreement through the date of
termination, any options or bonus shares of CEL-SCI then held by
Mr. Kersten will become fully vested and the expiration date of any
options which would expire during the four year period following
his termination of employment will be extended to the date which is
four years after his termination of employment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Patricia B. Prichep / Eyal Talor, Ph.D.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 31, 2016, CEL-SCI entered into a three-year employment
agreement with Patricia B. Prichep, CEL-SCI&#x2019;s Senior Vice
President of Operations. The employment agreement with Ms. Prichep,
which is essentially the same as Ms. Prichep&#x2019;s prior
employment agreement entered into on August 30, 2013 provided that,
during the term of the agreement, CEL-SCI would pay Ms. Prichep an
annual salary of $245,804 plus any increases approved by the Board
of Directors during the period of the employment
agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 31, 2016, CEL-SCI entered into a three-year employment
agreement with Eyal Talor, Ph.D., CEL-SCI&#x2019;s Chief Scientific
Officer. The employment agreement with Dr. Talor, which is
essentially the same as Dr. Talor&#x2019;s prior employment
agreement entered into on August 30, 2013, provided that, during
the term of the agreement, CEL-SCI would pay Dr. Talor an annual
salary of $303,453 plus any increases approved by the Board of
Directors during the period of the employment
agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">66</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px;">
<font style="font-family: Times New Roman; font-size: 13px">If Ms.
Prichep or Dr. Talor resigns within ninety (90) days of the
occurrence of any of the following events: (i) a relocation (or
demand for relocation) of employee&#x2019;s place of employment to a
location more than ten (10) miles from the employee&#x2019;s current
place of employment, (ii) a significant and material reduction in
the employee&#x2019;s authority, job duties or level of
responsibility or (iii) the imposition of significant and material
limitations on the employee&#x2019;s autonomy in her or his
position, the employment agreement will be terminated and the
employee will be paid the salary provided by the employment
agreement through the date of termination and the unvested portion
of any stock options held by the employee will vest
immediately.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In the
event there is a change in the control of CEL-SCI, the employment
agreements with Ms. Prichep and Dr. Talor allow Ms. Prichep and/or
Dr. Talor (as the case may be) to resign from her or his position
at CEL-SCI and receive a lump-sum payment from CEL-SCI equal to 18
months of salary ($368,706 and $455,180 respectively). In addition,
the unvested portion of any stock options held by the employee will
vest immediately ($222,568 and $222,568 respectively). For purposes
of the employment agreements, a change in the control of CEL-SCI
means: (1) the merger of CEL-SCI with another entity if after such
merger the shareholders of CEL-SCI do not own at least 50% of
voting capital stock of the surviving corporation; (2) the sale of
substantially all of the assets of CEL-SCI; (3) the acquisition by
any person of more than 50% of CEL-SCI's common stock; or (4) a
change in a majority of CEL-SCI's directors which has not been
approved by the incumbent directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
employment agreements with Ms. Prichep and Dr. Talor will also
terminate upon the death of the employee, the employee&#x2019;s
physical or mental disability, willful misconduct, an act of fraud
against CEL-SCI, or a breach of the employment agreement by the
employee. If the employment agreement is terminated for any of
these reasons the employee, or her or his legal representatives, as
the case may be, will be paid the salary provided by the employment
agreement through the date of termination.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Compensation Committee Interlocks and Insider
Participation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
has a compensation committee comprised of Mr. Bruno Baillavoine and
Dr. Peter Young, both of whom are independent
directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">During
the year ended September 30, 2017, no director of CEL-SCI was also
an executive officer of another entity, which had an executive
officer of CEL-SCI serving as a director of such entity or as a
member of the compensation committee of such entity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="text-decoration: underline">Loan
from Officer and Director</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Between
December 2008 and June 2009, CEL-SCI&#x2019;s President, and a
director, Maximilian de Clara, loaned CEL-SCI
$1,104,057.&#xA0;&#xA0;Between July 2009 and July 2015, the loan
from Mr. de Clara bore interest at 15% per year. At Mr. de
Clara&#x2019;s option, the loan was convertible into shares of
CEL-SCI&#x2019;s common stock, determined by dividing the amount to
be converted by $100.00.&#xA0;&#xA0;In accordance with the loan
agreement, CEL-SCI issued Mr. de Clara warrants to purchase 6,593
shares of CEL-SCI&#x2019;s common stock at a price of $100.00 per
share.&#xA0;&#xA0;These warrants expired on December 24,
2014.&#xA0;&#xA0;In consideration for an extension of the due date,
Mr. de Clara received warrants to purchase 7,397 shares of
CEL-SCI&#x2019;s common stock at a price of $125.00 per
share.&#xA0;&#xA0;These warrants expired on January 6,
2015.&#xA0;&#xA0;In consideration of Mr. de Clara&#x2019;s agreement
to subordinate his note to the convertible preferred shares and
convertible debt as part of a prior year settlement agreement,
CEL-SCI extended the maturity date of the note to July 6, 2015.
&#xA0;&#xA0;In August 2014, the loan was transferred to the de
Clara Trust, of which CEL-SCI&#x2019;s Chief Executive Officer,
Geert Kersten, is the trustee and a beneficiary.&#xA0;&#xA0;Mr. de
Clara continued to receive the interest payments.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">67</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On June
29, 2015, CEL-SCI extended the maturity date of the note to July 6,
2017, lowered the interest rate to 9% per year and changed the
conversion price to $14.75, the closing stock price on the previous
trading day.&#xA0;&#xA0;&#xA0;The new terms were effective July 7,
2015.&#xA0;&#xA0; Concurrently, CEL-SCI extended the expiration
date of the Series N warrants to August 18,
2017.&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 11, 2015, at the request of Lake Whillans Vehicle I, LLC,
the note was extended for one year to July 6, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
January 12, 2016, CEL-SCI owed the de Clara Trust $1,105,989, which
amount included accrued and unpaid interest. On January 13, 2016,
the de Clara Trust demanded payment on the note payable. At the
same time CEL-SCI sold 120,000 shares of its common stock and
120,000 Series X warrants to the de Clara Trust for approximately
$1,100,000. Each warrant allows the de Clara Trust to purchase one
share of CEL-SCI&#x2019;s common stock at a price of $9.25 per share
at any time on or before January 13, 2021.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Stock Option, Bonus and Compensation Plans</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
has Incentive Stock Option Plans, Non-Qualified Stock Option, Stock
Bonus, Stock Compensation Plans and an Incentive Stock Bonus Plan.
All Stock Option, Bonus and Compensation Plans have been approved
by the stockholders. A summary description of these Plans follows.
In some cases these Plans are collectively referred to as the
"Plans".</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Incentive Stock Option Plan</font>.
The Incentive Stock Option Plans authorize the issuance of shares
of CEL-SCI's common stock to persons who exercise options granted
pursuant to the Plans. Only CEL-SCI&#x2019;s employees may be
granted options pursuant to the Incentive Stock Option
Plans.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Options
may not be exercised until one year following the date of grant.
Options granted to an employee then owning more than 10% of the
common stock of CEL-SCI may not be exercisable by its terms after
five years from the date of grant. Any other option granted
pursuant to the Plans may not be exercisable by its terms after ten
years from the date of grant.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
purchase price per share of common stock purchasable under an
option is determined by the CEL-SCI&#x2019;s Compensation Committee
but cannot be less than the fair market value of the common stock
on the date of the grant of the option (or 110% of the fair market
value in the case of a person owning more than 10% of CEL-SCI's
outstanding shares).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Non-Qualified Stock Option
Plans</font>. The Non-Qualified Stock Option Plans authorize the
issuance of shares of CEL-SCI's common stock to persons that
exercise options granted pursuant to the Plans. CEL-SCI's
employees, directors, officers, consultants and advisors are
eligible to be granted options pursuant to the Plans, provided
however that bona fide services must be rendered by such
consultants or advisors and such services must not be in connection
with sale a capital-raising transaction or promoting
CEL-SCI&#x2019;s common stock. The option exercise price is
determined by CEL-SCI&#x2019;s Compensation Committee.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Stock Bonus Plan</font>. Under the
Stock Bonus Plans shares of CEL-SCI&#x2019;s common stock may be
issued to CEL-SCI's employees, directors, officers, consultants and
advisors, provided however that bona fide services must be rendered
by consultants or advisors and such services must not be in
connection with a capital-raising transaction or promoting
CEL-SCI&#x2019;s common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">68</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Stock Compensation Plan</font>. Under
the Stock Compensation Plan, shares of CEL-SCI&#x2019;s common stock
may be issued to CEL-SCI&#x2019;s employees, directors, officers,
consultants and advisors in payment of salaries, fees and other
compensation owed to these persons. However, bona fide services
must be rendered by consultants or advisors and such services must
not be in connection with the offer or sale of securities in a
capital-raising transaction or promoting CEL-SCI&#x2019;s common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Incentive Stock Bonus Plan</font>.
Under the 2014 Incentive Stock Bonus Plan, shares of
CEL-SCI&#x2019;s common stock may be issued to executive officers
and other employees who contribute significantly to the success of
CEL-SCI, to participate in its future prosperity and growth and
aligns their interests with those of CEL-SCI&#x2019;s shareholders.
The purpose of the Plan is to provide long term incentive for
outstanding service to CEL-SCI and its shareholders and to assist
in recruiting and retaining people of outstanding ability and
initiative in executive and management positions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Other Information Regarding the
Plans</font>. The Plans are administered by CEL-SCI's Compensation
Committee (&#x201C;the Committee&#x201D;), each member of which is a
director of CEL-SCI. The members of the Committee were selected by
CEL-SCI's Board of Directors and serve for a one-year tenure and
until their successors are elected. A member of the Committee may
be removed at any time by action of the Board of Directors. Any
vacancies which may occur on the Committee will be filled by the
Board of Directors. The Committee is vested with the authority to
interpret the provisions of the Plans and supervise the
administration of the Plans. In addition, the Committee is
empowered to select those persons to whom shares or options are to
be granted, to determine the number of shares subject to each grant
of a stock bonus or an option and to determine when, and upon what
conditions, shares or options granted under the Plans will vest or
otherwise be subject to forfeiture and cancellation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In the
discretion of the Committee, any option granted pursuant to the
Plans may include installment exercise terms such that the option
becomes fully exercisable in a series of cumulating portions. The
Committee may also accelerate the date upon which any option (or
any part of any options) is first exercisable. Any shares issued
pursuant to the Stock Bonus Plans or Stock Compensation Plan and
any options granted pursuant to the Incentive Stock Option Plans or
the Non-Qualified Stock Option Plans will be forfeited if the
"vesting" schedule established by the Committee administering the
Plans at the time of the grant is not met. For this purpose,
vesting means the period during which the employee must remain an
employee of CEL-SCI or the period of time a non-employee must
provide services to CEL-SCI. At the time an employee ceases working
for CEL-SCI (or at the time a non-employee ceases to perform
services for CEL-SCI), any shares or options not fully vested will
be forfeited and cancelled. At the discretion of the Committee
payment for the shares of common stock underlying options may be
paid through the delivery of shares of CEL-SCI's common stock
having an aggregate fair market value equal to the option price,
provided such shares have been owned by the option holder for at
least one year prior to such exercise. A combination of cash and
shares of common stock may also be permitted at the discretion of
the Committee.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Options
are generally non-transferable except upon death of the option
holder. Shares issued pursuant to the Stock Bonus Plans will
generally not be transferable until the person receiving the shares
satisfies the vesting requirements imposed by the Committee when
the shares were issued.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">69</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Board of Directors of CEL-SCI may at any time, and from time to
time, amend, terminate, or suspend one or more of the Plans in any
manner it deems appropriate, provided that such amendment,
termination or suspension will not adversely affect rights or
obligations with respect to shares or options previously
granted.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Stock Options</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
following tables show information concerning the options granted
during the fiscal year ended September 30, 2017, to the persons
named below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="width: 40%;">
<div><font style="font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td colspan="8" style="vertical-align: bottom; width: 60%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-weight: bold"><font style="font-size: 11px; font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Options
Granted</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-weight: bold"><font style="font-size: 11px; font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Name&#xA0;</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center"><font style="font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-weight: bold"><font style="font-size: 11px; font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Grant
Date</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center"><font style="font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-weight: bold"><font style="font-size: 11px; font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Options
Granted</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center"><font style="font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-weight: bold"><font style="font-size: 11px; font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Price Per
Share</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center"><font style="font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-weight: bold"><font style="font-size: 11px; font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Expiration
Date</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/28/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;180,000</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
2.18</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/27/2027</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Patricia
Prichep</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/28/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;120,000</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
2.18</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/27/2027</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Eyal
Talor</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/28/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;120,000</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
2.18</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/27/2027</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Daniel
Zimmerman</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">6/29/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;6,000</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
1.87</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">6/28/2027</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">9/18/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;20,000</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
1.59</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">9/17/2027</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/28/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;90,000</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
2.18</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/27/2027</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/28/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;20,000</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
2.18</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/27/2027</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">6/12/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;7,500</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
2.50</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">6/11/2027</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Peter
Young</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/28/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;20,000</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
2.18</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">7/27/2027</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Peter
Young</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">6/12/2017</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;7,500</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;$
2.50</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">6/11/2027</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
following tables show information concerning the options cancelled
and exercised during the fiscal year ended September 30, 2017, to
the persons named below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="width: 24%;">
<div><font>&#xA0;</font></div>
</td>
<td colspan="6" style="vertical-align: bottom; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Options
Cancelled</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 24%;">
<div><font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">&#xA0;</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div><font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">&#xA0;</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Weighted</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Weighted
Average</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 24%;">
<div><font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">&#xA0;</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div><font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">&#xA0;</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Average</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Remaining
Contractual</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Employee</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Total
Options</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Exercise
Price</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Term
(Years)</font></font></font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="width: 24%;">
<div><font>&#xA0;</font></div>
</td>
<td colspan="6" style="vertical-align: bottom; width: 75%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
None</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="width: 24%;">
<div><font>&#xA0;</font></div>
</td>
<td colspan="6" style="vertical-align: bottom; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Options
Exercised</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 24%;">
<div><font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">&#xA0;</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">&#xA0;Date
of</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Shares
Acquired</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">&#xA0;&#xA0;&#xA0;Value</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Name</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Exercise</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">On
Exercise</font></font></font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 24%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: bold; font-family: Times New Roman;">Realized</font></font></font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="width: 24%;">
<div><font>&#xA0;</font></div>
</td>
<td colspan="6" style="vertical-align: bottom; width: 75%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">None</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">70</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following lists the outstanding options held by the persons named
below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:28%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 90%; font-weight: bold;">Shares underlying unexercised</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:28%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 90%; font-family: Times New Roman; font-weight: bold;">Option which are:</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold; padding-bottom: 2px;">Exercise</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Expiration</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Name</font></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Exercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Unexercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Price</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Date</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Geert
R. Kersten</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,354</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(1)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/23/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,334</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,560</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,080</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">---------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">42,928</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,666</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,920</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">180,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.18</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/27/27</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">---------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">199,586</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patricia
B. Prichep</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,868</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(1)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/23/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,320</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,624</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20,812</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,376</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.18</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/27/27</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">129,376</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Eyal
Talor, Ph.D.</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">963</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(1)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/23/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/19</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,497</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,624</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,200</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">71</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="null"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18,084</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">95.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/06/19</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,376</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/22</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.18</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/27/27</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">129,376</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Daniel
Zimmerman, Ph.D.</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">900</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,568</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/17/17</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">900</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">52.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">08/05/24</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,667</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/25/25</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,334</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/21/26</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18,669</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,333</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/25/25</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,666</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/21/26</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1.87</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/28/27</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1.59</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/17/27</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">29,999</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">03/04/18</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/20/20</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">172.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">04/14/21</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">09/30/19</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">900</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">97.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">05/17/22</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">900</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">57.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">06/30/23</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">02/25/24</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.18</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">07/27/27</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">----------</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Options awarded to
employees who did not collect a salary, or reduced or deferred
their salary between September 15, 2008 and June 30, 2009. For
example, Mr. Kersten and Ms. Prichep did not collect any salary
between September 30, 2008 and June 30, 2009.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(2)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Long-term
performance options: The Board of Directors has identified the
successful Phase III clinical trial for Multikine to be the most
important corporate event to create shareholder value. Therefore,
one third of the options can be exercised when the first 400
patients are enrolled in CEL-SCI's Phase III head and neck cancer
clinical trial. One third of the options can be exercised when all
of the patients have been enrolled in the Phase III clinical trial.
One third of the options can be exercised when the Phase III trial
is completed. The grant-date fair value of these options awarded to
the senior management of the Company amounts to $3.3 million in
total.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">72</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Summary</font>. The following shows
certain information as of September 30, 2017 concerning the stock
options and stock bonuses granted by CEL-SCI. Each option
represents the right to purchase one share of CEL-SCI's common
stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="font-family: Times New Roman; font-weight: bold;">Name of
Plan</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Total Shares Reserved Under Plans</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Shares Reserved for Outstanding
Options</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Shares Issued</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Remaining Options/Shares Under
Plans</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Incentive Stock
Option Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">138,400</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">124,758</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">454</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Non-Qualified Stock
Option</font> <font style="font-family: Times New Roman; font-size: 13px">Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,187,200</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,115,086</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">42,830</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Stock Bonus
Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">383,760</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">206,390</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">177,337</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Stock Compensation
Plan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">134,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">115,590</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">18,410</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Incentive Stock
Bonus Plan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">640,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">624,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Of the
shares issued pursuant to CEL-SCI's Stock Bonus Plans, 124,268
shares were issued as part of CEL-SCI's contribution to its 401(k)
plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
following table shows the weighted average exercise price of the
outstanding options granted pursuant to CEL-SCI&#x2019;s Incentive
and Non-Qualified Stock Option Plans as of September 30, 2017,
CEL-SCI&#x2019;s most recent fiscal year end. CEL-SCI's Incentive
and Non-Qualified Stock Option Plans have been approved by
CEL-SCI's shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 58%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;"><font style="font-family: Times New Roman; font-weight: bold;">Plan
category</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Number of Securities to be Issued Upon Exercise of
Outstanding Options (a)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Weighted-Average Exercise Price of Outstanding
Options</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Number of Securities Remaining Available For Future
Issuance Under Equity Compensation Plans, Excluding
SecuritiesReflected in Column (a)</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Incentive Stock
Option Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">124,758</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">38.82</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">454</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Non-Qualified Stock
Option Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,115,086</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.93</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">42,830</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Long Term Incentive Plans - Awards in Last Fiscal Year</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">See
footnote 9 to the financial statements included as part of this
report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">73</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: -96px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM
12. <font style="text-decoration: underline">SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
following table shows, as of December 1, 2017, information with
respect to the only persons owning beneficially 5% or more of
CEL-SCI&#x2019;s outstanding common stock and the number and
percentage of outstanding shares owned by each director and officer
of CEL-SCI and by the officers and directors as a group. Unless
otherwise indicated, each owner has sole voting and investment
powers over his shares of common stock.</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%;">
<div style="border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; font-size: 11px;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-weight: bold;">Name and
Address<br></font></div>
</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Number of Shares (1)<br></font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Percent of Class (2)<br></font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Geert R.
Kersten</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,394,267</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">(3)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">10.9</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Patricia B.
Prichep</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">189,174</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1.6</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Eyal Talor,
Ph.D.</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">139,448</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1.2</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Daniel H.
Zimmerman, Ph.D.</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">34,753</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">*</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">53,500</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">*</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Peter R. Young,
Ph.D.</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">208 Hewitt Drive,
Suite 103-143</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Waco, TX
76712</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">23,445</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">*</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">8229 Boone Blvd.,
Suite 802</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA
22182</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,167</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">*</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">All Officers and
Directors</font></div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">as a Group (7
persons)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,843,754</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14.2</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">*Less
than 1%</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">74</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Includes shares
issuable prior to February 28, 2018 upon the exercise of options,
convertible notes or warrants granted to the following
persons:</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin: 0px; padding-top: 0px; padding-bottom: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-left:0px;font-size:13px;margin-top:0px;margin-bottom:0px;width:100%;margin-right:0px;font-family:Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:86%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-size: 11px">
<div>
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px"><font style="font-family: Times New Roman; font-weight: bold">&#xA0;</font></div>
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px"><font style="font-family: Times New Roman; font-weight: bold">Name</font></div>
</div>
</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times New Roman;font-size:11px;">Options, Notes or Warrants ExercisablePrior to
February 28, 2018</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:86%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Geert R. Kersten,
Esq.</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">909,031</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">(3)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Patricia B.
Prichep</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">49,481</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Eyal Talor,
Ph.D.</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">19,460</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Daniel Zimmerman,
Ph.D.</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,002</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,500</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Peter R. Young,
Ph.D.</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,254</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Bruno
Baillavoine</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,167</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(2)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Amount includes
shares referred to in (1) above but excludes shares which may be
issued upon the exercise or conversion of other options, warrants
and other convertible securities previously issued by
CEL-SCI.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px">(3)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Amount includes
shares held in trust for the benefit of Mr. Kersten's children and
warrants held in the de Clara Trust, of which Mr. Kersten is a
beneficiary. Mr. Kersten is the stepson of Maximilian de Clara,
CEL-SCI&#x2019;s former president and director.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
13.</font> <font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">See
Item 11 of this report, &#x201C;Loan from Officer and
Director,&#x201D; for information concerning modifications to the
terms of a loan originally made by Maximilian de Clara,
CEL-SCI&#x2019;s former President and director, and subsequently
transferred to the de Clara Trust. Geert Kersten, CEL-SCI&#x2019;s
Chief Executive Officer and a director, is a beneficiary of the de
Clara Trust.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; text-decoration: underline; font-family: Times New Roman; font-size: 13px">
</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px;">ITEM
14.</font> <font style="font-weight: bold; text-decoration: underline; font-family: Times New Roman; font-size: 13px">
PRINCIPAL ACCOUNTING FEES AND SERVICES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">BDO
USA, LLP served as CEL-SCI&#x2019;s independent registered public
accountant for the two years ended September 30, 2017. The
following table shows the aggregate fees billed to CEL-SCI for
these years by BDO USA, LLP:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:28%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Year Ended September 30,</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2017</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2016</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Audit
Fees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">375,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">311,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Audit Related
Fees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Tax
Fees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">All Other
Fees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">75</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Audit
fees represent amounts billed for professional services rendered
for the audit of CEL-SCI&#x2019;s annual financial statements and
the reviews of the financial statements included in CEL-SCI&#x2019;s
10-Q reports for the fiscal year and all regulatory
filings.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Before
BDO USA, LLP was engaged by CEL-SCI to render audit or non-audit
services, the engagement was approved by CEL-SCI&#x2019;s audit
committee. CEL-SCI&#x2019;s Board of Directors is of the opinion
that the Audit Fees charged by BDO USA, LLP are consistent with BDO
USA, LLP maintaining its independence from CEL-SCI.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 84px; margin-right: 0px; text-indent: -84px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">See the
Financial Statements attached to this
Report.&#xA0;<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 7%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Exhibits</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3(a)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Articles of Incorporation</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 3(a) of CEL-SCI's combined Registration
Statement on Form S-1 and Post-Effective Amendment ("Registration
Statement"), Registration Nos. 2-85547-D and 33-7531.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3(b)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amended Articles</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 3(a) of CEL-SCI's Registration Statement on
Form S-1, Registration Nos. 2-85547-D and 33-7531.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3(c)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amended Articles (Name change only)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Filed
as Exhibit 3(c) to CEL-SCI's Registration Statement on Form S-1
Registration Statement (No. 33-34878).</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3(d)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Bylaws</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 3(b) of CEL-SCI's Registration Statement on
Form S-1, Registration Nos. 2-85547-D and 33-7531.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3(e)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amended Bylaws</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 3(ii) of CEL-SCI&#x2019;s report on Form 8-K
dated March 16, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Shareholders Rights Agreement, as Amended</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 4&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4(b)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Incentive Stock Option Plan</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 4 (b) filed on September 25, 2012 with the
Company&#x2019;s registration statement on Form S&#xAC;8 (File
number 333-184092.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4(c)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Non-Qualified Stock Option Plan</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 4 (b) filed on August 19, 2014 with the
Company&#x2019;s registration statement on Form S&#xAC;8 (File
number 333-198244).</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">76</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="null"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4(d)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Stock Bonus Plan</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 4 (d) filed on September 25, 2012 with the
Company&#x2019;s registration statement on Form S&#xAC;8 (File
number 333-184092.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4(e)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Stock Compensation Plan</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 4 (e) filed on September 25, 2012 with the
Company&#x2019;s registration statement on Form S&#xAC;8 (File
number 333-184092.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4(f)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2014 Incentive Stock Bonus Plan</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Filed
with this Amendment No. 2 to the Company&#x2019;s annual report on
Form 10-K for the year ended September 30, 2014.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4(g)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Form of Convertible Note (June 2017 Financing)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4(h)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Form of Convertible Note (July 207 Financing)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(f)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement (together&#xA0;with schedule required
by Instruction 2 to&#xA0;Item 601 of Regulation S-K) pertaining
to&#xA0;Series K notes and warrants, together with the exhibits to
the Securities Purchase&#xA0;Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10 to&#xA0;CEL-SCI&#x2019;s report on Form
8-K dated&#xA0;August 4, 2006.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(g)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Subscription Agreement (together with&#xA0;Schedule required by
Instruction 2 toItem 601 of Regulation S-K) pertaining
to&#xA0;April 2007 sale of 800,000 shares of&#xA0;CEL-SCI&#x2019;s
common stock, 400,000&#xA0;Series L warrants and 400,000 Series
M&#xA0;Warrants</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10 of&#xA0;CEL-SCI&#x2019;s report on Form
8-K dated April&#xA0;18, 2007</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(h)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Warrant Adjustment Agreement with&#xA0;Laksya Ventures</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(i) of&#xA0;CEL-SCI&#x2019;s report on
Form 8-K dated August&#xA0;3, 2010</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(l)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
First Amendment to Development Supply&#xA0;and Distribution
Agreement with Orient&#xA0;Europharma.</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(m)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2010.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(m)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Exclusive License and Distribution&#xA0;Agreement with
Teva&#xA0;Pharmaceutical Industries&#xA0;Ltd.</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(n)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2010.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(n)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Lease Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(o)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2010.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(o)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Promissory Note with Maximilian de&#xA0;Clara, together with
Amendments 1 and 2</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(p)&#xA0;filed with CEL-SCI&#x2019;s 10-K
report for the&#xA0;year ended September 30, 2010.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">77</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="null"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(p)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Licensing Agreement with Byron&#xA0;Biopharma</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(i) of&#xA0;CEL-SCI&#x2019;s report on
Form 8-K dated March&#xA0;27, 2009</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(z)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Development, Supply and Distribution&#xA0;Agreement with Orient
Europharma</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit&#xA0;10(z)&#xA0;filed with CEL-SCI&#x2019;s
report on Form&#xA0;10-K for the year ended September 30,
2003.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(aa)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement and&#xA0;form of the Series F
warrants, which is&#xA0;and exhibit to the Securities
Purchase&#xA0;Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(aa)&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated&#xA0;October 3, 2011.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(bb)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Placement Agent Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(bb)&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated&#xA0;October 3, 2011.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(cc)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities&#xA0;&#xA0;Purchase Agreement,&#xA0;&#xA0;together
with&#xA0;&#xA0;the form of the Series H warrant, which is an
exhibit to the securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(cc) of CEL-SCI&#x2019;s report on Form
8-K dated January 25, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(dd)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Placement Agent Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(dd)&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated January 25, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align: top; width: 7%;">
10(ee)<br></td>
<td colspan="1" style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Warrant Amendment Agreement, together with the form of the Series P
warrant, which is an exhibit to the Warrant Amendment
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(ee)&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated February 10, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(ff)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Placement Agent Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(ff)&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated February 10, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(gg)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities&#xA0;&#xA0;Purchase&#xA0;&#xA0;Agreement&#xA0;&#xA0;and
the form of the&#xA0;&#xA0;Series
Q&#xA0;&#xA0;&#xA0;warrant,&#xA0;&#xA0;which is
an&#xA0;&#xA0;exhibit to the Securities Purchase
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(gg)&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated June 18, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(hh)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Placement Agent Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(hh)&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated June 18, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ii)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities&#xA0;&#xA0;Purchase&#xA0;&#xA0;Agreement&#xA0;&#xA0;and
the form of the&#xA0;&#xA0;Series
R&#xA0;&#xA0;&#xA0;warrant,&#xA0;&#xA0;which is
an&#xA0;&#xA0;exhibit to the Securities Purchase
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(ii)&#xA0;of CEL-SCI&#x2019;s report on
Form 8-K dated December 5, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (jj)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Placement Agent Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(jj)&#xA0;&#xA0;of CEL-SCI&#x2019;s report
on Form 8-K dated December 5, 2012.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">78</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="null"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (nn)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Underwriting Agreement, together with the form of Series S warrant
which is an exhibit to the underwriting agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
dated October 8, 2013.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (oo)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Underwriting Agreement, together with the form of Series S warrant
which is an exhibit to the underwriting agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
dated December 19, 2013.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (pp)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Underwriting Agreement, together with the form of Series T warrant
which is an exhibit to the warrant agent agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
dated April 15, 2014.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (qq)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Underwriting Agreement, together with the form of Series S warrant
which is an exhibit to the warrant agent agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
dated October 23, 2014.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (rr)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Assignment and Assumption Agreement with Teva Pharmaceutical
Industries, Ltd. and GCP Clinical Studies, Ltd.</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(rr) of CEL-SCI&#x2019;s report on Form
10-K/A report for the&#xA0;year ended September 30, 2014 dated
April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ss)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Service Agreement with GCP Clinical Studies, Ltd., together with
Amendment 1 thereto*</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(ss) of CEL-SCI&#x2019;s first amendment
to its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (tt)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Joinder Agreement with PLIVA Hrvatska d.o.o.</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(tt) of CEL-SCI&#x2019;s first amendment
to its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (uu)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Master Service Agreement with Ergomed Clinical Research,
Ltd.,&#xA0;&#xA0;and Clinical Trial Orders thereunder</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(uu) of CEL-SCI&#x2019;s first amendment
to its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (vv)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Co-Development and Revenue Sharing Agreement with Ergomed Clinical
Research Ltd., dated April 19, 2013, as amended</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(vv) of CEL-SCI&#x2019;s first amendment
to its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ww)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Co-Development and Revenue Sharing Agreement
II:&#xA0;&#xA0;Cervical Intraepithelial Neoplasia in HIV/HPV
co-infected women, with Ergomed Clinical Research Ltd., dated
October 10, 2013, as amended</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(ww) of CEL- first amendment to its Form
10-K report for the&#xA0;year ended September 30, 2014 dated April
17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (xx)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Co-Development and Revenue Sharing Agreement III: Anal warts and
anal intraepithelial neoplasia in HIV/HPV co-infected patients,
with Ergomed Clinical Research Ltd., dated October 24,
2013</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(xx) of CEL-SCI&#x2019;s first amendment
to its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">79</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="null"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (yy)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Master Services Agreement with Aptiv Solutions, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(yy) of CEL-SCI&#x2019;s first amendment
to its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (zz)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Project Agreement Number 1 with Aptiv Solutions, Inc. together with
Amendments 1 and 2 thereto*</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(zz) of CEL-SCI&#x2019;s first amendment
to its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (aaa)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Second Amendment to Development Supply and Distribution Agreement
with Orient Europharma</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(aaa) of CEL-SCI&#x2019;s first amendment
to its Form 10-K report for the&#xA0;year ended September 30, 2014
dated April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (bbb)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amended and Restated Promissory Note with Maximilian de
Clara</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(bbb) of CEL-SCI&#x2019;s report on Form
10-K/A report for the&#xA0;year ended September 30, 2014 dated
April 17, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ccc)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Placement Agent Agreement dated May 22,</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
filed on May 26, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2015 by and among CEL-SCI Corporation and Dawson James Securities,
Inc.</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ddd)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Warrant Agent Agreement (as amended),</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10 (ccc) of CEL-SCI&#x2019;s report on Form
8-K filed on May 29, 2015.</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Series V warrants</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (eee)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Assignment of Proceeds and Investment Agreement between CEL-SCI
Corporation and Lake Whillans Vehicle 1.</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10 (ddd) of CEL-SCI&#x2019;s report on Form
8-K filed on October 16, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (fff)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Placement Agent Agreement dated October 22, 2015 by and among
CEL-SCI Corporation and Dawson James Securities, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 1.1 of CEL-SCI&#x2019;s report on Form 8-K
filed on October 23, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ggg)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Warrant Agent Agreement, Series W warrants</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10 (eee) of CEL-SCI&#x2019;s report on Form
8-K filed on October 23, 2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (iii)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amendment to Co-Development and Revenue</font> <font style="color: #000000; font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Sharing Agreement with Ergomed Clinical</font></font> <font style="color: #000000; font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research,
Ltd., dated September 15, 2015</font></font></font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10 (iii)&#xA0;filed with CEL-SCI&#x2019;s
10-K report for the&#xA0;year ended September 30,
2015.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (jjj)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(jjj) of CEL-SCI&#x2019;s report on Form
8-K dated May 19, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">80</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="null"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (kkk)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(kkk) of CEL-SCI&#x2019;s report on Form
8-K dated August 24, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (lll)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Termination Agreement with Maximilian de Clara</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(lll) of CEL-SCI&#x2019;s report on Form
8-K dated September 2, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (mmm)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Employment Agreement with Geert Kersten (2016-2019)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(mmm) of CEL-SCI&#x2019;s report on Form
8-K dated September 2, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (nnn)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Employment Agreement with Patricia Prichep (2016-2019)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(nnn) of CEL-SCI&#x2019;s report on Form
8-K dated September 2, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ooo)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Employment Agreement with Eyal Taylor (2016-2019)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(ooo) of CEL-SCI&#x2019;s report on Form
8-K dated September 2, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ppp)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(ppp) of CEL-SCI&#x2019;s report on Form
8-K dated December 1, 2016.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (qqq)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(qqq) of CEL-SCI&#x2019;s report on Form
8-K dated February 16, 2017.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (rrr)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(rrr) of CEL-SCI&#x2019;s report on Form
8-K dated March 8, 2017.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (sss)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(sss) of CEL-SCI&#x2019;s report on Form
8-K dated April 30, 2017.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (ttt)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(ttt) of CEL-SCI&#x2019;s report on Form
8-K dated July 27, 2017.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10 (uuu)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(uuu) of CEL-SCI&#x2019;s report on Form
8-K dated August 18, 2017.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(vvv)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Incorporated
by reference to Exhibit 10(vvv) of CEL-SCI&#x2019;s report on Form
8-K dated August 22, 2017.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(www)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amendment No. 1 to Assignment of Proceeds and Investment
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 7%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 7%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10(xxx)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amendment to Convertible Promissory Notes</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 120px;">
<font style="font-family: Times New Roman; font-size: 13px">23.1</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Consent of BDO USA,
LLP</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 120px;">
<font style="font-family: Times New Roman; font-size: 13px">31</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Rule 13a-14(a)
Certifications</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table;">
<div style="display: table-row;">
<div style="text-align: left; display: table-cell; width: 120px;">
<font style="font-family: Times New Roman; font-size: 13px">32</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Section 1350
Certifications</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">*&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Portions of this
exhibit have been omitted pursuant to a request for confidential
treatment filed with the Commission under Rule 24b-2 of the
Securities Exchange Act of 1934. The omitted confidential material
has been filed separately with the Commission. The location of the
omitted confidential information is indicated in the exhibit with
asterisks (*)</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">81</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI CORPORATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
TABLE OF CONTENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 84%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 16%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Page</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 84%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 16%;">
<div style="text-align: right; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>
</td>
<td style="vertical-align: top; width: 16%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">F-
2</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 84%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 16%;">
<div style="text-align: right; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 100%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">FINANCIAL
STATEMENTS FOR THE YEARS ENDED SEPTEMBER 30, 2017 and
2016:</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: top; width: 100%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Balance
Sheets</font></div>
</td>
<td style="vertical-align: top; width: 16%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">F-
3</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 84%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Statements
of Operations</font></div>
</td>
<td style="vertical-align: top; width: 16%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">F-
4</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Statements
of Stockholders&#x2019; Deficit</font></div>
</td>
<td style="vertical-align: top; width: 16%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">F-
5</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 84%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Statements
of Cash Flows</font></div>
</td>
<td style="vertical-align: top; width: 16%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">F-
6</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Notes
to Financial Statements</font></div>
</td>
<td style="vertical-align: top; width: 16%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">F-
8</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-1</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Report of Independent Registered Public Accounting
Firm</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Board of Directors and Stockholders</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Vienna, Virginia</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We have
audited the accompanying balance sheets of CEL-SCI Corporation (the
&#x201C;Company&#x201D;) as of September 30, 2017 and 2016 and the
related statements of operations, stockholders&#x2019; deficit, and
cash flows for the years then ended. These financial statements are
the responsibility of the Company&#x2019;s management. Our
responsibility is to express an opinion on these financial
statements based on our audits.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We
conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of
material misstatement. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over
financial reporting. Our audits included consideration of internal
control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for
the purpose of expressing an opinion on the effectiveness of the
Company&#x2019;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management, as
well as evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for our
opinion.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In our
opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of the Company at
September 30, 2017 and 2016, and the results of its operations and
its cash flows for the years then ended, in conformity with
accounting principles generally accepted in the United States of
America.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company has negative working
capital, stockholders&#x2019; deficit, a history of net losses and
expects to incur substantial losses for the foreseeable future that
raise substantial doubt about its ability to continue as a going
concern. Management's plans in regard to these matters are also
described in Note 2. The financial statements do not include any
adjustments that might result from the outcome of this
uncertainty.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
/s/ BDO USA, LLP</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
McLean, Virginia</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
December 29, 2017</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">BALANCE SHEETS</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">SEPTEMBER 30, 2017 and 2016</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ASSETS</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
Assets:</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Cash
and cash equivalents</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,369,438</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,917,996</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Receivables</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">218,481</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">394,515</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Prepaid
expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">826,429</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">981,677</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deposits
- current portion</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">150,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">154,995</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Inventory
used for R&amp;D and manufacturing</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">672,522</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,008,642</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Current Assets</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,236,870</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,457,825</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Plant,
property and equipment</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,793,220</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,350,836</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patent
costs, net</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">223,167</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">256,547</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deposits</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,670,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,820,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Assets</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">22,924,174</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">24,886,125</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LIABILITIES
AND STOCKHOLDERS' DEFICIT</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
Liabilities:</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Accounts
payable</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,196,334</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,091,512</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Accrued
expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">936,698</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">378,672</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Due
to employees</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">693,831</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">538,278</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Notes
payable, net of discounts</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">994,258</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Derivative
instruments, current portion</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,984</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Other
current liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">12,449</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">3,310</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Total
Current Liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,844,554</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,011,772</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Derivative
instruments, net of current portion</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,042,418</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,394,934</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Lease
liability</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,211,925</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,011,023</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Deferred
revenue</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">125,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">125,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Other
liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">37,254</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">22,609</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">26,261,151</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,565,338</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Commitments
and Contingencies</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">STOCKHOLDERS'
DEFICIT</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Preferred
stock, $.01 par value- 200,000 shares authorized;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;-0-
shares issued and outstanding</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Common
stock, $.01 par value - 600,000,000 shares authorized;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;11,903,133
and 6,248,035 shares issued and outstanding</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;at
September 30, 2017 and 2016, respectively</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">119,031</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62,480</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Additional
paid-in capital</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">296,298,401</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">284,649,429</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Accumulated
deficit</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(299,754,409</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(285,391,122</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
stockholders' deficit</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3,336,977</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(679,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
LIABILITIES AND STOCKHOLDERS' DEFICIT</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">22,924,174</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">24,886,125</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px;">
See notes to financial statements</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-3</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">STATEMENTS OF OPERATIONS</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">YEARS ENDED SEPTEMBER 30, 2017 and
2016</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Grant
and other income</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">69,020</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">285,055</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
expenses:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Research
and development</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,606,985</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,445,382</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;General
&amp; administrative</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,800,348</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6,486,501</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
operating expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">21,407,333</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">23,931,883</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(21,338,313</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(23,646,828</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Gain
on derivative instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,007,215</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,013,726</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
expense, net</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4,032,189</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,879,390</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(14,363,287</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Modification
of warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(63,768</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss available to common shareholders</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(14,427,055</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">NET
LOSS PER COMMON SHARE</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;BASIC</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1.83</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;DILUTED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1.91</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">WEIGHTED
AVERAGE COMMON SHARES</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;OUTSTANDING</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;BASIC</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,891,843</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,866,204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;DILUTED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,902,647</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,866,204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">See
notes to financial statements<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-4</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: 13px; font-family: Times New Roman;">
<tr>
<td colspan="6" rowspan="1" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:1%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:98%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:1%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="6" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:1%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:98%;font-size:13px;">STATEMENTS OF STOCKHOLDERS'
DEFICIT</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:1%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="6" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:1%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:98%;font-size:13px;">YEARS ENDED SEPTEMBER 30, 2017 and
2016</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:1%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold;">Additional</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold;">Common</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold;">Stock</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold;">Paid-In</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; font-weight: bold;">Accumulated</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Shares</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Amount</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Capital</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Deficit</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Total</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
OCTOBER 1, 2015</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,503,975</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">45,040</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">269,071,320</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(273,878,630</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,762,270</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,660,930</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,609</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,357,087</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,373,696</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="2" style="vertical-align: bottom; width: 48%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">Issuance of warrants in connection
with</font><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,722,073</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,722,073</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">401(k)
contributions paid in common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,340</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">163</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">161,408</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">161,571</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued to nonemployees for service</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">49,953</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">689,813</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">690,313</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - employees</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,837</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">168</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,012,515</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,012,683</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - non-employees</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">79,359</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">79,359</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
SEPTEMBER 30, 2016</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,248,035</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62,480</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">284,649,429</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(285,391,122</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(679,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,738,920</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">47,389</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,482,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,530,306</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td colspan="2" style="vertical-align: bottom; width: 48%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">Issuance of warrants in connection
with</font><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;sale
of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,665,683</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,665,683</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Warrants
issued with notes payable</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,108,867</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,108,867</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="3" style="vertical-align: bottom; width: 61%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">Beneficial conversion feature on notes
payable</font><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;"><br></font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,108,867</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,108,867</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">401(k)
contributions paid in common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">79,941</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">799</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">150,509</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">151,308</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Conversion
of notes payable to common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">266,686</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,667</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">448,033</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">450,700</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
issued to nonemployees for service</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">76,551</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">766</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">203,817</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">204,583</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Ergomed stock
issuance</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">480,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,800</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,305,600</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,310,400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - employees</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">130</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,481,120</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,481,250</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
based compensation - non-employees</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">24,925</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">24,925</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(14,363,287</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(14,363,287</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 35%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">BALANCE,
SEPTEMBER 30, 2017</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">11,903,133</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">119,031</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">296,298,401</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(299,754,409</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 13%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3,336,977</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px;">
See notes to financial statements</font><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-5</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">STATEMENTS OF CASH FLOWS</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">YEARS ENDED SEPTEMBER 30, 2017 and
2016</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(14,363,287</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Adjustments
to reconcile net loss to</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;net
cash used in operating activities:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Depreciation
and amortization</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">632,915</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">663,988</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Share
based payments for services</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">232,847</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">751,651</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Equity
based compensation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,380,500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,113,433</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Common
stock contributed to 401(k) plan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">151,308</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">161,571</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Ergomed
stock issuance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,310,400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Loss
on retired equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,187</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">248</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Gain
on derivative instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(11,007,215</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(14,013,726</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Amortization
of debt discount</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">917,692</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Capitalized
lease interest</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">200,902</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">227,773</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;(Increase)/decrease
in assets:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Receivables</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(129,307</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,960</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Prepaid
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">151,909</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,999</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Inventory
used for R&amp;D and manufacturing</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">336,120</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">393,197</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deposits</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">154,995</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">145,005</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Increase/(decrease)
in liabilities:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Accounts
payable</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,420,816</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2,389,931</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Accrued
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">558,026</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">290,097</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deferred
revenue</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,639</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Due
to employees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">256,303</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">72,397</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:12px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Deferred
rent liability</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,995</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,896</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used in operating activities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(13,791,894</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(23,082,493</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Purchases
of equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(10,525</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(31,405</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Expenditures
for patent costs</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(6,477</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,819</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used in investing activities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(17,002</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(34,224</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Proceeds
from issuance of common stock and warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,519,306</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,420,301</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Payment
on related party loan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,104,057</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Proceeds
from notes payable</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,745,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Payments
on obligations under capital lease</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3,968</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(8,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash provided by financing activities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">13,260,338</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">20,308,031</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;NET
DECREASE IN CASH AND CASH EQUIVALENTS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(548,558</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2,808,686</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS, BEGINNING OF YEAR</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,917,996</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,726,682</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS, END OF YEAR</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,369,438</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,917,996</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0;</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">See
notes to financial statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-6</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">STATEMENTS OF CASH FLOWS</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">YEARS ENDED SEPTEMBER 30, 2017 and
2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND
FINANCING ACTIVITIES:</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">2017</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; font-family:Times New Roman;color:#000;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;font-weight:bold;width:80%;font-size:11px;">2016</font><font style="text-align: left; color:#000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Receivable
due under the litigation funding arrangement offset</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;by
the same amount payable to the legal firm providing the
services</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(305,341</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">305,341</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Conversion
of notes payable to common stock</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">450,700</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Lease
payments included in accounts payable at year end</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,890</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">815</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fair
value of warrants issued in connection with public
offering</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,665,683</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,722,073</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Financing
costs included in accounts payable at year end</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">35,605</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">46,605</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Prepaid
consulting services paid with issuance of common stock</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(3,339</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18,021</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Conversion
of accrued salaries and fees to notes payable</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">275,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Cash
paid for interest expense</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,888,612</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,900,567</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0;<br>
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px;">See notes to
financial statements</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-7</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
NOTES TO FINANCIAL STATEMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">1.&#xA0;&#xA0;
ORGANIZATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation (the Company) was incorporated on March 22, 1983, in
the state of Colorado, to finance research and development in
biomedical science and ultimately to engage in marketing and
selling products.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company is focused on finding the best way to activate the immune
system to fight cancer and infectious diseases. Its lead
investigational therapy, Multikine&#xAE; (Leukocyte Interleukin,
Injection), is currently in a pivotal Phase 3 clinical trial
involving head and neck cancer, for which the Company has received
Orphan Drug Status from the United States Food and Drug
Administration (FDA). If the primary endpoint of this global study
is achieved, the results will be used to support applications to
regulatory agencies around the world for worldwide commercial
marketing approvals as a first line cancer therapy.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s immune therapy, Multikine, is being used in a
different way than immune therapy is usually used. It is given
before any other therapy has been administered because that is when
the immune system is thought to be strongest.<font style="color: #404040">&#xA0;</font>It is also administered locally to
treat tumors or infections<font style="color: #404040">.</font> For
example, <font style="color: #404040">i</font>n the Phase 3
clinical trial, Multikine is given locally at the site of the tumor
as a first line treatment before surgery, radiation and/or
chemotherapy. The goal is to help the intact immune system kill the
micro metastases that usually cause recurrence of the cancer. In
short, CEL-SCI believes that local administration and
administration before weakening of the immune system by
chemotherapy and radiation will result in higher efficacy with less
or no toxicity.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Multikine
(Leukocyte Interleukin, Injection) is the full name of this
investigational therapy, which, for simplicity, is referred to in
the remainder of this document as Multikine. Multikine is the
trademark that the Company has registered for this investigational
therapy, and this proprietary name is subject to FDA review in
connection with the Company&#x2019;s future anticipated regulatory
submission for approval. Multikine has not been licensed or
approved by the FDA or any other regulatory agency. Neither has its
safety or efficacy been established for any use. Further research
is required, and early-phase clinical trial results must be
confirmed in the Phase 3 clinical trial of this investigational
therapy that is in progress.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Multikine has been
cleared by the regulators in twenty four countries around the
world, including the U.S. FDA, for a global Phase 3 clinical trial
in advanced primary (not yet treated) head and neck cancer
patients. On September 26, 2016, the Company received verbal notice
from the FDA that the Phase 3 clinical trial has been placed on
clinical hold. <font style="color: #000000">On August 10, 2017, the
Company received a letter from the FDA stating that the clinical
hold that had been imposed on the Phase 3 cancer study with
Multikine has been removed and that all clinical trial activities
for the Phase 3 study may resume.</font> <font style="color: #000000">On December 7, 2017, the Company announced that
the Independent Data Monitoring Committee (IDMC) has completed its
review of the Phase 3 study data. The data from all 928 enrolled
patients were provided to the IDMC by the Clinical Research
Organization (CRO) responsible for data management of this Phase 3
study. The IDMC made the following observation and recommendation:
a) the IDMC saw no evidence of any significant safety questions and
b) the IDMC recommends continuing the study. On December 11, 2017,
the Company announced that the Phase 3 study was fully enrolled.
The activities in the Phase 3 study are now focused on the
follow-up of the patients enrolled to determine if there is a
survival benefit in favor of Multikine.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-8</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;
OPERATIONS AND FINANCING</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has incurred significant costs since its inception in
connection with the acquisition of certain patented and unpatented
proprietary technology and know-how relating to the human
immunological defense system, patent applications, research and
development, administrative costs, construction of laboratory
facilities, and clinical trials.&#xA0; The Company has funded such
costs with proceeds from loans and the public and private sale of
its securities.&#xA0; The Company will be required to raise
additional capital or find additional long-term financing in order
to continue with its research efforts.&#xA0; To date, the Company
has not generated any revenue from product sales.&#xA0; As a
result, the Company has been dependent upon the proceeds from the
sale of its securities to meet all of its liquidity and capital
requirements and anticipates having to do so in the future. During
fiscal year 2017 and 2016, the Company raised net proceeds of
approximately $13.3 million and $21.4 million, respectively,
through the sale of stock and the issuance of convertible notes.
The ability of the Company to complete the necessary clinical
trials and obtain FDA approval for the sale of products to be
developed on a commercial basis is uncertain. Ultimately, the
Company must complete the development of its products, obtain the
appropriate regulatory approvals and obtain sufficient revenues to
support its cost structure.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company is currently running a large multi-national Phase 3
clinical trial for head and neck cancer with its partners TEVA
Pharmaceuticals and Orient Europharma. To finance the study beyond
the next twelve months, the Company plans to raise additional
capital in the form of corporate partnerships, debt and/or equity
financings. The Company believes that it will be able to obtain
additional financing because it has done so consistently in the
past and because Multikine is a product in the Phase 3 clinical
trial stage. However, there can be no assurance that the Company
will be successful in raising additional funds on a timely basis or
that the funds will be available to the Company on acceptable terms
or at all.&#xA0; If the Company does not raise the necessary
amounts of money, it may have to curtail its operations until such
time as it is able to raise the required funding.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
financial statements have been prepared assuming that the Company
will continue as a going concern, but due to the Company's negative
working capital, stockholders' deficit, recurring losses from
operations and future liquidity needs, there is substantial doubt
about the Company&#x2019;s ability to continue as a going concern.
The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Since
the Company launched its Phase 3 clinical trial for Multikine, the
Company has incurred expenses of approximately $45.9 million as of
September 30, 2017 on direct costs for the Phase 3 clinical trial.
The Company estimates it will incur additional expenses of
approximately $13.0 million for the remainder of the Phase 3
clinical trial.&#xA0; It should be noted that this estimate is
based only on the information currently available in the
Company&#x2019;s contracts with the Clinical Research Organizations
responsible for managing the Phase 3 clinical trial and does not
include other related costs, e.g., the manufacturing of the
drug.<font style="color: #FF0000">&#xA0;</font>This number can be
affected by the speed of enrollment, foreign currency exchange
rates and many other factors, some of which cannot be
foreseen.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-9</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Nine
hundred twenty-eight (928) head and neck cancer patients have been
enrolled and have completed treatment in the Phase 3 study. The
study endpoint is a 10% increase in overall survival of patients
between the two main comparator groups in favor of the group
receiving the Multikine treatment regimen. The determination if the
study end point is met will occur when there are a total of 298
deaths in those two groups.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On June
12, 2017, the Company&#x2019;s shareholders approved a reverse split
of the Company&#x2019;s common stock which became effective on the
NYSE American on June 15, 2017. On that date, every twenty five
issued and outstanding shares of the Company&#x2019;s common stock
automatically converted into one outstanding share. As a result of
the reverse stock split, the number of the Company&#x2019;s
outstanding shares of common stock decreased from 230,127,331
(pre-split) shares to 9,201,645 (post-split) shares. In addition,
by reducing the number of the Company&#x2019;s outstanding shares,
the Company&#x2019;s loss per share in all prior periods increased
by a factor of twenty five. The reverse stock split affected all
stockholders of the Company&#x2019;s common stock uniformly, and did
not affect any stockholder&#x2019;s percentage of ownership
interest. The par value of the Company&#x2019;s stock remained
unchanged at $0.01 per share and the number of authorized shares of
common stock remained the same after the reverse stock
split.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.&#xA0;&#xA0;
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Cash and Cash Equivalents</font> &#x2013; For
purposes of the statements of cash flows, cash and cash equivalents
consist principally of unrestricted cash on deposit and short-term
money market funds. The Company considers all highly liquid
investments with a maturity when purchased of less than three
months as cash and cash equivalents.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Prepaid Expenses</font> &#x2013; Prepaid
expenses are payments for future services to be rendered and are
expensed over the time period for which the service is rendered.
Prepaid expenses may also include payment for goods to be received
within one year of the payment date.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Inventory</font> &#x2013; Inventory consists of
manufacturing production advances and bulk purchases of laboratory
supplies to be consumed in the manufacturing of the Company&#x2019;s
product for clinical studies. Inventories are stated at the lower
of cost or market, where cost is determined using the first-in,
first out method applied on a consistent basis.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Deposits</font> &#x2013; The deposits are
required by the lease agreement for the manufacturing facility and
by the clinical research organization (CRO)
agreements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Plant, property and equipment</font>&#x2013;
The leased manufacturing facility is recorded at total project
costs incurred and is depreciated over the 20-year useful life of
the building. Research and office equipment is recorded at cost and
depreciated using the straight-line method over estimated useful
lives of five to seven years. Leasehold improvements are
depreciated over the shorter of the estimated useful life of the
asset or the term of the lease. Repairs and maintenance which do
not extend the life of the asset are expensed when incurred. The
plant, property and equipment are reviewed on a quarterly basis to
assess impairment, if any.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-10</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Patents</font> &#x2013; Patent expenditures are
capitalized and amortized using the straight-line method over the
shorter of the expected useful life or the legal life of the patent
(17 years). In the event changes in technology or other
circumstances impair the value or life of the patent, appropriate
adjustment to the asset value and period of amortization is made.
An impairment loss is recognized when estimated future undiscounted
cash flows expected to result from the use of the asset, and from
disposition, are less than the carrying value of the asset. The
amount of the impairment loss would be the difference between the
estimated fair value of the asset and its carrying
value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Leases &#x2013;</font> Leases are categorized
as either operating or capital leases at inception. Operating lease
costs are recognized on a straight-line basis over the term of the
lease. An asset and a corresponding liability for the capital lease
obligation are established for the cost of capital leases. The
capital lease obligation is amortized over the life of the lease.
For build-to-suit leases, the Company establishes an asset and
liability for the estimated construction costs incurred to the
extent that it is involved in the construction of structural
improvements or takes construction risk prior to the commencement
of the lease. Upon occupancy of facilities under build-to-suit
leases, the Company assesses whether these arrangements qualify for
sales recognition under the sale-leaseback accounting guidance. If
a lease does not meet the criteria to qualify for a sale-leaseback
transaction, the established asset and liability remain on the
Company's balance sheet. See Note 11.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Deferred Rent</font> &#x2013; Certain of the
Company&#x2019;s operating leases provide for minimum annual
payments that adjust over the life of the lease.&#xA0; The
aggregate minimum annual payments are expensed on a straight-line
basis over the minimum lease term. The Company recognizes a
deferred rent liability for rent escalations when the amount of
straight-line rent exceeds the lease payments, and reduces the
deferred rent liability when the lease payments exceed the
straight-line rent expense.&#xA0; For tenant improvement allowances
and rent holidays, the Company records a deferred rent liability
and amortizes the deferred rent over the lease term as a reduction
to rent expense.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Derivative Instruments</font> - The Company
has entered into financing arrangements that consist of
freestanding derivative instruments that contain embedded
derivative features, specifically, the settlement provisions in the
warrant agreements preclude the warrants from being treated as
equity. The Company accounts for these arrangements in accordance
with Accounting Standards Codification (ASC) 815, &#x201C;Accounting
for Derivative Instruments and Hedging Activities&#x201D;. In
accordance with accounting principles generally accepted in the
United States (U.S. GAAP), derivative instruments and hybrid
instruments are recognized as either assets or liabilities on the
balance sheet and are measured at fair value with gains or losses
recognized in earnings or other comprehensive income depending on
the nature of the derivative or hybrid instruments. The Company
determines the fair value of derivative instruments and hybrid
instruments based on available market data using appropriate
valuation models, giving consideration to all of the rights and
obligations of each instrument. The derivative liabilities are
remeasured at fair value at the end of each reporting period as
long as they are outstanding.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Grant Income</font> &#x2013; The Company's
grant arrangements are handled on a reimbursement basis. Grant
income under the arrangements is recognized when costs are
incurred.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-11</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Research and Development Costs</font> &#x2013;
Research and development expenditures are expensed as incurred.
Management accrues CRO expenses and clinical trial study expenses
based on services performed and relies on the CROs to provide
estimates of those costs applicable to the completion stage of a
study. Estimated accrued CRO costs are subject to revisions as such
studies progress to completion. The Company charges revisions to
estimated expense in the period in which the facts that give rise
to the revision become known.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Net Loss Per Common Share</font> &#x2013; The
Company calculates net loss per common share in accordance with ASC
260 &#x201C;Earnings Per Share&#x201D; (ASC 260). Basic and diluted
net loss per common share was determined by dividing net loss
applicable to common shareholders by the weighted average number of
common shares outstanding during the period. The Company&#x2019;s
potentially dilutive shares, which include outstanding common stock
options, restricted stock units, convertible preferred stock and
common stock warrants, have not been included in the computation of
diluted net loss per share for all periods as the result would be
anti-dilutive.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Concentration of Credit Risk</font> &#x2013;
Financial instruments, which potentially subject the Company to
concentrations of credit risk, consist of cash and cash
equivalents.&#xA0; The Company maintains its cash and cash
equivalents with high quality financial institutions.&#xA0; At
times, these accounts may exceed federally insured limits.&#xA0;
The Company has not experienced any losses in such bank
accounts.&#xA0; The Company believes it is not exposed to
significant credit risk related to cash and cash equivalents. All
non-interest bearing cash balances were fully insured<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>up to
$250,000 at September 30, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Income Taxes</font> &#x2013; The Company uses
the asset and liability method of accounting for income taxes.
Under the asset and liability method, deferred tax assets and
liabilities are recognized for future tax consequences attributable
to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases and
operating and tax loss carryforwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences
are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date. The Company
records a valuation allowance to reduce the deferred tax assets to
the amount that is more likely than not to be recognized. A full
valuation allowance was recorded against the deferred tax assets as
of September 30, 2017 and 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Use of Estimates</font> &#x2013; The
preparation of financial statements in conformity U.S. GAAP
requires management to make estimates and assumptions that affect
the amounts reported in the financial statements and the
accompanying disclosures. <font style="color: #000000">These
estimates are based on management&#x2019;s best knowledge of current
events and actions the Company may undertake in the future.
Estimates are used in accounting for, among other items, inventory
obsolescence, accruals, stock options, useful lives for
depreciation and amortization of long-lived assets, deferred tax
assets and the related valuation allowance, and the valuation of
derivative liabilities.</font><font style="color: #444444">&#xA0;</font>Actual results could differ from
estimates, although management does not generally believe such
differences would materially affect the financial statements in any
given year. However, in regard to the valuation of derivative
liabilities determined using various valuation techniques including
the Black-Scholes and binomial pricing methodologies, significant
fluctuations may materially affect the financial statements in a
given year. The Company considers such valuations to be significant
estimates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-12</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Fair Value Measurements</font> &#x2013; The
Company evaluates financial assets and liabilities subject to fair
value measurements in accordance with a fair value hierarchy to
prioritize the inputs used to measure fair value. A financial
instrument&#x2019;s level within the fair value hierarchy is based
on the lowest level of input significant to the fair value
measurement, where Level 1 is the highest and Level 3 is the
lowest. See Note 14 for the definition of levels and the
classification of assets and liabilities in those
levels.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Stock-Based Compensation</font> &#x2013;
Compensation cost for all stock-based awards is measured at fair
value as of the grant date in accordance with the provisions of ASC
718, &#x201C;Compensation &#x2013; Stock Compensation.&#x201D; The
fair value of stock options is calculated using the Black-Scholes
option pricing model. The Black-Scholes model requires various
judgmental assumptions including volatility and expected option
life. The stock-based compensation cost is recognized on the
straight line allocation method as expense over the requisite
service or vesting period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Equity
instruments issued to non-employees are accounted for in accordance
with ASC 505-50, &#x201C;Equity-Based Payments to
Non-Employees.&#x201D; Accordingly, compensation is recognized when
goods or services are received and may be measured using the
Black-Scholes valuation model, based on the type of award. The
Black-Scholes model requires various judgmental assumptions
regarding the fair value of the equity instruments at the
measurement date and the expected life of the options.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has Incentive Stock Option Plans, Non-Qualified Stock
Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an
Incentive Stock Bonus Plan. In some cases, these Plans are
collectively referred to as the &#x201C;Plans.&#x201D; All Plans have
been approved by the Company&#x2019;s stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s stock options are not transferable, and the actual
value of the stock options that an employee may realize, if any,
will depend on the excess of the market price on the date of
exercise over the exercise price. The Company has based its
assumption for stock price volatility on the variance of daily
closing prices of the Company&#x2019;s stock. The risk-free interest
rate assumption was based on the U.S. Treasury rate at date of the
grant with term equal to the expected life of the option.
Historical data was used to estimate option exercise and employee
termination within the valuation model. The expected term of
options represents the period of time that options granted are
expected to be outstanding and has been determined based on an
analysis of historical exercise behavior. If any of the assumptions
used in the Black-Scholes model change significantly, stock-based
compensation expense for new awards may differ materially in the
future from that recorded in the current period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Vesting
of restricted stock granted under the Incentive Stock Bonus Plan is
subject to service, performance or market conditions and meets the
classification of equity awards. These awards were measured at fair
market value on the grant-dates for issuances where the attainment
of performance criteria is probable and at fair value on the
grant-dates, using a Monte Carlo simulation for issuances where the
attainment of performance criteria is uncertain. The total
compensation cost will be expensed over the estimated requisite
service period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-13</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">Recent Accounting
Pronouncements</font> <font style="color: #000000; font-family: Times New Roman">&#x2013;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In May 2017, the FASB issued ASU
2017-09,&#xA0;</font><font style="font-style: italic; color: #000000">Compensation &#x2013; Stock
Compensation (Topic 718)</font><font style="color: #000000">, which
affects any entity that changes the terms or conditions of a
share-based payment award.&#xA0; This Update amends the definition
of modification by qualifying that modification accounting does not
apply to changes to outstanding share-based payment awards that do
not affect the total fair value, vesting requirements, or
equity/liability classification of the awards.&#xA0; The amendments
in this Update are effective for all entities for annual periods,
and interim periods within those annual periods, beginning after
December 15, 2017. Early adoption is permitted, including adoption
in any interim period, for (1) public business entities for
reporting periods for which financial statements have not yet been
issued and (2) all other entities for reporting periods for which
financial statements have not yet been made available for issuance.
The amendments in this Update should be applied prospectively to an
award modified on or after the adoption date. The Company is
currently evaluating the impact the adoption of the standard will
have on the Company&#x2019;s financial position or results of
operations.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In July 2017, the FASB issued ASU
2017-11,&#xA0;</font><font style="font-style: italic; color: #000000">Earnings Per Share (Topic
260), Distinguishing Liabilities from Equity (Topic 480), and
Derivative and Hedging (Topic 815)</font><font style="color: #000000">. The amendments in Part I of this Update change
the classification analysis of certain equity-linked financial
instruments (or embedded features) with down-round features. When
determining whether certain financial instruments should be
classified as liabilities or equity instruments, a down-round
feature no longer precludes equity classification when assessing
whether the instrument is indexed to an entity&#x2019;s own stock.
The amendments also clarify existing disclosure requirements for
equity-classified instruments. As a result, a freestanding
equity-linked financial instrument (or embedded conversion option)
no longer would be accounted for as a derivative liability at fair
value as a result of the existence of a down-round feature. For
freestanding equity classified financial instruments, the
amendments require entities that present earnings per share
(&#x201C;EPS&#x201D;) in accordance with Topic 260 to recognize the
effect of the down-round feature when it is triggered. That effect
is treated as a dividend and as a reduction of income available to
common shareholders in basic EPS. Convertible instruments with
embedded conversion options that have down- round features are now
subject to the specialized guidance for contingent beneficial
conversion features (in Subtopic 470-20,&#xA0;</font><font style="font-style: italic; color: #000000">Debt&#x2014;Debt with
Conversion and Other Options</font><font style="color: #000000">),
including related EPS guidance (in Topic 260). The amendments in
Part II of this Update recharacterize the indefinite deferral of
certain provisions of Topic 480 that now are presented as pending
content in the Accounting Standards Codification, to a scope
exception. Those amendments do not have an accounting
effect.</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">For
public business entities, the amendments in Part I of this Update
are effective for fiscal years, and interim periods within those
fiscal years, beginning after December 15, 2018. For all other
entities, the amendments in Part I of this Update are effective for
fiscal years beginning after December 15, 2019, and interim periods
within fiscal years beginning after December 15, 2020. Early
adoption is permitted for all entities, including adoption in an
interim period. If an entity early adopts the amendments in an
interim period, any adjustments should be reflected as of the
beginning of the fiscal year that includes that interim period. The
amendments in Part I of this Update should be applied either
retrospectively to outstanding financial instruments with a
down-round feature by means of a cumulative-effect adjustment to
the statement of financial position as of the beginning of the
first fiscal year and interim period(s) in which the pending
content that links to this paragraph is effective or
retrospectively to outstanding financial instruments with a
down-round feature for each prior reporting period presented in
accordance with the guidance on accounting changes in paragraphs
250-10-45-5 through 45-10. The amendments in Part II of this Update
do not require any transition guidance because those amendments do
not have an accounting effect.&#xA0;The Company is currently
evaluating the impact the adoption of the standard will have on the
Company&#x2019;s financial position or results of
operations.&#xA0;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-14</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><a name="_AEIOULastRenderedPageBreakAEIOU77">
<!--anchor--></a><font style="color: #000000">In August 2017, the
FASB issued ASU 2017-12,&#xA0;</font><font style="font-style: italic; color: #000000">Derivatives and Hedging (Topic
850)</font><font style="color: #000000">, the objective of which is
to improve the financial reporting of hedging relationships to
better portray the economic results of an entity&#x2019;s risk
management activities in its financial statements. In addition, the
amendments in this Update make certain targeted improvements to
simplify the application and disclosure of the hedge accounting
guidance in current general accepted accounting
principles.&#xA0;&#xA0;For public business entities, the amendments
in&#xA0;this Update are effective for fiscal years beginning after
December 15, 2018, and interim periods within those fiscal years.
For all other entities, the amendments are effective for fiscal
years beginning after December 15, 2019, and interim periods
beginning after December 15, 2020. Early adoption is permitted in
any period after issuance.&#xA0;&#xA0;For cash flow and net
investment hedges existing at the date of adoption, an entity
should apply a cumulative-effect adjustment related to eliminating
the separate&#xA0;measurement of ineffectiveness to accumulated
other comprehensive income with a corresponding adjustment to the
opening balance of retained earnings as of the beginning of the
fiscal year that an entity adopts the amendments in this Update.
The amended presentation and disclosure guidance is required only
prospectively.&#xA0;&#xA0;The Company is currently evaluating the
impact the adoption of the standard will have on the
Company&#x2019;s financial position or results of
operations.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In February 2016, the FASB issued</font> ASU
<font style="color: #000000">2016-02,&#xA0;</font><font style="font-style: italic; color: #000000">Leases</font><font style="color: #000000">, which will require most leases (with the
exception of leases with terms of less than one year) to be
recognized on the balance sheet as an asset and a lease liability.
Leases will be classified as an operating lease or a financing
lease. Operating leases are expensed using the straight-line method
whereas financing leases will be treated similarly to a capital
lease under the current standard. The new standard will be
effective for annual and interim periods, within those fiscal
years, beginning after December 15, 2018, but early adoption is
permitted. The new standard must be presented using the modified
retrospective method beginning with the earliest comparative period
presented. The Company is currently evaluating the effect of the
new standard on its financial statements and related
disclosures.</font> Although the Company has not completed its
evaluation of the impact of the adoption of ASU 2016-02, because
the Company&#x2019;s most significant operating lease is currently
on its balance sheet (see Note 11), the adoption of ASU 2016-02 is
not expected to have a material impact to the financial
statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In March 2016, the FASB issued ASU No.
2016-09,</font> <font style="font-style: italic; color: #000000">Compensation - Stock
Compensation (Topic 718): Improvements to Employee Share-Based
Payment Accounting.</font> <font style="color: #000000">ASU 2016-09
simplifies several aspects of the accounting for share-based
payment award transactions, including income tax consequences,
classification of awards as either equity or liabilities and
classification on the statement of cash flows. The new standard
will be effective for annual and interim periods, within those
fiscal years, beginning after December 15, 2016 but early adoption
is permitted. The Company does not expect the adoption of this new
amendment to have a material impact on its financial statements and
related disclosures. The estimated forfeiture rate is based on
historical information, however, the Company will no longer
estimate the forfeiture rate on share based payments, but rather
recognize forfeitures as they occur.<br></font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company has considered all other recently issued accounting
pronouncements and does not believe the adoption of such
pronouncements will have a material impact on its financial
statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-15</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.&#xA0;&#xA0;
WARRANTS AND NON-EMPLOYEE OPTIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
following chart represents the warrants and non-employee options
outstanding at September 30, 2017:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Warrant</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 25px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Issue Date</font></font></font></font></div>
</td>
<td style="vertical-align: middle; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 10px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;"><font style="color: rgb(0, 0, 0); font-weight: bold;">Shares Issuable upon
Exercise of</font> <font style="color: rgb(0, 0, 0); font-weight: bold;">Warrants</font></font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;"><font style="color: rgb(0, 0, 0); font-weight: bold;">Exercise</font>
<font style="color: rgb(0, 0, 0); font-weight: bold;">Price</font></font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Expiration Date</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="color: rgb(0, 0, 0); font-family: Times New Roman; font-weight: bold;">
Refer-ence</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
U</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">4/17/2014</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">17,821</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$43.75</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10/17/2017</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
DD</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/8/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,360,960</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$4.50</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
12/1/2017</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
EE</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/8/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,360,960</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$4.50</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
12/1/2017</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
N</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/18/2008</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">85,339</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.00</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8/18/2018</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
S</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">10/11/13-
10/24/14</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,037,120</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$31.25</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10/11/2018</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
V</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">5/28/2015</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">810,127</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$19.75</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
5/28/2020</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
W</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">10/28/2015</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">688,930</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$16.75</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10/28/2020</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
X</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1/13/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">120,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$9.25</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
1/13/2021</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
Y</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2/15/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">26,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$12.00</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2/15/2021</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
ZZ</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">5/23/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">20,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$13.75</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
5/18/2021</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
BB</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/26/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">16,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$13.75</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8/22/2021</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
Z</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">5/23/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">264,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$13.75</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/23/2021</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
FF</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/8/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">68,048</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.91</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
12/1/2021</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
CC</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/8/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">680,480</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$5.00</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
12/8/2021</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
HH</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2/23/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">20,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.13</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2/16/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
AA</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/26/2016</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">200,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$13.75</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2/22/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
JJ</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">3/14/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">30,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.13</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3/8/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
LL</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">4/30/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">26,398</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.59</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4/30/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
MM</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">6/22/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">893,491</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$1.86</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
6/22/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
NN</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">7/24/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">539,300</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.52</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
7/24/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
OO</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">7/31/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">60,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.52</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
7/31/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
QQ</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/22/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">87,500</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.50</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8/22/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
GG</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2/23/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">400,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.00</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8/23/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
II</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">3/14/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">600,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.00</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
9/14/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
KK</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">5/3/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">395,970</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.04</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/3/2022</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
PP</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/28/2017</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,750,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.30</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2/28/2023</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Consultants</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/28/12-
7/28/17</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">42,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.18-
$70.00</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
12/27/17- 7/27/27</font></div>
</td>
<td style="vertical-align: middle; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">3</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-16</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
following chart represents the warrants and non-employee options
outstanding at September 30, 2016:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Warrant</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Issue
Date</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Shares Issuable
upon Exercise of Warrants</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Exercise
Price</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Expiration
Date</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times New Roman; font-weight: bold;">Refer-ence</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
N</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8/18/08</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
113,785</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$13.18</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8/18/17</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
R</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">12/6/12</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
105,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$100.00</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">12/6/16</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
U</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">4/17/14</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
17,821</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$43.75</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">10/17/17</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
S</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">10/11/13
-10/24/14</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
1,037,120</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">$31.25</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">10/11/18</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
V</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5/28/15</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
810,127</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$19.75</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5/28/20</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
W</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">10/28/15</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
688,930</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$16.75</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">10/28/20</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
X</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1/13/16</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
120,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$9.25</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1/13/21</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
Y</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2/15/16</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
26,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$12.00</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2/15/21</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
ZZ</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5/23/16</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
20,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$13.75</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5/18/21</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
Z</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">5/23/16</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
264,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$13.75</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">11/23/21</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
AA</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8/26/16</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
200,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$13.75</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2/22/22</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
BB</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8/26/16</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
16,000</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$13.75</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8/22/21</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
P</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2/10/12</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">23,600</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">$112.50</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3/6/17</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 14%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Consultants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">12/2/11-
7/1/16</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">25,600</font></div>
</td>
<td style="vertical-align: middle; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">$9.25-
$87.50</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">10/27/16-
6/30/19</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-17</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Warrant Liabilities</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
table below presents the warrant liabilities and their respective
balances at September 30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2017</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2016</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series S
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">32,773</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,111,361</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series U
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series V
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">72,912</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,620,253</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series W
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">83,754</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,799,858</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series Z
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">77,216</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">970,604</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series ZZ
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,753</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">70,609</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series AA
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">65,087</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">763,661</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series BB
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,322</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">58,588</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series CC
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">394,220</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series DD
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,492</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series EE
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,492</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series FF
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">47,154</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series GG
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">342,173</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series HH
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16,014</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series II
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">511,636</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series JJ
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">24,203</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series KK
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">345,720</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series LL
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">20,481</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total warrant
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,053,402</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,394,934</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
table below presents the gains on the warrant liabilities for the
years ended September 30:</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2017</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2016</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series S
Warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,078,588</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,252,193</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series U
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">44,552</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series V
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,547,341</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,658,228</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series W
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,716,104</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,260,913</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series Z
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">893,388</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">997,226</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series ZZ
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">65,856</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">75,229</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series AA
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">698,574</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">672,246</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series BB
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">54,266</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">53,139</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series CC
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">666,203</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series DD
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">437,780</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series EE
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">685,915</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series FF
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">73,828</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series GG
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">272,464</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series HH
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,616</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series II
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">404,823</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series JJ
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">20,410</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series KK
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">25,564</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series LL
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">352,495</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net gain on warrant
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,007,215</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,013,726</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-18</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company reviews all outstanding warrants in accordance with the
requirements of ASC 815. This topic provides that an entity should
use a two-step approach to evaluate whether an equity-linked
financial instrument (or embedded feature) is indexed to its own
stock, including evaluating the instrument&#x2019;s contingent
exercise and settlement provisions. The warrant agreements provide
for adjustments to the exercise price for certain dilutive events.
Under the provisions of ASC 815, the warrants are not considered
indexed to the Company&#x2019;s stock because future equity
offerings or sales of the Company&#x2019;s stock are not an input to
the fair value of a &#x201C;fixed-for-fixed&#x201D; option on equity
shares, and equity classification is therefore
precluded.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
accordance with ASC 815, derivative liabilities must be measured at
fair value upon issuance and re-valued at the end of each reporting
period through expiration. Any change in fair value between the
respective reporting periods is recognized as a gain or loss in the
statement of operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Issuance of Fiscal 2017 Warrant Liabilities</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
April 30, 2017, the Company entered into a securities purchase
agreement with an institutional investor whereby it sold 527,960
shares of its common stock for net proceeds of approximately $1.4
million, or $2.875 per share, in a registered direct offering. In a
concurrent private placement, the Company also issued to the
purchaser of the Company&#x2019;s common stock Series KK warrants to
purchase 395,970 shares of common stock. The warrants can be
exercised at a price of $3.04 per share at any time on or after
November 3, 2017 and expire on November 3, 2022. In addition, the
Company issued 26,398 Series LL warrants to the placement agent as
part of its compensation. The Series LL warrants are exercisable on
October 30, 2017 at a price of $3.59 per share and expire on April
30, 2022. The fair value of the Series KK and LL warrants of
approximately $0.7 million on the date of issuance was recorded as
a warrant liability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
March 14, 2017, the Company sold 600,000 registered shares of
common stock and 600,000 Series II warrants to purchase 600,000
unregistered shares of common stock at combined offering price of
$2.50 per share.&#xA0; The Series II warrants have an exercise
price of $3.00 per share and expire September 14, 2022.
<font style="color: #000000">In addition, the Company issued 30,000
Series JJ warrants to purchase 30,000 shares of unregistered common
stock to the placement agent. The Series JJ warrants have an
exercise price $3.13 and expire on March 8, 2022.
The&#xA0;net&#xA0;proceeds from this
offering&#xA0;were&#xA0;approximately $1.3&#xA0;million.</font> The
fair value of the Series II and JJ warrants of approximately $1.0
million on the date of issuance was recorded as a warrant
liability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
February 23, 2017, the Company sold 400,000 registered shares of
common stock and 400,000 Series GG warrants to purchase 400,000
unregistered shares of common stock at a combined price of $2.50
per share.&#xA0; The Series GG warrants have an exercise price of
$3.00 per share and expire August 23, 2022. <font style="color: #000000">In addition, the Company issued to the placement
agent 20,000 Series HH warrants to purchase 20,000 shares of
unregistered common stock. The Series HH warrants have an exercise
price $3.13 and expire on February 16, 2022.
The&#xA0;net&#xA0;proceeds from this
offering&#xA0;were&#xA0;approximately $0.8&#xA0;million.</font> The
fair value of the Series GG and HH warrants of approximately $0.6
million on the date of issuance was recorded as a warrant
liability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-19</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On December 8, 2016, the Company sold 1,360,960
shares of common stock and warrants to purchase common stock at a
price of $3.13 in a public offering. The warrants consist of
680,480 Series CC warrants to purchase 680,480 shares of common
stock, 1,360,960 Series DD warrants to purchase 1,360,960 shares of
common stock and 1,360,960 Series EE warrants to purchase 1,360,960
shares of common stock. The Series CC warrants were immediately
exercisable, expire in five-years from the offering date and have
an exercise price of $5.00 per share. The Series DD warrants were
immediately exercisable and have an exercise price of $4.50 per
share. On June 5, 2017 and June 29, 2017, the expiration date of
the Series DD warrants was extended from June 8, 2017 to July 10,
2017 and then to August 10, 2017. On August 29, 2017, the
expiration date of the Series DD warrants was extended to December
1, 2017. The Series EE warrants are immediately exercisable and
have an exercise price of $4.50 per share. On August 29, 2017, the
initial expiration date of the Series EE warrants was extended from
September 8, 2017 to December 1, 2017. In addition, the Company
issued 68,048 Series FF warrants to purchase 68,048 shares of
common stock to the placement agent. The FF warrants expire on
December 1, 2021 and have an exercise price $3.91.
Net&#xA0;proceeds from this offering&#xA0;were&#xA0;approximately
$3.7&#xA0;million.</font> The fair value of the Series CC, DD, EE
and FF warrants of approximately $2.3 million on the date of
issuance was recorded as a warrant liability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series AA and BB Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On August 26, 2016, the Company closed a
registered direct offering of&#xA0;400,000 shares of common stock
and 200,000 Series AA warrants to purchase 200,000 shares of common
stock. The common stock and warrants were sold at a combined per
unit price of $12.50 for proceeds of approximately $4.5 million,
net of placement agent&#x2019;s commissions and offering expenses.
The Series AA warrants may be exercised at any time after February
22, 2017 and on or before February 22, 2022 at a price of $13.75
per share.</font> The Company also issued 16,000 Series BB warrants
to the placement agent as part of its compensation. The Series BB
warrants may be exercised at any time on or after February 22, 2017
and on or before August 22, 2021 at a price of $13.75 per share.
The fair value of the Series AA and Series BB warrants of
approximately $1.5 million on the date of issuance was recorded as
a warrant liability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series Z and ZZ Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On May
23, 2016, the Company closed a registered direct offering of
400,000 shares of common stock and 264,000 Series Z warrants to
purchase shares of common stock. The common stock and warrants were
sold at a combined per unit price of $12.50 for net proceeds of
approximately $4.6 million, net of placement agent&#x2019;s
commissions and offering expenses. The Series Z warrants may be
exercised at any time on or after November 23, 2016 and on or
before November 23, 2021 at a price of $13.75 per share. The
Company also issued 20,000 Series ZZ warrants to the placement
agent as part of its compensation. The Series ZZ warrants may be
exercised at any time on or after November 23, 2016 and on or
before May 18, 2021 at a price of $13.75 per share. The fair value
of the Series Z and Series ZZ warrants of approximately $2.1
million on the date of issuance was recorded as a warrant
liability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-20</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series W Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 28, 2015, the Company closed an underwritten public
offering of 688,930 shares of common stock and 688,930 Series W
warrants to purchase shares of common stock. The common stock and
warrants were sold at a combined per unit price of $16.75 for net
proceeds of approximately $10.5 million, net of underwriting
discounts and commissions and offering expenses. The Series W
warrants are immediately exercisable at a price of $16.75 and
expire on October 28, 2020. The fair value at issuance of the
Series W warrants of approximately $5.1 million was recorded as
warrant liability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Expiration of Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
March 16, 2017, 23,600 Series P warrants, with an exercise price of
$112.50, expired. The fair value of the Series P warrants was $0 on
the date of expiration.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 6, 2016, 105,000 Series R warrants, with an exercise price
of $100.00, expired. The fair value of the Series R warrants was $0
on the date of expiration.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 22, 2015, 48,000 Series Q warrants, with an exercise price
of $125.00, expired. The fair value of the Series Q warrants was $0
on the date of expiration.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">2.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Equity Warrants</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series PP and Series QQ Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 22, 2017, the Company entered into a securities purchase
agreement with institutional investors whereby it sold 1,750,000
shares of its common stock for net proceeds of approximately $3.2
million, or $2.00 per share, in a registered direct offering. In a
concurrent private placement, the Company also issued to the
purchasers of the Company&#x2019;s common stock Series PP warrants
to purchase 1,750,000 shares of common stock. The warrants can be
exercised at a price of $2.30 per share at any time on or after
February 28, 2018 and expire on February 28, 2023. In addition, the
Company issued 87,500 Series QQ warrants to the placement agent as
part of its compensation. The Series QQ warrants are exercisable on
February 22, 2018 at a price of $2.50 per share and expire on
August 22, 2022. The Series PP and Series QQ warrants qualify for
equity treatment in accordance with ASC 815. The relative fair
value of the warrants was approximately $1.4 million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series OO Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On July
26, 2017, the Company entered into a securities purchase agreement
with an investor whereby it sold 100,000 shares of its common stock
for gross proceeds of $229,000, or $2.29 per share, in a registered
offering. In a concurrent private placement, the Company also
issued to the purchaser of the common stock Series OO warrants to
purchase 60,000 shares of the Company&#x2019;s common stock. The
warrants can be exercised at a price of $2.52 per share, commencing
six months after the date of issuance and ending five years after
the date of issuance. The Series OO warrants qualify for equity
treatment in accordance with ASC 815. The relative fair value of
the warrants was approximately $62,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-21</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series NN Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On July
24, 2017, in connection with the issuances of convertible notes
(See Note 7), the Company issued the note holders Series NN
warrants which entitle the purchasers to acquire up to an aggregate
of 539,300 shares of the Company&#x2019;s common stock. The warrants
are exercisable at a fixed price of $2.52 per share and expire on
July 24, 2022. Shares issuable upon the exercise of the notes and
warrants were restricted securities unless registered. The shares
were registered effective September 1, 2017. Proceeds from the sale
of notes payable and the issuance of the warrants were
approximately $1.2 million. <font style="color: #000000">The
Company allocated the proceeds received to the notes and the Series
NN warrants on a relative fair value basis. As a result of such
allocation, the Company determined the initial carrying value of
the Series NN warrants to be approximately $0.5 million. The Series
NN warrants qualify for equity treatment in accordance with ASC
815.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series MM Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On June
22, 2017, in connection with the issuance of convertible notes (see
Note 7), the Company issued the note holders Series MM warrants,
which entitle the purchasers to acquire up to an aggregate of
893,491 shares of the Company&#x2019;s common stock. The Series MM
warrants are exercisable at a price of $1.86 per share and expire
on June 22, 2022. Shares issuable upon the exercise of the notes
and warrants were restricted securities unless registered. The
shares were registered effective August 8, 2017. Proceeds from the
sale of notes payable and the issuance of the warrants were $1.5
million. <font style="color: #000000">The Company allocated
proceeds received to the Notes and the Series MM warrants on a
relative fair value basis. As a result of such allocation, the
Company determined the initial carrying value of the Series MM
warrants to be approximately $0.6 million. The Series MM warrants
qualify for equity treatment in accordance with ASC
815.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series X Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
January 2016, the Company sold 120,000 shares of its common stock
and 120,000 Series X warrants to the de Clara Trust for
approximately $1.1 million. The de Clara Trust is controlled by
Geert Kersten, the Company's Chief Executive Officer and a
director. Each Series X warrant allows the de Clara Trust to
purchase one share of the Company's common stock at a price of
$9.25 per share at any time on or before January 13, 2021. The
Series X warrants qualify for equity treatment in accordance with
ASC 815. The relative fair value of the warrants was approximately
$417,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series Y Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
February 15, 2016, the Company sold 52,000 shares of its common
stock and 26,000 Series Y warrants to a private investor for
$624,000. Each Series Y warrant allows the holder to purchase one
share of the Company's common stock at a price of $12.00 per share
at any time on or before February 15, 2021. The Series Y warrants
qualify for equity treatment in accordance with ASC 815. The
relative fair value on the date of issuance of the warrants was
approximately $144,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-22</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series N Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Series
N warrants were previously issued in connection with a financing
and were subsequently transferred to the de Clara Trust, of which
the Company&#x2019;s CEO, Geert Kersten, is a
beneficiary.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On July
17, 2017, the Series N warrants held in the de Clara Trust were
modified. The modification extended the expiration date by one year
to expire on August 18, 2018; the 113,785 warrants outstanding were
reduced by 25% to 85,339 warrants outstanding; and the exercise
price was reduced to $3.00 per share. The incremental cost of this
modification was approximately $64,000, which was recorded as a
deemed dividend.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Options and Shares Issued to Consultants</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company typically enters into consulting arrangements in exchange
for common stock or stock options. During the years ended September
30, 2017 and 2016 the Company issued 76,551 and 49,954 shares,
respectively, of common stock to consultants of which 68,352 and
31,360 shares, respectively, were restricted shares. Under these
arrangements, the common stock was issued with stock prices ranging
between $1.73 and $7.25 per share.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Additionally,
during the years ended September 30, 2017 and 2016 the Company
issued to consultants 20,000 and 16,400 options, respectively, to
purchase common stock with an exercise price of $2.18 per share and
a fair value of $1.87 per share. The aggregate values of the
issuances of restricted common stock and common stock options are
recorded as prepaid expenses and are charged to general and
administrative expenses over the periods of service.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the years ended September 30, 2017 and 2016, the Company recorded
total expense of approximately $233,000 and $752,000, respectively,
relating to these consulting agreements. At September 30, 2017 and
2016, approximately $45,000 and $48,000, respectively, are included
in prepaid expenses. As of September 30, 2017, 42,000 options
issued to consultants as payment for services remained outstanding,
all of which were issued from the Non-Qualified Stock Option plans
and are fully vested.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">5.&#xA0;&#xA0;
PLANT, PROPERTY AND EQUIPMENT</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Plant,
property and equipment consisted of the following at September
30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Leased
manufacturing facility</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,183,756</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,183,756</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,169,158</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,158,633</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Furniture
and equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">124,369</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">133,499</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Leasehold
improvements</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">131,910</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">131,910</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">24,609,193</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">24,607,798</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accumulated
depreciation and amortization</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(7,815,973</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(7,256,962</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
plant, property and equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">16,793,220</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">17,350,836</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-23</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company is not the legal owner of the manufacturing building, but
is deemed to be the owner for accounting purposes, based on the
accounting guidance for build-to-suit leases. See Note 11,
Commitments and Contingencies&#x2013;Lease Obligations, for
additional information.<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>As of
September 30, 2017 and 2016, accumulated depreciation on the
manufacturing building is approximately $4.6 million and $4.1
million, respectively. Depreciation expense for the years ended
September 30, 2017 and 2016 totaled approximately $593,000 and,
$626,000, respectively. Depreciation expense includes depreciation
on the leased manufacturing building of approximately $514,000,
which is included in research and development costs on the
Statements of Operations. During the year ended September 30, 2017,
the Company purchased an asset under a lease classified as a
capital lease. That asset has a net book value of approximately
$21,000 on September 30, 2017. Amortization of the capital lease
asset is included in general and administrative expenses on the
Statements of Operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">6.&#xA0;&#xA0;
PATENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Patents
consisted of the following at September 30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patents</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,535,087</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,528,610</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accumulated
amortization</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,311,920</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,272,063</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patents,
net</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">223,167</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">256,547</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the years ended September 30, 2017 and 2016,there was no impairment
of patent costs. Amortization expense for the years ended September
30, 2017 and 2016 totaled approximately $40,000 and $38,000,
respectively. The total estimated future amortization is as
follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td colspan="1" rowspan="1" style="vertical-align: bottom; width: 86%;">
<div style="border-bottom: 2px solid rgb(0, 0, 0);">
<div>
<div style="text-align: center"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Years
ending September 30,</font></div>
</div>
</div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 13px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">37,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">35,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">32,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2022</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Thereafter</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">66,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="margin-left:0px;padding-bottom:4px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">223,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-24</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
7.&#xA0;&#xA0; NOTES PAYABLE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On July
24, 2017, the Company issued Series NN convertible notes in the
aggregate principal amount of $1.2 million to 12 individual
investors. A trust in which Geert Kersten, the Company&#x2019;s
Chief Executive Officer, holds a beneficial interest participated
in the offering and purchased a note in the principal amount of
$250,000. Patricia B. Prichep, the Company&#x2019;s Senior Vice
President of Operations, participated in the offering and purchased
a note in the principal amount of $25,000. The Series NN Notes bear
interest at 4% per year and are due on December 22, 2017. At the
option of the note holders, the Series NN Notes can be converted
into shares of the Company&#x2019;s common stock at a fixed
conversion rate of $2.29, the closing price on July 21, 2017. The
purchasers of the convertible notes also received Series NN
warrants which entitle the purchasers to acquire up to 539,300
shares of the Company&#x2019;s common stock. The warrants are
exercisable at a price of $2.52 per share and expire on July 24,
2022. Shares issuable upon the exercise of the warrants were
restricted securities unless registered. The shares were registered
effective September 1, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Series NN Notes were issued together with Series NN warrants, as
discussed in the preceding section. Upon issuance of the Series NN
Notes and Series NN warrants, the Company allocated proceeds
received to the notes and warrants on a relative fair value basis.
As a result of such allocation, the Company determined the initial
carrying value of the Series NN Notes to be approximately $0.7
million, the initial carrying value of the Series NN warrants to be
approximately $0.5 million, and recorded a debt discount in the
amount of approximately $0.5 million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On June 22, 2017, CEL-SCI issued Series MM
convertible notes in the aggregate principal amount of $1.5 million
to six individual investors.</font> The Series MM Notes bear
interest at 4% per year and are due on December 22, 2017. At the
option of the note holders, the Series MM Notes can be converted
into shares of the Company&#x2019;s common stock at a fixed
conversion rate of $1.69. The number of shares of the
Company&#x2019;s common stock issued upon conversion will be
determined by dividing the principal amount to be converted by
$1.69, which could result in the issuance of 893,491 shares of the
Company&#x2019;s common stock. The purchasers of the convertible
notes also received Series MM warrants which entitle the purchasers
to acquire up to 893,491 shares of the Company&#x2019;s common
stock. The warrants are exercisable at a price of $1.86 per share
and expire on June 22, 2022. Shares issuable upon the exercise of
the warrants were restricted securities unless registered. The
shares were registered effective August 8, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Series MM Notes were issued together with Series MM warrants, as
discussed in the preceding section. Upon issuance of the Series MM
Notes and Series MM warrants, the Company allocated proceeds
received to the notes and warrants on a relative fair value basis.
As a result of such allocation, the Company determined the initial
carrying value of the Series MM Notes to be approximately $0.9
million, the initial carrying value of the Series MM warrants to be
approximately $0.6 million, and recorded a debt discount in the
amount of approximately $0.6 million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">During
the quarter ended September 30, 2017, two note holders converted
their Series MM notes into shares of common stock. The face value
of the converted notes was $450,700. The unamortized debt discount
relating to the converted notes was charged to interest
expense.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-25</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Pursuant to the guidance in ASC 815-40,</font>
<font style="font-style: italic; color: #000000">Contracts in
Entity&#x2019;s Own Equity</font><font style="color: #000000">, the
Company evaluated whether the conversion feature of the note needed
to be bifurcated from the host instrument as a freestanding
financial instrument. Under ASC 815-40, to qualify for equity
classification (or non-bifurcation, if embedded) the instrument (or
embedded feature) must be both (1) indexed to the issuer&#x2019;s
own stock and (2) meet the requirements of the equity
classification guidance. Based upon the Company&#x2019;s analysis,
it was determined the conversion option is indexed to its own stock
and also met all the criteria for equity classification.
Accordingly, the conversion option is not required to be bifurcated
from the host instrument as a freestanding financial instrument.
Since the conversion feature meets the equity scope exception from
derivative accounting, the Company then evaluated whether the
conversion feature needed to be separately accounted for as an
equity component under ASC 470-20,</font> <font style="font-style: italic; color: #000000">Debt with Conversion and Other
Options</font><font style="color: #000000">. Based upon the
Company&#x2019;s analysis, it was determined that a beneficial
conversion feature existed as a result of the reduction in the face
value of the Series MM and NN Notes, due to a portion of proceeds
being allocated to the related warrants, and thus the conversion
features needed to be separately accounted for as an equity
component. The Company recorded beneficial conversion features
relating to the Series MM and NN notes of approximately $603,000
and $506,000, respectively, which were also recorded as debt
discounts.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
total debt discount on both Series MM and NN notes is being
amortized to interest expense using the effective interest method
over the expected term of the notes. At September 30, 2017, the
remaining debt discount is approximately $1.3 million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">During
the year ended September 30, 2017, the Company recorded
approximately $941,000 in interest expense related to the Series MM
and NN notes, of which approximately $23,000 was recorded as
accrued interest, and approximately $918,000 was recorded as
amortization of the debt discount.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Series MM and Series NN notes are secured by a first lien on all of
the Company&#x2019;s assets.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">8.
&#xA0; INCOME TAXES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">At
September 30, 2017 and 2016, the Company had federal net operating
loss carryforwards of approximately $187.8 million and $169.7
million, respectively. The NOLs begin to expire during the fiscal
year ending September 30, 2019 and become fully expired by the end
of the fiscal year ended 2037. In addition, the Company has a
general business credit as a result of the credit for increasing
research activities (&#x201C;R&amp;D credit&#x201D;) of approximately
$1.2 million at September 30, 2017 and 2016. The R&amp;D credit
begins to expire during the fiscal year ending September 30, 2020
and is fully expired during the fiscal year ended 2029. Deferred
taxes consisted of the following at September 30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-26</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
operating loss carryforwards</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">70,752,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">64,366,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">R&amp;D
credit</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,221,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,221,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock-based
compensation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,292,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,379,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Capitalized
R&amp;D</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21,160,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18,508,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vacation
and other</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">121,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">179,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
deferred tax assets</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">99,546,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,653,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fixed
assets and intangibles</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(523,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(49,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
deferred tax liability</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(523,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(49,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
deferred tax asset</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">99,023,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,604,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Valuation
allowance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(99,023,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(90,604,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Ending
Balance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
assessing the realization of deferred tax assets, management
considered whether it was more likely than not that some, or all,
of the deferred tax asset will be realized. The ultimate
realization of the deferred tax assets is dependent upon the
generation of future taxable income. Management has considered the
history of the Company&#x2019;s operating losses and believes that
the realization of the benefit of the deferred tax assets cannot be
reasonably assured. In addition, under Internal Revenue Code
Section 382, the Company&#x2019;s ability to utilize these net
operating loss carryforwards may be limited or eliminated in the
event of future changes in ownership.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has no federal or state current or deferred tax expense or
benefit. The Company&#x2019;s effective tax rate differs from the
applicable federal statutory tax rate. The reconciliation of these
rates is as follows at September 30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Federal
Rate</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">34.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">34.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">State
tax rate, net of federal benefit</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6.44</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3.92</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">State
tax rate change</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(3.91</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(22.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
adjustments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(3.39</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.03</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Permanent differences</font> <font style="font-size: 70%; vertical-align: top; color: #000000">(1)</font></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25.49</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">44.90</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:24px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Change
in valuation allowance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(58.63</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(60.79</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:24px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Effective
tax rate</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">0.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">%</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">0.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">%</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td rowspan="3" style="vertical-align: middle; width: 100%">
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; color: #000000">(1)</font>
<font style="color: #000000">Primarily due to the approximate $11
million and $14 million gain on derivative instruments from the
change in fair value of the Company&#x2019;s warrant liabilities
during the years ended September 30, 2017 and 2016,
respectively.</font></font></div>
</td>
</tr><tr>
<td><br></td>
</tr><tr>
<td><br></td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-27</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company applies the provisions of ASC 740, <font style="font-style: italic">&#x201C;Accounting for Uncertainty in Income
Taxes,&#x201D;</font> which requires financial statement benefits to
be recognized for positions taken for tax return purposes when it
is more likely than not that the position will be sustained. The
Company has elected to reflect any tax penalties or interest
resulting from tax assessments on uncertain tax positions as a
component of tax expense. The Company has generated federal net
operating losses in tax years ending September 30, 1998 through
2016. These years remain open to examination by the major domestic
taxing jurisdictions to which the Company is subject.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.&#xA0;&#xA0;&#xA0;
STOCK COMPENSATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company recognized the following expenses for options issued or
vested and restricted stock awarded during the year:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:28%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 5%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 90%; font-size: 11px;">Year Ended September 30,</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 5%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Employees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,380,500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,113,433</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Non-employees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">232,847</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">751,651</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Stock
compensation expenses were recorded as general and administrative
expense. During the years ended September 30, 2017 and 2016,
non-employee stock compensation excluded approximately $45,000 and
$48,000, respectively, for future services to be performed (Note
12).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the years ended September 30, 2017 and 2016 the fair value of each
option grant was estimated on the date of grant using the
Black-Scholes option-pricing model with the following
assumptions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 71%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman;">2017</font></font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman;">2016</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 71%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Expected
stock price volatility</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">88.54
&#x2013; 90.67%</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">75.58
&#x2013; 80.9%</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Risk-free
interest rate</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">2.18
&#x2013; 2.29%</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">0.71
&#x2013; 1.56%</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 71%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Expected
life of options</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">9.69
&#x2013; 10 Years</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">3.0
&#x2013; 9.69 Years</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Expected
dividend yield</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">-</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">-</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Non-Qualified Stock Option
Plans</font> &#x2013; At September 30, 2017, the Company has
collectively authorized the issuance of 1,187,200 shares of common
stock under its Non-Qualified Stock Option Plans. Options typically
vest over a three-year period and expire no later than ten years
after the grant date. Terms of the options were determined by the
Company&#x2019;s Compensation Committee, which administers the
plans. The Company&#x2019;s employees, directors, officers, and
consultants or advisors are eligible to be granted options under
the Non-Qualified Stock Option Plans.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-28</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Incentive Stock Option Plans</font>
&#x2013; At September 30, 2017, the Company had collectively
authorized the issuance of 138,400 shares of common stock under its
Incentive Stock Option Plans. Options typically vest over a
three-year period and expire no later than ten years after the
grant date. Terms of the options were determined by the
Company&#x2019;s Compensation Committee, which administers the
plans. Only the Company&#x2019;s employees are eligible to be
granted options under the Incentive Stock Option
Plans.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Activity in the
Company&#x2019;s Non-Qualified and Incentive Stock Option Plans for
the two years ended September 30, 2017 is summarized as
follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Non-Qualified and Incentive Stock Option Plans</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="4" rowspan="1" style="vertical-align:bottom;width:40%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 2%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 96%; font-size: 11px;">Outstanding</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 2%; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="4" rowspan="1" style="vertical-align:bottom;width:40%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 2%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 96%; font-size: 11px;">Exercisable</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 2%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Weighted</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Weighted</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Weighted</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Ave</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Aggregate</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times New Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Weighted</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Ave</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Aggregate</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Number of</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Average</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Remaining Contractual</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Intrinsic</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Number of</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Average</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Remaining Contractual</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Intrinsic</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Shares</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Exercise Price</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Term (Years)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Value</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Shares</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Exercise Price</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Term (Years)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Value</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding
at October 1, 2015</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">301,511</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">67.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.98</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">181,102</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">78.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.01</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vested</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">56,069</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted
(a)</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">48,544</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">21.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">145.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">145.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cancelled</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding
at September 30, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">343,575</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">59.22</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.35</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">232,931</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">66.28</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4.76</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vested</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">63,812</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">18.45</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted
(b)</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">932,825</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.17</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,795</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9.46</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20,761</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">88.80</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">20,761</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">88.80</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cancelled</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:20%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:20%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding
at September 30, 2017</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,239,844</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16.44</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8.50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,400</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">275,982</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">53.53</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4.91</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(a)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Includes 16,400
stock options granted to consultants</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(b)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Includes 20,000
stock options granted to consultants</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-29</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">A
summary of the status of the Company&#x2019;s non-vested options for
the two years ended September 30, 2017 is presented
below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Number of Options</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Weighted Average Grant Date Fair
Value</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unvested
at October 1, 2015</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">120,409</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">43.09</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vested</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(56,069</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">48,544</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unvested
at September 30, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">110,644</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">36.96</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Vested</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(63,812</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">932,825</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(15,795</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unvested
at September 30, 2017</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">963,862</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4.91</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Incentive Stock Bonus Plan</font>
&#x2013; Up to 640,000 shares are authorized under the 2014
Incentive Stock Bonus Plan. The shares will only be earned upon the
achievement of certain milestones leading to the commercialization
of the Company&#x2019;s Multikine technology, or specified increases
in the market price of the Company&#x2019;s stock<font style="font-size: 13px">.</font> If the performance or market criteria
are not met as specified in the Incentive Stock Bonus Plan, all or
a portion of the awarded shares will be forfeited. The fair value
of the shares on the grant date was calculated using the market
value on the grant-date for issuances where the attainment of
performance criteria is likely and using a Monte Carlo simulation
for issuances where the attainment of performance criteria is
uncertain. The grant date fair value of shares issued that remain
outstanding as of September 30, 2017 was approximately $8.6
million. The total value of the shares, if earned, is being
expensed over the requisite service periods for each milestone,
provided the requisite service periods are rendered, regardless of
whether the market conditions are met. No compensation cost is
recognized for awards where the requisite service period is not
rendered. During the years ended September 30, 2017 and 2016, the
Company recorded expense relating to the issuance of restricted
stock pursuant to the plan of approximately $633,000 and $634,000,
respectively. At September 30, 2017, the Company has unrecognized
compensation expense of approximately $2.5 million which is
expected to be recognized over a weighted average period of four
years.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-30</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">A
summary of the status of the Company&#x2019;s restricted common
stock issued from the Incentive Stock Bonus Plan for the two years
ended September 30, 2017 is presented below:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Number of Shares</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">Weighted Average Grant Date Fair
Value</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Unvested at
September 30, 2015</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">604,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Vested</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Unvested at
September 30, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">604,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13.75</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Vested</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(136,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Unvested at
September 30, 2017</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">468,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 4px;">$</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 4px;">13.75</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 4px; font-size: 13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Stock Bonus Plans</font> &#x2013; At
September 30, 2017, the Company was authorized to issue up to
383,760 shares of common stock under its Stock Bonus Plans. All
employees, directors, officers, consultants, and advisors are
eligible to be granted shares. During the year ended September 30,
2017, 79,941 shares were issued to the Company&#x2019;s 401(k) plan
for a cost of approximately $151,000. During the year ended
September 30, 2016, 16,340 shares were issued to the
Company&#x2019;s 401(k) plan for a cost of approximately $162,000.
As of September 30, 2017, the Company has issued a total of 206,390
shares of common stock from the Stock Bonus Plans.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Stock Compensation Plans</font>
&#x2013; At September 30, 2017, 134,000 shares were authorized for
use in the Company&#x2019;s Stock Compensation Plans. During the
years ended September 30, 2017, and 2016, 23,202 and 18,593 shares,
respectively, were issued from the Stock Compensation Plans to
consultants for payment of services at a cost of approximately
$60,000 and $234,000, respectively. During the year ended September
30, 2017 and 2016, 13,000 and 3,837 shares, respectively, were
issued to employees from the Stock Compensation Plans as part of
their compensation at a cost of approximately $24,000 and $45,000,
respectively. As of September 30, 2017, the Company has issued
115,590 shares of common stock from the Stock Compensation
Plans.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">10.&#xA0;
EMPLOYEE BENEFIT PLAN</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company maintains a defined contribution retirement plan,
qualifying under Section 401(k) of the Internal Revenue Code,
subject to the Employee Retirement Income Security Act of 1974, as
amended, and covering substantially all Company employees. Each
participant&#x2019;s contribution is matched by the Company with
shares of common stock that have a value equal to 100% of the
participant&#x2019;s contribution, not to exceed the lesser of
$10,000 or 6% of the participant&#x2019;s total compensation. The
Company&#x2019;s contribution of common stock is valued each quarter
based upon the closing bid price of the Company&#x2019;s common
stock. Total expense, including plan maintenance, for the years
ended September 30, 2017 and 2016, in connection with this Plan was
approximately $163,000 and $168,000, respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-31</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">11.&#xA0;
COMMITMENTS AND CONTINGENCIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Clinical Research Agreements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
March 2013, the Company entered into an agreement with Aptiv
Solutions to provide certain clinical research services in
accordance with a master service agreement. The Company will
reimburse Aptiv for costs incurred. The agreement required the
Company to make $600,000 in advance payments which are being
credited against future invoices in $150,000 annual increments
through December 2017. As of September 30, 2017, the total balance
advanced is $150,000 and is classified as a current
asset.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In April 2013, the Company entered into a
co-development and revenue sharing agreement with Ergomed. Under
the agreement, Ergomed will contribute up to $10 million towards
the study in the form of offering discounted clinical services in
exchange for a single digit percentage of milestone and royalty
payments, up to a specific maximum amount</font>. In October 2015,
the Company entered into a second <font style="color: #292929">co-development and revenue sharing agreement with
Ergomed</font> for an additional $2 million, for a total of $12
million. The Company accounted for the co-development and revenue
sharing agreement in accordance with ASC 808 &#x201C;Collaborative
Arrangements&#x201D;. The Company determined the payments to Ergomed
are within the scope of ASC 730 &#x201C;Research and
Development.&#x201D; Therefore, the Company records the discount on
the clinical services as a credit to research and development
expense on its Statements of Operations. Since the Company entered
into the co-development and revenue sharing agreement with Ergomed,
it has incurred research and development expenses of approximately
$25.0 million related to Ergomed&#x2019;s services. This amount is
net of Ergomed&#x2019;s discount of approximately $8.4 million.
During the years ended September 30, 2017 and 2016, the Company
recorded, approximately $5.8 million and $7.2 million,
respectively, as research and development expense related to
Ergomed&#x2019;s services. These amounts were net of Ergomed&#x2019;s
discount of approximately $2.1 million in each of the periods
presented.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2013, the Company entered into two co-development and
profit sharing agreements with Ergomed.&#xA0; One agreement
supports the Phase 1 study being conducted at UCSF for the
development of Multikine as a potential treatment for peri-anal
warts in HIV/HPV co-infected men and women.&#xA0; The other
agreement focuses on the development of Multikine as a potential
treatment for cervical dysplasia in HIV/HPV co-infected women.
Ergomed will assume up to $3 million in clinical and regulatory
costs for each study.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company is currently involved in a pending arbitration proceeding,
CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a
PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet AG).
T<font style="color: #000000">he Company initiated the proceedings
against inVentiv Health Clinical, LLC, or inVentiv, the former
third-party CRO, and is seeking payment for damages related to
inVentiv&#x2019;s prior involvement in the ongoing Phase 3 clinical
trial of Multikine. The arbitration claim, initiated under the
Commercial Rules of the American Arbitration Association, alleges
(i) breach of contract, (ii) fraud in the inducement, and (iii)
common law fraud. Currently, the Company is seeking at least $50
million in damages in its amended statement of
claim.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-32</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In an
amended statement of claim, the Company asserted the claims set
forth above as well as an additional claim for professional
malpractice.&#xA0;&#xA0;The arbitrator subsequently granted
inVentiv&#x2019;s motion to dismiss the professional malpractice
claim based on the &#x201C;economic loss doctrine&#x201D; which,
under New Jersey law, is a legal doctrine that, under certain
circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#xA0;&#xA0;The arbitrator
denied the remainder of inVentiv&#x2019;s motion, which had sought
to dismiss certain other aspects of the amended statement of
claim.&#xA0;&#xA0;In particular, the arbitrator rejected
inVentiv&#x2019;s argument that several aspects of the amended
statement of claim were beyond the arbitrator&#x2019;s
jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the pending arbitration proceedings, inVentiv has
asserted counterclaims against the Company for (i) breach of
contract, seeking at least $2 million in damages for services
allegedly performed by inVentiv; (ii) breach of contract, seeking
at least $1 million in damages for the Company&#x2019;s alleged use
of inVentiv&#x2019;s name in connection with publications and
promotions in violation of the parties&#x2019; contract; (iii)
opportunistic breach, restitution and unjust enrichment, seeking at
least $20 million in disgorgement of alleged unjust profits
allegedly made by the Company as a result of the purported breaches
referenced in subsection (ii); and (iv) defamation, seeking at
least $1 million in damages for allegedly defamatory statements
made about inVentiv. The Company believes inVentiv&#x2019;s
counterclaims are meritless. However, if inVentiv successfully
asserts any of its counterclaims, such an adverse determination
could have a material adverse effect on the Company&#x2019;s
business, results, financial condition and liquidity.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2015 the Company signed an arbitration funding agreement
with a company established by Lake Whillans Litigation Finance,
LLC, a firm specializing in funding litigation expenses. Pursuant
to the agreement, an affiliate of Lake Whillans provides the
Company with funding for litigation expenses to support its
arbitration claims against inVentiv. The funding is available to
the Company to fund the expenses of the ongoing arbitration and
will only be repaid when the Company receives proceeds from the
arbitration. During the year ended September 30, 2016, the Company
recognized a gain of approximately $1.1 million on the
derecognition of legal fees to record the transfer of the liability
that existed prior to the execution of the financing agreement from
the Company to Lake Whillans. The gain on derecognition of legal
fees is recorded as a reduction of general and administration
expenses on the Statement of Operations. All related legal fees are
directly billed to and paid by Lake Whillans. As part of the
agreement with Lake Whillans, the law firm agreed to cap its fees
and expenses for the arbitration at $5 million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
arbitration has been going on longer than expected, but it is
finally nearing its end. The hearing (the &#x201C;trial&#x201D;)
started on September 26, 2016. The last witness in the arbitration
hearing testified on Wednesday, November 8, 2017, and no further
witnesses or testimony are expected. With that final witness, the
testimony phase of the arbitration concluded. All that remains at
the trial level are closing statements and post-trial
submissions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Lease Agreements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases a manufacturing facility near Baltimore, Maryland
under an operating lease (the San Tomas lease). The building was
remodeled in accordance with the Company&#x2019;s specifications so
that it can be used by the Company to manufacture Multikine for the
Company&#x2019;s Phase 3 clinical trial and sales of the drug if
approved by the FDA. The lease is for a term of twenty years and
requires annual base rent to escalate each year at 3%. The Company
is required to pay all real estate and personal property taxes,
insurance premiums, maintenance expenses, repair costs and
utilities. The lease allows the Company, at its election, to extend
the lease for two ten-year periods or to purchase the building at
the end of the 20-year lease. The Company contributed approximately
$9.3 million towards the tenant-directed improvements, of which
$3.2 million is being refunded during years six through twenty
through reduced rental payments. The landlord paid approximately
$11.9 million towards the purchase of the building, land and the
tenant-directed improvements. The asset was placed in service in
October 2008.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-33</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Because the terms of the original lease agreements
required the Company to be responsible for cost overruns, if there
had been any, but of which there were none, the Company was deemed
to be the owner of the building for accounting purposes under the
build-to-suit guidance in ASC 840-40-55. In addition to the tenant
improvements the Company incurred and capitalized on its balance
sheet, the Company recorded an asset for tenant-directed
improvements and for the costs paid by the lessor to purchase the
building and to perform improvements, as well as a corresponding
liability for the landlord costs. Upon completion of the
improvements, the Company did not meet the
&#x201C;sale-leaseback&#x201D; criteria under ASC 840-40-25,</font>
<font style="font-style: italic; color: #000000">Accounting for
Leases, Sale-Leaseback Transactions,</font> <font style="color: #000000">and therefore, treated the lease as a financing
obligation. Therefore, the asset and corresponding liability were
not be derecognized.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
of September 30, 2017 and 2016, the leased building asset has a net
book value of approximately $16.6 million and $17.1 million and the
landlord liability as a balance of $13.2 million and $13.0 million.
The leased asset is being depreciated using a straight line method
of the 20 year lease term to a residual value. The landlord
liability is being amortized over the 20 years using the effective
interest method.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company was required to deposit the equivalent of one year of base
rent in accordance with the San Tomas lease. When the Company meets
the minimum cash balance required by the lease, the deposit will be
returned to the Company. The approximate $1.7 million deposit is
included in non-current assets on September 30, 2017 and
2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Approximate future
minimum lease payments under the San Tomas lease as of September
30, 2017 are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td colspan="1" rowspan="1" style="vertical-align: bottom; width: 86%;">
<div style="border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Years
ending September 30,</font></div>
</div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 13px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,747,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,808,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,872,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,937,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2022</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,004,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Thereafter</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">13,758,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
future minimum lease obligation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">23,126,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Less:
imputed interest on financing obligation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(9,914,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
present value of lease financing obligation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">13,212,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company subleases a portion of its rental space on a month to month
term lease, which requires a 30 day notice for termination. The
sublease rent for the years ended September 30, 2017 and 2016 was
approximately $69,000 and $67,000, respectively, and is recorded in
grant income and other in the statements of
operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases its research and development laboratory under a 60
month lease which expires February 28, 2017. In September 2016, the
lease was extended through February 28, 2022. The operating lease
includes escalating rental payments. The Company is recognizing the
related rent expense on a straight line basis over the full 60
month term of the lease at the rate of approximately $13,000 per
month. As of September 30, 2017 and 2016, the Company has recorded
a deferred rent liability of approximately $5,000 and $2,000,
respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-34</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases its office headquarters under a 60 month lease which
expires June 30, 2020. The operating lease includes escalating
rental payments. The Company is recognizing the related rent
expense on a straight line basis over the full 60 month term of the
lease at the rate approximately $8,000 per month. As of September
30, 2017 and 2016, the Company has recorded a deferred rent
liability of approximately $18,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases office equipment under a capital lease arrangement.
The terms of the capital lease is 60 months and expires on October
31, 2021. The monthly lease payment is $505. The lease bears
interest at approximately 6.25% per annum. The Company&#x2019;s
previous equipment lease expired on September 30,
2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Approximate
future minimum annual lease payments due under non-cancelable
operating leases, excluding the San Tomas lease, for the years
ending after September 30, 2017 are as follows:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 86%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Years
ending September 30,</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">251,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">258,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">238,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">163,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2022</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">69,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Thereafter</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
future minimum lease obligation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">979,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Rent
expense, for the years ended September 30, 2017 and 2016, excluding
the rent paid on the San Tomas lease, was approximately $245,000
and $234,000, respectively. The Company&#x2019;s three leases expire
between June 2020 and October 2028.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Vendor Obligations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Further, the
Company has contingent obligations with other vendors for work that
will be completed in relation to the Phase 3 trial. The timing of
these obligations cannot be determined at this time. CEL-SCI
estimates it will incur additional expenses of approximately $13.0
million for the remainder of the Phase 3 clinical trial. It should
be noted that this estimate is based only on the information
currently available in CEL-SCI&#x2019;s contracts with the Clinical
Research Organizations responsible for managing the Phase 3
clinical trial and does not include other related costs, e.g. the
manufacturing of the drug.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-35</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">12.&#xA0;
RELATED PARTY TRANSACTIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On July
24, 2017, the Company issued convertible notes (Series NN Notes) in
the aggregate principal amount of $1.2 million to 12 individual
investors. A trust in which Geert Kersten, the Company&#x2019;s
Chief Executive Officer, holds a beneficial interest participated
in the offering and purchased a note in the principal amount of
$250,000. Patricia B. Prichep, the Company&#x2019;s Senior Vice
President of Operations, participated in the offering and purchased
a note in the principal amount of $25,000. The terms of the
trust&#x2019;s Note and Ms. Prichep&#x2019;s Note were identical to
the other participants. The number of shares of the Company&#x2019;s
common stock issued upon conversion will be determined by dividing
the principal amount to be converted by $2.29, which would result
in the issuance of 109,170 shares to the trust and 10,917 shares to
Ms. Prichep upon conversion. Along with the other purchasers of the
convertible notes, the trust and Ms. Prichep also received Series
NN warrants to purchase up to 109,170 and 10,917 shares,
respectively, of the Company&#x2019;s common stock. The Series NN
warrants are exercisable at a fixed price of $2.52 per share and
expire on July 24, 2022. Shares issuable upon the exercise of the
notes and warrants were restricted securities unless registered.
The shares were registered effective September 1,
2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On June 22, 2017, CEL-SCI issued convertible notes
(Series MM Notes) in the aggregate principal amount of $1.5 million
to six individual investors.</font> Geert Kersten, the
Company&#x2019;s Chief Executive Officer, participated in the
offering and purchased notes in the principal amount of $250,000.
The terms of Mr. Kersten&#x2019;s Note were identical to the other
participants. The number of shares of the Company&#x2019;s common
stock issued upon conversion will be determined by dividing the
principal amount to be converted by $1.69, which would result in
the issuance of 147,929 shares to Mr. Kersten upon conversion.
Along with the other purchasers of the convertible notes, Mr.
Kersten also received Series MM warrants to purchase up to 147,929
shares of the Company&#x2019;s common stock. The Series MM warrants
are exercisable at a fixed price of $1.86 per share and expire on
June 22, 2022. Shares issuable upon the exercise of the notes and
warrants were restricted securities unless registered. The shares
were registered effective August 8, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">No
interest payments were made to officers during the year ended
September 30, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Effective August
31, 2016, the Company issued Maximilian de Clara, the
Company&#x2019;s then President and a director, through the de Clara
Trust, 26,000 shares of restricted stock in payment of past
services. The de Clara Trust was established by Maximilian de
Clara, the Company&#x2019;s former President and a director. The
shares were issued as follows; 13,000 shares upon his resignation
on August 31, 2016 and 13,000 on August 31, 2017. The total value
of the shares issued was approximately $176,000, of which
approximately $24,000 was expensed during the year ended September
30, 2017 and $152,000 was expensed during the year ended September
30, 2016. On September 30, 2016, the fair value accrued for
unissued shares was approximately $101,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
January 13, 2016, the de Clara Trust demanded payment on a note
payable, of which the balance, including accrued and unpaid
interest, was approximately $1.1 million. The Company&#x2019;s Chief
Executive Officer, Geert Kersten, is a beneficiary of the de Clara
Trust. When the de Clara Trust demanded payment on the note, the
Company sold 120,000 shares of its common stock and 120,000 Series
X warrants to the de Clara Trust for approximately $1.1 million.
Each warrant allows the de Clara Trust to purchase one share of the
Company's common stock at a price of $9.25 per share at any time on
or before January 13, 2021.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-36</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">No
interest payments were made to Mr. de Clara or the de Clara Trust
during the year ended September 30, 2017. During the year ended
September 30, 2016, the Company paid approximately $43,000 interest
expense to Mr. de Clara.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">13.&#xA0;
STOCKHOLDERS&#x2019; EQUITY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 22, 2017, the Company entered into a securities purchase
agreement with institutional investors whereby it sold 1,750,000
shares of its common stock for net proceeds of approximately $3.2
million, or $2.00 per share, in a registered direct offering. In a
concurrent private placement, the Company also issued to the
purchasers of the Company&#x2019;s common stock Series PP warrants
to purchase 1,750,000 shares of common stock. In addition, the
Company issued 87,500 Series QQ warrants to the placement agent as
part of its compensation. See Note 4 for more information with
respect to the Series PP &amp; QQ warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 15, 2017, the Company entered into a Securities Purchase
Agreement with Ergomed plc, the Company&#x2019;s Clinical Research
Provider, to facilitate the payment of some of the accounts payable
balances due Ergomed. Under the Agreement, the Company issued
Ergomed 480,000 shares, with a fair market value of approximately
$1.3 million, as a forbearance fee in exchange for Ergomed&#x2019;s
agreement to provisionally forbear collection of the payables. In
an amount equal to the net proceeds from the resales of the shares
issued to Ergomed. The Company recorded the full amount of the
expense upon issuance and will credit any amounts realized through
reduction of the payables. During the quarter ended September 30,
2017, 64,792 shares were resold and the Company reduced the expense
by approximately $107,000. The net expense of $1.2 million recorded
during the quarter is included in interest expense.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On July
26, 2017, the Company entered into a securities purchase agreement
with an investor whereby it sold 100,000 shares of its common stock
for gross proceeds of $229,000, or $2.29 per share, in a registered
offering. In a concurrent private placement, the Company also
issued to the purchaser of that common stock Series OO warrants to
purchase 60,000 shares of the Company&#x2019;s common stock. See
Note 4 for more information with respect to the Series OO
warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
April 30, 2017, the Company entered into a securities purchase
agreement with an institutional investor whereby it sold 527,960
shares of its common stock for net proceeds of approximately $1.4
million, or $2.875 per share, in a registered direct offering. In a
concurrent private placement, the Company also issued to the
purchaser of the Company&#x2019;s common stock, Series KK warrants
to purchase 395,970 shares of common stock. In addition, the
Company issued 26,398 Series LL warrants to the Placement Agent as
part of its compensation. See Note 4 for more information with
respect to the Series KK and LL warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
March 14, 2017, the Company sold 600,000 registered shares of
common stock and 600,000 Series II warrants to purchase 600,000
unregistered shares of common stock at combined offering price of
$2.50 per share.&#xA0; <font style="color: #000000">In addition,
the Company issued 30,000 Series JJ warrants to purchase 30,000
shares of unregistered common stock to the placement agent.
The&#xA0;net&#xA0;proceeds from this
offering&#xA0;were&#xA0;approximately $1.3&#xA0;million.</font> See
Note 4 for more information with respect to the Series II and JJ
warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-37</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
February 23, 2017, the Company sold 400,000 registered shares of
common stock and 400,000 Series GG warrants to purchase 400,000
unregistered shares of common stock at a combined price of $2.50
per share.&#xA0; <font style="color: #000000">In addition, the
Company issued to the placement agent, 20,000 Series HH warrants to
purchase 20,000 shares of unregistered common stock.
The&#xA0;net&#xA0;proceeds from this
offering&#xA0;were&#xA0;approximately $0.8&#xA0;million.</font> See
Note 4 for more information with respect to the Series GG and HH
warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On December 8, 2016, the Company sold 1,360,960
shares of common stock and warrants to purchase common stock at a
price of $3.13 in a public offering. The warrants consist of
680,480 Series CC warrants to purchase 680,480 shares of common
stock, 1,360,960 Series DD warrants to purchase 1,360,960 shares of
common stock and 1,360,960 Series EE warrants to purchase 1,360,960
shares of common stock. In addition, the Company issued 68,048
Series FF warrants to purchase 68,048 shares of common stock to the
placement agent. Net&#xA0;proceeds from this
offering&#xA0;were&#xA0;approximately $3.7&#xA0;million.</font> See
Note 4 for more information with respect to the Series CC, DD, EE
and FF warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On August 26, 2016, the Company closed a
registered direct offering of&#xA0;400,000 shares of common stock
and Series AA warrants to purchase up to 200,000 shares of common
stock. Each share of common stock was sold together with a Series
AA warrant to purchase one-half of a share of common stock for the
combined purchase price of $13.75.</font> The Company also issued
16,000 Series BB warrants to the placement agent as part of its
compensation. The Company received proceeds from the sale of Series
AA and Series BB shares and warrants of approximately $4.5 million,
net of placement agent&#x2019;s commissions and offering expenses.
See Note 4 for more information with respect to the Series AA and
BB warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On May
23, 2016, the Company closed a registered direct offering of
400,000 shares of common stock and 264,000 Series Z warrants to
purchase shares of common stock. The common stock and warrants were
sold at a combined per unit price of $13.75 for net proceeds of
approximately $4.6 million, net of placement agent&#x2019;s
commissions and offering expenses. The Company also issued 20,000
Series ZZ warrants to the placement agent as part of its
compensation. The Series ZZ warrants may be exercised at any time
on or after November 23, 2016 and on or before May 18, 2021 at a
price of $13.75 per share. See Note 4 for more information with
respect to the Series Z and ZZ warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 28, 2015, the Company closed an underwritten public
offering of 688,930 shares of common stock and 688,930 Series W
warrants to purchase shares of common stock. The common stock and
warrants were sold at a combined price of $16.75 for net proceeds
of approximately $10.5 million, net of underwriting commissions and
offering expenses. See Note 4 for more information with respect to
the Series W warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">14.&#xA0;
FAIR VALUE MEASUREMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
accordance with the provisions of ASC 820, &#x201C;<font style="font-style: italic">Fair Value Measurements</font>,&#x201D; the
Company determines fair value as the price that would be received
to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date.
The Company generally applies the income approach to determine fair
value. This method uses valuation techniques to convert future
amounts to a single present amount. The measurement is based on the
value indicated by current market expectations about those future
amounts.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">ASC 820
establishes a fair value hierarchy that prioritizes the inputs used
to measure fair value. The hierarchy gives the highest priority to
active markets for identical assets and liabilities (Level 1
measurement) and the lowest priority to unobservable inputs (Level
3 measurement). The Company classifies fair value balances based on
the observability of those inputs. The three levels of the fair
value hierarchy are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-38</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 1 &#x2013;
Observable inputs such as quoted prices in active markets for
identical assets or liabilities</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 2 &#x2013;
Inputs other than quoted prices that are observable for the asset
or liability, either directly or indirectly. These include quoted
prices for similar assets or liabilities in active markets, quoted
prices for identical or similar assets or liabilities in markets
that are not active and amounts derived from valuation models where
all significant inputs are observable in active
markets</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 3 &#x2013;
Unobservable inputs that reflect management&#x2019;s
assumptions</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For
disclosure purposes, assets and liabilities are classified in their
entirety in the fair value hierarchy level based on the lowest
level of input that is significant to the overall fair value
measurement. The Company&#x2019;s assessment of the significance of
a particular input to the fair value measurement requires judgment
and may affect the placement within the fair value hierarchy
levels.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
table below sets forth the liabilities measured at fair value on a
recurring basis, by input level, on the balance sheet at September
30, 2017:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:44%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Quoted Prices in Active Markets for Identical
Liabilities (Level 1)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Significant Other Observable Inputs (Level
2)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Significant Unobservable Inputs (Level
3)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Total</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Derivative
Instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">32,773</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,020,629</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,053,402</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
table below sets forth the liabilities measured at fair value on a
recurring basis, by input level, on the balance sheet at September
30, 2016:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:44%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 11px; font-weight: bold;">
&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Quoted Prices in Active Markets for Identical
Liabilities (Level 1)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Significant Other Observable Inputs (Level
2)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Significant Unobservable Inputs (Level
3)</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-weight: bold;">Total</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Derivative
Instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">3,111,361</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,283,573</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">8,394,934</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
following sets forth the reconciliation of beginning and ending
balances related to fair value measurements using significant
unobservable inputs (Level 3), as of September 30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;margin-right:0px;margin-left:0px;width:100%;font-size:13px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2017</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font></font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-weight: bold; font-size: 11px;"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2016</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Beginning
balance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,283,573</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,323,032</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Issuances</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,665,683</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">8,722,073</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;padding-bottom:2px;margin-left:24px;">&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Net realized and
unrealized derivative gain</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(7,928,627</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(9,761,532</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Ending
balance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,029,629</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">$</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">5,283,573</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-39</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
fair values of the Company&#x2019;s derivative instruments disclosed
above under Level 3 are primarily derived from valuation models
where significant inputs such as historical price and volatility of
the Company&#x2019;s stock as well as U.S. Treasury Bill rates are
observable in active markets. At September 30, 2017, the
Company&#x2019;s Level 3 derivative instruments have a weighted
average fair value of $0.29 per share and a weighted average
exercise price of $5.41 per share. Fair values were determined
using a weighted average risk free interest rate of 1.85% and 80%
volatility. The instruments have a weighted average time to
maturity of 4.55 years. At September 30, 2016, the Company&#x2019;s
Level 3 derivative instruments have a weighted average fair value
of $2.50 per share and a weighted average exercise price of $21.50
per share. Fair values were determined using a weighted average
risk free interest rate of 1.04% and 75% volatility.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
15. NET LOSS PER COMMON SHARE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Basic
loss per share is computed by dividing net loss available to common
shareholders by the weighted average number of common shares
outstanding during the period. The Company&#x2019;s potentially
dilutive shares, which include outstanding common stock options,
common stock warrants, restricted stock and shares issuable on
convertible debt, have not been included in the computation of
diluted net loss per share for all periods presented, as the result
would be anti-dilutive. For the years presented, the gain on
derivative instruments is not included in net loss available to
common shareholders for purposes of computing dilutive loss per
share because its effect is anti-dilutive.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
following table provides a reconciliation of the numerators and
denominators of the basic and diluted per-share
computations:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 3%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 94%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Year Ended September 30, 2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 3%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Net Loss</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Weighted Average Shares</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">LPS</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic
loss per share</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">(14,427,055</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">7,891,843</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1.83</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Less: gain on derivatives</font><font style="font-size: 70%; vertical-align: top; color: #000000">(1)</font></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(677,287</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">10,804</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Dilutive
loss per share</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(15,104,342</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">7,902,647</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1.91</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; text-indent: 0px; margin-right: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table; margin-left: 24px;">
<div style="display: table-row;">
<div style="text-align: justify; display: table-cell; width: 36px;">
<font style="font-family: Times New Roman; font-size: 13px">(1)</font></div>
<div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Includes series GG
and II warrants<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-40</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 3%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 94%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Year Ended September 30, 2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 3%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Net Loss</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">Weighted Average Shares</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times New Roman; font-size: 11px; font-weight: bold;">LPS</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic
and dilutive loss per share</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(11,512,492</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">4,866,204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2.37</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
gain on derivative instruments that contain exercise prices lower
than the average market share price during the period is excluded
from the numerator and the related shares are excluded from the
denominator in calculating diluted loss per share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
accordance with the contingently issuable shares guidance of FASB
ASC Topic 260, <font style="font-style: italic">Earnings Per
Share</font>, the calculation of diluted net loss per share
excludes the following dilutive securities because their inclusion
would have been anti-dilutive as of September 30:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:13px;font-family:Times New Roman;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2017</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times New Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2016</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Options and
Warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,538,130</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,675,281</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Convertible
Debt</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,166,106</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Unvested Restricted
Stock</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">604,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">604,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">4,308,236</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">4,279,281</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
16. SUBSEQUENT EVENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
accordance with ASC 855, &#x201C;<font style="font-style: italic">Subsequent Events</font>&#x201D;, the Company
has reviewed subsequent events through the date of the
filing.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 19, 2017 the Company received subscription agreements for
the purchase of 1,289,478 shares of CEL-SCI common stock at a price
of $1.90 in the principal amount of $2,450,000 from 19 investors.
The common stock will be restricted unless registered. The
purchasers of the common stock also received warrants which entitle
the purchasers to acquire up to 1,289,478 shares of the
Company&#x2019;s common stock. The warrants are exercisable at a
fixed price of $2.09 per share, will not be exercisable for 6
months and one day and will expire on December 18, 2022. Shares
issuable upon the exercise of the warrants will be restricted
securities unless registered.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 18, 2017 CEL-SCI Corporation appointed Robert Watson to
its Board of Directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">On November 2, 2017, holders of convertible notes
in the principal amount of $1.1 million sold in June 2017 and
holders of convertible notes in the principal amount of $1.2
million sold in July 2017 agreed to extend the maturity date of
these notes to September 21, 2018. In consideration for the
extension of the maturity date of the convertible notes, the
Company issued a total of 716,400 Series RR warrants to the
convertible note holders that agreed to the extension. Each Series
RR warrant entitles the holder to purchase one share of the
Company&#x2019;s common stock. The Series RR warrants may be
exercised at any time on or before October 30, 2022 at an exercise
price of $1.65 per share.</font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-41</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
accordance with Section 13 or 15(a) of the Securities Exchange Act
of 1934, the Registrant has caused this Report to be signed on its
behalf by the undersigned, thereunto duly authorized on the
29<font style="font-size: 70%; vertical-align: top">th</font> day
of December 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" style="width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>CEL-SCI CORPORATION</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 3%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:</font></div>
</td>
<td style="width: 35%; border-bottom: 2px solid black">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/</font>
<font style="font-size: 13px; font-family: Times New Roman">Geert
R. Kersten</font></div>
</td>
<td style="width: 12%; border-bottom: 2px solid #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Geert R. Kersten,
Chief Executive Officer<br></font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-size: 13px; font-family: Times New Roman">Pursuant to the
requirements of the Securities Act of l934, this Report has been
signed below by the following persons on behalf of the Registrant
and in the capacities and on the dates indicated.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="width: 27%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Signature</font></div>
</td>
<td style="text-indent: 0px; width: 32%; margin-left: 12px; margin-right: 0px">
<div style="text-align: left; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Title</font></div>
</td>
<td style="text-indent: 0px; width: 19%; margin-left: 0px; margin-right: 0px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-size: 13px; font-family: Times New Roman">
Date</font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 27%; border-bottom: 2px solid black">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Geert R.
Kersten</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Chief Executive,
Principal</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Geert R.
Kersten</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Accounting,
Principal Financial</font></div>
</td>
<td style="width: 19%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Officer and a
Director</font></div>
</td>
<td style="width: 19%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font><font style="font-size: 13px; font-family: Times New Roman">December 29,
2017<br></font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%; border-bottom: 2px solid black">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/Peter R.
Young</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Director</font></div>
</td>
<td style="width: 19%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font><font style="font-size: 13px; font-family: Times New Roman">December 29,
2017<br></font></font></div>
</div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Dr. Peter R.
Young</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 32%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 19%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="width: 27%; border-bottom: 2px solid black">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Bruno
Baillavoine</font></div>
</td>
<td style="width: 32%">
<div style="text-align: justify; margin-left: 36px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Director</font></div>
</td>
<td style="width: 19%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font><font style="font-size: 13px; font-family: Times New Roman">December 29,
2017<br></font></font></div>
</div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 300px"><font style="font-size: 13px; font-family: Times New Roman"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>cvm_ex231.htm
<DESCRIPTION>CONSENTS OF EXPERTS AND COUNSEL
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 23.1</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Consent
of Independent Registered Public Accounting Firm</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Vienna,
Virginia</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We
hereby consent to the incorporation by reference in the
Registration Statements on Form S&#xAC;3 (File numbers 333-162039,
333-161504, 333-162792, 333-184094, 333-186103, 333-196243 and
333-205444) and Form S&#xAC;8 (File numbers 333-117088, 333-140792,
333-162265, 333-179477, 333-184092 333-198244, 333-206538 and
333-214031) of CEL-SCI Corporation of our report dated December 29,
2017, relating to the financial statements, which appear in this
Form 10-K. Our report on the financial statements contains an
explanatory paragraph regarding the Company&#x2019;s ability to
continue as a going concern.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">/s/BDO
USA, LLP</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">McLean,
Virginia</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">December
29, 2017<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 31</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #325592; font-family: Times New Roman; font-size: 13px">
CERTIFICATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">I,
Geert Kersten, of CEL-SCI Corporation, certify that:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
I have reviewed this annual report on Form 10-K of CEL-SCI
Corporation;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the
periods presented in this report;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
The registrant's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this report is being prepared;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such internal control over financial reporting, or cause such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">c)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;evaluated
the effectiveness of the registrant&#x2019;s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">d)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;disclosed
in this report any change in the registrant&#x2019;s internal
control over financial reporting that occurred during the
registrant&#x2019;s most recent fiscal quarter (the
registrant&#x2019;s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant&#x2019;s internal control over
financial reporting; and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of the internal control over
financial reporting, to the registrant's auditors and the audit
committee of the registrant's board of directors (or persons
performing the equivalent functions):</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;all
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#x2019;s
ability to record, process, summarize and report financial
information; and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;any
fraud, whether or not material, that involves management or other
employees who have significant role in the registrant&#x2019;s
internal control over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 304px"><font style="font-family: Times New Roman; font-size: 13px">December 29,
2017&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="display: table-cell; width: 224px"><font style="font-family: Times New Roman; font-size: 13px">By: <font style="text-decoration: underline">/s/ Geert
Kersten</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 336px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
R. Kersten</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 336px">
<font style="font-family: Times New Roman; font-size: 13px">Principal Executive
Officer</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #325592; font-family: Times New Roman; font-size: 13px">
CERTIFICATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">I,
Geert Kersten, of CEL-SCI Corporation, certify that:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
I have reviewed this annual report on Form 10-K of CEL-SCI
Corporation;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the
periods presented in this report;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
The registrant's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and
internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in
which this report is being prepared;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such internal control over financial reporting, or cause such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">c)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;evaluated
the effectiveness of the registrant&#x2019;s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">d)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;disclosed
in this report any change in the registrant&#x2019;s internal
control over financial reporting that occurred during the
registrant&#x2019;s most recent fiscal quarter (the
registrant&#x2019;s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant&#x2019;s internal control over
financial reporting; and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of the internal control over
financial reporting, to the registrant's auditors and the audit
committee of the registrant's board of directors (or persons
performing the equivalent functions):</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;all
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#x2019;s
ability to record, process, summarize and report financial
information; and</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;any
fraud, whether or not material, that involves management or other
employees who have significant role in the registrant&#x2019;s
internal control over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 304px"><font style="font-family: Times New Roman; font-size: 13px">December 29,
2017&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="display: table-cell; width: 224px"><font style="font-family: Times New Roman; font-size: 13px">By: <font style="text-decoration: underline">/s/ Geert
Kersten</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 336px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
R. Kersten</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 336px">
<font style="font-family: Times New Roman; font-size: 13px">Principal Financial
Officer</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2017 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 32</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the Annual Report of CEL-SCI Corporation (the
&#x201C;Company&#x201D;) on Form 10-K for the period ending September
30, 2017 as filed with the Securities and Exchange Commission (the
&#x201C;Report&#x201D;), Geert Kersten, the Chief Executive and
Principal Financial Officer of the Company, certifies, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to the best of his
knowledge:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">(1)&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The Report fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font>(2)</font>&#xA0;</div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The information
contained in the Report fairly presents, in all material respects
the financial condition and results of the Company.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 304px"><font style="font-family: Times New Roman; font-size: 13px">December 29,
2017&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="display: table-cell; width: 224px"><font style="font-family: Times New Roman; font-size: 13px">By: <font style="text-decoration: underline; font-size: 13px">/s/ Geert
Kersten</font>&#xA0;&#xA0;&#xA0;&#xA0;<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 48px">
<div style="text-align: justify; margin-left: 216px; margin-right: 0px; text-indent: 0px;">
&#xA0;&#xA0;&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Geert Kersten,
Chief Executive and Principal&#xA0;</font></div>
<div style="text-align: justify; margin-left: 216px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
Financial and Accounting Officer<br></font></div>
<div style="text-align: justify; margin-left: 216px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 216px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 216px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 216px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>cvm_10k000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_10k000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M  (1 Q$ /P#W^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPL]M8)YRG*RR$NP/U.:W"!2BEJ%%+82C&*LD- IPHHIE!1110 4444 %%%%
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M(T:\UJ]6VLXRQ_B<_=0>I-<>*Q'M?W=,SJ3YO=1+X>T6;7=5CM8P?+!W2O\
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M*ZCL?1D3K)&LBG*L 0?8T^LKPQ*T_A7296SN>SB)SZ[!6K7DFX4444 %%%%
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MJ=JA:YLB25'\2'K7G$,JRH''XBO9P=12IVZH\S$P:G<Q1<Q6&KSM<7I</TC
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M(F6-BGWE5L8)'/ ]#Z547PLBPW$0NW_?FV).P<>3MQ^>T5'IGA&'2M7^UPO
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ML$J .#Z"O1-B\C'48J":2VLK9I96CAAC&2S84*/6ANP7MJ8WAO$%YK=G$?\
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M>]=<K!E!!!!Z$&O,+%HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (E O\# 2(  A$! Q$!_\0
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MM>+/ EGXKCM=>CFAN7E<7+W 69M1M8%C5(,A6^;KRQ(%:O[#/_!:C]I73?\
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M +47@;PC\-?B)#JMRG]FZ!<QRV0T]4C,4Q=;RZ4,6,N?WO 4?*.I_.O]@_\
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MITJ;[/>P6T$L]O,\4$VKO,&6XA9.;=LX) ((- 'ZZT5^,?[,'_!SCXT^-_\
MP56TOP!J?A/P99?LW^-/'&I^ _"GBZWM+H7]_?6Z1BWW7#7)@;S9+BT)585(
M6\CYX.?JW_@X6_X*@>/O^"37[%_ACXB_#K2/!^M:WK7C6U\-SP>)+6YN;5+>
M6QO[AG58)X7$F^UC )<C!;Y22" #[OHHKR_]MWXUZK^S7^Q?\7?B+H5OI]WK
M?@'P5K/B33X+^-WM9KBSL9KB))51D<QEXU#!74D$X8'F@#U"BOP^_9C_ ."N
MO_!53]L3X!:-\4?AS^S3\!?$_@37UN7L-0CN/LSW0M[B6WF"P3:ZDP(EAE4
MQY.W(!!!/KNB?\'$OBWXI?\ !"CXL?M*^'O WA[0/BI\)==LO#>IZ#JZW%WI
M#W,NH:? \JA)(I=A@O20AD#)(A!+J 7 /UDHK\8/A/\ \%&O^"NGQQ^%GAKQ
MKX6_9=^ &J>&?&&E6NMZ1>?VC%!]KL[F%)H)?+D\0+(FZ-U;:ZJPS@@'(KZ9
M_:U_:)_X*)^$/@G\%K[X0? ;X4>*O'&M^'VN/B5IVJ:A#';>']4VP;8+4MJ\
M(:/+3\K)./D7Y_4 _0:BOPO_ &&?^"V?_!2W_@H##J&J_#K]G_X">(_#7AO7
MQH&OW<<CV+V,Z['E0+<ZVC.5C<$,BLISP2>*^Y/^".?_  4\\>_\%"?C+^TW
MX=\::1X0TRR^"_C=O#6B/HMK<0RW5L)[R/?<F6>4-)BW3E @R6^7D8 /NRBO
M@#]GW_@JK\0OBO\ \%=_VF_@%J.C>#(?!WP7\,IK6B7EM:7*ZG=3&*S<K<NU
MPT3)FX?A(D/"\\'/Q3^QO_P6G_X*A?\ !0#X1/X[^$?[.OP \6^%([^72VOO
M.-ABYB5&=/+N=<BDX$B<[<'/!.#0!^ZM%?EC^R;_ ,%\?'_Q^_8 _:M\2^)/
MAWH/@OX[_LKV-U_;6BR>?<:1-=I'=^6&02"1<365S')&)F(\L$2?/QV'_!"K
M_@NA/_P57_9C\<W7BFP\-:%\7_AVLUSJ6EZ5#-%I]W9NKM:W4*2RR2;<JT4B
M^8Q#(#E1(H !^CU%?E#^QW_P<->)O'__  2%UC]H+XH^$[.#Q(?$.L>'-.;P
MEX9U&[T/3);;3A<VT^I#SY98;=IL1/()!S(G"@,Z_8__  2Q_P""AUC_ ,%'
M/V9M(\6P:5K5GJEKIFG+K5[)X?N]+T;4M0EM(Y+IM,:YR\UK'/YL88DD;!DL
M"&8 ^EZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH _%/PK\??"7_!-?_@ZB^.NL_&O5[7P3X<^-7@ZR_P"$6\1ZH?)T
MZ7$>GC;).WRQ)OL[B,NQ"!X%!(W+7W?I_P#P70_9J\5_MB^#O@AX4\?6_C_Q
M?XV5OL-UX30:WI4,@R1%+=6[.BML61R1E42-F=D&,^P_M=_L'_"#]O3P5;>'
M_B[X!T+QQIUB[26AO4:.YL6888P7$3)-%N &=CKG ST%<A^QG_P24_9T_P""
M?6MW.J?"+X6:%X4UB[B:"34VGN=1U 1L<M&MS=22RHAXRJL <#(X% 'YB_\
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MY1U7[3BWQ+(Y_P!'\L8.W[H"@ _!/XS_ /!/3]J']G__ ()#?"SXWZ7^T?\
M&7QW\#]>\.Z;<^*_ 6DZ_J&F?\(QH]S&@\F&,W,UO-;HK>6Q\E50,K&(H'*_
M1O\ P5^\._!;PW_P:Q?"./\ 9_>\F^&MSXMTVYM)K^59-1ENG2_-T;PK\OVD
M3^8LBKA5*[4 0**_<?P!^SAX)^&/[/>G?"G1_#]M'\/=+T0>'+?1;F22\A_L
M\1>3]G=IF=Y%,9*G>S$@G)-?/=E_P0C_ &5]/_9?O?@O'\,[K_A6.H:]'XFF
MT%_%NMO"-12(Q+<([7ADC.PX*HX5L L"0" #X7_X*X3_ +*'[0O[9'PH^&_Q
M9\8_$O\ 9V^-GA[P5::AX6^+%G/:Z?HC6DB.T=O)<F?> LOVD*62':_F 2_.
M W)?\$_/V_?BI^RO_P %=?AG^SG:?M6:+^VC\,/B':W"W&I6^V^OO#TB0SR)
M(UZLDV]E$(9P;F4>67)1&VD_K#^UI_P3<^!W[=7@72/#OQ8^'.B>,M.\/QF+
M3'N6F@O-.0JJLL-U"Z3QA@J[@L@W%5)R0*Q/V,O^"2_[.O\ P3YUJZU3X0_"
MW0_">L7D36\NIM/<ZC?^4Q!:-;BZDEE5"0,JK ' R.!0!^87_!#+]L?X;?\
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M=K<V>H:3I_F0_;4N(C#.9)@WG/(\9VF0OOP!AA@8\VU__@B]^S1XI_8YT3X
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M^W5\$?V=?^"75WX?^(/QC^%?@77F\;:E=C3?$/BRPTR[,+P6@63RIY5?82K
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MC=@8X R:]7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\[?^"I7Q-^+/Q0_:
M!UK1/@MXB\1:5<?LS^"H_B?K5II&H2VT7BC57O8I+#0KI4($T,UA8:INB?*D
MW-NQ4XX_1*OC[X!_\$DOA_K%SXZ\9_M ?#GX2?%?XJ?$7Q;J'B#4-3U70+;7
M8]-M"RP:=IUK->6XE$-O8P6J;=JCS!(1D') -+XE?\%,+R_\9_L_:+\(? UC
M\23^T7X:U7Q-H&H:AXB_L.PTVWLHM.G#7;K;7,BH\5\PS'&[I+&B&,AV>+@/
M!?\ P6#\9ZS\/+/QUK7P2LM!\ Z9\0$^&/BJ_/C=;B_T[5SJ_P#9+SV-L+()
M>:>ES) IFEFM9SF;%L5C5I8/V3/^"7?Q!_9O_:6^%MV^K>#9OA;\&;WQ]:^%
M[:"\N6U.#1M>FTZYL;1HVMQ&#:R07<1Q*0(A;[>ZI9U3_@F'X]OOV&/%?PR7
M5_" U[7?C4_Q'M[@W5Q]D33F\71ZT(F;R-XN/LR%-H0IYN!OV_/0!T7BK_@J
MMKFF>!/'?Q4TGX5+K'P ^&FMWNCZYXH'B0QZ[<1V%P;;4=0L=*6T>.>SMIDE
MW-)>0RNEM.R1-B,2YOQ+_P""K_C7P[>_M":GX:^#.E^(_ _[-5WO\3ZS/XX6
MRN-6L!I=MJ<LVFVZV4JS3Q02REX9Y;="%@\N:1I76#%\3_\ !.'XP6W[//Q.
M_9U\/:M\/HO@Q\4-;U>\/BFYU"[3Q+X=TS5[N2[U"P33A:O;W<NZ>YCBN6O(
M0JS(6A<Q$2]3JO\ P3D\6'X'?MK^$[#4/#$+_M%Q7\/A/?=7!BTY)O#%MI$0
MO6\HLF)H&8^6)?W9!Y;*@ W_ (E_\%&/%$WC'QU;?"KX66_Q%T3X4:-9:SXN
MO+SQ/_8UUFZM%OX[+3;?[+.+J[%DR3%)Y+6/,\"B4EV*>D? W]L&W^+O[ /A
MKX\7>AOH]IKO@:'QM/I"7?VIK-'LA=M )MB>85&5W;%SC.T=*^$/B_\ %,_\
M$Y/B!\7_  IX>^(WP0TOQ3XY\&:'<ZUH_C34M1TC5;34H-'73%O="M!9O_PD
MB3Q6:*MM;/"WVFW,1D\R5E3[8_X)S_!/4/A]_P $R?@M\/O&VD&TU/3?AUI&
MBZ[I5S]Z"0:?%%/;R8[J=R-@]0<'O0!X]^SY^RUXN_:[_8Q\)_%C7/C!\4=&
M^-'Q#\.VGBW3=5T3Q7J%CH'ABXNH4N[2TBT2.4:;<VEN'2)EN[::2X4.97=F
M!'F_[1WCFVC_ ."JR^$/BYXD^/=_I-C\$-!U/^S_ (53>-X;%M8?6-6ANKQK
M7PZ[21B18D56N,_*B+N8K7K?@3]G?]I[]GS]GU/@AX U+X0R^$="M8_#OA+X
M@:KJFH1Z[X;T54CBA$NC):/!>WEI#NCCD&H6Z3F*)W2++H8+']CSXU?LX_MA
M:9X^^'D7@WXIZ1;_  BT3X<75QX_\?:EI>N7=W87]_<R7TTT>EW_ )[3+=(6
M+,IW[^,8R <9\=/%VD?#;X+_  :O?A/KOQZT33_$'Q\\)Z/JO_";ZGXO@U.\
M@DN46>VV>('%V;.1&4,B#R)#N&&8-C]!:^0/VK?@=^T!^U?\*O!OVKP?\'?#
M?BOX??$CP_XUL;"+X@:E?:?J]OI\S32PRW1T2*2WD8[57;;S#!))&,'TJT\
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M_&+P-\$O'FL?!F/PE\./C/X@B\'0WLWB^.ZUG2M99+E&#62VHBDL3=VDL"7
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MM<O;&2/_ (\C9V?F6\+QRPDSBZ21',B*CA=[<5\.?^"&\_POTZR^'NF_"_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *H>*?#-EXT\,:CH^IP_:=-U:UELKN'>R>;%(A1UW*0PRI(R"",\&K]%
M '/_  G^%NA? [X6>&O!7A:Q_LOPSX/TJUT32+/SI)_LEG;0I#!%YDC-(^V-
M%7<[,QQDDG)KH*** "BBB@ HHHH **** "BBB@ KD_CC\#O"G[27PIUGP1XW
MT:#7O#&O1+%>6<KO'NV.LD<B21LLD4L<B))'+&RR1R1HZ,K*".LHH \@^'/[
M"WPZ^%=EXI&DV_C!]3\9V"Z5JNNZCXVUO4_$#VBA_+@BU6YNY+ZWC0RR.BP3
MH(WD=UVNQ8]M\%?@KX9_9W^&6E^#O!VEC2/#VD"3[/;^?+<.SRRO--+)-*S2
MS32RR2222R,TDDDCN[,S$GJ:* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M & (RC#/% '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBHK2]AOXB\$L<R!VC+1L& 96*LN1W# @CL01VH EHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKS.']LSX4W'[3LGP7C^(/A6
M3XJPV/\ :,OA=-01M1BAV+)\T8/ROY3K*(S\YB82;=GS4 >F45P*?M5_"^7X
MYO\ "]?B1X";XEQC<_A(>(+0ZZH\@7.39>9YX_<$2_<_U9#?=YJ?P1^TQ\./
MB9\3==\%>'/B!X(\0>,O"^_^V=!TW7;6[U/2-CB-OM%M&YEAPY"G>HP2!U-
M';UPGA[_ ).:\7?]BQH?_I7J]=W7">'O^3FO%W_8L:'_ .E>KT =W01D444
M?FC^T3^SOXN_X(L?&;Q%^T'\ ] NO$7P*\37!U+XL_"S3U&[2R!^\U[1TX5'
M103- ,*RJ>B@-!]\_L\?M#^#?VK?@SH/Q ^'^O67B7PEXEMA=6%_:ME77HR,
MI^9)$8%71@&1E*L 017:,H=2",@\$'O7YE_'_P""?B[_ ((=?&S6?CI\%=$O
MO$/[-/BFZ.H?%3X::<F^3PM(?]9K^CQ9 554 S0+A=J]D"M;@'Z:T5RGP/\
MCAX3_:2^$VA>.? VNV'B7PIXEM5O-.U&S?=%<1GCZJRD%61@&5E96 ((KJZ
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M5?%&N:7X?TV>]MM.CNM0N5MXGN;F9(((@S$#?)+(B*.Y85O5^9'A?XU^-O\
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M N9[2T@GB;XW+JGFS1)%,&4J?#GV[!:(Y?&%+%_FKU#_ ()(?\*R_P"%Y?\
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MO)LL[HL]RP+LH+;1P=J*H PH% '?45^?5S_P5?\ V@?V5)WB_:,_9(\:QZ/
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M\.J:5?)&\8NK>5 \;['"NN01PR@CH0#735\P?MQ?\$KO!_[:?CG0/&]OXO\
MB-\*_B;X3L3IFC^+?!.NR:=>6]KYAD^S21?-#+"7))4H"<D;L<5C_M0?$S]L
M#X!?$K2&^%WPN^'GQX^'$.EVMM=6]UXF'AWQ=+>KE9YWEE46!1AL8!$4YWC
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M@/X2> O#7BJ^GGN9=:M-(B_M+?-N\W;<,#*BMO8%58+@XQBO::** /G33O\
M@FCX4\.ZKKEQHGCOXS^'8O$.LWNO7=IIGCB]M[<W=Y.]Q.ZJ&XS([8YX& .
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M-<Z+J+1^)O",C)&J )IMS@0;@N"4<XSE5% 'V917YY/^V/\ MR?L8NJ?%_\
M9[\._'SPI;<3>)_@Y?N-66,=&;1[K$LTI'582J ]#TK[OLOB+IY^&,/BW5//
M\-:5_9:ZO=C64%G+I4/E>:_VD,<1-&N=X)^4JV3Q0!O45\W#_@H/J+^$1XV3
MX)?%=_A88/MW_"3"*P^T&RQN^W#2_M/]H&WV?/M\C[1MY$!KZ#\,>)M/\:>&
M]/UC2+VUU+2=6MH[VRO+:020W<$BAXY$8<,K*001P010!>HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@"PV$LHS]Y0)&^P* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSMVLRIN H ^K:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6O'?Q)U/6Y?%^G6&O:@^E6QT][2WAUB188XX+*VLV,5JD>T"5FW.V]F/;?\
M!-3X%_&76_CI^QA\)O$OP2^(W@ ?L=R>+9?&?BS5=.^S>'-8-S'/;68TFZSB
M^\XR1LY4+@,Y =06H _:ZN$\/?\ )S7B[_L6-#_]*]7KM[J%KBUDC65X&=2J
MR( 6C)'WAN!&1UY!'J#7F7PM\.7GAC]H?QE!>Z]JWB*5_#NB2"YU".U25%-S
MJPV 6\,2;1@GE2V6/.,  'J-%%% !1110 4444 %%%% !1110 4444 %%%%
M!7@'[<__  3'^#?_  40\/6L'Q'\+)-KFE8;1_$^ERFPU_0G5MR/;7B?.NUO
MF"-NC+ $H<5[_10!^;8\2_MB_P#!)+Y=<M]4_;*^ ]C_ ,Q&QC6+XC^'+<=Y
M8<[-351W!\USDL8U&*^MOV+/^"B_P<_X*!^#FU;X6^-=,UV>U7_B8:1(3;:O
MI#@[62YLY,2Q$-E=Q7:2#M9AS7MU?*7[9W_!&SX*_ME^+T\:3:9JOPZ^*]FQ
MEL/B!X'O6T3Q!:S8XD::+Y9SV_?*YQP"M 'U;17YS#XH?MM?\$ROW?C7P]!^
MV/\ "6RPHU_PM;+IGC[3(1_%/I^3%?%1@#R3YC'+.PKZ+_8P_P""LGP$_;U<
MV/P_\?:<_BF'<MWX6U96TO7[)U_UB/9S;9&V'AFC#H#_ !4 ?1U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5\D?ML?\$>/AW^U?X_B^)/AC4M<^#'QRTX9T_XA^#)/L>HLV/N7D8(C
MO8CA0RR_,4&T.JDBOK>B@#X5_9L_:X_::_9S^./ASX0_M)_#.X\=6GB*Z73M
M!^+OP^L'GTF]<@E?[6LE&_3WP,M* (<G@;59Z^ZJ*^=/^"@/[/'QP^+UCX9\
M0_ 7XQ#X9^,O!TEQ*-)U73DOO#GBQ91&/L]^FTRH%V';+%ED\Q\+DAE /HNB
MO@3X/?\ !;8_"/XA:?\ #7]K_P !7?[.?Q O9/L^GZ[<2_:O!'B=Q_'::F,I
M"3]XQSD>6"H:3<<5]ZZ=J-OJ^GP7=I/#=6MU&LT,T+AXYD895E8<$$$$$<'-
M $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PGA[_DYKQ=
M_P!BQH?_ *5ZO7=UPGA[_DYKQ=_V+&A_^E>KT =W1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7SQ^V?\ \$J?@+^WU$)_B1\/M)O_ !!!
MM-IXDT_=IVNV3+]QH[V$K+\A (5V9,C[IKZ'HH _.D_LC?MK?\$^6\WX)?%S
M3_VD_ %I]WP1\5Y1#X@@B'_+.UUJ/'F/C 'VD+&H'"FMKP/_ ,' W@'P)XGM
M/"W[27P]^(W[+GBZZ?R8_P#A+]->XT"^D[BVU6!3#(@YS(ZQIQUK[\K)\;^!
M-#^)GA>[T3Q'HVE>(-%OT\NZT_4K2.[M;E?[KQR JP]B* (?AU\3?#?Q@\(V
MNO\ A/Q!HGB?0KY=UMJ.DWT5[:7 ]4EC9E;\#6Y7P9\0?^#?CX5:#XPNO%WP
M#\5_$+]F'QG<GS)+GP!J[PZ5>N.@N=-D+021C_GF@C7@5D?\)1_P4-_8L_Y"
MFA_"S]K[PE:];K29E\&>+G0=7>%]UDY Y"199B",\B@#]"J*^%?AI_P<)_ B
MY\50^%OBW!XY_9O\;2?*=&^)N@S:.DA& S1W>&MFCR1AVD3((.*^T? /Q&\/
M_%;PQ;ZWX7UW1O$FC78S!?Z5>QWEK,.ORR1LRMU'0]Z -FBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F/C!\
M%_"7[07P]U#PGXY\-:)XM\-:JGEW>F:K9I=6TP[$HX(W#J&'*G!!!%<]\'_V
M?- _8Y_9IM_ ?PB\,VMAH_A2QNO^$>T.YU.X,'G.\LZPO<S&:54::0Y8[]@;
MA<*%KTBB@#X'^%7_  78T/X>^/;+P!^U5\/?$?[+_CZ[E-O:W6O,+SPEK3C^
M*TUB,>01W/F;53(!<FONW0M>L?%&C6VHZ9>6NHZ?>QK-;W5K,LT-PC#*NCJ2
MK*1T(.*R/BK\(O"OQT\#7OAGQIX<T/Q7X=U)-EUIFKV4=Y:SC_:CD!4^QQD=
MJ^:?V5_^".G@']AK]HQ?&?P@\6_$GP/X1N8[@:E\.8==>[\)WTLJD+.+><.\
M,B,Q<&.0<A0,+N5@#ZXHK\N_CG^TE)<J/B?\3OA;^T5\5_!>N>)/$.DQM\-M
M7OHK3X;6^E:I/IL,<MA8W4$TEQ)]F>>>Z?<T3NT<;;45:]%_X)7_ /!8/X-?
M'J\\7_#]?C9INN3^&];6V\*2^+[K^RO$6JZ=+;0RBWGBNA'+<7%K<-<6S2!6
M:1(8G<N[,[ 'W_10#D44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9Q\7Z2OBP:#_ &GI
M_P#;C6AOQIWVE/M9M@XC,WE9W^6'(7?C&2!G- &C1110 5PGA[_DYKQ=_P!B
MQH?_ *5ZO7=UPGA[_DYKQ=_V+&A_^E>KT =W1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &!\2?A5X7^,WA6?0O%_AO
M0?%6B7/^NT_6-/BOK67M\T4JLIZGJ*^,/'O_  ;S? J#Q1<>)?A!J'Q%_9P\
M7SG>VI_#3Q+<:5%,PZ+):,7MS'ZHB(""17W=10!^? ^%_P#P4-_9!Y\-_$#X
M2_M5>&;;I8>*]./A/Q*R#I'%<VY:U=L<&2?D]<5XU\:_^"[GC7P5\>="\*_&
M/PY\0OV,["'19[K4[_4_"4?C+3[N[-Q#'%Y5[;[E-N 9 9%B #E<G!&/ULKY
MS_:%^'/Q-TC]K/1OB#X'\&>%/'6E-X-O/"^HZ?JWB1M'>)Y;RWN%<?Z)<+(A
M6-E(.* /$OAC^VS=^*/&WPKU/P3^U/\ #_XX:#XL\76V@:KI&FZ1IT4\%O/:
MW4GF-Y$IFA=6B0@.HZ\CFOOFOS!_:%_X(NZ+^VM\4_!MUXC_ &7OA%\)TM->
M34-=\3^#_&<EOJTUJL,P*(MK86V^5I6A(=WR-GI7<_\ #I;]H+]G ^9\ ?VS
M/B5:V$!S'X=^*%C;^,K%U[0K<N$G@C';8&8 8SWH _06BOSY;]H?_@HM^SP,
M>+/@%\$OCS80#YKKX?>+Y?#]XR?WVAU)2&?')6,8)X%-_P"(AOP?\*B8?CA\
M"?VC_@;+%_KK[7/!4U[H_N8[NU+^8!W(C% 'Z$45\J_!?_@N'^R/\?O*'AS]
MH#X;K+/Q%!J^I?V)/(?01WHA<GVQFOIGPMXPTGQUHT>HZ)JFG:QI\W,=U8W*
M7$,GT="5/YT :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X3XL_8EN8/'^N^(/AY\4O'WPF;Q;=?;]=T[08-*O=/U"\*A7
MO4AU"SN1;W+JJ[VAV)(1OD1W)8\WXK_X([_LY?$[X9?\(WXX^%_A[Q_+/--=
MWNO^((1<^(=1NIF+37,NHC;<"1V/\#HJ@*J*B(BK]-44 >6_L>_L=^"/V%?@
MO;_#_P"'D&L6?A:SNIKJUM=1U>YU-K3S""8XY)W=UB&!M0' Y/4DGYC^(^M?
M\%$/@C\1M=O_  _H_P"SI\<? T^H3SZ9I8N+SPQX@M[8R,8H/,D+VORH57<S
M,21DFONZB@#X#T__ (+6>/\ X:W,5G\8OV+OVE_!5T7$<MUX7TJ'QII5N3QE
MKFT=25]"L9SV%?;/Q0^+WA?X(_#G4/%_C+7])\*>&-(B6:^U35KE+2ULU9E1
M3)(Y"KEF51D\E@.IKHZS/&7@O1_B+X7O=$\0:3IFNZ+J49AN]/U&U2ZM;I#S
MMDC<%77@<$$4 <;\+_VOOA-\;UB/@SXG_#SQ=YW,?]C>([._W_3RI&KT6OD7
MXI?\$%/V.?C"9?[7_9[^'EJ9LECHMH^B'GT^Q/#C\*D_9)_X(L?!G]AOXV6?
MC7X9W7Q)T#[%;S6R:#)XSU"\T2194*'S+::1_,V@Y7<Q"L V,@$ 'UM17@?[
M<O[,/Q7_ &CK'PXWPJ_: \0? C4-#>X>ZEL/#ECK=OJXD$>P317./]7L;;M8
M ^:V0<*1\\G]F'_@HQ\.O^0-^U#\$_B-L^Z?%GPY_L?S?][[ YQ^% 'Z!45X
M=^P]+^T@?"NN1_M'P_!==:BNHUT>;X=2:D;:X@VG>TZ7HW*^[&-A(/S<# SY
MI^U!^WY\=_V>_C?K.CZ+^R#X\^)7@*Q$)L?%7ASQ3ILDNI;H4>3%@^)H]DC/
M'\Q^;9N'!% 'UY17Y_R?\' N@>#/E^('[,_[7OP\V?ZVYU/X;R36(]2LT,K[
MA[A:^T/@K\<O#_Q[^"VA>/\ 0I+V+PYXAL%U*VDU.RET^>.$@G,L4RJ\>,'.
MX#@9&00: .PHKY<\9_\ !5[X7>)=1\.>'/@WXR^&GQ>\;^+IYHK"RT_QG:)I
MVGQ0JIFNK^ZB\YH(4WQJ L4DLCRHJ1D;V3J_!'[2?COP3\7?#7@SXN^$_#6B
MOXY>:W\-^(/#.L3:CI=[>1027+V$ZSP0RV]PUO#-+&1YD<BV\OSHX5& />**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_G\_X5KH7[-7_
M  7M'Q2\;^,-5^($/BKXAO<V'Q(^'7CF"YN-(DNM4ATVV\-:Q83!A]G@4_9)
MX;<M(L#Q%2FPHO\ 0'7RN?\ @BY^SB?V]1^TA_PKRP'Q,$AO3)YC?V<=1)'_
M !,_LG^J^V#&?-Q]\F7'G8E !\!?'W]@R'QI_P %9UU+X=^+O$WQ*_:=\,?$
MB'XD^+O&MH;NQTOX6>#%@8VGA6>,7,D,\]VJ^3#"B>=-&\SR+' 'W>:?\$H_
M"6F_#7X\_L _&3PUXAUO5?BE^U*WCE?BK?3:W-<-XQ6".YGWW$#N47[)/&N#
M$J#,(W;FYK])]0_X-_\ ]DC5OVC)/BU=?"F:Y^(<OB+_ (2M]8E\6:V[OJ?V
MC[3]H,9O/*/[[YMFS9VVXXKO_P!G_P#X),_L[?LL?M(Z_P#%WP!\+=$\-_$+
MQ+]H^VZI#<7,BIY[[YOL\$DK06V\]?(CCX)7[I((!]#74S6]K)(L3SLBEEC0
M@-(0/NC<0,GIR0/4BO,OA;XCO/$_[0_C*>]T'5O#LJ>'=$C%MJ$EJ\KJ+G5C
MO!MYI4VG)'+!LJ>,8)]1KA/#W_)S7B[_ +%C0_\ TKU>@#NZ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /)OC+^P9\$?VB?-/COX0_#7Q=+-G=/JOANSNIP3U(E>,NI]P
M0:^:_%'_  ;<_LE:AJ\NI^&O WB#X;ZQ+R;[P?XLU/2G7TVQK.8ACV2ONVB@
M#X"_X<G^/OAN=WPQ_;9_:D\-[>8;?Q+K-MXLL[?T58KF)?E]BQ^M+_PR_P#\
M%#_A?C^P?VH?@Q\3EC^X/&?PX_L<R#L'.G2'\Q7WY10!\!_\+U_X*/\ PQ_Y
M#GP'_9Q^*'E_>_X0[QO>:(9O]W^T4;;^-'_#W3X^_#S/_"Q/V"OCMIGE_P"M
M_P"$-U?3?%^/7;Y#Q[_PK[\HH ^ S_P<<? WPC_R47P9^T#\(-O^M/C+X:ZC
M;>1Z[O(6;I[9KT+X:?\ !>K]CGXL^7_9?[0WPZM?,Z?VS>MHN/K]L6+'XU]=
M5YU\3_V0?A-\;A)_PF?PO^'?B[SO]9_;7ANSO]_U\V-LT :'PU_:1^'?QG53
MX/\ 'O@OQ6'&5.C:W;7VX>WE.U0?M._'2W_9F^ /BKQY=:;=:S%X8L&O/L-M
M(D<MVV0JQAG.U<LP&X]!DX/2OFSXF?\ !O-^QE\5F=K_ . GA+3I6.5DT.:Z
MT4QMV*BTEB Q],>U?.G[<W_! OPE\%?V2/'FK?"CXI_M0^'7TS3&GC\,:/XU
MN]3TW445E+1263QRR3*%!8*ISE0><4 ?;7_#1'QV_P"C=/\ R_M/_P#B*]$_
M9B^.EO\ M,_ 'PKX\M=-NM&B\3V"WGV&YD226T;)5HRR':V&4C<.HP<#I7Y>
MGQM\>OA*-W@3]NCQYXIM(O\ 5Z5X^_9QU6[#_P"_>P6:SG_OFNH_89^(W_!0
MKX#_ +(W@..U^"/P1^)?AI-,$MA86_B"^\*^(5A9F<+<IJ$?E1RG=G&  ",C
MK0!^JU%? 3?\%F_BM\*QCXL?L.?M(^'-G^NF\'0V?C6V@]6,EM)'\@[L!^%:
M/A;_ (.1/V2[_58],\3>.=?^&NMR?\P[QEX4U/2ID]=SM 8AC//[R@#[LHKR
M'X/_ /!0#X%_M B/_A"/C'\,?%4LO2#3/$UG<3CV:)9-ZGV(!KUX'(H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FRQ+/$R.H=
M'!5E89# ]013J* /SW_;D_X(>? _QCX^\->._#W[-OP[\6V&F07FG>)O!VB6
MEMX=NM<M[AH7CO;2:-[>+[=;O"0JS2QI)%<S@R*RQUW?[.7[-US?M\'_  7X
M5^$7B+X(?!#X':E-K]C8>)=5M[W5=8OF@NX8;:%8KR[9+6-[V:9Y9YA(7CAC
M2,QEFK[-HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KA/#W_ "<UXN_[%C0__2O5Z[NN$\/?\G->+O\ L6-#_P#2O5Z
M.[HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVY6!Z$$=:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML]1>8D;76YENHU4#KD&U8G_?%;5 !1110 4444 %%%% !1110 4444 %%%%
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M=]/*E:MOXC?L\> /C"K#Q;X&\'>*0XPPU?1;:^W#W\U&KY_^)7_!"O\ 8_\
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M=W10!PG_  RY\,O^B=>!/_!!:?\ QNC_ (9<^&7_ $3KP)_X(+3_ .-UW=%
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M[+(OG0GR91NVNQ.W;@@'U!_PRY\,O^B=>!/_  06G_QNC_AESX9?]$Z\"?\
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MESX9?]$Z\"?^""T_^-UW=% '"?\ #+GPR_Z)UX$_\$%I_P#&Z/\ AESX9?\
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M/X8>*O$<UIHWB&Y@\2:B[Z)IVLZIH\K6UQI]B9X?](1;M)+:2ZW+$DL;A?-
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MA_;>_P""?GPN^*WBNST;3_$7C;23?WUOI,,L5E$_G2)B)9))'"X0?>=CG/-
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MGZ9JOPP\'L$US5+>PO&N-)8RK$JS67D_:T+,R[08?F5@PROS4 ?25%?'DO\
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MYH/B?QK8B<C3TMKNV%\("1*;2::)(;L*%9_]'>3,:F090%J\:_:!_P"#A/X
M3?"WQU8_"3XP>")_B?X<TN[O[>+Q-X9\12Z/I_V2<13M??9+0S*BD, %^9BR
M%0RL"0#] J*^:/CK_P %5_@O^Q-^SS\.?&GQQ^)'AKPL?'^GVTMD;"QO[O\
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M:$K-E8BRI(-T =6C'VC^WQ^U'XE_9:_X)V_$;XN:-H=G:^*_"/A.;7K?2-<
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MO+^2T5]NQKDVT,BVP8,K#SRF5.X?+S0!].45^>?_  41_P"#@3X=?L,?MB_
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MT'PYH/QDL=4U/Q+?Z9I=@8-!U4VK7>HJ6L[>2Y^R^1#*^&!25T,;(ZR!&1@
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M43_8EE>:;RS#]B14W?:'V^^_\.\/VZ_^DBO_ )@3P_\ _'J^_P"B@#X*T/\
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M'GXW9YQVKZKHH _,']L#X?\ Q_T7_@I/X5'C3XR_$?Q9^S]9:M#\08_#&@?
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M=?&;7;[Q78W_ (9NBFAP_:VEAN;G,>U("0C),Q\ML<,:^[?^">GP5\8?#_\
MX+B_MR^)M2\(>(M%\'>,4\)R:+J]UI,UMIVMR0Z>RSFVG9!',4=V#^6QPQ.[
MFOT)HH **** /+/VP?A1\3?C-\'FT7X3?%K_ (4MXL-[#./$?_"+VOB/; N[
MS(/LMRRQ_/E?GSE=O'6OE/\ X=X?MU_])%?_ # GA_\ ^/5]_P!% 'Q5X/\
M^"=G[0_BCX2?%'P7\:?VLC\8=#\?>%KG0M/@'PQTSPZ=#NY<;;PO:RDW"@95
MH7PK ]1W\[_;+_90_;<_;U\8^'O#-O\ $3P+\ ?A[8VL#>(SINGVOBM-8U&U
MNENK:]LUN((KB/$T4!$3R1!!&27E/!_1FB@#X _X=X?MU_\ 217_ ,P)X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBJ^J:K;:'IEQ>WMQ!9V=G$T]Q<3R"
M.*"-069V8X"J "23P * +%%0V%_!JMC#=6LT5S;7,:RPS1.'25&&596'!!!!
M!'7-34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &9XU\/-XN\&ZMI*75Q8MJ=E-:+<V\TL,MN9$9-Z/$\<B,N<A
MHW1@1E64X(_.?]JC_@DMXK\#_L(:]H%EXSL?B=9Z5XEN/'FL:#XMO-1L](U^
M$Z=?-=6LB>;>QJ$U.[?48%6WPSVULMR;B=&OF_2NO,_VI/V1O _[8O@%- \;
M:??2K:-++IVI:9J,^F:IH\TD+P/+:W=NZ2Q,T4DD; -MD1V1U=&92 ?(7[&_
MAK1/C=_P3GU_X>>!;3XA?LRZCX)DC'CGPUI%[:/+:W-UH<%_+;Z;<JUQ!:6=
MS]L@N!+9"WE!:5PEM/*[#G?V??AAX?\ V@_@!_P3D\ ^.O#FD^+_  #>?"-=
M=N]&UBW2[TR]U"U\/:7#:^?;2 Q3[([V\=%D5@K*' #(K#[C_9]_9.\#_LQ?
M!MO OA/3;N+1;EI9;^:^U"XO]0U>>50DL]U=S.T\\K(JIO=R52..--J1HJXG
MBO\ 8'^%OB_X/_#OP-+HFL:=H/PEBMX/!\FC>)=4T?4] 2"Q>P18=0M+B*\
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M'UOX?ZUI\@CM+"T6^MXVU/3M7EDGBF#ZC(MLTT<\<<<B%%'T%\2_^"='P?\
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M^TNJ6Z!5-?<GPX_8:^&/PE\76&MZ#H-_:WVDZSJ^OZ<LNNZA=6VEW>JDF_\
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M%7<[,QQDDG)H _+KX:?M)_'+P?\ L=_"+QK-J_CCP%\)%^'6EWR>(OAQ\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>cvm-20170930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 172274 09302017 10K.xfr; Date: 2017%2D12%2D29T16:05:42Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:CVM="http://cel-sci.com/20170930">
    <link:schemaRef xlink:href="cvm-20170930.xsd" xlink:type="simple" />
    <xbrli:context id="From2015-10-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_SeriesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_SeriesRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_CollaborativeArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_CollaborativeArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesZZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesAAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesBBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesZZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesZZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesAAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesAAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesBBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesBBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_OutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:OutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_ExercisableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">CVM:ExercisableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesZZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesAAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesBBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SanTomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CVM:SanTomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SanTomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CVM:SanTomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesDDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesDDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesDDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesDDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesEEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesEEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesEEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesEEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesFFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesFFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesGGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesGGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesGGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesGGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesHHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesHHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesJJMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesJJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesJJMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesJJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesKKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesKKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesKKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesKKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesLLMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesLLMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesLLMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesLLMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesDDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesDDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesEEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesEEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesFFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesGGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesGGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesHHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesJJMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesJJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesKKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesKKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesLLMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesLLMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesDDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesDDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesEEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesEEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesGGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesGGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesHHMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesIIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesJJMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesJJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesKKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesKKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesLLMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesLLMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeriesFFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesUMember10948898">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesUMember10948961">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesDDMember10948961">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesDDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesDDMember10949008">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesDDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesEEMember10949008">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesEEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesEEMember10949054">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesEEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesSMember10949117">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesSMember10949164">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesVMember10949164">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesVMember10949210">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesWMember10949210">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesWMember10949257">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesXMember10949257">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesXMember10949304">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesYMember10949304">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesYMember10949351">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesZZMember10949351">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesZZMember10949429">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesZZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesBBMember10949429">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesBBMember10949476">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesBBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesZMember10949476">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesZMember10949538">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesFFMember10949538">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesFFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesFFMember10949600">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesFFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesCCMember10949600">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesCCMember10949663">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesHHMember10949663">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesHHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesHHMember10949710">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesHHMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesAAMember10949710">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesAAMember10949772">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesAAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesJJMember10949772">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesJJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesJJMember10949834">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesJJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesLLMember10949834">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesLLMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesLLMember10949881">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesLLMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesMMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesMMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesMMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesMMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesNNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesNNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesNNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesNNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesOOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesOOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesOOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesOOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesQQMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesQQMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesQQMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesQQMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesIIMember10950146">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesIIMember10950224">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesIIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesKKMember10950224">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesKKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesKKMember10950287">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesKKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesPPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesPPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesPPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesPPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_SeriesGGMember11155475">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesGGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_SeriesGGMember11155569">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CVM:SeriesGGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SeriesYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2016-10-01to2017-09-30">CEL SCI CORP</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2016-10-01to2017-09-30">0000725363</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2016-10-01to2017-09-30">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2016-10-01to2017-09-30">2017-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2016-10-01to2017-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2016-10-01to2017-09-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2016-10-01to2017-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2016-10-01to2017-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2016-10-01to2017-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2016-10-01to2017-09-30">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2016-10-01to2017-09-30">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2016-10-01to2017-09-30">2017</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2369438</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">2917996</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">5726682</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">218481</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">394515</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">826429</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">981677</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">150000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">154995</us-gaap:DepositsAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">672522</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1008642</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">4236870</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">5457825</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">16793220</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">17350836</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">223167</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">256547</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositAssets contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1670917</us-gaap:DepositAssets>
    <us-gaap:DepositAssets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1820917</us-gaap:DepositAssets>
    <us-gaap:Assets contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">22924174</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">24886125</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">8196334</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">3091512</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">936698</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">378672</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">693831</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">538278</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">10844554</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">4011772</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2042418</us-gaap:DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">8394934</us-gaap:DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">125000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">125000</us-gaap:DeferredRevenue>
    <us-gaap:Liabilities contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">26261151</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">25565338</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">119031</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">62480</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">296298401</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">284649429</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">-299754409</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-285391122</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">-3336977</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-679213</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">-4762270</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">45040</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">269071320</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-273878630</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">62480</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">284649429</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-285391122</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">119031</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">296298401</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-299754409</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">22924174</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">24886125</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">11903133</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">6248035</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">11903133</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-09-30" unitRef="Shares" decimals="INF">6248035</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OtherIncome contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">285055</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">69020</us-gaap:OtherIncome>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">17445382</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">15606985</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-10-01to2017-09-30_us-gaap_CollaborativeArrangementMember" unitRef="USD" decimals="0">5800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-10-01to2016-09-30_us-gaap_CollaborativeArrangementMember" unitRef="USD" decimals="0">7200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">6486501</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">5800348</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">23931883</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">21407333</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-23646828</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-21338313</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">14013726</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">11007215</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesSMember" unitRef="USD" decimals="0">3078588</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesSMember" unitRef="USD" decimals="0">4252193</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesUMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesVMember" unitRef="USD" decimals="0">1547341</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesUMember" unitRef="USD" decimals="0">44552</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesVMember" unitRef="USD" decimals="0">4658228</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesWMember" unitRef="USD" decimals="0">1716104</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesZMember" unitRef="USD" decimals="0">893388</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesZZMember" unitRef="USD" decimals="0">65856</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesAAMember" unitRef="USD" decimals="0">698574</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesBBMember" unitRef="USD" decimals="0">54266</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesWMember" unitRef="USD" decimals="0">3260913</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesZMember" unitRef="USD" decimals="0">997226</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesZZMember" unitRef="USD" decimals="0">75229</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesAAMember" unitRef="USD" decimals="0">672246</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesBBMember" unitRef="USD" decimals="0">53139</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesCCMember" unitRef="USD" decimals="0">666203</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesCCMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesDDMember" unitRef="USD" decimals="0">437780</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesDDMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesEEMember" unitRef="USD" decimals="0">685915</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesEEMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesFFMember" unitRef="USD" decimals="0">73828</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesFFMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesGGMember" unitRef="USD" decimals="0">272464</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesGGMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesHHMember" unitRef="USD" decimals="0">13616</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesHHMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesIIMember" unitRef="USD" decimals="0">404823</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesIIMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesJJMember" unitRef="USD" decimals="0">20410</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesJJMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesKKMember" unitRef="USD" decimals="0">25564</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesKKMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-10-01to2017-09-30_custom_SeriesLLMember" unitRef="USD" decimals="0">352495</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2015-10-01to2016-09-30_custom_SeriesLLMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:InterestIncomeOther contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1879390</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-4032189</us-gaap:InterestIncomeOther>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-11512492</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-14363287</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-11512492</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-14363287</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-11512492</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-14427055</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">-2.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2016-10-01to2017-09-30" unitRef="USDPShares" decimals="INF">-1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">-2.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2016-10-01to2017-09-30" unitRef="USDPShares" decimals="INF">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">21373696</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">10530306</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">16609</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">21357087</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">47389</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10482917</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-8722073</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-4665683</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-8722073</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-4665683</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">161571</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">151308</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">163</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">161408</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">799</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">150509</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">690313</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">204583</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">689813</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">766</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">203817</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2012683</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1481250</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">168</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2012515</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">130</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1481120</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">79359</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">24925</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">79359</CVM:EquityBasedCompensationNonemployees>
    <CVM:EquityBasedCompensationNonemployees contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">24925</CVM:EquityBasedCompensationNonemployees>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">663988</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">632915</us-gaap:DepreciationAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">751651</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">232847</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2113433</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1380500</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">248</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1187</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1960</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-129307</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">15999</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">151909</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">393197</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">336120</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">145005</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">154995</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-2389931</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">5420816</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">290097</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">558026</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1639</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">72397</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">256303</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">1896</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1995</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-23082493</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-13791894</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">31405</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">10525</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2819</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">6477</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-34224</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-17002</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">21420301</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">10519306</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1104057</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">0</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">8213</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">3968</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">20308031</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">13260338</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-2808686</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-548558</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">305341</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-305341</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">815</CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd>
    <CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1890</CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd>
    <CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-8722073</CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants>
    <CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-4665683</CVM:IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants>
    <CVM:IncreaseInDirectFinancingCosts contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">46605</CVM:IncreaseInDirectFinancingCosts>
    <CVM:IncreaseInDirectFinancingCosts contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">35605</CVM:IncreaseInDirectFinancingCosts>
    <CVM:IncreaseInPrepaidServices contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">18021</CVM:IncreaseInPrepaidServices>
    <CVM:IncreaseInPrepaidServices contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-3339</CVM:IncreaseInPrepaidServices>
    <us-gaap:InterestPaidNet contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">1900567</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1888612</us-gaap:InterestPaidNet>
    <us-gaap:FixturesAndEquipmentGross contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">3169158</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FixturesAndEquipmentGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">3158633</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">124369</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">133499</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">131910</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">131910</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">24609193</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">24607798</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">7815973</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">7256962</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">626000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">593000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1535087</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1528610</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1311920</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1272063</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">38000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">40000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">70752000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">64366000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">6292000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">6379000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <CVM:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">21160000</CVM:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <CVM:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">18508000</CVM:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">121000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">179000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">99546000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">90653000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">99023000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">90604000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">99023000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">90604000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.0392</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.0644</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">-0.2213</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">-0.0391</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">-0.0339</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.4508</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.2549</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">-0.6084</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">-0.5863</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2113433</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1380500</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <CVM:NonemployeesShareBasedCompensation contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">751651</CVM:NonemployeesShareBasedCompensation>
    <CVM:NonemployeesShareBasedCompensation contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">232847</CVM:NonemployeesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.7558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.8854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.9067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.0218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.01056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.0229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <CVM:ExpectedLifeOfOptionsMin1 contextRef="From2015-10-01to2016-09-30">P3Y</CVM:ExpectedLifeOfOptionsMin1>
    <CVM:ExpectedLifeOfOptionsMin1 contextRef="From2016-10-01to2017-09-30">P9Y8M8D</CVM:ExpectedLifeOfOptionsMin1>
    <CVM:ExpectedLifeOfOptionsMax contextRef="From2015-10-01to2016-09-30">P9Y8M8D</CVM:ExpectedLifeOfOptionsMax>
    <CVM:ExpectedLifeOfOptionsMax contextRef="From2016-10-01to2017-09-30">P10Y</CVM:ExpectedLifeOfOptionsMax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <CVM:WeightedAverageGrantDateFairValueEnding contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">36.96</CVM:WeightedAverageGrantDateFairValueEnding>
    <CVM:WeightedAverageGrantDateFairValueEnding contextRef="From2016-10-01to2017-09-30" unitRef="USDPShares" decimals="INF">4.91</CVM:WeightedAverageGrantDateFairValueEnding>
    <CVM:WeightedAverageGrantDateFairValueEnding contextRef="From2016-10-01to2017-09-30_custom_RestrictedStockAwardsMember" unitRef="USDPShares" decimals="INF">13.75</CVM:WeightedAverageGrantDateFairValueEnding>
    <CVM:WeightedAverageGrantDateFairValueEnding contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="USDPShares" decimals="INF">13.75</CVM:WeightedAverageGrantDateFairValueEnding>
    <us-gaap:RestrictedStockExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">634000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">633000</us-gaap:RestrictedStockExpense>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">168000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">163000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-10-01to2017-09-30_custom_SanTomasMember" unitRef="USD" decimals="0">245000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-10-01to2016-09-30_custom_SanTomasMember" unitRef="USD" decimals="0">234000</us-gaap:LeaseAndRentalExpense>
    <CVM:RDDeferredRentLiability contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">5000</CVM:RDDeferredRentLiability>
    <CVM:RDDeferredRentLiability contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">2000</CVM:RDDeferredRentLiability>
    <CVM:DeferredRentLiability contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">18000</CVM:DeferredRentLiability>
    <CVM:DeferredRentLiability contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">18000</CVM:DeferredRentLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2053402</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">8394934</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesSMember" unitRef="USD" decimals="0">32773</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesUMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesVMember" unitRef="USD" decimals="0">72912</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesWMember" unitRef="USD" decimals="0">83754</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesZMember" unitRef="USD" decimals="0">77216</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesZZMember" unitRef="USD" decimals="0">4753</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesAAMember" unitRef="USD" decimals="0">65087</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesBBMember" unitRef="USD" decimals="0">4322</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesWMember" unitRef="USD" decimals="0">1799858</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesZMember" unitRef="USD" decimals="0">970604</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesZZMember" unitRef="USD" decimals="0">70609</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesAAMember" unitRef="USD" decimals="0">763661</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesBBMember" unitRef="USD" decimals="0">58588</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesSMember" unitRef="USD" decimals="0">3111361</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesUMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesVMember" unitRef="USD" decimals="0">1620253</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesCCMember" unitRef="USD" decimals="0">394220</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesDDMember" unitRef="USD" decimals="0">5492</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesEEMember" unitRef="USD" decimals="0">5492</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesFFMember" unitRef="USD" decimals="0">47154</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesGGMember" unitRef="USD" decimals="0">342173</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesHHMember" unitRef="USD" decimals="0">16014</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesIIMember" unitRef="USD" decimals="0">511636</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesJJMember" unitRef="USD" decimals="0">24203</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesKKMember" unitRef="USD" decimals="0">345720</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_custom_SeriesLLMember" unitRef="USD" decimals="0">20481</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesCCMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesDDMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesEEMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesGGMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesHHMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesIIMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesJJMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesKKMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesLLMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_custom_SeriesFFMember" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">32773</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2020629</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">3111361</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2016-09-30_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">5283573</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2029629</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">5283573</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">6323032</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">8722073</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">4665683</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-9761532</us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-7928627</us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-15104342</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">-2.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4866204</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">7891843</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4866204</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">7902647</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NotesAndLoansPayableCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">994258</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:NotesAndLoansPayableCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">10984</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
    <us-gaap:DerivativeInstrumentsAndHedgesLiabilities contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">12449</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">3310</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">13211925</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">13011023</us-gaap:FinanceLeaseLiability>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">37254</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">22609</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2016-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharesIssued contextRef="AsOf2015-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4503975</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6248035</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">11903133</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1660930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4738920</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">16340</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">79941</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">49953</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">76551</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <CVM:AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">16837</CVM:AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions>
    <CVM:AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">13000</CVM:AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions>
    <CVM:WarrantsIssuedWithNotesPayable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:WarrantsIssuedWithNotesPayable>
    <CVM:WarrantsIssuedWithNotesPayable contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1108867</CVM:WarrantsIssuedWithNotesPayable>
    <CVM:WarrantsIssuedWithNotesPayable contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1108867</CVM:WarrantsIssuedWithNotesPayable>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1108867</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1108867</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">266686</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">450700</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2667</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">448033</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">1310400</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4800</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1305600</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">480000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">917692</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">2745000</us-gaap:ProceedsFromNotesPayable>
    <CVM:ConversionOfAccruedSalariesAndFeesToNotesPayable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:ConversionOfAccruedSalariesAndFeesToNotesPayable>
    <CVM:ConversionOfAccruedSalariesAndFeesToNotesPayable contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">275000</CVM:ConversionOfAccruedSalariesAndFeesToNotesPayable>
    <CVM:OperationsAndFinancingTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has incurred significant costs since&#13;its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating&#13;to the human immunological defense system, patent applications, research and development, administrative costs, construction of&#13;laboratory facilities, and clinical trials.&amp;#160; The Company has funded such costs with proceeds from loans and the public and&#13;private sale of its securities.&amp;#160; The Company will be required to raise additional capital or find additional long-term financing&#13;in order to continue with its research efforts.&amp;#160; To date, the Company has not generated any revenue from product sales.&amp;#160;&#13;As a result, the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and&#13;capital requirements and anticipates having to do so in the future. During fiscal year 2017 and 2016, the Company raised net proceeds&#13;of approximately $13.3 million and $21.4 million, respectively, through the sale of stock and the issuance of convertible notes.&#13;The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed&#13;on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate&#13;regulatory approvals and obtain sufficient revenues to support its cost structure.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is currently running a large multi-national&#13;Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. To finance the study&#13;beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or&#13;equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently&#13;in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, there can be no assurance that the&#13;Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on&#13;acceptable terms or at all.&amp;#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations&#13;until such time as it is able to raise the required funding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements have been&#13;prepared assuming that the Company will continue as a going concern, but due to the Company&amp;#8217;s negative working capital,&#13;stockholders&amp;#8217; deficit, recurring losses from operations and future liquidity needs, there is substantial doubt about&#13;the Company&amp;#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that&#13;might result from the outcome of this uncertainty.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Since the Company launched its Phase 3 clinical&#13;trial for Multikine, the Company has incurred expenses of approximately $45.9 million as of September 30, 2017 on direct costs&#13;for the Phase 3 clinical trial. The Company estimates it will incur additional expenses of approximately $13.0 million for the&#13;remainder of the Phase 3 clinical trial.&amp;#160; It should be noted that this estimate is based only on the information currently&#13;available in the Company&amp;#8217;s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical&#13;trial and does not include other related costs, e.g., the manufacturing of the drug.&lt;font style="color: red"&gt;&amp;#160;&lt;/font&gt;This&#13;number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot&#13;be foreseen.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Nine hundred twenty-eight (928) head and neck&#13;cancer patients have been enrolled and have completed treatment in the Phase 3 study. The study endpoint is a 10% increase in overall&#13;survival of patients between the two main comparator groups in favor of the group receiving the Multikine treatment regimen. The&#13;determination if the study end point is met will occur when there are a total of 298 deaths in those two groups.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 12, 2017, the Company&amp;#8217;s shareholders&#13;approved a reverse split of the Company&amp;#8217;s common stock which became effective on the NYSE American on June 15, 2017. On that&#13;date, every twenty five issued and outstanding shares of the Company&amp;#8217;s common stock automatically converted into one outstanding&#13;share. As a result of the reverse stock split, the number of the Company&amp;#8217;s outstanding shares of common stock decreased from&#13;230,127,331 (pre-split) shares to 9,201,645 (post-split) shares. In addition, by reducing the number of the Company&amp;#8217;s outstanding&#13;shares, the Company&amp;#8217;s loss per share in all prior periods increased by a factor of twenty five. The reverse stock split affected&#13;all stockholders of the Company&amp;#8217;s common stock uniformly, and did not affect any stockholder&amp;#8217;s percentage of ownership&#13;interest. The par value of the Company&amp;#8217;s stock remained unchanged at $0.01 per share and the number of authorized shares&#13;of common stock remained the same after the reverse stock split.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</CVM:OperationsAndFinancingTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt; &amp;#8211; For&#13;purposes of the statements of cash flows, cash and cash equivalents consist principally of unrestricted cash on deposit and short-term&#13;money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months&#13;as cash and cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Prepaid Expenses&lt;/i&gt; &amp;#8211; Prepaid expenses&#13;are payments for future services to be rendered and are expensed over the time period for which the service is rendered. Prepaid&#13;expenses may also include payment for goods to be received within one year of the payment date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Inventory&lt;/i&gt; &amp;#8211; Inventory consists&#13;of manufacturing production advances and bulk purchases of laboratory supplies to be consumed in the manufacturing of the Company&amp;#8217;s&#13;product for clinical studies. Inventories are stated at the lower of cost or market, where cost is determined using the first-in,&#13;first out method applied on a consistent basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Deposits&lt;/i&gt; &amp;#8211; The deposits are required&#13;by the lease agreement for the manufacturing facility and by the clinical research organization (CRO) agreements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Plant, property and equipment&lt;/i&gt;&amp;#8211;&#13;The leased manufacturing facility is recorded at total project costs incurred and is depreciated over the 20-year useful life of&#13;the building. Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful&#13;lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset&#13;or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The plant,&#13;property and equipment are reviewed on a quarterly basis to assess impairment, if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Patents&lt;/i&gt; &amp;#8211; Patent expenditures are&#13;capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the&#13;patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate&#13;adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted&#13;cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The&#13;amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Leases &amp;#8211;&lt;/i&gt; Leases are categorized&#13;as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term&#13;of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of capital leases.&#13;The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset&#13;and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural&#13;improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit&#13;leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.&#13;If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on&#13;the Company's balance sheet. See Note 11.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Deferred Rent&lt;/i&gt; &amp;#8211; Certain of the&#13;Company&amp;#8217;s operating leases provide for minimum annual payments that adjust over the life of the lease.&amp;#160; The aggregate&#13;minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent&#13;liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent&#13;liability when the lease payments exceed the straight-line rent expense.&amp;#160; For tenant improvement allowances and rent holidays,&#13;the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Derivative Instruments&lt;/i&gt; - The Company&#13;has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features,&#13;specifically, the settlement provisions in the warrant agreements preclude the warrants from being treated as equity. The Company&#13;accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &amp;#8220;Accounting for Derivative&#13;Instruments and Hedging Activities&amp;#8221;. In accordance with accounting principles generally accepted in the United States (U.S.&#13;GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are&#13;measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the&#13;derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based&#13;on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each&#13;instrument. The derivative liabilities are remeasured at fair value at the end of each reporting period as long as they are outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Grant Income&lt;/i&gt; &amp;#8211; The Company's grant&#13;arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt; &amp;#8211;&#13;Research and development expenditures are expensed as incurred. Management accrues CRO expenses and clinical trial study expenses&#13;based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a&#13;study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions&#13;to estimated expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt; &amp;#8211; The&#13;Company calculates net loss per common share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (ASC 260). Basic and diluted&#13;net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number&#13;of common shares outstanding during the period. The Company&amp;#8217;s potentially dilutive shares, which include outstanding common&#13;stock options, restricted stock units, convertible preferred stock and common stock warrants, have not been included in the computation&#13;of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt; &amp;#8211;&#13;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&amp;#160;&#13;The Company maintains its cash and cash equivalents with high quality financial institutions.&amp;#160; At times, these accounts may&#13;exceed federally insured limits.&amp;#160; The Company has not experienced any losses in such bank accounts.&amp;#160; The Company believes&#13;it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were&#13;fully insured&amp;#160;up to $250,000 at September 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Income Taxes&lt;/i&gt; &amp;#8211; The Company uses&#13;the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities&#13;are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing&#13;assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities&#13;are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are&#13;expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in&#13;income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets&#13;to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets&#13;as of September 30, 2017 and 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt; &amp;#8211; The preparation&#13;of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported&#13;in the financial statements and the accompanying disclosures. These estimates are based on management&amp;#8217;s best knowledge of&#13;current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory&#13;obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, deferred tax assets&#13;and the related valuation allowance, and the valuation of derivative liabilities.&lt;font style="color: #444444"&gt;&amp;#160;&lt;/font&gt;Actual&#13;results could differ from estimates, although management does not generally believe such differences would materially affect the&#13;financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using various&#13;valuation techniques including the Black-Scholes and binomial pricing methodologies, significant fluctuations may materially affect&#13;the financial statements in a given year. The Company considers such valuations to be significant estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt; &amp;#8211; The Company&#13;evaluates financial assets and liabilities subject to fair value measurements in accordance with a fair value hierarchy to prioritize&#13;the inputs used to measure fair value. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest&#13;level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. See Note 14 for&#13;the definition of levels and the classification of assets and liabilities in those levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt; &amp;#8211; Compensation&#13;cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &amp;#8220;Compensation&#13;&amp;#8211; Stock Compensation.&amp;#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model.&#13;The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based&#13;compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity instruments issued to non-employees are&#13;accounted for in accordance with ASC 505-50, &amp;#8220;Equity-Based Payments to Non-Employees.&amp;#8221; Accordingly, compensation is&#13;recognized when goods or services are received and may be measured using the Black-Scholes valuation model, based on the type of&#13;award. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the&#13;measurement date and the expected life of the options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has Incentive Stock Option Plans,&#13;Non-Qualified Stock Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases,&#13;these Plans are collectively referred to as the &amp;#8220;Plans.&amp;#8221; All Plans have been approved by the Company&amp;#8217;s stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s stock options are not transferable,&#13;and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on&#13;the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of&#13;daily closing prices of the Company&amp;#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at&#13;date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and&#13;employee termination within the valuation model. The expected term of options represents the period of time that options granted&#13;are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions&#13;used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in&#13;the future from that recorded in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Vesting of restricted stock granted under the&#13;Incentive Stock Bonus Plan is subject to service, performance or market conditions and meets the classification of equity awards.&#13;These awards were measured at fair market value on the grant-dates for issuances where the attainment of performance criteria is&#13;probable and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance&#13;criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt; &amp;#8211;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2017, the FASB issued ASU 2017-09,&amp;#160;&lt;i&gt;Compensation&#13;&amp;#8211; Stock Compensation (Topic 718)&lt;/i&gt;, which affects any entity that changes the terms or conditions of a share-based payment&#13;award.&amp;#160; This Update amends the definition of modification by qualifying that modification accounting does not apply to changes&#13;to outstanding share-based payment awards that do not affect the total fair value, vesting requirements, or equity/liability classification&#13;of the awards.&amp;#160; The amendments in this Update are effective for all entities for annual periods, and interim periods within&#13;those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period,&#13;for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other&#13;entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in&#13;this Update should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating&#13;the impact the adoption of the standard will have on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2017, the FASB issued ASU 2017-11,&amp;#160;&lt;i&gt;Earnings&#13;Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging (Topic 815)&lt;/i&gt;. The amendments&#13;in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features)&#13;with down-round features. When determining whether certain financial instruments should be classified as liabilities or equity&#13;instruments, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to&#13;an entity&amp;#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As&#13;a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as&#13;a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity classified financial&#13;instruments, the amendments require entities that present earnings per share (&amp;#8220;EPS&amp;#8221;) in accordance with Topic 260 to&#13;recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and as a reduction of&#13;income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down-&#13;round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20,&amp;#160;&lt;i&gt;Debt&amp;#8212;Debt&#13;with Conversion and Other Options&lt;/i&gt;), including related EPS guidance (in Topic 260). The amendments in Part II of this Update&#13;recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Accounting&#13;Standards Codification, to a scope exception. Those amendments do not have an accounting effect.&amp;#160;For public business entities,&#13;the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning&#13;after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning&#13;after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted&#13;for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments&#13;should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part I of this&#13;Update should be applied either retrospectively to outstanding financial instruments with a down-round feature by means of a cumulative-effect&#13;adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the&#13;pending content that links to this paragraph is effective or retrospectively to outstanding financial instruments with a down-round&#13;feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5&#13;through 45-10. The amendments in Part II of this Update do not require any transition guidance because those amendments do not&#13;have an accounting effect.&amp;#160;The Company is currently evaluating the impact the adoption of the standard will have on the Company&amp;#8217;s&#13;financial position or results of operations.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2017, the FASB issued ASU 2017-12,&amp;#160;&lt;i&gt;Derivatives&#13;and Hedging (Topic 850)&lt;/i&gt;, the objective of which is to improve the financial reporting of hedging relationships to better portray&#13;the economic results of an entity&amp;#8217;s risk management activities in its financial statements. In addition, the amendments in&#13;this Update make certain targeted improvements to simplify the application and disclosure of the hedge accounting guidance in current&#13;general accepted accounting principles.&amp;#160;&amp;#160;For public business entities, the amendments in&amp;#160;this Update are effective&#13;for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the&#13;amendments are effective for fiscal years beginning after December 15, 2019, and interim periods beginning after December 15, 2020.&#13;Early adoption is permitted in any period after issuance.&amp;#160;&amp;#160;For cash flow and net investment hedges existing at the date&#13;of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate&amp;#160;measurement of ineffectiveness&#13;to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the&#13;beginning of the fiscal year that an entity adopts the amendments in this Update. The amended presentation and disclosure guidance&#13;is required only prospectively.&amp;#160;&amp;#160;The Company is currently evaluating the impact the adoption of the standard will have&#13;on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued ASU 2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;,&#13;which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance&#13;sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases&#13;are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current&#13;standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December&#13;15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning&#13;with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial&#13;statements and related disclosures. Although the Company has not completed its evaluation of the impact of the adoption of ASU&#13;2016-02, because the Company&amp;#8217;s most significant operating lease is currently on its balance sheet (see Note 11), the adoption&#13;of ASU 2016-02 is not expected to have a material impact to the financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2016, the FASB issued ASU No.&#13;2016-09, &lt;i&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&lt;/i&gt; ASU&#13;2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including income tax&#13;consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The&#13;new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016&#13;but early adoption is permitted. The Company does not expect the adoption of the new amendment to have a material impact on its financial statements and related&#13;disclosures March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee&#13;Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions,&#13;including income tax consequences, classification of awards as either equity or liabilities and classification on the statement&#13;of cash flows. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after&#13;December 15, 2016 but early adoption is permitted. The Company  does not expect the adoption of the new amendment to have&#13;a material impact on its financial statements and related disclosures. The estimated forfeiture rate is based on historical&#13;information, however, the Company will no longer estimate the forfeiture rate on share based payments, but rather recognize&#13;forfeitures as they occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has considered all other recently&#13;issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following chart represents the warrants&#13;and non-employee options outstanding at September 30, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issuable upon Exercise of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Expiration Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 12%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Refer-ence&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4/17/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$43.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/17/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,360,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$4.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/1/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,360,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$4.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/1/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/18/2008&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;85,339&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/18/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/11/13- 10/24/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,037,120&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/11/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/28/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;810,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5/28/2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/28/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;688,930&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$16.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/28/2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series X&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1/13/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$9.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1/13/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Y&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/15/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/15/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5/18/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;11/23/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;68,048&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/1/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;680,480&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/23/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/16/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/14/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/8/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series LL&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4/30/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,398&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;4/30/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series MM&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6/22/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;893,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;6/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series NN&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7/24/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;539,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;7/24/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series OO&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7/31/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;7/31/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series QQ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;87,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/23/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;400,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/23/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/14/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;600,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;9/14/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/3/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;395,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;11/3/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series PP&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/28/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,750,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/28/2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/28/12- 7/28/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.18- $70.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/27/17- 7/27/27&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following chart represents the warrants&#13;and non-employee options outstanding at September 30, 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 20%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issuable upon Exercise of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Expiration Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Refer-ence&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/18/08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;113,785&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/18/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series R&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/6/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;105,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$100.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/6/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4/17/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$43.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/17/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/11/13 -10/24/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,037,120&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/11/18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;810,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;688,930&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$16.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series X&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1/13/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$9.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1/13/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series Y&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/15/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/15/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/18/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11/23/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/22/22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/22/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series P&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/10/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$112.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/6/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/2/11- 7/1/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$9.25- $87.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/27/16- 6/30/19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Warrant Liabilities&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below presents the warrant liabilities&#13;and their respective balances at September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,111,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series U warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;72,912&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,620,253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;83,754&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,799,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;77,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;970,604&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,753&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;70,609&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;65,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;763,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,322&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;58,588&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;394,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,154&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;342,173&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;511,636&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;345,720&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series LL warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,481&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,053,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,394,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The table below presents the gains on the warrant liabilities for&#13;the years ended September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,078,588&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,252,193&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series U warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;44,552&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,547,341&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,658,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,716,104&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,260,913&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;893,388&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;997,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;65,856&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;698,574&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;672,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;54,266&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;53,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;666,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;437,780&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;685,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;73,828&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;272,464&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,616&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;404,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Series LL warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;352,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Net gain on warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11,007,215&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,013,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews all outstanding warrants&#13;in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether&#13;an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&amp;#8217;s&#13;contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain&#13;dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&amp;#8217;s stock because&#13;future equity offerings or sales of the Company&amp;#8217;s stock are not an input to the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221;&#13;option on equity shares, and equity classification is therefore precluded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 815, derivative liabilities&#13;must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in&#13;fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Fiscal 2017 Warrant Liabilities&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 30, 2017, the Company entered into&#13;a securities purchase agreement with an institutional investor whereby it sold 527,960 shares of its common stock for net proceeds&#13;of approximately $1.4 million, or $2.875 per share, in a registered direct offering. In a concurrent private placement, the Company&#13;also issued to the purchaser of the Company&amp;#8217;s common stock Series KK warrants to purchase 395,970 shares of common stock.&#13;The warrants can be exercised at a price of $3.04 per share at any time on or after November 3, 2017 and expire on November 3,&#13;2022. In addition, the Company issued 26,398 Series LL warrants to the placement agent as part of its compensation. The Series&#13;LL warrants are exercisable on October 30, 2017 at a price of $3.59 per share and expire on April 30, 2022. The fair value of the&#13;Series KK and LL warrants of approximately $0.7 million on the date of issuance was recorded as a warrant liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 14, 2017, the Company sold 600,000&#13;registered shares of common stock and 600,000 Series II warrants to purchase 600,000 unregistered shares of common stock at combined&#13;offering price of $2.50 per share.&amp;#160; The Series II warrants have an exercise price of $3.00 per share and expire September&#13;14, 2022. In addition, the Company issued 30,000 Series JJ warrants to purchase 30,000 shares of unregistered common stock to the&#13;placement agent. The Series JJ warrants have an exercise price $3.13 and expire on March 8, 2022. The&amp;#160;net&amp;#160;proceeds from&#13;this offering&amp;#160;were&amp;#160;approximately $1.3&amp;#160;million. The fair value of the Series II and JJ warrants of approximately&#13;$1.0 million on the date of issuance was recorded as a warrant liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 23, 2017, the Company sold 400,000&#13;registered shares of common stock and 400,000 Series GG warrants to purchase 400,000 unregistered shares of common stock at a combined&#13;price of $2.50 per share.&amp;#160; The Series GG warrants have an exercise price of $3.00 per share and expire August 23, 2022. In&#13;addition, the Company issued to the placement agent 20,000 Series HH warrants to purchase 20,000 shares of unregistered common&#13;stock. The Series HH warrants have an exercise price $3.13 and expire on February 16, 2022. The&amp;#160;net&amp;#160;proceeds from this&#13;offering&amp;#160;were&amp;#160;approximately $0.8&amp;#160;million. The fair value of the Series GG and HH warrants of approximately $0.6&#13;million on the date of issuance was recorded as a warrant liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 8, 2016, the Company sold 1,360,960&#13;shares of common stock and warrants to purchase common stock at a price of $3.13 in a public offering. The warrants consist of&#13;680,480 Series CC warrants to purchase 680,480 shares of common stock, 1,360,960 Series DD warrants to purchase 1,360,960 shares&#13;of common stock and 1,360,960 Series EE warrants to purchase 1,360,960 shares of common stock. The Series CC warrants were immediately&#13;exercisable, expire in five-years from the offering date and have an exercise price of $5.00 per share. The Series DD warrants&#13;were immediately exercisable and have an exercise price of $4.50 per share. On June 5, 2017 and June 29, 2017, the expiration date&#13;of the Series DD warrants was extended from June 8, 2017 to July 10, 2017 and then to August 10, 2017. On August 29, 2017, the&#13;expiration date of the Series DD warrants was extended to December 1, 2017. The Series EE warrants are immediately exercisable&#13;and have an exercise price of $4.50 per share. On August 29, 2017, the initial expiration date of the Series EE warrants was extended&#13;from September 8, 2017 to December 1, 2017. In addition, the Company issued 68,048 Series FF warrants to purchase 68,048 shares&#13;of common stock to the placement agent. The FF warrants expire on December 1, 2021 and have an exercise price $3.91. Net&amp;#160;proceeds&#13;from this offering&amp;#160;were&amp;#160;approximately $3.7&amp;#160;million. The fair value of the Series CC, DD, EE and FF warrants of approximately&#13;$2.3 million on the date of issuance was recorded as a warrant liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series AA and BB Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 26, 2016, the Company closed a registered&#13;direct offering of&amp;#160;400,000 shares of common stock and 200,000 Series AA warrants to purchase 200,000 shares of common stock.&#13;The common stock and warrants were sold at a combined per unit price of $12.50 for proceeds of approximately $4.5 million, net&#13;of placement agent&amp;#8217;s commissions and offering expenses. The Series AA warrants may be exercised at any time after February&#13;22, 2017 and on or before February 22, 2022 at a price of $13.75 per share. The Company also issued 16,000 Series BB warrants to&#13;the placement agent as part of its compensation. The Series BB warrants may be exercised at any time on or after February 22, 2017&#13;and on or before August 22, 2021 at a price of $13.75 per share. The fair value of the Series AA and Series BB warrants of approximately&#13;$1.5 million on the date of issuance was recorded as a warrant liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series Z and ZZ Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 23, 2016, the Company closed a registered&#13;direct offering of 400,000 shares of common stock and 264,000 Series Z warrants to purchase shares of common stock. The common&#13;stock and warrants were sold at a combined per unit price of $12.50 for net proceeds of approximately $4.6 million, net of placement&#13;agent&amp;#8217;s commissions and offering expenses. The Series Z warrants may be exercised at any time on or after November 23, 2016&#13;and on or before November 23, 2021 at a price of $13.75 per share. The Company also issued 20,000 Series ZZ warrants to the placement&#13;agent as part of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23, 2016 and on or&#13;before May 18, 2021 at a price of $13.75 per share. The fair value of the Series Z and Series ZZ warrants of approximately $2.1&#13;million on the date of issuance was recorded as a warrant liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series W Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 28, 2015, the Company closed an underwritten&#13;public offering of 688,930 shares of common stock and 688,930 Series W warrants to purchase shares of common stock. The common&#13;stock and warrants were sold at a combined per unit price of $16.75 for net proceeds of approximately $10.5 million, net of underwriting&#13;discounts and commissions and offering expenses. The Series W warrants are immediately exercisable at a price of $16.75 and expire&#13;on October 28, 2020. The fair value at issuance of the Series W warrants of approximately $5.1 million was recorded as warrant&#13;liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Expiration of Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 16, 2017, 23,600 Series P warrants,&#13;with an exercise price of $112.50, expired. The fair value of the Series P warrants was $0 on the date of expiration.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 6, 2016, 105,000 Series R warrants,&#13;with an exercise price of $100.00, expired. The fair value of the Series R warrants was $0 on the date of expiration.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 22, 2015, 48,000 Series Q warrants,&#13;with an exercise price of $125.00, expired. The fair value of the Series Q warrants was $0 on the date of expiration.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;2.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Equity Warrants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series PP and Series QQ Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 22, 2017, the Company entered into&#13;a securities purchase agreement with institutional investors whereby it sold 1,750,000 shares of its common stock for net proceeds&#13;of approximately $3.2 million, or $2.00 per share, in a registered direct offering. In a concurrent private placement, the Company&#13;also issued to the purchasers of the Company&amp;#8217;s common stock Series PP warrants to purchase 1,750,000 shares of common stock.&#13;The warrants can be exercised at a price of $2.30 per share at any time on or after February 28, 2018 and expire on February 28,&#13;2023. In addition, the Company issued 87,500 Series QQ warrants to the placement agent as part of its compensation. The Series&#13;QQ warrants are exercisable on February 22, 2018 at a price of $2.50 per share and expire on August 22, 2022. The Series PP and&#13;Series QQ warrants qualify for equity treatment in accordance with ASC 815. The relative fair value of the warrants was approximately&#13;$1.4 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series OO Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 26, 2017, the Company entered into a&#13;securities purchase agreement with an investor whereby it sold 100,000 shares of its common stock for gross proceeds of $229,000,&#13;or $2.29 per share, in a registered offering. In a concurrent private placement, the Company also issued to the purchaser of the&#13;common stock Series OO warrants to purchase 60,000 shares of the Company&amp;#8217;s common stock. The warrants can be exercised at&#13;a price of $2.52 per share, commencing six months after the date of issuance and ending five years after the date of issuance.&#13;The Series OO warrants qualify for equity treatment in accordance with ASC 815. The relative fair value of the warrants was approximately&#13;$62,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series NN Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, in connection with the issuances&#13;of convertible notes (See Note 7), the Company issued the note holders Series NN warrants which entitle the purchasers to acquire&#13;up to an aggregate of 539,300 shares of the Company&amp;#8217;s common stock. The warrants are exercisable at a fixed price of $2.52&#13;per share and expire on July 24, 2022. Shares issuable upon the exercise of the notes and warrants were restricted securities unless&#13;registered. The shares were registered effective September 1, 2017. Proceeds from the sale of notes payable and the issuance of&#13;the warrants were approximately $1.2 million. The Company allocated the proceeds received to the notes and the Series NN warrants&#13;on a relative fair value basis. As a result of such allocation, the Company determined the initial carrying value of the Series&#13;NN warrants to be approximately $0.5 million. The Series NN warrants qualify for equity treatment in accordance with ASC 815.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series MM Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 22, 2017, in connection with the issuance&#13;of convertible notes (see Note 7), the Company issued the note holders Series MM warrants, which entitle the purchasers to acquire&#13;up to an aggregate of 893,491 shares of the Company&amp;#8217;s common stock. The Series MM warrants are exercisable at a price of&#13;$1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the notes and warrants were restricted securities&#13;unless registered. The shares were registered effective August 8, 2017. Proceeds from the sale of notes payable and the issuance&#13;of the warrants were $1.5 million. The Company allocated proceeds received to the Notes and the Series MM warrants on a relative&#13;fair value basis. As a result of such allocation, the Company determined the initial carrying value of the Series MM warrants to&#13;be approximately $0.6 million. The Series MM warrants qualify for equity treatment in accordance with ASC 815.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series X Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2016, the Company sold 120,000 shares&#13;of its common stock and 120,000 Series X warrants to the de Clara Trust for approximately $1.1 million. The de Clara Trust is controlled&#13;by Geert Kersten, the Company's Chief Executive Officer and a director. Each Series X warrant allows the de Clara Trust to purchase&#13;one share of the Company's common stock at a price of $9.25 per share at any time on or before January 13, 2021. The Series X warrants&#13;qualify for equity treatment in accordance with ASC 815. The relative fair value of the warrants was approximately $417,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series Y Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 15, 2016, the Company sold 52,000&#13;shares of its common stock and 26,000 Series Y warrants to a private investor for $624,000. Each Series Y warrant allows the holder&#13;to purchase one share of the Company's common stock at a price of $12.00 per share at any time on or before February 15, 2021.&#13;The Series Y warrants qualify for equity treatment in accordance with ASC 815. The relative fair value on the date of issuance&#13;of the warrants was approximately $144,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Series N Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Series N warrants were previously issued in&#13;connection with a financing and were subsequently transferred to the de Clara Trust, of which the Company&amp;#8217;s CEO, Geert Kersten,&#13;is a beneficiary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 17, 2017, the Series N warrants held&#13;in the de Clara Trust were modified. The modification extended the expiration date by one year to expire on August 18, 2018; the&#13;113,785 warrants outstanding were reduced by 25% to 85,339 warrants outstanding; and the exercise price was reduced to $3.00 per&#13;share. The incremental cost of this modification was approximately $64,000, which was recorded as a deemed dividend.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;3.&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Options and Shares Issued to Consultants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company typically enters into consulting&#13;arrangements in exchange for common stock or stock options. During the years ended September 30, 2017 and 2016 the Company issued&#13;76,551 and 49,954 shares, respectively, of common stock to consultants of which 68,352 and 31,360 shares, respectively, were restricted&#13;shares. Under these arrangements, the common stock was issued with stock prices ranging between $1.73 and $7.25 per share.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, during the years ended September&#13;30, 2017 and 2016 the Company issued to consultants 20,000 and 16,400 options, respectively, to purchase common stock with an exercise&#13;price of $2.18 per share and a fair value of $1.87 per share. The aggregate values of the issuances of restricted common stock&#13;and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods&#13;of service.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended September 30, 2017 and&#13;2016, the Company recorded total expense of approximately $233,000 and $752,000, respectively, relating to these consulting agreements.&#13;At September 30, 2017 and 2016, approximately $45,000 and $48,000, respectively, are included in prepaid expenses. As of September&#13;30, 2017, 42,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the&#13;Non-Qualified Stock Option plans and are fully vested.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Plant, property and equipment consisted of the&#13;following at September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 50%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 23%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Leased manufacturing facility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$ 21,183,756&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$ 21,183,756&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Research equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,169,158&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,158,633&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;124,369&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;133,499&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;131,910&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;131,910&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;24,609,193&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;24,607,798&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(7,815,973)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(7,256,962)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net plant, property and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 16,793,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 17,350,836&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is not the legal owner of the manufacturing&#13;building, but is deemed to be the owner for accounting purposes, based on the accounting guidance for build-to-suit leases. See&#13;Note 11, Commitments and Contingencies&amp;#8211;Lease Obligations, for additional information.&amp;#160;As of September 30, 2017 and 2016,&#13;accumulated depreciation on the manufacturing building is approximately $4.6 million and $4.1 million, respectively. Depreciation&#13;expense for the years ended September 30, 2017 and 2016 totaled approximately $593,000 and, $626,000, respectively. Depreciation&#13;expense includes depreciation on the leased manufacturing building of approximately $514,000, which is included in research and&#13;development costs on the Statements of Operations. During the year ended September 30, 2017, the Company purchased an asset under&#13;a lease classified as a capital lease. That asset has a net book value of approximately $21,000 on September 30, 2017. Amortization&#13;of the capital lease asset is included in general and administrative expenses on the Statements of Operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Patents consisted of the following at September&#13;30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 48%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 1,535,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 1,528,610&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,311,920)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,272,063)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Patents, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 223,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 256,547&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended September 30, 2017 and&#13;2016,there was no impairment of patent costs. Amortization expense for the years ended September 30, 2017 and 2016 totaled approximately&#13;$40,000 and $38,000, respectively. The total estimated future amortization is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Years ending September 30,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 60%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 37,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;35,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;32,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;28,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;66,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 223,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, the Company issued Series&#13;NN convertible notes in the aggregate principal amount of $1.2 million to 12 individual investors. A trust in which Geert Kersten,&#13;the Company&amp;#8217;s Chief Executive Officer, holds a beneficial interest participated in the offering and purchased a note in the&#13;principal amount of $250,000. Patricia B. Prichep, the Company&amp;#8217;s Senior Vice President of Operations, participated in the&#13;offering and purchased a note in the principal amount of $25,000. The Series NN Notes bear interest at 4% per year and are due&#13;on December 22, 2017. At the option of the note holders, the Series NN Notes can be converted into shares of the Company&amp;#8217;s&#13;common stock at a fixed conversion rate of $2.29, the closing price on July 21, 2017. The purchasers of the convertible notes also&#13;received Series NN warrants which entitle the purchasers to acquire up to 539,300 shares of the Company&amp;#8217;s common stock. The&#13;warrants are exercisable at a price of $2.52 per share and expire on July 24, 2022. Shares issuable upon the exercise of the warrants&#13;were restricted securities unless registered. The shares were registered effective September 1, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Series NN Notes were issued together with&#13;Series NN warrants, as discussed in the preceding section. Upon issuance of the Series NN Notes and Series NN warrants, the Company&#13;allocated proceeds received to the notes and warrants on a relative fair value basis. As a result of such allocation, the Company&#13;determined the initial carrying value of the Series NN Notes to be approximately $0.7 million, the initial carrying value of the&#13;Series NN warrants to be approximately $0.5 million, and recorded a debt discount in the amount of approximately $0.5 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 22, 2017, CEL-SCI issued Series MM convertible&#13;notes in the aggregate principal amount of $1.5 million to six individual investors. The Series MM Notes bear interest at 4% per&#13;year and are due on December 22, 2017. At the option of the note holders, the Series MM Notes can be converted into shares of the&#13;Company&amp;#8217;s common stock at a fixed conversion rate of $1.69. The number of shares of the Company&amp;#8217;s common stock issued&#13;upon conversion will be determined by dividing the principal amount to be converted by $1.69, which could result in the issuance&#13;of 893,491 shares of the Company&amp;#8217;s common stock. The purchasers of the convertible notes also received Series MM warrants&#13;which entitle the purchasers to acquire up to 893,491 shares of the Company&amp;#8217;s common stock. The warrants are exercisable&#13;at a price of $1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the warrants were restricted securities&#13;unless registered. The shares were registered effective August 8, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Series MM Notes were issued together with&#13;Series MM warrants, as discussed in the preceding section. Upon issuance of the Series MM Notes and Series MM warrants, the Company&#13;allocated proceeds received to the notes and warrants on a relative fair value basis. As a result of such allocation, the Company&#13;determined the initial carrying value of the Series MM Notes to be approximately $0.9 million, the initial carrying value of the&#13;Series MM warrants to be approximately $0.6 million, and recorded a debt discount in the amount of approximately $0.6 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended September 30, 2017,&#13;two note holders converted their Series MM notes into shares of common stock. The face value of the converted notes was $450,700.&#13;The unamortized debt discount relating to the converted notes was charged to interest expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the guidance in ASC 815-40, &lt;i&gt;Contracts&#13;in Entity&amp;#8217;s Own Equity&lt;/i&gt;, the Company evaluated whether the conversion feature of the note needed to be bifurcated from&#13;the host instrument as a freestanding financial instrument. Under ASC 815-40, to qualify for equity classification (or non-bifurcation,&#13;if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer&amp;#8217;s own stock and (2) meet the requirements&#13;of the equity classification guidance. Based upon the Company&amp;#8217;s analysis, it was determined the conversion option is indexed&#13;to its own stock and also met all the criteria for equity classification. Accordingly, the conversion option is not required to&#13;be bifurcated from the host instrument as a freestanding financial instrument. Since the conversion feature meets the equity scope&#13;exception from derivative accounting, the Company then evaluated whether the conversion feature needed to be separately accounted&#13;for as an equity component under ASC 470-20, &lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt;. Based upon the Company&amp;#8217;s analysis,&#13;it was determined that a beneficial conversion feature existed as a result of the reduction in the face value of the Series MM&#13;and NN Notes, due to a portion of proceeds being allocated to the related warrants, and thus the conversion features needed to&#13;be separately accounted for as an equity component. The Company recorded beneficial conversion features relating to the Series&#13;MM and NN notes of approximately $603,000 and $506,000, respectively, which were also recorded as debt discounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The total debt discount on both Series MM and&#13;NN notes is being amortized to interest expense using the effective interest method over the expected term of the notes. At September&#13;30, 2017, the remaining debt discount is approximately $1.3 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2017, the&#13;Company recorded approximately $941,000 in interest expense related to the Series MM and NN notes, of which approximately $23,000&#13;was recorded as accrued interest, and approximately $918,000 was recorded as amortization of the debt discount.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Series MM and Series NN notes are secured&#13;by a first lien on all of the Company&amp;#8217;s assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2017 and 2016, the Company&#13;had federal net operating loss carryforwards of approximately $187.8 million and $169.7 million, respectively. The NOLs begin to&#13;expire during the fiscal year ending September 30, 2019 and become fully expired by the end of the fiscal year ended 2037. In addition,&#13;the Company has a general business credit as a result of the credit for increasing research activities (&amp;#8220;R&amp;#38;D credit&amp;#8221;)&#13;of approximately $1.2 million at September 30, 2017 and 2016. The R&amp;#38;D credit begins to expire during the fiscal year ending&#13;September 30, 2020 and is fully expired during the fiscal year ended 2029. Deferred taxes consisted of the following at September&#13;30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 46%"&gt;&lt;font style="font-size: 8pt"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 14%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 14%"&gt;&lt;font style="font-size: 8pt"&gt;70,752,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 13%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 13%"&gt; &lt;font style="font-size: 8pt"&gt;64,366,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;R&amp;#38;D credit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,221,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,221,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,292,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,379,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Capitalized R&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;21,160,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;18,508,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Vacation and other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;121,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;179,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;99,546,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;90,653,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Fixed assets and intangibles&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(523,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(49,000)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(523,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(49,000)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;99,023,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;90,604,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(99,023,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(90,604,000)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Ending Balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt; &lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt; &lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In assessing the realization of deferred tax&#13;assets, management considered whether it was more likely than not that some, or all, of the deferred tax asset will be realized.&#13;The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income. Management has considered&#13;the history of the Company&amp;#8217;s operating losses and believes that the realization of the benefit of the deferred tax assets&#13;cannot be reasonably assured. In addition, under Internal Revenue Code Section 382, the Company&amp;#8217;s ability to utilize these&#13;net operating loss carryforwards may be limited or eliminated in the event of future changes in ownership.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has no federal or state current&#13;or deferred tax expense or benefit. The Company&amp;#8217;s effective tax rate differs from the applicable federal statutory tax rate.&#13;The reconciliation of these rates is as follows at September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 46%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Federal Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;34.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;34.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;State tax rate, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;6.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3.92&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;State tax rate change&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(3.91)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(22.00)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Other adjustments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(3.39)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(0.03)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Permanent differences (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;25.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;44.90&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(58.63)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(60.79)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Effective tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td rowspan="3"&gt;&lt;font style="font-size: 8pt"&gt;(1) Primarily due to the approximate $11 million and $14 million gain on derivative instruments from the change in fair value of the Company&amp;#8217;s warrant liabilities during the years ended September 30, 2017 and 2016, respectively.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applies the provisions of ASC 740,&#13;&lt;i&gt;&amp;#8220;Accounting for Uncertainty in Income Taxes,&amp;#8221;&lt;/i&gt; which requires financial statement benefits to be recognized for&#13;positions taken for tax return purposes when it is more likely than not that the position will be sustained. The Company has elected&#13;to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense.&#13;The Company has generated federal net operating losses in tax years ending September 30, 1998 through 2016. These years remain&#13;open to examination by the major domestic taxing jurisdictions to which the Company is subject.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognized the following expenses&#13;for options issued or vested and restricted stock awarded during the year:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Year Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; width: 26%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 36%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 38%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1,380,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2,113,433&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$ 232,847&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$ 751,651&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock compensation expenses were recorded as&#13;general and administrative expense. During the years ended September 30, 2017 and 2016, non-employee stock compensation excluded&#13;approximately $45,000 and $48,000, respectively, for future services to be performed (Note 12).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended September 30, 2017 and&#13;2016 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the&#13;following assumptions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 45%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 29%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;88.54 &amp;#8211; 90.67%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;75.58 &amp;#8211; 80.9%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2.18 &amp;#8211; 2.29%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;0.71 &amp;#8211; 1.56%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected life of options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;9.69 &amp;#8211; 10 Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3.0 &amp;#8211; 9.69 Years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Non-Qualified Stock Option Plans&lt;/u&gt; &amp;#8211;&#13;At September 30, 2017, the Company has collectively authorized the issuance of 1,187,200 shares of common stock under its Non-Qualified&#13;Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms&#13;of the options were determined by the Company&amp;#8217;s Compensation Committee, which administers the plans. The Company&amp;#8217;s&#13;employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option&#13;Plans.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Incentive Stock Option Plans&lt;/u&gt; &amp;#8211;&#13;At September 30, 2017, the Company had collectively authorized the issuance of 138,400 shares of common stock under its Incentive&#13;Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms&#13;of the options were determined by the Company&amp;#8217;s Compensation Committee, which administers the plans. Only the Company&amp;#8217;s&#13;employees are eligible to be granted options under the Incentive Stock Option Plans.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Activity in the Company&amp;#8217;s Non-Qualified&#13;and Incentive Stock Option Plans for the two years ended September 30, 2017 is summarized as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;Non-Qualified and Incentive Stock Option&#13;Plans&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Ave&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Ave&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Term (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Term (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at October 1, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;301,511&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$67.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;181,102&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$78.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;56,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$31.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Granted (a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;48,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$21.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$145.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$145.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;343,575&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$59.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;232,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$66.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;63,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$18.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Granted (b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;932,825&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,795&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$9.46&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$88.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$88.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Outstanding at September 30, 2017&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,239,844&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$16.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;275,982&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$53.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;4.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="4" style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Includes 16,400 stock options granted to consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 35px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 35px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;(b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Includes 20,000 stock options granted to consultants&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the status of the Company&amp;#8217;s&#13;non-vested options for the two years ended September 30, 2017 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested at October 1, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;120,409&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 43.09&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(56,069)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;48,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2,240)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;110,644&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 36.96&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(63,812)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;932,825&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(15,795)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;963,862&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 4.91&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Incentive Stock Bonus Plan&lt;/u&gt; &amp;#8211; Up&#13;to 640,000 shares are authorized under the 2014 Incentive Stock Bonus Plan. The shares will only be earned upon the achievement&#13;of certain milestones leading to the commercialization of the Company&amp;#8217;s Multikine technology, or specified increases in the&#13;market price of the Company&amp;#8217;s stock. If the performance or market criteria are not met as specified in the Incentive Stock&#13;Bonus Plan, all or a portion of the awarded shares will be forfeited. The fair value of the shares on the grant date was calculated&#13;using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte&#13;Carlo simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of shares issued&#13;that remain outstanding as of September 30, 2017 was approximately $8.6 million. The total value of the shares, if earned, is being&#13;expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless&#13;of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service period is not&#13;rendered. During the years ended September 30, 2017 and 2016, the Company recorded expense relating to the issuance of restricted&#13;stock pursuant to the plan of approximately $633,000 and $634,000, respectively. At September 30, 2017, the Company has unrecognized&#13;compensation expense of approximately $2.5 million which is expected to be recognized over a weighted average period of four years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the status of the Company&amp;#8217;s&#13;restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2017 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 47%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Weighted&amp;#160;Average&amp;#160;Grant&amp;#160;Date&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(136,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;468,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Stock Bonus Plans&lt;/u&gt; &amp;#8211; At September&#13;30, 2017, the Company was authorized to issue up to 383,760 shares of common stock under its Stock Bonus Plans. All employees,&#13;directors, officers, consultants, and advisors are eligible to be granted shares. During the year ended September 30, 2017, 79,941&#13;shares were issued to the Company&amp;#8217;s 401(k) plan for a cost of approximately $151,000. During the year ended September 30,&#13;2016, 16,340 shares were issued to the Company&amp;#8217;s 401(k) plan for a cost of approximately $162,000. As of September 30, 2017,&#13;the Company has issued a total of 206,390 shares of common stock from the Stock Bonus Plans.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Stock Compensation Plans&lt;/u&gt; &amp;#8211; At September&#13;30, 2017, 134,000 shares were authorized for use in the Company&amp;#8217;s Stock Compensation Plans. During the years ended September&#13;30, 2017, and 2016, 23,202 and 18,593 shares, respectively, were issued from the Stock Compensation Plans to consultants for payment&#13;of services at a cost of approximately $60,000 and $234,000, respectively. During the year ended September 30, 2017 and 2016, 13,000&#13;and 3,837 shares, respectively, were issued to employees from the Stock Compensation Plans as part of their compensation at a cost&#13;of approximately $24,000 and $45,000, respectively. As of September 30, 2017, the Company has issued 115,590 shares of common stock&#13;from the Stock Compensation Plans.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains a defined contribution&#13;retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security&#13;Act of 1974, as amended, and covering substantially all Company employees. Each participant&amp;#8217;s contribution is matched by&#13;the Company with shares of common stock that have a value equal to 100% of the participant&amp;#8217;s contribution, not to exceed&#13;the lesser of $10,000 or 6% of the participant&amp;#8217;s total compensation. The Company&amp;#8217;s contribution of common stock is&#13;valued each quarter based upon the closing bid price of the Company&amp;#8217;s common stock. Total expense, including plan maintenance,&#13;for the years ended September 30, 2017 and 2016, in connection with this Plan was approximately $163,000 and $168,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Clinical Research Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2013, the Company entered into an agreement&#13;with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will&#13;reimburse Aptiv for costs incurred. The agreement required the Company to make $600,000 in advance payments which are being credited&#13;against future invoices in $150,000 annual increments through December 2017. As of September 30, 2017, the total balance advanced&#13;is $150,000 and is classified as a current asset.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2013, the Company entered into a co-development&#13;and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the study in&#13;the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments,&#13;up to a specific maximum amount. In October 2015, the Company entered into a second &lt;font style="color: #292929"&gt;co-development&#13;and revenue sharing agreement with Ergomed&lt;/font&gt; for an additional $2 million, for a total of $12 million. The Company accounted&#13;for the co-development and revenue sharing agreement in accordance with ASC 808 &amp;#8220;Collaborative Arrangements&amp;#8221;. The Company&#13;determined the payments to Ergomed are within the scope of ASC 730 &amp;#8220;Research and Development.&amp;#8221; Therefore, the Company&#13;records the discount on the clinical services as a credit to research and development expense on its Statements of Operations.&#13;Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development&#13;expenses of approximately $25.0 million related to Ergomed&amp;#8217;s services. This amount is net of Ergomed&amp;#8217;s discount of&#13;approximately $8.4 million. During the years ended September 30, 2017 and 2016, the Company recorded, approximately $5.8 million&#13;and $7.2 million, respectively, as research and development expense related to Ergomed&amp;#8217;s services. These amounts were net&#13;of Ergomed&amp;#8217;s discount of approximately $2.1 million in each of the periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2013, the Company entered into two&#13;co-development and profit sharing agreements with Ergomed.&amp;#160; One agreement supports the Phase 1 study being conducted at UCSF&#13;for the development of Multikine as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women.&amp;#160; The other&#13;agreement focuses on the development of Multikine as a potential treatment for cervical dysplasia in HIV/HPV co-infected women.&#13;Ergomed will assume up to $3 million in clinical and regulatory costs for each study.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is currently involved in a pending&#13;arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet&#13;AG). The Company initiated the proceedings against inVentiv Health Clinical, LLC, or inVentiv, the former third-party CRO, and&#13;is seeking payment for damages related to inVentiv&amp;#8217;s prior involvement in the ongoing Phase 3 clinical trial of Multikine.&#13;The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract,&#13;(ii) fraud in the inducement, and (iii) common law fraud. Currently, the Company is seeking at least $50 million in damages in&#13;its amended statement of claim.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In an amended statement of claim, the Company&#13;asserted the claims set forth above as well as an additional claim for professional malpractice.&amp;#160;&amp;#160;The arbitrator subsequently&#13;granted inVentiv&amp;#8217;s motion to dismiss the professional malpractice claim based on the &amp;#8220;economic loss doctrine&amp;#8221;&#13;which, under New Jersey law, is a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim&#13;alongside a claim for breach of contract.&amp;#160;&amp;#160;The arbitrator denied the remainder of inVentiv&amp;#8217;s motion, which had&#13;sought to dismiss certain other aspects of the amended statement of claim.&amp;#160;&amp;#160;In particular, the arbitrator rejected inVentiv&amp;#8217;s&#13;argument that several aspects of the amended statement of claim were beyond the arbitrator&amp;#8217;s jurisdiction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the pending arbitration proceedings,&#13;inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in damages for&#13;services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the Company&amp;#8217;s&#13;alleged use of inVentiv&amp;#8217;s name in connection with publications and promotions in violation of the parties&amp;#8217; contract;&#13;(iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits&#13;allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking&#13;at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv&amp;#8217;s counterclaims&#13;are meritless. However, if inVentiv successfully asserts any of its counterclaims, such an adverse determination could have a material&#13;adverse effect on the Company&amp;#8217;s business, results, financial condition and liquidity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2015 the Company signed an arbitration&#13;funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation&#13;expenses. Pursuant to the agreement, an affiliate of Lake Whillans provides the Company with funding for litigation expenses to&#13;support its arbitration claims against inVentiv. The funding is available to the Company to fund the expenses of the ongoing arbitration&#13;and will only be repaid when the Company receives proceeds from the arbitration. During the year ended September 30, 2016, the&#13;Company recognized a gain of approximately $1.1 million on the derecognition of legal fees to record the transfer of the liability&#13;that existed prior to the execution of the financing agreement from the Company to Lake Whillans. The gain on derecognition of&#13;legal fees is recorded as a reduction of general and administration expenses on the Statement of Operations. All related legal&#13;fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to cap&#13;its fees and expenses for the arbitration at $5 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The arbitration has been going on longer than&#13;expected, but it is finally nearing its end. The hearing (the &amp;#8220;trial&amp;#8221;) started on September 26, 2016. The last witness&#13;in the arbitration hearing testified on Wednesday, November 8, 2017, and no further witnesses or testimony are expected. With that&#13;final witness, the testimony phase of the arbitration concluded. All that remains at the trial level are closing statements and&#13;post-trial submissions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Lease Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases a manufacturing facility&#13;near Baltimore, Maryland under an operating lease (the San Tomas lease). The building was remodeled in accordance with the Company&amp;#8217;s&#13;specifications so that it can be used by the Company to manufacture Multikine for the Company&amp;#8217;s Phase 3 clinical trial and&#13;sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each&#13;year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses,&#13;repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase&#13;the building at the end of the 20-year lease. The Company contributed approximately $9.3 million towards the tenant-directed improvements,&#13;of which $3.2 million is being refunded during years six through twenty through reduced rental payments. The landlord paid approximately&#13;$11.9 million towards the purchase of the building, land and the tenant-directed improvements. The asset was placed in service&#13;in October 2008.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Because the terms of the original lease agreements&#13;required the Company to be responsible for cost overruns, if there had been any, but of which there were none, the Company was&#13;deemed to be the owner of the building for accounting purposes under the build-to-suit guidance in ASC 840-40-55. In addition to&#13;the tenant improvements the Company incurred and capitalized on its balance sheet, the Company recorded an asset for tenant-directed&#13;improvements and for the costs paid by the lessor to purchase the building and to perform improvements, as well as a corresponding&#13;liability for the landlord costs. Upon completion of the improvements, the Company did not meet the &amp;#8220;sale-leaseback&amp;#8221;&#13;criteria under ASC 840-40-25, &lt;i&gt;Accounting for Leases, Sale-Leaseback Transactions,&lt;/i&gt; and therefore, treated the lease as a&#13;financing obligation. Therefore, the asset and corresponding liability were not be derecognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2017 and 2016, the leased&#13;building asset has a net book value of approximately $16.6 million and $17.1 million and the landlord liability as a balance of&#13;$13.2 million and $13.0 million. The leased asset is being depreciated using a straight line method of the 20 year lease term to&#13;a residual value. The landlord liability is being amortized over the 20 years using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company was required to deposit the equivalent&#13;of one year of base rent in accordance with the San Tomas lease. When the Company meets the minimum cash balance required by the&#13;lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets on September&#13;30, 2017 and 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Approximate future minimum lease payments under&#13;the San Tomas lease as of September 30, 2017 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Years ending September 30,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 64%; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 36%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 1,747,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,808,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,872,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,937,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,004,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,758,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total future minimum lease obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;23,126,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less: imputed interest on financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(9,914,000)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net present value of lease financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 13,212,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company subleases a portion of its rental&#13;space on a month to month term lease, which requires a 30 day notice for termination. The sublease rent for the years ended September&#13;30, 2017 and 2016 was approximately $69,000 and $67,000, respectively, and is recorded in grant income and other in the statements&#13;of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases its research and development&#13;laboratory under a 60 month lease which expires February 28, 2017. In September 2016, the lease was extended through February 28,&#13;2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight&#13;line basis over the full 60 month term of the lease at the rate of approximately $13,000 per month. As of September 30, 2017 and&#13;2016, the Company has recorded a deferred rent liability of approximately $5,000 and $2,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases its office headquarters under&#13;a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing&#13;the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately $8,000 per&#13;month. As of September 30, 2017 and 2016, the Company has recorded a deferred rent liability of approximately $18,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases office equipment under a&#13;capital lease arrangement. The terms of the capital lease is 60 months and expires on October 31, 2021. The monthly lease payment&#13;is $505. The lease bears interest at approximately 6.25% per annum. The Company&amp;#8217;s previous equipment lease expired on September&#13;30, 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Approximate future minimum annual lease payments&#13;due under non-cancelable operating leases, excluding the San Tomas lease, for the years ending after September 30, 2017 are as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font-size: 8pt"&gt;Years ending September 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 48%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 251,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;258,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;238,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;163,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;69,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total future minimum lease obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 979,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rent expense, for the years ended September&#13;30, 2017 and 2016, excluding the rent paid on the San Tomas lease, was approximately $245,000 and $234,000, respectively. The Company&amp;#8217;s&#13;three leases expire between June 2020 and October 2028.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Vendor Obligations&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Further, the Company has contingent obligations&#13;with other vendors for work that will be completed in relation to the Phase 3 trial. The timing of these obligations cannot be&#13;determined at this time. CEL-SCI estimates it will incur additional expenses of approximately $13.0 million for the remainder of&#13;the Phase 3 clinical trial. It should be noted that this estimate is based only on the information currently available in CEL-SCI&amp;#8217;s&#13;contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other&#13;related costs, e.g. the manufacturing of the drug.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2017, the Company issued convertible&#13;notes (Series NN Notes) in the aggregate principal amount of $1.2 million to 12 individual investors. A trust in which Geert Kersten,&#13;the Company&amp;#8217;s Chief Executive Officer, holds a beneficial interest participated in the offering and purchased a note in the&#13;principal amount of $250,000. Patricia B. Prichep, the Company&amp;#8217;s Senior Vice President of Operations, participated in the&#13;offering and purchased a note in the principal amount of $25,000. The terms of the trust&amp;#8217;s Note and Ms. Prichep&amp;#8217;s Note&#13;were identical to the other participants. The number of shares of the Company&amp;#8217;s common stock issued upon conversion will&#13;be determined by dividing the principal amount to be converted by $2.29, which would result in the issuance of 109,170 shares to&#13;the trust and 10,917 shares to Ms. Prichep upon conversion. Along with the other purchasers of the convertible notes, the trust&#13;and Ms. Prichep also received Series NN warrants to purchase up to 109,170 and 10,917 shares, respectively, of the Company&amp;#8217;s&#13;common stock. The Series NN warrants are exercisable at a fixed price of $2.52 per share and expire on July 24, 2022. Shares issuable&#13;upon the exercise of the notes and warrants were restricted securities unless registered. The shares were registered effective&#13;September 1, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 22, 2017, CEL-SCI issued convertible&#13;notes (Series MM Notes) in the aggregate principal amount of $1.5 million to six individual investors. Geert Kersten, the Company&amp;#8217;s&#13;Chief Executive Officer, participated in the offering and purchased notes in the principal amount of $250,000. The terms of Mr.&#13;Kersten&amp;#8217;s Note were identical to the other participants. The number of shares of the Company&amp;#8217;s common stock issued&#13;upon conversion will be determined by dividing the principal amount to be converted by $1.69, which would result in the issuance&#13;of 147,929 shares to Mr. Kersten upon conversion. Along with the other purchasers of the convertible notes, Mr. Kersten also received&#13;Series MM warrants to purchase up to 147,929 shares of the Company&amp;#8217;s common stock. The Series MM warrants are exercisable&#13;at a fixed price of $1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the notes and warrants were&#13;restricted securities unless registered. The shares were registered effective August 8, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;No interest payments were made to officers during&#13;the year ended September 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective August 31, 2016, the Company issued&#13;Maximilian de Clara, the Company&amp;#8217;s then President and a director, through the de Clara Trust, 26,000 shares of restricted&#13;stock in payment of past services. The de Clara Trust was established by Maximilian de Clara, the Company&amp;#8217;s former President&#13;and a director. The shares were issued as follows; 13,000 shares upon his resignation on August 31, 2016 and 13,000 on August 31,&#13;2017. The total value of the shares issued was approximately $176,000, of which approximately $24,000 was expensed during the year&#13;ended September 30, 2017 and $152,000 was expensed during the year ended September 30, 2016. On September 30, 2016, the fair value&#13;accrued for unissued shares was approximately $101,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 13, 2016, the de Clara Trust demanded&#13;payment on a note payable, of which the balance, including accrued and unpaid interest, was approximately $1.1 million. The Company&amp;#8217;s&#13;Chief Executive Officer, Geert Kersten, is a beneficiary of the de Clara Trust. When the de Clara Trust demanded payment on the&#13;note, the Company sold 120,000 shares of its common stock and 120,000 Series X warrants to the de Clara Trust for approximately&#13;$1.1 million. Each warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $9.25 per&#13;share at any time on or before January 13, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;No interest payments were made to Mr. de Clara&#13;or the de Clara Trust during the year ended September 30, 2017. During the year ended September 30, 2016, the Company paid approximately&#13;$43,000 interest expense to Mr. de Clara.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <CVM:StockholdersEquityTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 22, 2017, the Company entered into&#13;a securities purchase agreement with institutional investors whereby it sold 1,750,000 shares of its common stock for net proceeds&#13;of approximately $3.2 million, or $2.00 per share, in a registered direct offering. In a concurrent private placement, the Company&#13;also issued to the purchasers of the Company&amp;#8217;s common stock Series PP warrants to purchase 1,750,000 shares of common stock.&#13;In addition, the Company issued 87,500 Series QQ warrants to the placement agent as part of its compensation. See Note 4 for more&#13;information with respect to the Series PP &amp;#38; QQ warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 15, 2017, the Company entered into&#13;a Securities Purchase Agreement with Ergomed plc, the Company&amp;#8217;s Clinical Research Provider, to facilitate the payment of&#13;some of the accounts payable balances due Ergomed. Under the Agreement, the Company issued Ergomed 480,000 shares, with a fair&#13;market value of approximately $1.3 million, as a forbearance fee in exchange for Ergomed&amp;#8217;s agreement to provisionally forbear&#13;collection of the payables. In an amount equal to the net proceeds from the resales of the shares issued to Ergomed. The Company&#13;recorded the full amount of the expense upon issuance and will credit any amounts realized through reduction of the payables. During&#13;the quarter ended September 30, 2017, 64,792 shares were resold and the Company reduced the expense by approximately $107,000.&#13;The net expense of $1.2 million recorded during the quarter is included in interest expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 26, 2017, the Company entered into a&#13;securities purchase agreement with an investor whereby it sold 100,000 shares of its common stock for gross proceeds of $229,000,&#13;or $2.29 per share, in a registered offering. In a concurrent private placement, the Company also issued to the purchaser of that&#13;common stock Series OO warrants to purchase 60,000 shares of the Company&amp;#8217;s common stock. See Note 4 for more information&#13;with respect to the Series OO warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 30, 2017, the Company entered into&#13;a securities purchase agreement with an institutional investor whereby it sold 527,960 shares of its common stock for net proceeds&#13;of approximately $1.4 million, or $2.875 per share, in a registered direct offering. In a concurrent private placement, the Company&#13;also issued to the purchaser of the Company&amp;#8217;s common stock, Series KK warrants to purchase 395,970 shares of common stock.&#13;In addition, the Company issued 26,398 Series LL warrants to the Placement Agent as part of its compensation. See Note 4 for more&#13;information with respect to the Series KK and LL warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 14, 2017, the Company sold 600,000&#13;registered shares of common stock and 600,000 Series II warrants to purchase 600,000 unregistered shares of common stock at combined&#13;offering price of $2.50 per share.&amp;#160; In addition, the Company issued 30,000 Series JJ warrants to purchase 30,000 shares of&#13;unregistered common stock to the placement agent. The&amp;#160;net&amp;#160;proceeds from this offering&amp;#160;were&amp;#160;approximately $1.3&amp;#160;million.&#13;See Note 4 for more information with respect to the Series II and JJ warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 23, 2017, the Company sold 400,000&#13;registered shares of common stock and 400,000 Series GG warrants to purchase 400,000 unregistered shares of common stock at a combined&#13;price of $2.50 per share.&amp;#160; In addition, the Company issued to the placement agent, 20,000 Series HH warrants to purchase 20,000&#13;shares of unregistered common stock. The&amp;#160;net&amp;#160;proceeds from this offering&amp;#160;were&amp;#160;approximately $0.8&amp;#160;million.&#13;See Note 4 for more information with respect to the Series GG and HH warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 8, 2016, the Company sold 1,360,960&#13;shares of common stock and warrants to purchase common stock at a price of $3.13 in a public offering. The warrants consist of&#13;680,480 Series CC warrants to purchase 680,480 shares of common stock, 1,360,960 Series DD warrants to purchase 1,360,960 shares&#13;of common stock and 1,360,960 Series EE warrants to purchase 1,360,960 shares of common stock. In addition, the Company issued&#13;68,048 Series FF warrants to purchase 68,048 shares of common stock to the placement agent. Net&amp;#160;proceeds from this offering&amp;#160;were&amp;#160;approximately&#13;$3.7&amp;#160;million. See Note 4 for more information with respect to the Series CC, DD, EE and FF warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 26, 2016, the Company closed a registered&#13;direct offering of&amp;#160;400,000 shares of common stock and Series AA warrants to purchase up to 200,000 shares of common stock.&#13;Each share of common stock was sold together with a Series AA warrant to purchase one-half of a share of common stock for the combined&#13;purchase price of $13.75. The Company also issued 16,000 Series BB warrants to the placement agent as part of its compensation.&#13;The Company received proceeds from the sale of Series AA and Series BB shares and warrants of approximately $4.5 million, net of&#13;placement agent&amp;#8217;s commissions and offering expenses. See Note 4 for more information with respect to the Series AA and BB&#13;warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 23, 2016, the Company closed a registered&#13;direct offering of 400,000 shares of common stock and 264,000 Series Z warrants to purchase shares of common stock. The common&#13;stock and warrants were sold at a combined per unit price of $13.75 for net proceeds of approximately $4.6 million, net of placement&#13;agent&amp;#8217;s commissions and offering expenses. The Company also issued 20,000 Series ZZ warrants to the placement agent as part&#13;of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23, 2016 and on or before May 18,&#13;2021 at a price of $13.75 per share. See Note 4 for more information with respect to the Series Z and ZZ warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 28, 2015, the Company closed an underwritten&#13;public offering of 688,930 shares of common stock and 688,930 Series W warrants to purchase shares of common stock. The common&#13;stock and warrants were sold at a combined price of $16.75 for net proceeds of approximately $10.5 million, net of underwriting&#13;commissions and offering expenses. See Note 4 for more information with respect to the Series W warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</CVM:StockholdersEquityTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with the provisions of ASC 820,&#13;&amp;#8220;&lt;i&gt;Fair Value Measurements&lt;/i&gt;,&amp;#8221; the Company determines fair value as the price that would be received to sell an&#13;asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company&#13;generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts&#13;to a single present amount. The measurement is based on the value indicated by current market expectations about those future amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC 820 establishes a fair value hierarchy that&#13;prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets&#13;and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies&#13;fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;o&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 1 &amp;#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;o&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 2 &amp;#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;o&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 3 &amp;#8211; Unobservable inputs that reflect management&amp;#8217;s assumptions&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For disclosure purposes, assets and liabilities&#13;are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the&#13;overall fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement&#13;requires judgment and may affect the placement within the fair value hierarchy levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below sets forth the liabilities measured&#13;at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Derivative Instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,020,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,053,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below sets forth the liabilities measured&#13;at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Derivative Instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,111,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,394,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following sets forth the reconciliation&#13;of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September&#13;30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,323,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;Issuances&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,665,683&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,722,073&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; Net realized and unrealized derivative gain&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(7,928,627&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(9,761,532&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,029,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair values of the Company&amp;#8217;s derivative&#13;instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical&#13;price and volatility of the Company&amp;#8217;s stock as well as U.S. Treasury Bill rates are observable in active markets. At September&#13;30, 2017, the Company&amp;#8217;s Level 3 derivative instruments have a weighted average fair value of $0.29 per share and a weighted&#13;average exercise price of $5.41 per share. Fair values were determined using a weighted average risk free interest rate of 1.85%&#13;and 80% volatility. The instruments have a weighted average time to maturity of 4.55 years. At September 30, 2016, the Company&amp;#8217;s&#13;Level 3 derivative instruments have a weighted average fair value of $2.50 per share and a weighted average exercise price of $21.50&#13;per share. Fair values were determined using a weighted average risk free interest rate of 1.04% and 75% volatility.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share is computed by dividing&#13;net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company&amp;#8217;s&#13;potentially dilutive shares, which include outstanding common stock options, common stock warrants, restricted stock and shares&#13;issuable on convertible debt, have not been included in the computation of diluted net loss per share for all periods presented,&#13;as the result would be anti-dilutive. For the years presented, the gain on derivative instruments is not included in net loss available&#13;to common shareholders for purposes of computing dilutive loss per share because its effect is anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides a reconciliation&#13;of the numerators and denominators of the basic and diluted per-share computations:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Year Ended September 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;LPS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 8pt"&gt;Basic loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(14,427,055&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,891,843&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less: gain on derivatives(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(677,287&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Dilutive loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(15,104,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,902,647&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Includes series GG and II warrants&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Year Ended September 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;LPS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Basic and dilutive loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(11,512,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,866,204&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The gain on derivative instruments that contain&#13;exercise prices lower than the average market share price during the period is excluded from the numerator and the related shares&#13;are excluded from the denominator in calculating diluted loss per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with the contingently issuable&#13;shares guidance of FASB ASC Topic 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, the calculation of diluted net loss per share excludes the following&#13;dilutive securities because their inclusion would have been anti-dilutive as of September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Options and Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,538,130&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,675,281&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Convertible Debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,166,106&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested Restricted Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,308,236&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,279,281&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 855, &amp;#8220;&lt;i&gt;Subsequent&#13;Events&lt;/i&gt;&amp;#8221;, the Company has reviewed subsequent events through the date of the filing.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 19, 2017 the Company received subscription&#13;agreements for the purchase of 1,289,478 shares of CEL-SCI common stock at a price of $1.90 in the principal amount of $2,450,000&#13;from 19 investors. The common stock will be restricted unless registered. The purchasers of the common stock also received warrants&#13;which entitle the purchasers to acquire up to 1,289,478 shares of the Company&amp;#8217;s common stock. The warrants are exercisable&#13;at a fixed price of $2.09 per share, will not be exercisable for 6 months and one day and will expire on December 18, 2022. Shares&#13;issuable upon the exercise of the warrants will be restricted securities unless registered.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 18, 2017 CEL-SCI Corporation appointed&#13;Robert Watson to its Board of Directors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 2, 2017, holders of convertible&#13;notes in the principal amount of $1.1 million sold in June 2017 and holders of convertible notes in the principal amount of $1.2&#13;million sold in July 2017 agreed to extend the maturity date of these notes to September 21, 2018. In consideration for the extension&#13;of the maturity date of the convertible notes, the Company issued a total of 716,400 Series RR warrants to the convertible note&#13;holders that agreed to the extension. Each Series RR warrant entitles the holder to purchase one share of the Company&amp;#8217;s common&#13;stock. The Series RR warrants may be exercised at any time on or before October 30, 2022 at an exercise price of $1.65 per share.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of the statements of cash flows,&#13;cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers&#13;all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses are payments for future services&#13;to be rendered and are expensed over the time period for which the service is rendered. Prepaid expenses may also include payment&#13;for goods to be received within one year of the payment date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventory consists of manufacturing production&#13;advances and bulk purchases of laboratory supplies to be consumed in the manufacturing of the Company&amp;#8217;s product for clinical&#13;studies. Inventories are stated at the lower of cost or market, where cost is determined using the first-in, first out method&#13;applied on a consistent basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <CVM:Deposits2 contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;/i&gt;The deposits are required by&#13;the lease agreement for the manufacturing facility and by the clinical research organization (CRO) agreements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</CVM:Deposits2>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The leased manufacturing facility is recorded&#13;at total project costs incurred and is depreciated over the 20-year useful life of the building. Research and office equipment&#13;is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold&#13;improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and&#13;maintenance which do not extend the life of the asset are expensed when incurred. The plant, property and equipment are reviewed&#13;on a quarterly basis to assess impairment, if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Patent expenditures are capitalized and amortized&#13;using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the&#13;event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset&#13;value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected&#13;to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment&#13;loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Leases are categorized as either operating&#13;or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset&#13;and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease&#13;obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset and liability for&#13;the estimated construction costs incurred to the extent that it is involved in the construction of structural improvements or&#13;takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit leases, the Company&#13;assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance. If a lease does&#13;not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on the Company's&#13;balance sheet. See Note 11.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain of the Company&amp;#8217;s operating leases&#13;provide for minimum annual payments that adjust over the life of the lease.&amp;#160; The aggregate minimum annual payments are expensed&#13;on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when&#13;the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed&#13;the straight-line rent expense.&amp;#160; For tenant improvement allowances and rent holidays, the Company records a deferred rent&#13;liability and amortizes the deferred rent over the lease term as a reduction to rent expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into financing arrangements&#13;that consist of freestanding derivative instruments that contain embedded derivative features, specifically, the settlement provisions&#13;in the warrant agreements preclude the warrants from being treated as equity. The Company accounts for these arrangements in accordance&#13;with Accounting Standards Codification (ASC) 815, &amp;#8220;Accounting for Derivative Instruments and Hedging Activities&amp;#8221;.&#13;In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid&#13;instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses&#13;recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company&#13;determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation&#13;models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured&#13;at fair value at the end of each reporting period as long as they are outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DerivativesReportingOfDerivativeActivity>
    <CVM:GrantIncomePolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company's grant arrangements are handled&#13;on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</CVM:GrantIncomePolicyTextBlock>
    <CVM:ResearchAndDevelopmentGrantRevenues contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenditures are expensed&#13;as incurred. Management accrues CRO expenses and clinical trial study expenses based on services performed and relies on the CROs&#13;to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to&#13;revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the&#13;facts that give rise to the revision become known.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</CVM:ResearchAndDevelopmentGrantRevenues>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company calculates net loss per common&#13;share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (ASC 260). Basic and diluted net loss per common share was determined&#13;by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the&#13;period. The Company&amp;#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units,&#13;convertible preferred stock and common stock warrants, have not been included in the computation of diluted net loss per share&#13;for all periods as the result would be anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments, which potentially subject&#13;the Company to concentrations of credit risk, consist of cash and cash equivalents.&amp;#160; The Company maintains its cash and cash&#13;equivalents with high quality financial institutions.&amp;#160; At times, these accounts may exceed federally insured limits.&amp;#160;&#13;The Company has not experienced any losses in such bank accounts.&amp;#160; The Company believes it is not exposed to significant&#13;credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured&amp;#160;up to $250,000&#13;at September 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the asset and liability method&#13;of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future&#13;tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities&#13;and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using&#13;enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered&#13;or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that&#13;includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is&#13;more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September&#13;30, 2017 and 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements&#13;and the accompanying disclosures. These estimates are based on management&amp;#8217;s best knowledge of current events and actions&#13;the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals,&#13;stock options, useful lives for depreciation and amortization of long-lived assets, deferred tax assets and the related valuation&#13;allowance, and the valuation of derivative liabilities.&lt;font style="color: #444444"&gt;&amp;#160;&lt;/font&gt;Actual results could differ from&#13;estimates, although management does not generally believe such differences would materially affect the financial statements in&#13;any given year. However, in regard to the valuation of derivative liabilities determined using various valuation techniques including&#13;the Black-Scholes and binomial pricing methodologies, significant fluctuations may materially affect the financial statements&#13;in a given year. The Company considers such valuations to be significant estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates financial assets and&#13;liabilities subject to fair value measurements in accordance with a fair value hierarchy to prioritize the inputs used to measure&#13;fair value. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of input significant&#13;to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. See Note 14 for the definition of levels&#13;and the classification of assets and liabilities in those levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation cost for all stock-based awards&#13;is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &amp;#8220;Compensation &amp;#8211; Stock&#13;Compensation.&amp;#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes&#13;model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost&#13;is recognized on the straight line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity instruments issued to non-employees are&#13;accounted for in accordance with ASC 505-50, &amp;#8220;Equity-Based Payments to Non-Employees.&amp;#8221; Accordingly, compensation is&#13;recognized when goods or services are received and may be measured using the Black-Scholes valuation model, based on the type of&#13;award. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the&#13;measurement date and the expected life of the options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has Incentive Stock Option Plans,&#13;Non-Qualified Stock Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases,&#13;these Plans are collectively referred to as the &amp;#8220;Plans.&amp;#8221; All Plans have been approved by the Company&amp;#8217;s stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s stock options are not transferable,&#13;and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on&#13;the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of&#13;daily closing prices of the Company&amp;#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at&#13;date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and&#13;employee termination within the valuation model. The expected term of options represents the period of time that options granted&#13;are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions&#13;used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in&#13;the future from that recorded in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Vesting of restricted stock granted under the&#13;Incentive Stock Bonus Plan is subject to service, performance or market conditions and meets the classification of equity awards.&#13;These awards were measured at fair market value on the grant-dates for issuances where the attainment of performance criteria is&#13;probable and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance&#13;criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <CVM:DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following chart represents the warrants&#13;and non-employee options outstanding at September 30, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issuable upon Exercise of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Expiration Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 12%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Refer-ence&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4/17/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$43.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/17/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,360,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$4.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/1/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,360,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$4.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/1/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/18/2008&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;85,339&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/18/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/11/13- 10/24/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,037,120&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/11/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/28/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;810,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5/28/2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/28/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;688,930&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$16.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/28/2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series X&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1/13/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$9.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1/13/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Y&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/15/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/15/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5/18/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;11/23/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;68,048&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/1/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;680,480&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/23/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/16/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/14/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/8/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series LL&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4/30/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,398&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;4/30/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series MM&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6/22/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;893,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;6/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series NN&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7/24/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;539,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;7/24/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series OO&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7/31/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;7/31/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series QQ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;87,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/23/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;400,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/23/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/14/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;600,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;9/14/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/3/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;395,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;11/3/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series PP&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/28/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,750,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/28/2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/28/12- 7/28/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.18- $70.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/27/17- 7/27/27&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following chart represents the warrants&#13;and non-employee options outstanding at September 30, 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 20%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issuable upon Exercise of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Expiration Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Refer-ence&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/18/08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;113,785&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/18/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series R&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/6/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;105,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$100.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/6/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series U&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4/17/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$43.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/17/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/11/13 -10/24/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,037,120&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/11/18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;810,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/28/15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;688,930&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$16.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/28/20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series X&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1/13/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$9.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1/13/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series Y&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/15/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/15/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/18/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11/23/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/22/22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/22/21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Series P&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/10/12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;23,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$112.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/6/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/2/11- 7/1/16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$9.25- $87.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/27/16- 6/30/19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</CVM:DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below presents the warrant liabilities&#13;and their respective balances at September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,111,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series U warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;72,912&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,620,253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;83,754&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,799,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;77,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;970,604&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,753&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;70,609&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;65,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;763,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,322&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;58,588&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;394,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,154&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;342,173&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;511,636&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;345,720&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series LL warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,481&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,053,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,394,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;The table below presents the gains on the warrant liabilities for&#13;the years ended September 30:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,078,588&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,252,193&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series U warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;44,552&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,547,341&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,658,228&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,716,104&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,260,913&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;893,388&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;997,226&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;65,856&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;75,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;698,574&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;672,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;54,266&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;53,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;666,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;437,780&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;685,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;73,828&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;272,464&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,616&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;404,823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Series LL warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;352,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Net gain on warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11,007,215&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,013,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 50%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 23%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Leased manufacturing facility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$ 21,183,756&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;$ 21,183,756&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Research equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,169,158&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;3,158,633&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;124,369&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;133,499&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;131,910&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;131,910&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;24,609,193&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;24,607,798&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(7,815,973)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(7,256,962)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net plant, property and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 16,793,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 17,350,836&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 48%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 1,535,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 1,528,610&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accumulated amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,311,920)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(1,272,063)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Patents, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 223,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 256,547&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Years ending September 30,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 60%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 37,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;35,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;32,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;28,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;25,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;66,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 223,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt; &lt;font style="font-size: 8pt"&gt;70,752,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt; &lt;font style="font-size: 8pt"&gt;64,366,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;R&amp;#38;D credit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,221,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,221,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,292,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;6,379,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Capitalized R&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;21,160,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;18,508,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Vacation and other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;121,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;179,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;99,546,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;90,653,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Fixed assets and intangibles&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(523,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(49,000)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total deferred tax liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(523,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(49,000)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;99,023,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;90,604,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(99,023,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(90,604,000)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 46%"&gt;&lt;font style="font-size: 8pt"&gt;Ending Balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; width: 14%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; width: 14%"&gt; &lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; width: 13%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right; width: 13%"&gt; &lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 46%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Federal Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;34.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;34.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;State tax rate, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;6.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3.92&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;State tax rate change&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(3.91)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(22.00)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Other adjustments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(3.39)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(0.03)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Permanent differences (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;25.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;44.90&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(58.63)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(60.79)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Effective tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <CVM:ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Year Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; width: 26%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 36%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 38%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1,380,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2,113,433&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$ 232,847&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$ 751,651&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CVM:ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 45%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 29%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;88.54 &amp;#8211; 90.67%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;75.58 &amp;#8211; 80.9%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2.18 &amp;#8211; 2.29%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;0.71 &amp;#8211; 1.56%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected life of options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;9.69 &amp;#8211; 10 Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3.0 &amp;#8211; 9.69 Years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 18%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Ave&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Ave&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;Average&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Contractual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&amp;#160;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Term (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Term (Years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at October 1, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;301,511&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$67.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;181,102&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$78.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;56,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$31.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Granted (a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;48,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$21.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$145.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$145.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;343,575&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$59.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;232,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$66.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;63,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$18.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Granted (b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;932,825&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,795&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$9.46&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$88.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,761&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$88.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;Outstanding at September 30, 2017&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,239,844&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$16.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;275,982&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$53.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;4.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <CVM:ScheduleOfNonvestedOptionsTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Number of Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested at October 1, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;120,409&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 43.09&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(56,069)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;48,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(2,240)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;110,644&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 36.96&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(63,812)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;932,825&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(15,795)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;963,862&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 4.91&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CVM:ScheduleOfNonvestedOptionsTableTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Derivative Instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,020,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,053,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Derivative Instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,111,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,394,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,323,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;Issuances&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,665,683&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,722,073&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; Net realized and unrealized derivative gain&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(7,928,627&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(9,761,532&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,029,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Year Ended September 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;LPS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 8pt"&gt;Basic loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(14,427,055&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,891,843&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less: gain on derivatives(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(677,287&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Dilutive loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(15,104,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,902,647&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(1.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Includes series GG and II warrants&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Year Ended September 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Net Loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;LPS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Basic and dilutive loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(11,512,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,866,204&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Options and Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,538,130&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,675,281&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Convertible Debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,166,106&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested Restricted Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,308,236&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,279,281&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <CVM:FullyInsuredAmountOfNoninterestBearingCashBalances contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">250000</CVM:FullyInsuredAmountOfNoninterestBearingCashBalances>
    <us-gaap:CapitalLeasedAssetsGross contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">21183756</us-gaap:CapitalLeasedAssetsGross>
    <us-gaap:CapitalLeasedAssetsGross contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">21183756</us-gaap:CapitalLeasedAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">66000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">28000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">32000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">35000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">37000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <CVM:FixedAssetsAndIntangibles contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">-523000</CVM:FixedAssetsAndIntangibles>
    <CVM:FixedAssetsAndIntangibles contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">-49000</CVM:FixedAssetsAndIntangibles>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-09-30_OutstandingMember" unitRef="Shares" decimals="INF">343575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-09-30_OutstandingMember" unitRef="Shares" decimals="INF">1239844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-09-30_ExercisableMember" unitRef="Shares" decimals="INF">232931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-09-30_ExercisableMember" unitRef="Shares" decimals="INF">275982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-09-30_custom_OutstandingMember" unitRef="Shares" decimals="INF">301511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-09-30_custom_ExercisableMember" unitRef="Shares" decimals="INF">181102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-10-01to2017-09-30_OutstandingMember" unitRef="Shares" decimals="INF">932825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-10-01to2016-09-30_custom_OutstandingMember" unitRef="Shares" decimals="INF">48544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2016-10-01to2017-09-30_OutstandingMember" unitRef="Shares" decimals="INF">15795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2015-10-01to2016-09-30_custom_OutstandingMember" unitRef="Shares" decimals="INF">2240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <CVM:NumberOfStocksExpired contextRef="From2016-10-01to2017-09-30_OutstandingMember" unitRef="Shares" decimals="INF">20761</CVM:NumberOfStocksExpired>
    <CVM:NumberOfStocksExpired contextRef="From2016-10-01to2017-09-30_ExercisableMember" unitRef="Shares" decimals="INF">20761</CVM:NumberOfStocksExpired>
    <CVM:NumberOfStocksExpired contextRef="From2015-10-01to2016-09-30_custom_OutstandingMember" unitRef="Shares" decimals="INF">4240</CVM:NumberOfStocksExpired>
    <CVM:NumberOfStocksExpired contextRef="From2015-10-01to2016-09-30_custom_ExercisableMember" unitRef="Shares" decimals="INF">4240</CVM:NumberOfStocksExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">59.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">16.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-09-30_ExercisableMember" unitRef="USDPShares" decimals="INF">66.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-09-30_ExercisableMember" unitRef="USDPShares" decimals="INF">53.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30_custom_OutstandingMember" unitRef="USDPShares" decimals="INF">67.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30_custom_ExercisableMember" unitRef="USDPShares" decimals="INF">78.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-10-01to2017-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">2.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-10-01to2016-09-30_custom_OutstandingMember" unitRef="USDPShares" decimals="INF">12.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2016-10-01to2017-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">9.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2015-10-01to2016-09-30_custom_OutstandingMember" unitRef="USDPShares" decimals="INF">21.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <CVM:WeightedAverageExercisePriceExpired contextRef="From2016-10-01to2017-09-30_OutstandingMember" unitRef="USDPShares" decimals="INF">88.80</CVM:WeightedAverageExercisePriceExpired>
    <CVM:WeightedAverageExercisePriceExpired contextRef="From2016-10-01to2017-09-30_ExercisableMember" unitRef="USDPShares" decimals="INF">88.80</CVM:WeightedAverageExercisePriceExpired>
    <CVM:WeightedAverageExercisePriceExpired contextRef="From2015-10-01to2016-09-30_custom_OutstandingMember" unitRef="USDPShares" decimals="INF">145.00</CVM:WeightedAverageExercisePriceExpired>
    <CVM:WeightedAverageExercisePriceExpired contextRef="From2015-10-01to2016-09-30_custom_ExercisableMember" unitRef="USDPShares" decimals="INF">145.00</CVM:WeightedAverageExercisePriceExpired>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-10-01to2017-09-30_OutstandingMember">P5Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-10-01to2017-09-30_ExercisableMember">P4Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2015-10-01to2016-09-30_custom_OutstandingMember">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2015-10-01to2016-09-30_custom_ExercisableMember">P5Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2016-10-01to2017-09-30_OutstandingMember">P8Y6M</CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2016-10-01to2017-09-30_ExercisableMember">P4Y10M28D</CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2015-10-01to2016-09-30_custom_OutstandingMember">P5Y4M6D</CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding contextRef="From2015-10-01to2016-09-30_custom_ExercisableMember">P4Y9M4D</CVM:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2016-09-30_OutstandingMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2017-09-30_OutstandingMember" unitRef="USD" decimals="0">1400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2015-09-30_custom_OutstandingMember" unitRef="USD" decimals="0">50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <CVM:NumberOfStockVested contextRef="From2016-10-01to2017-09-30_ExercisableMember" unitRef="Shares" decimals="INF">63812</CVM:NumberOfStockVested>
    <CVM:NumberOfStockVested contextRef="From2015-10-01to2016-09-30_custom_ExercisableMember" unitRef="Shares" decimals="INF">56069</CVM:NumberOfStockVested>
    <CVM:WeightedAverageExercisePriceVested contextRef="From2016-10-01to2017-09-30_ExercisableMember" unitRef="USDPShares" decimals="INF">18.45</CVM:WeightedAverageExercisePriceVested>
    <CVM:WeightedAverageExercisePriceVested contextRef="From2015-10-01to2016-09-30_custom_ExercisableMember" unitRef="USDPShares" decimals="INF">31.75</CVM:WeightedAverageExercisePriceVested>
    <CVM:NumberOfUnvestedOptionsEnding contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">110644</CVM:NumberOfUnvestedOptionsEnding>
    <CVM:NumberOfUnvestedOptionsEnding contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">963862</CVM:NumberOfUnvestedOptionsEnding>
    <CVM:ForfeitedOptions contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">-2240</CVM:ForfeitedOptions>
    <CVM:ForfeitedOptions contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">-15795</CVM:ForfeitedOptions>
    <CVM:GrantedOptions contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">48544</CVM:GrantedOptions>
    <CVM:GrantedOptions contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">932825</CVM:GrantedOptions>
    <CVM:VestedOptions contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">-56069</CVM:VestedOptions>
    <CVM:VestedOptions contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">-63812</CVM:VestedOptions>
    <CVM:NumberOfUnvestedOptionsBeginning contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">120409</CVM:NumberOfUnvestedOptionsBeginning>
    <CVM:NumberOfUnvestedOptionsBeginning contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">110644</CVM:NumberOfUnvestedOptionsBeginning>
    <CVM:WeightedAverageGrantDateFairValueBeginning contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">43.09</CVM:WeightedAverageGrantDateFairValueBeginning>
    <CVM:WeightedAverageGrantDateFairValueBeginning contextRef="From2016-10-01to2017-09-30" unitRef="USDPShares" decimals="INF">36.96</CVM:WeightedAverageGrantDateFairValueBeginning>
    <CVM:NumberOfUnvestedSharesBeginning contextRef="From2016-10-01to2017-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">604000</CVM:NumberOfUnvestedSharesBeginning>
    <CVM:NumberOfUnvestedSharesBeginning contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">604000</CVM:NumberOfUnvestedSharesBeginning>
    <CVM:VestedShares contextRef="From2016-10-01to2017-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">-136000</CVM:VestedShares>
    <CVM:VestedShares contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">0</CVM:VestedShares>
    <CVM:NumberOfUnvestedSharesEnding contextRef="From2016-10-01to2017-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">468000</CVM:NumberOfUnvestedSharesEnding>
    <CVM:NumberOfUnvestedSharesEnding contextRef="From2015-10-01to2016-09-30_custom_RestrictedStockAwardsMember" unitRef="Shares" decimals="INF">604000</CVM:NumberOfUnvestedSharesEnding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4866204</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4279281</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">4308236</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <CVM:AntidilutiveUnvestedRestrictedStock contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">604000</CVM:AntidilutiveUnvestedRestrictedStock>
    <CVM:AntidilutiveUnvestedRestrictedStock contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">604000</CVM:AntidilutiveUnvestedRestrictedStock>
    <CVM:AntidilutiveConvertibleDebt contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">0</CVM:AntidilutiveConvertibleDebt>
    <CVM:AntidilutiveConvertibleDebt contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">1166106</CVM:AntidilutiveConvertibleDebt>
    <CVM:OptionsAndWarrantsExcludedFromEarningsPerShare contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">3675281</CVM:OptionsAndWarrantsExcludedFromEarningsPerShare>
    <CVM:OptionsAndWarrantsExcludedFromEarningsPerShare contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">2538130</CVM:OptionsAndWarrantsExcludedFromEarningsPerShare>
    <CVM:ModificationOfWarrants1 contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">0</CVM:ModificationOfWarrants1>
    <CVM:ModificationOfWarrants1 contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">63768</CVM:ModificationOfWarrants1>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_SeriesNMember">2008-08-18</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_SeriesRMember">2012-12-06</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_SeriesPMember">2012-02-10</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesUMember">2014-04-17</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesVMember">2015-05-28</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesWMember">2015-10-28</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesZMember">2016-05-23</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesZZMember">2016-05-23</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesAAMember">2016-08-26</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesBBMember">2016-08-26</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesUMember10948898">2014-04-17</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesDDMember10948961">2016-12-08</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesEEMember10949008">2016-12-08</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesNMember">2008-08-18</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesVMember10949164">2015-05-28</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesWMember10949210">2015-10-28</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesXMember10949257">2016-01-13</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesYMember10949304">2016-02-15</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesZZMember10949351">2016-05-23</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesBBMember10949429">2016-08-26</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesZMember10949476">2016-05-23</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesFFMember10949538">2016-12-08</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesCCMember10949600">2016-12-08</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesHHMember10949663">2017-02-23</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesAAMember10949710">2016-08-26</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesJJMember10949772">2017-03-14</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesLLMember10949834">2017-04-30</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesMMMember">2017-06-22</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesNNMember">2017-07-24</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesOOMember">2017-07-31</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesQQMember">2017-08-22</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesIIMember10950146">2017-03-14</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesKKMember10950224">2017-05-03</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesPPMember">2017-08-28</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2016-10-01to2017-09-30_custom_SeriesGGMember11155475">2017-02-23</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesXMember">2016-01-13</CVM:Issuedate2>
    <CVM:Issuedate2 contextRef="From2015-10-01to2016-09-30_custom_SeriesYMember">2016-02-15</CVM:Issuedate2>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_SeriesNMember" unitRef="USDPShares" decimals="INF">13.18</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_SeriesRMember" unitRef="USDPShares" decimals="INF">100.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesWMember" unitRef="USDPShares" decimals="INF">16.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesXMember" unitRef="USDPShares" decimals="INF">9.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesYMember" unitRef="USDPShares" decimals="INF">12.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesZMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesZZMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesAAMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesBBMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesSMember" unitRef="USDPShares" decimals="INF">31.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesUMember" unitRef="USDPShares" decimals="INF">43.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesVMember" unitRef="USDPShares" decimals="INF">19.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2016-09-30_custom_SeriesPMember" unitRef="USDPShares" decimals="INF">112.50</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesUMember10948961" unitRef="USDPShares" decimals="INF">43.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesDDMember10949008" unitRef="USDPShares" decimals="INF">4.50</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesEEMember10949054" unitRef="USDPShares" decimals="INF">4.50</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesNMember" unitRef="USDPShares" decimals="INF">3.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesSMember10949164" unitRef="USDPShares" decimals="INF">31.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesVMember10949210" unitRef="USDPShares" decimals="INF">19.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesWMember10949257" unitRef="USDPShares" decimals="INF">16.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesXMember10949304" unitRef="USDPShares" decimals="INF">9.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesYMember10949351" unitRef="USDPShares" decimals="INF">12.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesZZMember10949429" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesBBMember10949476" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesZMember10949538" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesFFMember10949600" unitRef="USDPShares" decimals="INF">3.91</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesCCMember10949663" unitRef="USDPShares" decimals="INF">5.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesHHMember10949710" unitRef="USDPShares" decimals="INF">3.13</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesAAMember10949772" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesJJMember10949834" unitRef="USDPShares" decimals="INF">3.13</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesLLMember10949881" unitRef="USDPShares" decimals="INF">3.59</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesMMMember" unitRef="USDPShares" decimals="INF">1.86</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesNNMember" unitRef="USDPShares" decimals="INF">2.52</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesOOMember" unitRef="USDPShares" decimals="INF">2.52</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesQQMember" unitRef="USDPShares" decimals="INF">2.50</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesIIMember10950224" unitRef="USDPShares" decimals="INF">3.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesKKMember10950287" unitRef="USDPShares" decimals="INF">3.04</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesPPMember" unitRef="USDPShares" decimals="INF">2.30</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-09-30_custom_SeriesGGMember11155569" unitRef="USDPShares" decimals="INF">3.00</CVM:ExercisePrice>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_SeriesNMember" unitRef="Shares" decimals="INF">113785</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_SeriesRMember" unitRef="Shares" decimals="INF">105000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_ConsultantsMember" unitRef="Shares" decimals="INF">25600</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesWMember" unitRef="Shares" decimals="INF">688930</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesXMember" unitRef="Shares" decimals="INF">120000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesYMember" unitRef="Shares" decimals="INF">26000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesZMember" unitRef="Shares" decimals="INF">264000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesZZMember" unitRef="Shares" decimals="INF">20000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesAAMember" unitRef="Shares" decimals="INF">200000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesBBMember" unitRef="Shares" decimals="INF">16000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesSMember" unitRef="Shares" decimals="INF">1037120</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesUMember" unitRef="Shares" decimals="INF">17821</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesVMember" unitRef="Shares" decimals="INF">810127</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2016-09-30_custom_SeriesPMember" unitRef="Shares" decimals="INF">23600</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesUMember10948961" unitRef="Shares" decimals="INF">17821</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesDDMember10949008" unitRef="Shares" decimals="INF">1360960</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesEEMember10949054" unitRef="Shares" decimals="INF">1360960</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesNMember" unitRef="Shares" decimals="INF">85339</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesSMember10949164" unitRef="Shares" decimals="INF">1037120</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesVMember10949210" unitRef="Shares" decimals="INF">810127</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesWMember10949257" unitRef="Shares" decimals="INF">688930</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesXMember10949304" unitRef="Shares" decimals="INF">120000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesYMember10949351" unitRef="Shares" decimals="INF">26000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesZZMember10949429" unitRef="Shares" decimals="INF">20000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesBBMember10949476" unitRef="Shares" decimals="INF">16000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesZMember10949538" unitRef="Shares" decimals="INF">264000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesFFMember10949600" unitRef="Shares" decimals="INF">68048</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesCCMember10949663" unitRef="Shares" decimals="INF">680480</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesHHMember10949710" unitRef="Shares" decimals="INF">20000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesAAMember10949772" unitRef="Shares" decimals="INF">200000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesJJMember10949834" unitRef="Shares" decimals="INF">30000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesLLMember10949881" unitRef="Shares" decimals="INF">26398</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesMMMember" unitRef="Shares" decimals="INF">893491</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesNNMember" unitRef="Shares" decimals="INF">539300</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesOOMember" unitRef="Shares" decimals="INF">60000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesQQMember" unitRef="Shares" decimals="INF">87500</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesIIMember10950224" unitRef="Shares" decimals="INF">600000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesKKMember10950287" unitRef="Shares" decimals="INF">395970</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesPPMember" unitRef="Shares" decimals="INF">1750000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_ConsultantsMember" unitRef="Shares" decimals="INF">42000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-09-30_custom_SeriesGGMember11155569" unitRef="Shares" decimals="INF">400000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:ExercisePriceMinimum contextRef="AsOf2016-09-30_ConsultantsMember" unitRef="USDPShares" decimals="INF">9.25</CVM:ExercisePriceMinimum>
    <CVM:ExercisePriceMinimum contextRef="AsOf2017-09-30_custom_ConsultantsMember" unitRef="USDPShares" decimals="INF">2.18</CVM:ExercisePriceMinimum>
    <CVM:ExercisePriceMaximum contextRef="AsOf2016-09-30_ConsultantsMember" unitRef="USDPShares" decimals="INF">87.50</CVM:ExercisePriceMaximum>
    <CVM:ExercisePriceMaximum contextRef="AsOf2017-09-30_custom_ConsultantsMember" unitRef="USDPShares" decimals="INF">70.00</CVM:ExercisePriceMaximum>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_SeriesNMember">2017-08-18</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_SeriesRMember">2016-12-06</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_SeriesPMember">2017-03-06</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesSMember">2018-10-11</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesUMember">2017-10-17</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesVMember">2020-05-28</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesWMember">2020-10-28</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesZMember">2021-11-23</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesZZMember">2021-05-18</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesAAMember">2022-02-22</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesBBMember">2021-08-22</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesUMember10948898">2017-10-17</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesDDMember10948961">2017-12-01</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesEEMember10949008">2017-12-01</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesNMember">2018-08-18</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesSMember10949117">2018-10-11</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesVMember10949164">2020-05-28</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesWMember10949210">2020-10-28</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesXMember10949257">2021-01-13</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesYMember10949304">2021-02-15</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesZZMember10949351">2021-05-18</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesBBMember10949429">2021-08-22</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesZMember10949476">2021-11-23</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesFFMember10949538">2021-12-01</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesCCMember10949600">2021-12-08</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesHHMember10949663">2022-02-16</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesAAMember10949710">2022-02-22</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesJJMember10949772">2022-03-08</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesLLMember10949834">2022-04-30</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesMMMember">2022-06-22</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesNNMember">2022-07-24</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesOOMember">2022-07-31</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesQQMember">2022-08-22</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesIIMember10950146">2022-09-14</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesKKMember10950224">2022-11-03</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesPPMember">2023-02-28</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesGGMember11155475">2022-08-23</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesXMember">2021-01-13</CVM:ExpirationDate1>
    <CVM:ExpirationDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesYMember">2021-02-15</CVM:ExpirationDate1>
    <CVM:ExpirationStartDate contextRef="From2015-10-01to2016-09-30_ConsultantsMember">2016-10-27</CVM:ExpirationStartDate>
    <CVM:ExpirationStartDate contextRef="From2016-10-01to2017-09-30_custom_ConsultantsMember">2017-12-27</CVM:ExpirationStartDate>
    <CVM:ExpirationEndDate contextRef="From2015-10-01to2016-09-30_ConsultantsMember">2019-06-30</CVM:ExpirationEndDate>
    <CVM:ExpirationEndDate contextRef="From2016-10-01to2017-09-30_custom_ConsultantsMember">2027-07-27</CVM:ExpirationEndDate>
    <CVM:IssueStartDate contextRef="From2015-10-01to2016-09-30_ConsultantsMember">2011-12-02</CVM:IssueStartDate>
    <CVM:IssueStartDate contextRef="From2015-10-01to2016-09-30_custom_SeriesSMember">2013-10-11</CVM:IssueStartDate>
    <CVM:IssueStartDate contextRef="From2016-10-01to2017-09-30_custom_SeriesSMember10949117">2013-10-11</CVM:IssueStartDate>
    <CVM:IssueStartDate contextRef="From2016-10-01to2017-09-30_custom_ConsultantsMember">2012-12-28</CVM:IssueStartDate>
    <CVM:IssueEndDate1 contextRef="From2015-10-01to2016-09-30_ConsultantsMember">2016-07-01</CVM:IssueEndDate1>
    <CVM:IssueEndDate1 contextRef="From2015-10-01to2016-09-30_custom_SeriesSMember">2014-10-24</CVM:IssueEndDate1>
    <CVM:IssueEndDate1 contextRef="From2016-10-01to2017-09-30_custom_SeriesSMember10949117">2014-10-24</CVM:IssueEndDate1>
    <CVM:IssueEndDate1 contextRef="From2016-10-01to2017-09-30_custom_ConsultantsMember">2017-07-28</CVM:IssueEndDate1>
    <dei:EntityPublicFloat contextRef="AsOf2017-03-31" unitRef="USD" decimals="0">17625571</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2017-12-21" unitRef="Shares" decimals="INF">13206316</dei:EntityCommonStockSharesOutstanding>
    <CVM:CapitalizedLeaseInterest contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-227773</CVM:CapitalizedLeaseInterest>
    <CVM:CapitalizedLeaseInterest contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-200902</CVM:CapitalizedLeaseInterest>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">523000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">49000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;CEL-SCI Corporation (the Company) was incorporated&#13;on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage&#13;in marketing and selling products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is focused on finding the best way&#13;to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy, Multikine&amp;#174; (Leukocyte&#13;Interleukin, Injection), is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company&#13;has received Orphan Drug Status from the United States Food and Drug Administration (FDA). If the primary endpoint of this global&#13;study is achieved, the results will be used to support applications to regulatory agencies around the world for worldwide commercial&#13;marketing approvals as a first line cancer therapy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s immune therapy, Multikine,&#13;is being used in a different way than immune therapy is usually used. It is given before any other therapy has been administered&#13;because that is when the immune system is thought to be strongest.&lt;font style="color: #404040"&gt;&amp;#160;&lt;/font&gt;It is also administered&#13;locally to treat tumors or infections&lt;font style="color: #404040"&gt;.&lt;/font&gt; For example, &lt;font style="color: #404040"&gt;i&lt;/font&gt;n&#13;the Phase 3 clinical trial, Multikine is given locally at the site of the tumor as a first line treatment before surgery, radiation&#13;and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the&#13;cancer. In short, CEL-SCI believes that local administration and administration before weakening of the immune system by chemotherapy&#13;and radiation will result in higher efficacy with less or no toxicity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Multikine (Leukocyte Interleukin, Injection)&#13;is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this document as Multikine.&#13;Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject&#13;to FDA review in connection with the Company&amp;#8217;s future anticipated regulatory submission for approval. Multikine has not been&#13;licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.&#13;Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational&#13;therapy that is in progress.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Multikine has been cleared by the&#13;regulators in twenty four countries around the world, including the U.S. FDA, for a global Phase 3 clinical trial in advanced&#13;primary (not yet treated) head and neck cancer patients. On September 26, 2016, the Company received verbal notice from the&#13;FDA that the Phase 3 clinical trial has been placed on clinical hold. On August 10, 2017, the Company received a letter from&#13;the FDA stating that the clinical hold that had been imposed on the Phase 3 cancer study with Multikine has been removed and&#13;that all clinical trial activities for the Phase 3 study may resume. On December 7, 2017, the Company announced that the&#13;Independent Data Monitoring Committee (IDMC) has completed its review of the Phase 3 study data. The data from all 928&#13;enrolled patients were provided to the IDMC by the Clinical Research Organization (CRO) responsible for data management of&#13;this Phase 3 study. The IDMC made the following observation and recommendation: a) the IDMC saw no evidence of any&#13;significant safety questions and b) the IDMC recommends continuing the study. On December 11, 2017, the Company announced&#13;that the Phase 3 study was fully enrolled. The activities in the Phase 3 study are now focused on the follow-up of the&#13;patients enrolled to determine if there is a survival benefit in favor of Multikine.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Years ending September 30,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 64%; text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 36%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 1,747,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,808,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,872,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,937,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2,004,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;13,758,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total future minimum lease obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;23,126,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Less: imputed interest on financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(9,914,000)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net present value of lease financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 13,212,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font-size: 8pt"&gt;Years ending September 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 48%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 251,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;258,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;238,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;163,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;69,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: 0.25in"&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total future minimum lease obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$ 979,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1747000</us-gaap:CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1808000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1872000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1937000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2004000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">13758000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">23126000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">9914000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">13212000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">251000</us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">258000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">238000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">163000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">69000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">979000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <CVM:GainOnDerivativeInstruments contextRef="From2016-10-01to2017-09-30" unitRef="USD" id="Foot-00-0" decimals="0">-677287</CVM:GainOnDerivativeInstruments>
    <CVM:IncrementalCommonSharesAttributableToGainOnDerivatives contextRef="From2016-10-01to2017-09-30" unitRef="Shares" id="Foot-00-1" decimals="INF">10804</CVM:IncrementalCommonSharesAttributableToGainOnDerivatives>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2016-10-01to2017-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 47%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;Weighted&amp;#160;Average&amp;#160;Grant&amp;#160;Date&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;(136,000)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Unvested at September 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;468,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2016-10-01to2017-09-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2017, the FASB issued ASU 2017-09,&amp;#160;&lt;i&gt;Compensation&#13;&amp;#8211; Stock Compensation (Topic 718)&lt;/i&gt;, which affects any entity that changes the terms or conditions of a share-based payment&#13;award.&amp;#160; This Update amends the definition of modification by qualifying that modification accounting does not apply to changes&#13;to outstanding share-based payment awards that do not affect the total fair value, vesting requirements, or equity/liability classification&#13;of the awards.&amp;#160; The amendments in this Update are effective for all entities for annual periods, and interim periods within&#13;those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period,&#13;for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other&#13;entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in&#13;this Update should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating&#13;the impact the adoption of the standard will have on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2017, the FASB issued ASU 2017-11,&amp;#160;&lt;i&gt;Earnings&#13;Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging (Topic 815)&lt;/i&gt;. The amendments&#13;in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features)&#13;with down-round features. When determining whether certain financial instruments should be classified as liabilities or equity&#13;instruments, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to&#13;an entity&amp;#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As&#13;a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as&#13;a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity classified financial&#13;instruments, the amendments require entities that present earnings per share (&amp;#8220;EPS&amp;#8221;) in accordance with Topic 260 to&#13;recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and as a reduction of&#13;income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down-&#13;round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20,&amp;#160;&lt;i&gt;Debt&amp;#8212;Debt&#13;with Conversion and Other Options&lt;/i&gt;), including related EPS guidance (in Topic 260). The amendments in Part II of this Update&#13;recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Accounting&#13;Standards Codification, to a scope exception. Those amendments do not have an accounting effect.&amp;#160;For public business entities,&#13;the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning&#13;after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning&#13;after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted&#13;for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments&#13;should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part I of this&#13;Update should be applied either retrospectively to outstanding financial instruments with a down-round feature by means of a cumulative-effect&#13;adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the&#13;pending content that links to this paragraph is effective or retrospectively to outstanding financial instruments with a down-round&#13;feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5&#13;through 45-10. The amendments in Part II of this Update do not require any transition guidance because those amendments do not&#13;have an accounting effect.&amp;#160;The Company is currently evaluating the impact the adoption of the standard will have on the Company&amp;#8217;s&#13;financial position or results of operations.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2017, the FASB issued ASU 2017-12,&amp;#160;&lt;i&gt;Derivatives&#13;and Hedging (Topic 850)&lt;/i&gt;, the objective of which is to improve the financial reporting of hedging relationships to better portray&#13;the economic results of an entity&amp;#8217;s risk management activities in its financial statements. In addition, the amendments in&#13;this Update make certain targeted improvements to simplify the application and disclosure of the hedge accounting guidance in current&#13;general accepted accounting principles.&amp;#160;&amp;#160;For public business entities, the amendments in&amp;#160;this Update are effective&#13;for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the&#13;amendments are effective for fiscal years beginning after December 15, 2019, and interim periods beginning after December 15, 2020.&#13;Early adoption is permitted in any period after issuance.&amp;#160;&amp;#160;For cash flow and net investment hedges existing at the date&#13;of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate&amp;#160;measurement of ineffectiveness&#13;to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the&#13;beginning of the fiscal year that an entity adopts the amendments in this Update. The amended presentation and disclosure guidance&#13;is required only prospectively.&amp;#160;&amp;#160;The Company is currently evaluating the impact the adoption of the standard will have&#13;on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued ASU 2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;,&#13;which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance&#13;sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases&#13;are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current&#13;standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December&#13;15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning&#13;with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial&#13;statements and related disclosures. Although the Company has not completed its evaluation of the impact of the adoption of ASU&#13;2016-02, because the Company&amp;#8217;s most significant operating lease is currently on its balance sheet (see Note 11), the adoption&#13;of ASU 2016-02 is not expected to have a material impact to the financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2016, the FASB issued ASU No.&#13;2016-09, &lt;i&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&lt;/i&gt; ASU&#13;2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including income tax&#13;consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The&#13;new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016&#13;but early adoption is permitted. The Company does not expect the adoption of the new amendment to have a material impact on its financial statements and related&#13;disclosures March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee&#13;Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions,&#13;including income tax consequences, classification of awards as either equity or liabilities and classification on the statement&#13;of cash flows. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after&#13;December 15, 2016 but early adoption is permitted. The Company  does not expect the adoption of the new amendment to have&#13;a material impact on its financial statements and related disclosures. The estimated forfeiture rate is based on historical&#13;information, however, the Company will no longer estimate the forfeiture rate on share based payments, but rather recognize&#13;forfeitures as they occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has considered all other recently&#13;issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial&#13;statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Includes series GG and II warrants.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cvm-20170930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 172274 09302017 10K.xfr; Date: 2017%2D12%2D29T16:05:42Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9q9Zs7xRiXhun8uCaHMsOa+DKaPtxZ57KYkhsGZ+HQm6Tyksj8CGQyAxhM3mcRsP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:CVM="http://cel-sci.com/20170930" elementFormDefault="qualified" targetNamespace="http://cel-sci.com/20170930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - 1. ORGANIZATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/OperationsFinancing" id="OperationsFinancing">
	  <link:definition>00000008 - Disclosure - 2. OPERATIONS AND FINANCING</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" id="DerivativesLiabilitiesWarrantsAndOtherOptions">
	  <link:definition>00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipment" id="ResearchAndOfficeEquipment">
	  <link:definition>00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/Patents" id="Patents">
	  <link:definition>00000012 - Disclosure - 6. PATENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000013 - Disclosure - 7. NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000014 - Disclosure - 8. INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensation" id="StockCompensation">
	  <link:definition>00000015 - Disclosure - 9. STOCK COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000016 - Disclosure - 10. EMPLOYEE BENEFIT PLAN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000017 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000018 - Disclosure - 12. RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000019 - Disclosure - 13. STOCKHOLDERS EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000020 - Disclosure - 14. FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
	  <link:definition>00000021 - Disclosure - 15. NET LOSS PER COMMON SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - 16. SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" id="DerivativesLiabilitiesWarrantsAndOtherOptionsTables">
	  <link:definition>00000024 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" id="ResearchAndOfficeEquipmentTables">
	  <link:definition>00000025 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PatentsTables" id="PatentsTables">
	  <link:definition>00000026 - Disclosure - 6. PATENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000027 - Disclosure - 8. INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationTables" id="StockCompensationTables">
	  <link:definition>00000028 - Disclosure - 9. STOCK COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000029 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000030 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
	  <link:definition>00000031 - Disclosure - 15. NET LOSS PER COMMON SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" id="WarrantsAndNon-employeeOptionsDetails">
	  <link:definition>00000033 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" id="WarrantsAndNon-employeeOptionsDetails1">
	  <link:definition>00000034 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" id="PlantPropertyAndEquipmentDetails">
	  <link:definition>00000035 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" id="PlantPropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000036 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PatentsDetails" id="PatentsDetails">
	  <link:definition>00000037 - Disclosure - 6. PATENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PatentsDetails1" id="PatentsDetails1">
	  <link:definition>00000038 - Disclosure - 6. PATENTS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
	  <link:definition>00000039 - Disclosure - 6. PATENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" id="IncomeTaxesNetDeferredTaxAssetDetails">
	  <link:definition>00000040 - Disclosure - 8. INCOME TAXES Net deferred tax asset (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" id="IncomeTaxesReconciliationOfEffectiveTaxRateDetails">
	  <link:definition>00000041 - Disclosure - 8. INCOME TAXES Reconciliation of effective tax rate (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationAwardsDetails" id="StockCompensationAwardsDetails">
	  <link:definition>00000042 - Disclosure - 9. STOCK COMPENSATION Awards (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationAssumptionsDetails" id="StockCompensationAssumptionsDetails">
	  <link:definition>00000043 - Disclosure - 9. STOCK COMPENSATION Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" id="StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails">
	  <link:definition>00000044 - Disclosure - 9. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" id="StockCompensationNonvestedOptionsDetails">
	  <link:definition>00000045 - Disclosure - 9. STOCK COMPENSATION Nonvested Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationRsuDetails" id="StockCompensationRsuDetails">
	  <link:definition>00000046 - Disclosure - 9. STOCK COMPENSATION RSU (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StockCompensationDetailsNarrative" id="StockCompensationDetailsNarrative">
	  <link:definition>00000047 - Disclosure - 9. STOCK COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" id="EmployeeBenefitPlanDetailNarrative">
	  <link:definition>00000048 - Disclosure - 10. EMPLOYEE BENEFIT PLAN (Detail Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000049 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000050 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000051 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
	  <link:definition>00000052 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
	  <link:definition>00000053 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails" id="NetLossPerCommonShareDetails">
	  <link:definition>00000054 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails1" id="NetLossPerCommonShareDetails1">
	  <link:definition>00000055 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="CVM_EquityBasedCompensationNonemployees" name="EquityBasedCompensationNonemployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" name="LeasePaymentsIncludedInAccountsPayableAtYearEnd" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" name="IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInDirectFinancingCosts" name="IncreaseInDirectFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInPrepaidServices" name="IncreaseInPrepaidServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" name="DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NonemployeesShareBasedCompensation" name="NonemployeesShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpectedLifeOfOptionsMin1" name="ExpectedLifeOfOptionsMin1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpectedLifeOfOptionsMax" name="ExpectedLifeOfOptionsMax" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageGrantDateFairValueEnding" name="WeightedAverageGrantDateFairValueEnding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_RDDeferredRentLiability" name="RDDeferredRentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DeferredRentLiability" name="DeferredRentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" name="AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WarrantsIssuedWithNotesPayable" name="WarrantsIssuedWithNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable" name="ConversionOfAccruedSalariesAndFeesToNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_OperationsAndFinancingTextBlock" name="OperationsAndFinancingTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockholdersEquityTextBlock" name="StockholdersEquityTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Deposits2" name="Deposits2" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ResearchAndDevelopmentGrantRevenues" name="ResearchAndDevelopmentGrantRevenues" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" name="DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" name="ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ScheduleOfNonvestedOptionsTableTextBlock" name="ScheduleOfNonvestedOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" name="FullyInsuredAmountOfNoninterestBearingCashBalances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FixedAssetsAndIntangibles" name="FixedAssetsAndIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfStocksExpired" name="NumberOfStocksExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageExercisePriceExpired" name="WeightedAverageExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" name="WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfStockVested" name="NumberOfStockVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageExercisePriceVested" name="WeightedAverageExercisePriceVested" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfUnvestedOptionsEnding" name="NumberOfUnvestedOptionsEnding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ForfeitedOptions" name="ForfeitedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GrantedOptions" name="GrantedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_VestedOptions" name="VestedOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfUnvestedOptionsBeginning" name="NumberOfUnvestedOptionsBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageGrantDateFairValueBeginning" name="WeightedAverageGrantDateFairValueBeginning" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfUnvestedSharesBeginning" name="NumberOfUnvestedSharesBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_VestedShares" name="VestedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfUnvestedSharesEnding" name="NumberOfUnvestedSharesEnding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_AntidilutiveUnvestedRestrictedStock" name="AntidilutiveUnvestedRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_AntidilutiveConvertibleDebt" name="AntidilutiveConvertibleDebt" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" name="OptionsAndWarrantsExcludedFromEarningsPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ModificationOfWarrants1" name="ModificationOfWarrants1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Issuedate2" name="Issuedate2" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SharesIssuableUponExerciseOfwarrant" name="SharesIssuableUponExerciseOfwarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePriceMinimum" name="ExercisePriceMinimum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePriceMaximum" name="ExercisePriceMaximum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpirationDate1" name="ExpirationDate1" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpirationStartDate" name="ExpirationStartDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpirationEndDate" name="ExpirationEndDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IssueStartDate" name="IssueStartDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IssueEndDate1" name="IssueEndDate1" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CapitalizedLeaseInterest" name="CapitalizedLeaseInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainOnDerivativeInstruments" name="GainOnDerivativeInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncrementalCommonSharesAttributableToGainOnDerivatives" name="IncrementalCommonSharesAttributableToGainOnDerivatives" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesNMember" name="SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CSchleuningSeriesAMember" name="CSchleuningSeriesAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesCMember" name="SeriesCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesEMember" name="SeriesEMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesFMember" name="SeriesFMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesGMember" name="SeriesGMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesHMember" name="SeriesHMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesQMember" name="SeriesQMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesLMember" name="SeriesLMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesLRepricedMember" name="SeriesLRepricedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesMModifiedMember" name="SeriesMModifiedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesPMember" name="SeriesPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorsMember" name="PrivateInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WarrantsHeldbyOfficerAndDirectorMember" name="WarrantsHeldbyOfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKwarrantsMember" name="SeriesKwarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Financings2009WarrantsSeriesAToEMember" name="Financings2009WarrantsSeriesAToEMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Warrants2008SeriesNMember" name="Warrants2008SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesFAndGWarrantsMember" name="SeriesFAndGWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesQWarrantsMember" name="SeriesQWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ConvertibleNotesSettlementMember" name="ConvertibleNotesSettlementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncentiveStockOptionPlansMember" name="IncentiveStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NonQualifiedStockOptionPlansMember" name="NonQualifiedStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockBonusPlansMember" name="StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesRMember" name="SeriesRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesMModififedMember" name="SeriesMModififedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesOMember" name="SeriesOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_OutstandingMember" name="OutstandingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisableMember" name="ExercisableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesAThroughEWarrantsMember" name="SeriesAThroughEWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DeferredRentLiabilityMember" name="DeferredRentLiabilityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrantsMember" name="PrivateInvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants1Member" name="PrivateInvestorWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants2Member" name="PrivateInvestorWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants3Member" name="PrivateInvestorWarrants3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesSMember" name="SeriesSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesTMember" name="SeriesTMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesUMember" name="SeriesUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_BasicEpsMember" name="BasicEpsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DilutiveEpsMember" name="DilutiveEpsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DerivativeLiabilitiesGainMember" name="DerivativeLiabilitiesGainMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_BasicAndDilutiveEPSMember" name="BasicAndDilutiveEPSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKAndLWarrantsMember" name="SeriesKAndLWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKAndSeriesAThroughEWarrantsMember" name="SeriesKAndSeriesAThroughEWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesVMember" name="SeriesVMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesWMember" name="SeriesWMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesXMember" name="SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesYMember" name="SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesZMember" name="SeriesZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesZZMember" name="SeriesZZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesAAMember" name="SeriesAAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesBBMember" name="SeriesBBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SanTomasMember" name="SanTomasMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesCCMember" name="SeriesCCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesDDMember" name="SeriesDDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesEEMember" name="SeriesEEMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesFFMember" name="SeriesFFMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesGGMember" name="SeriesGGMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesHHMember" name="SeriesHHMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesIIMember" name="SeriesIIMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesJJMember" name="SeriesJJMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKKMember" name="SeriesKKMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesLLMember" name="SeriesLLMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesMMMember" name="SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesNNMember" name="SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesOOMember" name="SeriesOOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesQQMember" name="SeriesQQMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesPPMember" name="SeriesPPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsTablesAbstract" name="PatentsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CommitmentsAndContingenciesTablesAbstract" name="CommitmentsAndContingenciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsTablesAbstract" name="FairValueMeasurementsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NetLossPerCommonShareTablesAbstract" name="NetLossPerCommonShareTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" name="DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" name="DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_EmployeeBenefitPlanDetailsNarrativeAbstract" name="EmployeeBenefitPlanDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ResearchAndOfficeEquipmentDetailsAbstract" name="ResearchAndOfficeEquipmentDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" name="ResearchAndOfficeEquipmentDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsDetailsAbstract" name="PatentsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsDetailsNarrativeAbstract" name="PatentsDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" name="IncomeTaxesNetDeferredTaxAssetDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_LoanModification" name="LoanModification" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" name="IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes" name="EffectiveTaxRateReconciliationExpiredTaxAttributes" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" name="EffectiveTaxRateReconciliationAdjustmentToDeferreds" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockholdersEquityDetails1Abstract" name="StockholdersEquityDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationDetailsAbstract" name="StockCompensationDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationDetails3Abstract" name="StockCompensationDetails3Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfOptionsExercised" name="NumberOfOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NumberOfStocksCancelled" name="NumberOfStocksCancelled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageExercisePriceCancelled" name="WeightedAverageExercisePriceCancelled" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WeightedAverageRemainingContractualLifeInYearsGranted" name="WeightedAverageRemainingContractualLifeInYearsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationNonvestedOptionsDetailsAbstract" name="StockCompensationNonvestedOptionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GrantedWeightedAverageGrantDateFairValue" name="GrantedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationRsuDetailsAbstract" name="StockCompensationRsuDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GrantedShares" name="GrantedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ForfeitedShares" name="ForfeitedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockCompensationDetailsNarrativeAbstract" name="StockCompensationDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CommitmentsAndContingenciesDetailsAbstract" name="CommitmentsAndContingenciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" name="CommitmentsAndContingenciesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_TotalDeferredRentAsset" name="TotalDeferredRentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DeferredRentNetOfCurrentPortion" name="DeferredRentNetOfCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsDetailsAbstract" name="FairValueMeasurementsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsDetails1Abstract" name="FairValueMeasurementsDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_I.EarningsPerShareDetailsAbstract" name="I.EarningsPerShareDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_I.EarningsPerShareDetailsNarrativeAbstract" name="I.EarningsPerShareDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cvm-20170930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 172274 09302017 10K.xfr; Date: 2017%2D12%2D29T16:05:42Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20170930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20170930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20170930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20170930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20170930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OperationsFinancing" xlink:href="cvm-20170930.xsd#OperationsFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:href="cvm-20170930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:href="cvm-20170930.xsd#ResearchAndOfficeEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Patents" xlink:href="cvm-20170930.xsd#Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NotesPayable" xlink:href="cvm-20170930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxes" xlink:href="cvm-20170930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensation" xlink:href="cvm-20170930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:href="cvm-20170930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:href="cvm-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RelatedPartyTransactions" xlink:href="cvm-20170930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockholdersEquity" xlink:href="cvm-20170930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurements" xlink:href="cvm-20170930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShare" xlink:href="cvm-20170930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SubsequentEvents" xlink:href="cvm-20170930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20170930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:href="cvm-20170930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:href="cvm-20170930.xsd#ResearchAndOfficeEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsTables" xlink:href="cvm-20170930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesTables" xlink:href="cvm-20170930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationTables" xlink:href="cvm-20170930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:href="cvm-20170930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="cvm-20170930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:href="cvm-20170930.xsd#WarrantsAndNon-employeeOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:href="cvm-20170930.xsd#WarrantsAndNon-employeeOptionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:href="cvm-20170930.xsd#PlantPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20170930.xsd#PlantPropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails" xlink:href="cvm-20170930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails1" xlink:href="cvm-20170930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:href="cvm-20170930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:href="cvm-20170930.xsd#IncomeTaxesNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="cvm-20170930.xsd#IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:href="cvm-20170930.xsd#StockCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:href="cvm-20170930.xsd#StockCompensationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:href="cvm-20170930.xsd#StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:href="cvm-20170930.xsd#StockCompensationNonvestedOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:href="cvm-20170930.xsd#StockCompensationRsuDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20170930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20170930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20170930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:href="cvm-20170930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="loc_us-gaapNotesAndLoansPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesAndLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ModificationOfWarrants1" xlink:label="loc_CVMModificationOfWarrants1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_CVMModificationOfWarrants1" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CapitalizedLeaseInterest" xlink:label="loc_CVMCapitalizedLeaseInterest" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CVMCapitalizedLeaseInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. ORGANIZATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OperationsFinancing" xlink:title="00000008 - Disclosure - 2. OPERATIONS AND FINANCING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:title="00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:title="00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Patents" xlink:title="00000012 - Disclosure - 6. PATENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NotesPayable" xlink:title="00000013 - Disclosure - 7. NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - 8. INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensation" xlink:title="00000015 - Disclosure - 9. STOCK COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - 10. EMPLOYEE BENEFIT PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - 12. RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - 13. STOCKHOLDERS EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurements" xlink:title="00000020 - Disclosure - 14. FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShare" xlink:title="00000021 - Disclosure - 15. NET LOSS PER COMMON SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - 16. SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:title="00000024 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:title="00000025 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsTables" xlink:title="00000026 - Disclosure - 6. PATENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - 8. INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationTables" xlink:title="00000028 - Disclosure - 9. STOCK COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:title="00000029 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:title="00000030 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:title="00000031 - Disclosure - 15. NET LOSS PER COMMON SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:title="00000033 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:title="00000034 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:title="00000035 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="00000036 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails" xlink:title="00000037 - Disclosure - 6. PATENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails1" xlink:title="00000038 - Disclosure - 6. PATENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:title="00000039 - Disclosure - 6. PATENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:title="00000040 - Disclosure - 8. INCOME TAXES Net deferred tax asset (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="00000041 - Disclosure - 8. INCOME TAXES Reconciliation of effective tax rate (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:title="00000042 - Disclosure - 9. STOCK COMPENSATION Awards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:title="00000043 - Disclosure - 9. STOCK COMPENSATION Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:title="00000044 - Disclosure - 9. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:title="00000045 - Disclosure - 9. STOCK COMPENSATION Nonvested Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:title="00000046 - Disclosure - 9. STOCK COMPENSATION RSU (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:title="00000047 - Disclosure - 9. STOCK COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="00000048 - Disclosure - 10. EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000050 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000051 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:title="00000052 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:title="00000053 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:title="00000054 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:title="00000055 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details 1)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cvm-20170930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 172274 09302017 10K.xfr; Date: 2017%2D12%2D29T16:05:42Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20170930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20170930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20170930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20170930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20170930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OperationsFinancing" xlink:href="cvm-20170930.xsd#OperationsFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:href="cvm-20170930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:href="cvm-20170930.xsd#ResearchAndOfficeEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Patents" xlink:href="cvm-20170930.xsd#Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NotesPayable" xlink:href="cvm-20170930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxes" xlink:href="cvm-20170930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensation" xlink:href="cvm-20170930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:href="cvm-20170930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:href="cvm-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RelatedPartyTransactions" xlink:href="cvm-20170930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockholdersEquity" xlink:href="cvm-20170930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurements" xlink:href="cvm-20170930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShare" xlink:href="cvm-20170930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SubsequentEvents" xlink:href="cvm-20170930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20170930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:href="cvm-20170930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:href="cvm-20170930.xsd#ResearchAndOfficeEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsTables" xlink:href="cvm-20170930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesTables" xlink:href="cvm-20170930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationTables" xlink:href="cvm-20170930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:href="cvm-20170930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="cvm-20170930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:href="cvm-20170930.xsd#WarrantsAndNon-employeeOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:href="cvm-20170930.xsd#WarrantsAndNon-employeeOptionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:href="cvm-20170930.xsd#PlantPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20170930.xsd#PlantPropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails" xlink:href="cvm-20170930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails1" xlink:href="cvm-20170930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:href="cvm-20170930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:href="cvm-20170930.xsd#IncomeTaxesNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="cvm-20170930.xsd#IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:href="cvm-20170930.xsd#StockCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:href="cvm-20170930.xsd#StockCompensationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:href="cvm-20170930.xsd#StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:href="cvm-20170930.xsd#StockCompensationNonvestedOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:href="cvm-20170930.xsd#StockCompensationRsuDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20170930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20170930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20170930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:href="cvm-20170930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WarrantsIssuedWithNotesPayable" xlink:label="loc_CVMWarrantsIssuedWithNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWarrantsIssuedWithNotesPayable_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountIssued1_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:label="loc_CVMAdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMAdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_EquityBasedCompensationNonemployees" xlink:label="loc_CVMEquityBasedCompensationNonemployees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMEquityBasedCompensationNonemployees_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. ORGANIZATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OperationsFinancing" xlink:title="00000008 - Disclosure - 2. OPERATIONS AND FINANCING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:title="00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:title="00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Patents" xlink:title="00000012 - Disclosure - 6. PATENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NotesPayable" xlink:title="00000013 - Disclosure - 7. NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - 8. INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensation" xlink:title="00000015 - Disclosure - 9. STOCK COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - 10. EMPLOYEE BENEFIT PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - 12. RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - 13. STOCKHOLDERS EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurements" xlink:title="00000020 - Disclosure - 14. FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShare" xlink:title="00000021 - Disclosure - 15. NET LOSS PER COMMON SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - 16. SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:title="00000024 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:title="00000025 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsTables" xlink:title="00000026 - Disclosure - 6. PATENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - 8. INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationTables" xlink:title="00000028 - Disclosure - 9. STOCK COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:title="00000029 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:title="00000030 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:title="00000031 - Disclosure - 15. NET LOSS PER COMMON SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:title="00000033 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesDDMember" xlink:label="loc_CVMSeriesDDMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesDDMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesEEMember" xlink:label="loc_CVMSeriesEEMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesEEMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesNMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesSMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesVMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesWMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesXMember" xlink:label="loc_CVMSeriesXMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesXMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesYMember" xlink:label="loc_CVMSeriesYMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesYMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesZZMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesBBMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesZMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesFFMember" xlink:label="loc_CVMSeriesFFMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesFFMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesCCMember" xlink:label="loc_CVMSeriesCCMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesCCMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesHHMember" xlink:label="loc_CVMSeriesHHMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesHHMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesAAMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesJJMember" xlink:label="loc_CVMSeriesJJMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesJJMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesLLMember" xlink:label="loc_CVMSeriesLLMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesLLMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesMMMember" xlink:label="loc_CVMSeriesMMMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesMMMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesNNMember" xlink:label="loc_CVMSeriesNNMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesNNMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesOOMember" xlink:label="loc_CVMSeriesOOMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesOOMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesQQMember" xlink:label="loc_CVMSeriesQQMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesQQMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesGGMember" xlink:label="loc_CVMSeriesGGMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesGGMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesIIMember" xlink:label="loc_CVMSeriesIIMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesIIMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesKKMember" xlink:label="loc_CVMSeriesKKMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesKKMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesPPMember" xlink:label="loc_CVMSeriesPPMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesPPMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ConsultantsMember" xlink:label="loc_CVMConsultantsMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMConsultantsMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNMember_560" xlink:type="arc" order="561" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesRMember" xlink:label="loc_CVMSeriesRMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesRMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesUMember_580" xlink:type="arc" order="581" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember_590" xlink:type="arc" order="591" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember_600" xlink:type="arc" order="601" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember_610" xlink:type="arc" order="611" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesXMember" xlink:label="loc_CVMSeriesXMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesXMember_620" xlink:type="arc" order="621" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesYMember" xlink:label="loc_CVMSeriesYMember_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesYMember_630" xlink:type="arc" order="631" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZZMember_640" xlink:type="arc" order="641" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember_650" xlink:type="arc" order="651" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAAMember_660" xlink:type="arc" order="661" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember_670" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBBMember_670" xlink:type="arc" order="671" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesPMember" xlink:label="loc_CVMSeriesPMember_680" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesPMember_680" xlink:type="arc" order="681" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ConsultantsMember" xlink:label="loc_CVMConsultantsMember_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMConsultantsMember_690" xlink:type="arc" order="691" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_Issuedate2" xlink:label="loc_CVMIssuedate2_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMIssuedate2_850" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_CVMSharesIssuableUponExerciseOfwarrant_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMSharesIssuableUponExerciseOfwarrant_850" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePrice" xlink:label="loc_CVMExercisePrice_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMExercisePrice_850" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationDate1" xlink:label="loc_CVMExpirationDate1_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMExpirationDate1_850" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IssueStartDate" xlink:label="loc_CVMIssueStartDate_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMIssueStartDate_850" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IssueEndDate1" xlink:label="loc_CVMIssueEndDate1_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMIssueEndDate1_850" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationStartDate" xlink:label="loc_CVMExpirationStartDate_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMExpirationStartDate_850" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationEndDate" xlink:label="loc_CVMExpirationEndDate_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMExpirationEndDate_850" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePriceMinimum" xlink:label="loc_CVMExercisePriceMinimum_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMExercisePriceMinimum_850" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePriceMaximum" xlink:label="loc_CVMExercisePriceMaximum_850" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_850" xlink:to="loc_CVMExercisePriceMaximum_850" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:title="00000034 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesUMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZZMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAAMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBBMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesCCMember" xlink:label="loc_CVMSeriesCCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesCCMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesDDMember" xlink:label="loc_CVMSeriesDDMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesDDMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesEEMember" xlink:label="loc_CVMSeriesEEMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesEEMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesFFMember" xlink:label="loc_CVMSeriesFFMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesFFMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesGGMember" xlink:label="loc_CVMSeriesGGMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesGGMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesHHMember" xlink:label="loc_CVMSeriesHHMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesHHMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesIIMember" xlink:label="loc_CVMSeriesIIMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesIIMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesJJMember" xlink:label="loc_CVMSeriesJJMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesJJMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesKKMember" xlink:label="loc_CVMSeriesKKMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesKKMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesLLMember" xlink:label="loc_CVMSeriesLLMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesLLMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_770" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_770" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative_770" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainOnDerivative_770" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:title="00000035 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="00000036 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails" xlink:title="00000037 - Disclosure - 6. PATENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails1" xlink:title="00000038 - Disclosure - 6. PATENTS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:title="00000039 - Disclosure - 6. PATENTS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:title="00000040 - Disclosure - 8. INCOME TAXES Net deferred tax asset (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="00000041 - Disclosure - 8. INCOME TAXES Reconciliation of effective tax rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:title="00000042 - Disclosure - 9. STOCK COMPENSATION Awards (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:title="00000043 - Disclosure - 9. STOCK COMPENSATION Assumptions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:title="00000044 - Disclosure - 9. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_OutstandingMember" xlink:label="loc_CVMOutstandingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_CVMOutstandingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisableMember" xlink:label="loc_CVMExercisableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_CVMExercisableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStockVested" xlink:label="loc_CVMNumberOfStockVested_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStockVested_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfOptionsExercised" xlink:label="loc_CVMNumberOfOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfOptionsExercised_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStocksExpired" xlink:label="loc_CVMNumberOfStocksExpired_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStocksExpired_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStocksCancelled" xlink:label="loc_CVMNumberOfStocksCancelled_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStocksCancelled_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceVested" xlink:label="loc_CVMWeightedAverageExercisePriceVested_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceVested_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceExpired" xlink:label="loc_CVMWeightedAverageExercisePriceExpired_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceExpired_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceCancelled" xlink:label="loc_CVMWeightedAverageExercisePriceCancelled_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceCancelled_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_CVMWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:label="loc_CVMWeightedAverageRemainingContractualLifeInYearsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageRemainingContractualLifeInYearsGranted_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:title="00000045 - Disclosure - 9. STOCK COMPENSATION Nonvested Options (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:title="00000046 - Disclosure - 9. STOCK COMPENSATION RSU (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_RestrictedStockAwardsMember" xlink:label="loc_CVMRestrictedStockAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMRestrictedStockAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedSharesBeginning" xlink:label="loc_CVMNumberOfUnvestedSharesBeginning_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfUnvestedSharesBeginning_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_VestedShares" xlink:label="loc_CVMVestedShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMVestedShares_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantedShares" xlink:label="loc_CVMGrantedShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMGrantedShares_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ForfeitedShares" xlink:label="loc_CVMForfeitedShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMForfeitedShares_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedSharesEnding" xlink:label="loc_CVMNumberOfUnvestedSharesEnding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfUnvestedSharesEnding_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageGrantDateFairValueEnding" xlink:label="loc_CVMWeightedAverageGrantDateFairValueEnding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageGrantDateFairValueEnding_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:title="00000047 - Disclosure - 9. STOCK COMPENSATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="00000048 - Disclosure - 10. EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000050 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000051 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaapGainContingenciesByNatureAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGainContingenciesByNatureAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaapGainContingencyNatureDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGainContingenciesByNatureAxis" xlink:to="loc_us-gaapGainContingencyNatureDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaapGainContingencyNatureDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGainContingenciesByNatureAxis" xlink:to="loc_us-gaapGainContingencyNatureDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaapCollaborativeArrangementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapCollaborativeArrangementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SanTomasMember" xlink:label="loc_CVMSanTomasMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CVMSanTomasMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_TotalDeferredRentAsset" xlink:label="loc_CVMTotalDeferredRentAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMTotalDeferredRentAsset_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredRentNetOfCurrentPortion" xlink:label="loc_CVMDeferredRentNetOfCurrentPortion_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMDeferredRentNetOfCurrentPortion_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_RDDeferredRentLiability" xlink:label="loc_CVMRDDeferredRentLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMRDDeferredRentLiability_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredRentLiability" xlink:label="loc_CVMDeferredRentLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMDeferredRentLiability_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases_90" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:title="00000052 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:title="00000053 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:title="00000054 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:title="00000055 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details 1)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cvm-20170930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 172274 09302017 10K.xfr; Date: 2017%2D12%2D29T16:05:42Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_OutstandingMember" xlink:label="CVM_OutstandingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OutstandingMember" xlink:to="CVM_OutstandingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_OutstandingMember_lbl" xml:lang="en-US">Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisableMember" xlink:label="CVM_ExercisableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisableMember" xlink:to="CVM_ExercisableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisableMember_lbl" xml:lang="en-US">Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class Of Warrant Or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesNMember" xlink:label="CVM_SeriesNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesNMember" xlink:to="CVM_SeriesNMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesNMember_lbl" xml:lang="en-US">Series N [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesRMember" xlink:label="CVM_SeriesRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesRMember" xlink:to="CVM_SeriesRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesRMember_lbl" xml:lang="en-US">SeriesRMember</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesPMember" xlink:label="CVM_SeriesPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesPMember" xlink:to="CVM_SeriesPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesPMember_lbl" xml:lang="en-US">Series P [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ConsultantsMember" xlink:label="CVM_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConsultantsMember" xlink:to="CVM_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesSMember" xlink:label="CVM_SeriesSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesSMember" xlink:to="CVM_SeriesSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesSMember_lbl" xml:lang="en-US">Series S [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesUMember" xlink:label="CVM_SeriesUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesUMember" xlink:to="CVM_SeriesUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesUMember_lbl" xml:lang="en-US">Series U [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Ergomed Collaborative Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesVMember" xlink:label="CVM_SeriesVMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesVMember" xlink:to="CVM_SeriesVMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesVMember_lbl" xml:lang="en-US">Series V [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesWMember" xlink:label="CVM_SeriesWMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesWMember" xlink:to="CVM_SeriesWMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesWMember_lbl" xml:lang="en-US">Series W [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZMember" xlink:label="CVM_SeriesZMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesZMember" xlink:to="CVM_SeriesZMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesZMember_lbl" xml:lang="en-US">Series Z [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZZMember" xlink:label="CVM_SeriesZZMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesZZMember" xlink:to="CVM_SeriesZZMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesZZMember_lbl" xml:lang="en-US">Series ZZ [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesAAMember" xlink:label="CVM_SeriesAAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesAAMember" xlink:to="CVM_SeriesAAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesAAMember_lbl" xml:lang="en-US">Series AA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesBBMember" xlink:label="CVM_SeriesBBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesBBMember" xlink:to="CVM_SeriesBBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesBBMember_lbl" xml:lang="en-US">Series BB [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesWMember" xlink:to="CVM_SeriesWMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_SeriesWMember_2_lbl" xml:lang="en-US">Series V [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesXMember" xlink:label="CVM_SeriesXMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesXMember" xlink:to="CVM_SeriesXMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesXMember_lbl" xml:lang="en-US">Series X [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesYMember" xlink:label="CVM_SeriesYMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesYMember" xlink:to="CVM_SeriesYMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesYMember_lbl" xml:lang="en-US">Series Y [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_RestrictedStockAwardsMember" xlink:label="CVM_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RestrictedStockAwardsMember" xlink:to="CVM_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SanTomasMember" xlink:label="CVM_SanTomasMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SanTomasMember" xlink:to="CVM_SanTomasMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SanTomasMember_lbl" xml:lang="en-US">San Tomas</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesCCMember" xlink:label="CVM_SeriesCCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesCCMember" xlink:to="CVM_SeriesCCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesCCMember_lbl" xml:lang="en-US">Series CC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesDDMember" xlink:label="CVM_SeriesDDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesDDMember" xlink:to="CVM_SeriesDDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesDDMember_lbl" xml:lang="en-US">Series DD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesEEMember" xlink:label="CVM_SeriesEEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesEEMember" xlink:to="CVM_SeriesEEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesEEMember_lbl" xml:lang="en-US">Series EE [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesFFMember" xlink:label="CVM_SeriesFFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFFMember" xlink:to="CVM_SeriesFFMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesFFMember_lbl" xml:lang="en-US">Series FF [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesGGMember" xlink:label="CVM_SeriesGGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesGGMember" xlink:to="CVM_SeriesGGMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesGGMember_lbl" xml:lang="en-US">Series GG [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesHHMember" xlink:label="CVM_SeriesHHMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesHHMember" xlink:to="CVM_SeriesHHMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesHHMember_lbl" xml:lang="en-US">Series HH [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesIIMember" xlink:label="CVM_SeriesIIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesIIMember" xlink:to="CVM_SeriesIIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesIIMember_lbl" xml:lang="en-US">Series II [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesJJMember" xlink:label="CVM_SeriesJJMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesJJMember" xlink:to="CVM_SeriesJJMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesJJMember_lbl" xml:lang="en-US">Series JJ [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesKKMember" xlink:label="CVM_SeriesKKMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKKMember" xlink:to="CVM_SeriesKKMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesKKMember_lbl" xml:lang="en-US">Series KK [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesLLMember" xlink:label="CVM_SeriesLLMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesLLMember" xlink:to="CVM_SeriesLLMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesLLMember_lbl" xml:lang="en-US">Series LL [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesMMMember" xlink:label="CVM_SeriesMMMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesMMMember" xlink:to="CVM_SeriesMMMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesMMMember_lbl" xml:lang="en-US">Series MM [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesNNMember" xlink:label="CVM_SeriesNNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesNNMember" xlink:to="CVM_SeriesNNMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesNNMember_lbl" xml:lang="en-US">Series NN [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesOOMember" xlink:label="CVM_SeriesOOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesOOMember" xlink:to="CVM_SeriesOOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesOOMember_lbl" xml:lang="en-US">Series OO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesQQMember" xlink:label="CVM_SeriesQQMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQQMember" xlink:to="CVM_SeriesQQMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesQQMember_lbl" xml:lang="en-US">Series QQ [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesPPMember" xlink:label="CVM_SeriesPPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesPPMember" xlink:to="CVM_SeriesPPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesPPMember_lbl" xml:lang="en-US">Series PP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">FairValueByFairValueHierarchyLevel [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DocumentAndEntityInformationAbstract" xlink:label="CVM_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DocumentAndEntityInformationAbstract" xlink:to="CVM_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Adjustment to Deferreds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory used for R&amp;D and manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Plant, property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patent costs, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xml:lang="en-US">Due to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="us-gaap_NotesAndLoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayableCurrent" xlink:to="us-gaap_NotesAndLoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansPayableCurrent_lbl" xml:lang="en-US">Notes payable, net of discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl" xml:lang="en-US">Derivative instruments, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative instruments, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.01 par value- 200,000 shares authorized; -0- shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.01 par value - 600,000,000 shares authorized; 11,903,133 and 6,248,035 shares issued and outstanding at September 30, 2017 and 2016, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock Shares Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock Shares Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">GRANT INCOME AND OTHER</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General &amp; administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainOnDerivative_lbl" xml:lang="en-US">Gain on derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ModificationOfWarrants1" xlink:label="CVM_ModificationOfWarrants1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ModificationOfWarrants1" xlink:to="CVM_ModificationOfWarrants1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CVM_ModificationOfWarrants1_lbl" xml:lang="en-US">Modification of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">BALANCE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">BALANCE, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Issuance of warrants in connection with sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WarrantsIssuedWithNotesPayable" xlink:label="CVM_WarrantsIssuedWithNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WarrantsIssuedWithNotesPayable" xlink:to="CVM_WarrantsIssuedWithNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WarrantsIssuedWithNotesPayable_lbl" xml:lang="en-US">Warrants issued with notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">401(k) contributions paid in common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">401(k) contributions paid in common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Conversion of notes payable to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of notes payable to common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued to nonemployees for service</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued to nonemployees for service, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Ergomed stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Ergomed stock issuance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Equity based compensation - employees</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:label="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:to="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions_lbl" xml:lang="en-US">Equity based compensation - employees, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_EquityBasedCompensationNonemployees" xlink:label="CVM_EquityBasedCompensationNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EquityBasedCompensationNonemployees" xlink:to="CVM_EquityBasedCompensationNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_EquityBasedCompensationNonemployees_lbl" xml:lang="en-US">Equity based compensation - non-employees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">BALANCE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">BALANCE, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Share based payments for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Equity based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_2_lbl" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on retired equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainOnDerivative_2_lbl" xml:lang="en-US">Gain on derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CapitalizedLeaseInterest" xlink:label="CVM_CapitalizedLeaseInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CapitalizedLeaseInterest" xlink:to="CVM_CapitalizedLeaseInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CVM_CapitalizedLeaseInterest_lbl" xml:lang="en-US">Capitalized lease interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory used for R&amp;D and manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xml:lang="en-US">Due to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US">Deferred rent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Expenditures for patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xml:lang="en-US">Payment on related party loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on obligations under capital lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:label="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:to="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd_lbl" xml:lang="en-US">Lease payments included in accounts payable at year end</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:label="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:to="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants_lbl" xml:lang="en-US">Fair value of warrant liabilities on the date of issuance reclassed to liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncreaseInDirectFinancingCosts" xlink:label="CVM_IncreaseInDirectFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInDirectFinancingCosts" xlink:to="CVM_IncreaseInDirectFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInDirectFinancingCosts_lbl" xml:lang="en-US">Financing costs included in accounts payable at year end</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncreaseInPrepaidServices" xlink:label="CVM_IncreaseInPrepaidServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInPrepaidServices" xlink:to="CVM_IncreaseInPrepaidServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInPrepaidServices_lbl" xml:lang="en-US">Prepaid amount under consulting services paid with issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable" xlink:label="CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable" xlink:to="CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable_lbl" xml:lang="en-US">Conversion of accrued salaries and fees to notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="CVM_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NotesToFinancialStatementsAbstract" xlink:to="CVM_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">1. ORGANIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_OperationsAndFinancingTextBlock" xlink:label="CVM_OperationsAndFinancingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OperationsAndFinancingTextBlock" xlink:to="CVM_OperationsAndFinancingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_OperationsAndFinancingTextBlock_lbl" xml:lang="en-US">2. OPERATIONS AND FINANCING</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="CVM_SummaryOfSignificantAccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="CVM_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">4. WARRANTS AND NON-EMPLOYEE OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">5. PLANT, PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">6. PATENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">7. NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">8. INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">9. STOCK COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">10. EMPLOYEE BENEFIT PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">11. COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">12. RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockholdersEquityTextBlock" xlink:label="CVM_StockholdersEquityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityTextBlock" xlink:to="CVM_StockholdersEquityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockholdersEquityTextBlock_lbl" xml:lang="en-US">13. STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">14. FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">15. NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">16. SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_Deposits2" xlink:label="CVM_Deposits2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Deposits2" xlink:to="CVM_Deposits2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_Deposits2_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xml:lang="en-US">Plant, Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Rent (Asset)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xml:lang="en-US">Derivative Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantIncomePolicyTextBlock" xlink:label="CVM_GrantIncomePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantIncomePolicyTextBlock" xlink:to="CVM_GrantIncomePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ResearchAndDevelopmentGrantRevenues" xlink:label="CVM_ResearchAndDevelopmentGrantRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ResearchAndDevelopmentGrantRevenues" xlink:to="CVM_ResearchAndDevelopmentGrantRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ResearchAndDevelopmentGrantRevenues_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" xlink:label="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" xlink:to="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding_lbl" xml:lang="en-US">Derivative liabilities, warrants and other options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Plant, property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PatentsTablesAbstract" xlink:label="CVM_PatentsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsTablesAbstract" xlink:to="CVM_PatentsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsTablesAbstract_lbl" xml:lang="en-US">Net Loss Per Common Share Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Reconciliation of effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:label="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:to="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock_lbl" xml:lang="en-US">Employees and non-employees stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Assumptions for Option Pricing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Stock Option Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ScheduleOfNonvestedOptionsTableTextBlock" xlink:label="CVM_ScheduleOfNonvestedOptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfNonvestedOptionsTableTextBlock" xlink:to="CVM_ScheduleOfNonvestedOptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ScheduleOfNonvestedOptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of non-vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CommitmentsAndContingenciesTablesAbstract" xlink:label="CVM_CommitmentsAndContingenciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesTablesAbstract" xlink:to="CVM_CommitmentsAndContingenciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_CommitmentsAndContingenciesTablesAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Future minimum lease payments under the San Tomas lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum annual rental payments due under non-cancelable operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FairValueMeasurementsTablesAbstract" xlink:label="CVM_FairValueMeasurementsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsTablesAbstract" xlink:to="CVM_FairValueMeasurementsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueMeasurementsTablesAbstract_lbl" xml:lang="en-US">Fair Value Measurements Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Measured at fair value on a recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NetLossPerCommonShareTablesAbstract" xlink:label="CVM_NetLossPerCommonShareTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NetLossPerCommonShareTablesAbstract" xlink:to="CVM_NetLossPerCommonShareTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_NetLossPerCommonShareTablesAbstract_lbl" xml:lang="en-US">Net Loss Per Common Share Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Antidilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:label="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:to="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies Details</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" xlink:label="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" xlink:to="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances_lbl" xml:lang="en-US">Fully Insured Amount of non-interest bearing cash balances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_2_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_Issuedate2" xlink:label="CVM_Issuedate2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Issuedate2" xlink:to="CVM_Issuedate2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_Issuedate2_lbl" xml:lang="en-US">Issue Date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SharesIssuableUponExerciseOfwarrant" xlink:to="CVM_SharesIssuableUponExerciseOfwarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant_lbl" xml:lang="en-US">Shares Issuable upon Exercise of Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePrice" xlink:label="CVM_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePrice" xlink:to="CVM_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationDate1" xlink:label="CVM_ExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationDate1" xlink:to="CVM_ExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpirationDate1_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IssueStartDate" xlink:label="CVM_IssueStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueStartDate" xlink:to="CVM_IssueStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IssueStartDate_lbl" xml:lang="en-US">Issue Start date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IssueEndDate1" xlink:label="CVM_IssueEndDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueEndDate1" xlink:to="CVM_IssueEndDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IssueEndDate1_lbl" xml:lang="en-US">Issue End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationStartDate" xlink:label="CVM_ExpirationStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationStartDate" xlink:to="CVM_ExpirationStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpirationStartDate_lbl" xml:lang="en-US">Expiration start date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationEndDate" xlink:label="CVM_ExpirationEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationEndDate" xlink:to="CVM_ExpirationEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpirationEndDate_lbl" xml:lang="en-US">Expiration end date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePriceMinimum" xlink:label="CVM_ExercisePriceMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMinimum" xlink:to="CVM_ExercisePriceMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePriceMinimum_lbl" xml:lang="en-US">Exercise Price Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePriceMaximum" xlink:label="CVM_ExercisePriceMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMaximum" xlink:to="CVM_ExercisePriceMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePriceMaximum_lbl" xml:lang="en-US">Exercise Price Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Total warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainOnDerivative_3_lbl" xml:lang="en-US">Net gain on warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ResearchAndOfficeEquipmentDetailsAbstract" xlink:label="CVM_ResearchAndOfficeEquipmentDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ResearchAndOfficeEquipmentDetailsAbstract" xlink:to="CVM_ResearchAndOfficeEquipmentDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ResearchAndOfficeEquipmentDetailsAbstract_lbl" xml:lang="en-US">Plant Property And Equipment Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="us-gaap_CapitalLeasedAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasedAssetsGross" xlink:to="us-gaap_CapitalLeasedAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasedAssetsGross_lbl" xml:lang="en-US">Leased manufacturing facility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="us-gaap_FixturesAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FixturesAndEquipmentGross" xlink:to="us-gaap_FixturesAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FixturesAndEquipmentGross_lbl" xml:lang="en-US">Research equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Net research and office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" xlink:label="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" xlink:to="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract_lbl" xml:lang="en-US">Plant Property And Equipment Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Net Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PatentsDetailsAbstract" xlink:label="CVM_PatentsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsDetailsAbstract" xlink:to="CVM_PatentsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsDetailsAbstract_lbl" xml:lang="en-US">Patents Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PatentsDetailsNarrativeAbstract" xlink:label="CVM_PatentsDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsDetailsNarrativeAbstract" xlink:to="CVM_PatentsDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsDetailsNarrativeAbstract_lbl" xml:lang="en-US">Patents Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:label="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract_lbl" xml:lang="en-US">Income Taxes Net Deferred Tax Asset Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">R&amp;D credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Fixed assets and intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:to="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl" xml:lang="en-US">Capitalized R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US">Vacation and other</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_LoanModification" xlink:label="CVM_LoanModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_LoanModification" xlink:to="CVM_LoanModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_LoanModification_lbl" xml:lang="en-US">Loan modification</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FixedAssetsAndIntangibles" xlink:label="CVM_FixedAssetsAndIntangibles" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FixedAssetsAndIntangibles" xlink:to="CVM_FixedAssetsAndIntangibles_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_FixedAssetsAndIntangibles_lbl" xml:lang="en-US">Fixed assets and intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">DeferredTaxAssetsLiabilitiesNet</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:label="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract_lbl" xml:lang="en-US">Income Taxes Reconciliation Of Effective Tax Rate Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">State tax rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes" xlink:label="CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes" xlink:to="CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes_lbl" xml:lang="en-US">Expired tax attributes</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:label="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:to="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_lbl" xml:lang="en-US">Adjustment to Deferreds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockholdersEquityDetails1Abstract" xlink:label="CVM_StockholdersEquityDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityDetails1Abstract" xlink:to="CVM_StockholdersEquityDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockholdersEquityDetails1Abstract_lbl" xml:lang="en-US">Stock Compensation Awards Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US">Employees</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NonemployeesShareBasedCompensation" xlink:label="CVM_NonemployeesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonemployeesShareBasedCompensation" xlink:to="CVM_NonemployeesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NonemployeesShareBasedCompensation_lbl" xml:lang="en-US">Non-employees</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationDetailsAbstract" xlink:label="CVM_StockCompensationDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationDetailsAbstract" xlink:to="CVM_StockCompensationDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockCompensationDetailsAbstract_lbl" xml:lang="en-US">Stock Compensation Assumptions Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected stock price volatility, min</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected stock price volatility, max</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, min</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, max</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpectedLifeOfOptionsMin1" xlink:label="CVM_ExpectedLifeOfOptionsMin1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpectedLifeOfOptionsMin1" xlink:to="CVM_ExpectedLifeOfOptionsMin1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpectedLifeOfOptionsMin1_lbl" xml:lang="en-US">Expected life of options, min</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpectedLifeOfOptionsMax" xlink:label="CVM_ExpectedLifeOfOptionsMax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpectedLifeOfOptionsMax" xlink:to="CVM_ExpectedLifeOfOptionsMax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpectedLifeOfOptionsMax_lbl" xml:lang="en-US">Expected life of options, max</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStockVested" xlink:label="CVM_NumberOfStockVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStockVested" xlink:to="CVM_NumberOfStockVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfStockVested_lbl" xml:lang="en-US">Number of Options Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfOptionsExercised" xlink:label="CVM_NumberOfOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfOptionsExercised" xlink:to="CVM_NumberOfOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CVM_NumberOfOptionsExercised_lbl" xml:lang="en-US">Number of Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStocksExpired" xlink:label="CVM_NumberOfStocksExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStocksExpired" xlink:to="CVM_NumberOfStocksExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfStocksExpired_lbl" xml:lang="en-US">Number of Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStocksCancelled" xlink:label="CVM_NumberOfStocksCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStocksCancelled" xlink:to="CVM_NumberOfStocksCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfStocksCancelled_lbl" xml:lang="en-US">Number of Options Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceVested" xlink:label="CVM_WeightedAverageExercisePriceVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceVested" xlink:to="CVM_WeightedAverageExercisePriceVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageExercisePriceVested_lbl" xml:lang="en-US">Weighted Average Exercise Price Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceExpired" xlink:label="CVM_WeightedAverageExercisePriceExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceExpired" xlink:to="CVM_WeightedAverageExercisePriceExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageExercisePriceExpired_lbl" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceCancelled" xlink:label="CVM_WeightedAverageExercisePriceCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceCancelled" xlink:to="CVM_WeightedAverageExercisePriceCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageExercisePriceCancelled_lbl" xml:lang="en-US">Weighted Average Exercise Price Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:to="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years) Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:to="CVM_WeightedAverageRemainingContractualLifeInYearsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsGranted_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years) granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationNonvestedOptionsDetailsAbstract" xlink:label="CVM_StockCompensationNonvestedOptionsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationNonvestedOptionsDetailsAbstract" xlink:to="CVM_StockCompensationNonvestedOptionsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockCompensationNonvestedOptionsDetailsAbstract_lbl" xml:lang="en-US">Stock Compensation Nonvested Options Details</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedOptionsBeginning" xlink:label="CVM_NumberOfUnvestedOptionsBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedOptionsBeginning" xlink:to="CVM_NumberOfUnvestedOptionsBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfUnvestedOptionsBeginning_lbl" xml:lang="en-US">Number of unvested options, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_VestedOptions" xlink:label="CVM_VestedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_VestedOptions" xlink:to="CVM_VestedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_VestedOptions_lbl" xml:lang="en-US">Vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantedOptions" xlink:label="CVM_GrantedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantedOptions" xlink:to="CVM_GrantedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GrantedOptions_lbl" xml:lang="en-US">Granted options</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ForfeitedOptions" xlink:label="CVM_ForfeitedOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitedOptions" xlink:to="CVM_ForfeitedOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ForfeitedOptions_lbl" xml:lang="en-US">Forfeited options</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedOptionsEnding" xlink:label="CVM_NumberOfUnvestedOptionsEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedOptionsEnding" xlink:to="CVM_NumberOfUnvestedOptionsEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfUnvestedOptionsEnding_lbl" xml:lang="en-US">Number of unvested options, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageGrantDateFairValueBeginning" xlink:label="CVM_WeightedAverageGrantDateFairValueBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageGrantDateFairValueBeginning" xlink:to="CVM_WeightedAverageGrantDateFairValueBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageGrantDateFairValueBeginning_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantedWeightedAverageGrantDateFairValue" xlink:label="CVM_GrantedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantedWeightedAverageGrantDateFairValue" xlink:to="CVM_GrantedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GrantedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageGrantDateFairValueEnding" xlink:label="CVM_WeightedAverageGrantDateFairValueEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageGrantDateFairValueEnding" xlink:to="CVM_WeightedAverageGrantDateFairValueEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_WeightedAverageGrantDateFairValueEnding_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedSharesBeginning" xlink:label="CVM_NumberOfUnvestedSharesBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedSharesBeginning" xlink:to="CVM_NumberOfUnvestedSharesBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfUnvestedSharesBeginning_lbl" xml:lang="en-US">Number of unvested shares, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_VestedShares" xlink:label="CVM_VestedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_VestedShares" xlink:to="CVM_VestedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_VestedShares_lbl" xml:lang="en-US">Vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantedShares" xlink:label="CVM_GrantedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantedShares" xlink:to="CVM_GrantedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GrantedShares_lbl" xml:lang="en-US">Granted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ForfeitedShares" xlink:label="CVM_ForfeitedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitedShares" xlink:to="CVM_ForfeitedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ForfeitedShares_lbl" xml:lang="en-US">Forfeited shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedSharesEnding" xlink:label="CVM_NumberOfUnvestedSharesEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedSharesEnding" xlink:to="CVM_NumberOfUnvestedSharesEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfUnvestedSharesEnding_lbl" xml:lang="en-US">Number of unvested shares, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationDetailsNarrativeAbstract" xlink:label="CVM_StockCompensationDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationDetailsNarrativeAbstract" xlink:to="CVM_StockCompensationDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockCompensationDetailsNarrativeAbstract_lbl" xml:lang="en-US">Stock Compensation Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Expense recognized for options issued or vested during the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Expense relating to the restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xml:lang="en-US">Employee Benefits and Share-based Compensation, Noncash [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Expense for Company's contribution to employee benefit plan</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:to="CVM_CommitmentsAndContingenciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xml:lang="en-US">Total future minimum lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xml:lang="en-US">Less imputed interest on financing obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Net present value of lease financing obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="us-gaap_GainContingenciesByNatureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingenciesByNatureAxis" xlink:to="us-gaap_GainContingenciesByNatureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingenciesByNatureAxis_lbl" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense, including amortization of deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_TotalDeferredRentAsset" xlink:label="CVM_TotalDeferredRentAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_TotalDeferredRentAsset" xlink:to="CVM_TotalDeferredRentAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CVM_TotalDeferredRentAsset_lbl" xml:lang="en-US">Total deferred rent asset</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredRentNetOfCurrentPortion" xlink:label="CVM_DeferredRentNetOfCurrentPortion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentNetOfCurrentPortion" xlink:to="CVM_DeferredRentNetOfCurrentPortion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DeferredRentNetOfCurrentPortion_lbl" xml:lang="en-US">Deferred rent asset, non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_RDDeferredRentLiability" xlink:label="CVM_RDDeferredRentLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RDDeferredRentLiability" xlink:to="CVM_RDDeferredRentLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_RDDeferredRentLiability_lbl" xml:lang="en-US">R &amp; D deferred rent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredRentLiability" xlink:label="CVM_DeferredRentLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiability" xlink:to="CVM_DeferredRentLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_DeferredRentLiability_lbl" xml:lang="en-US">Deferred rent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases_lbl" xml:lang="en-US">Office equipment leased under a capital lease arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_2_lbl" xml:lang="en-US">Derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FairValueMeasurementsDetails1Abstract" xlink:label="CVM_FairValueMeasurementsDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsDetails1Abstract" xlink:to="CVM_FairValueMeasurementsDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueMeasurementsDetails1Abstract_lbl" xml:lang="en-US">Fair Value Measurements Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements_lbl" xml:lang="en-US">Settlements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US">Transfers to Level 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl" xml:lang="en-US">Net realized and unrealized derivative (gain)/loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_I.EarningsPerShareDetailsAbstract" xlink:label="CVM_I.EarningsPerShareDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_I.EarningsPerShareDetailsAbstract" xlink:to="CVM_I.EarningsPerShareDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_I.EarningsPerShareDetailsAbstract_lbl" xml:lang="en-US">Net Loss Per Common Share Details</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss - available to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GainOnDerivativeInstruments" xlink:label="CVM_GainOnDerivativeInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainOnDerivativeInstruments" xlink:to="CVM_GainOnDerivativeInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainOnDerivativeInstruments_lbl" xml:lang="en-US">Less: Gain on derivative Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of shares - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncrementalCommonSharesAttributableToGainOnDerivatives" xlink:label="CVM_IncrementalCommonSharesAttributableToGainOnDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncrementalCommonSharesAttributableToGainOnDerivatives" xlink:to="CVM_IncrementalCommonSharesAttributableToGainOnDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncrementalCommonSharesAttributableToGainOnDerivatives_lbl" xml:lang="en-US">Less: gain on derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average number of shares - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares - basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Loss per share - basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Loss per share - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">LPS - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_I.EarningsPerShareDetailsNarrativeAbstract" xlink:label="CVM_I.EarningsPerShareDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_I.EarningsPerShareDetailsNarrativeAbstract" xlink:to="CVM_I.EarningsPerShareDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_I.EarningsPerShareDetailsNarrativeAbstract_lbl" xml:lang="en-US">Net Loss Per Common Share Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" xlink:label="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" xlink:to="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_OptionsAndWarrantsExcludedFromEarningsPerShare_lbl" xml:lang="en-US">Options and Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_AntidilutiveConvertibleDebt" xlink:label="CVM_AntidilutiveConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_AntidilutiveConvertibleDebt" xlink:to="CVM_AntidilutiveConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_AntidilutiveConvertibleDebt_lbl" xml:lang="en-US">Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_AntidilutiveUnvestedRestrictedStock" xlink:label="CVM_AntidilutiveUnvestedRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_AntidilutiveUnvestedRestrictedStock" xlink:to="CVM_AntidilutiveUnvestedRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_AntidilutiveUnvestedRestrictedStock_lbl" xml:lang="en-US">Unvested Restricted Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_BasicAndDilutiveEPSMember" xlink:label="CVM_BasicAndDilutiveEPSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_BasicAndDilutiveEPSMember" xlink:to="CVM_BasicAndDilutiveEPSMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_BasicAndDilutiveEPSMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_BasicEpsMember" xlink:label="CVM_BasicEpsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_BasicEpsMember" xlink:to="CVM_BasicEpsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_BasicEpsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CSchleuningSeriesAMember" xlink:label="CVM_CSchleuningSeriesAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CSchleuningSeriesAMember" xlink:to="CVM_CSchleuningSeriesAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CSchleuningSeriesAMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:to="CVM_CommitmentsAndContingenciesDetailsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:label="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:to="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesTablesAbstract" xlink:to="CVM_CommitmentsAndContingenciesTablesAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CommitmentsAndContingenciesTablesAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConsultantsMember" xlink:to="CVM_ConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ConsultantsMember_doc" xml:lang="en-US">Consultants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ConvertibleNotesSettlementMember" xlink:label="CVM_ConvertibleNotesSettlementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConvertibleNotesSettlementMember" xlink:to="CVM_ConvertibleNotesSettlementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ConvertibleNotesSettlementMember_doc" xml:lang="en-US">Convertible Notes Settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiability" xlink:to="CVM_DeferredRentLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DeferredRentLiability_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredRentLiabilityMember" xlink:label="CVM_DeferredRentLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiabilityMember" xlink:to="CVM_DeferredRentLiabilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DeferredRentLiabilityMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentNetOfCurrentPortion" xlink:to="CVM_DeferredRentNetOfCurrentPortion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DeferredRentNetOfCurrentPortion_doc" xml:lang="en-US">Deferred Rent Net Of Current Portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:to="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Deposits2" xlink:to="CVM_Deposits2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Deposits2_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DerivativeLiabilitiesGainMember" xlink:label="CVM_DerivativeLiabilitiesGainMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DerivativeLiabilitiesGainMember" xlink:to="CVM_DerivativeLiabilitiesGainMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DerivativeLiabilitiesGainMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DilutiveEpsMember" xlink:label="CVM_DilutiveEpsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DilutiveEpsMember" xlink:to="CVM_DilutiveEpsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DilutiveEpsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:to="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes" xlink:to="CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisableMember" xlink:to="CVM_ExercisableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisableMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePrice" xlink:to="CVM_ExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMaximum" xlink:to="CVM_ExercisePriceMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePriceMaximum_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMinimum" xlink:to="CVM_ExercisePriceMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePriceMinimum_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpectedLifeOfOptionsMax" xlink:to="CVM_ExpectedLifeOfOptionsMax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpectedLifeOfOptionsMax_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpectedLifeOfOptionsMin1" xlink:to="CVM_ExpectedLifeOfOptionsMin1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpectedLifeOfOptionsMin1_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationDate1" xlink:to="CVM_ExpirationDate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpirationDate1_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationEndDate" xlink:to="CVM_ExpirationEndDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpirationEndDate_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationStartDate" xlink:to="CVM_ExpirationStartDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpirationStartDate_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_Financings2009WarrantsSeriesAToEMember" xlink:label="CVM_Financings2009WarrantsSeriesAToEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Financings2009WarrantsSeriesAToEMember" xlink:to="CVM_Financings2009WarrantsSeriesAToEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Financings2009WarrantsSeriesAToEMember_doc" xml:lang="en-US">Financings 2009 Warrants Series A To E.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ForfeitedShares" xlink:to="CVM_ForfeitedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ForfeitedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" xlink:to="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_FullyInsuredAmountOfNoninterestBearingCashBalances_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantedShares" xlink:to="CVM_GrantedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_GrantedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GrantedWeightedAverageGrantDateFairValue" xlink:to="CVM_GrantedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_GrantedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncentiveStockOptionPlansMember" xlink:label="CVM_IncentiveStockOptionPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncentiveStockOptionPlansMember" xlink:to="CVM_IncentiveStockOptionPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IncentiveStockOptionPlansMember_doc" xml:lang="en-US">Incentive Stock Option Plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:to="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants_doc" xml:lang="en-US">Increase In Derivative Liabilities From Issuance Of Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueEndDate1" xlink:to="CVM_IssueEndDate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IssueEndDate1_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueStartDate" xlink:to="CVM_IssueStartDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IssueStartDate_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Issuedate2" xlink:to="CVM_Issuedate2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Issuedate2_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ModificationOfWarrants1" xlink:to="CVM_ModificationOfWarrants1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ModificationOfWarrants1_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NetLossPerCommonShareTablesAbstract" xlink:to="CVM_NetLossPerCommonShareTablesAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NetLossPerCommonShareTablesAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NonQualifiedStockOptionPlansMember" xlink:label="CVM_NonQualifiedStockOptionPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonQualifiedStockOptionPlansMember" xlink:to="CVM_NonQualifiedStockOptionPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NonQualifiedStockOptionPlansMember_doc" xml:lang="en-US">Non Qualified Stock Option Plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonemployeesShareBasedCompensation" xlink:to="CVM_NonemployeesShareBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NonemployeesShareBasedCompensation_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfOptionsExercised" xlink:to="CVM_NumberOfOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfOptionsExercised_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStockVested" xlink:to="CVM_NumberOfStockVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfStockVested_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStocksCancelled" xlink:to="CVM_NumberOfStocksCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfStocksCancelled_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfStocksExpired" xlink:to="CVM_NumberOfStocksExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfStocksExpired_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedSharesBeginning" xlink:to="CVM_NumberOfUnvestedSharesBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfUnvestedSharesBeginning_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfUnvestedSharesEnding" xlink:to="CVM_NumberOfUnvestedSharesEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NumberOfUnvestedSharesEnding_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OperationsAndFinancingTextBlock" xlink:to="CVM_OperationsAndFinancingTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_OperationsAndFinancingTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OutstandingMember" xlink:to="CVM_OutstandingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_OutstandingMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PrivateInvestorWarrants1Member" xlink:label="CVM_PrivateInvestorWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants1Member" xlink:to="CVM_PrivateInvestorWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants1Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PrivateInvestorWarrants2Member" xlink:label="CVM_PrivateInvestorWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants2Member" xlink:to="CVM_PrivateInvestorWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants2Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PrivateInvestorWarrants3Member" xlink:label="CVM_PrivateInvestorWarrants3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants3Member" xlink:to="CVM_PrivateInvestorWarrants3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants3Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PrivateInvestorWarrantsMember" xlink:label="CVM_PrivateInvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrantsMember" xlink:to="CVM_PrivateInvestorWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PrivateInvestorsMember" xlink:label="CVM_PrivateInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorsMember" xlink:to="CVM_PrivateInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorsMember_doc" xml:lang="en-US">Private Investors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_RDDeferredRentLiability" xlink:to="CVM_RDDeferredRentLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_RDDeferredRentLiability_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ResearchAndDevelopmentGrantRevenues" xlink:to="CVM_ResearchAndDevelopmentGrantRevenues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ResearchAndDevelopmentGrantRevenues_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:to="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfNonvestedOptionsTableTextBlock" xlink:to="CVM_ScheduleOfNonvestedOptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ScheduleOfNonvestedOptionsTableTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesAThroughEWarrantsMember" xlink:label="CVM_SeriesAThroughEWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesAThroughEWarrantsMember" xlink:to="CVM_SeriesAThroughEWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesAThroughEWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesCMember" xlink:label="CVM_SeriesCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesCMember" xlink:to="CVM_SeriesCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesCMember_doc" xml:lang="en-US">Series C.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesEMember" xlink:label="CVM_SeriesEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesEMember" xlink:to="CVM_SeriesEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesEMember_doc" xml:lang="en-US">Series E.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesFAndGWarrantsMember" xlink:label="CVM_SeriesFAndGWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFAndGWarrantsMember" xlink:to="CVM_SeriesFAndGWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesFAndGWarrantsMember_doc" xml:lang="en-US">Series F And G Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesFMember" xlink:label="CVM_SeriesFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFMember" xlink:to="CVM_SeriesFMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesFMember_doc" xml:lang="en-US">Series F.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesGMember" xlink:label="CVM_SeriesGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesGMember" xlink:to="CVM_SeriesGMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesGMember_doc" xml:lang="en-US">Series G.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesHMember" xlink:label="CVM_SeriesHMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesHMember" xlink:to="CVM_SeriesHMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesHMember_doc" xml:lang="en-US">Series H.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesKAndLWarrantsMember" xlink:label="CVM_SeriesKAndLWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKAndLWarrantsMember" xlink:to="CVM_SeriesKAndLWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesKAndLWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesKAndSeriesAThroughEWarrantsMember" xlink:label="CVM_SeriesKAndSeriesAThroughEWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKAndSeriesAThroughEWarrantsMember" xlink:to="CVM_SeriesKAndSeriesAThroughEWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesKAndSeriesAThroughEWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesKwarrantsMember" xlink:label="CVM_SeriesKwarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKwarrantsMember" xlink:to="CVM_SeriesKwarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesKwarrantsMember_doc" xml:lang="en-US">Series K warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesLMember" xlink:label="CVM_SeriesLMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesLMember" xlink:to="CVM_SeriesLMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesLMember_doc" xml:lang="en-US">Series L.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesLRepricedMember" xlink:label="CVM_SeriesLRepricedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesLRepricedMember" xlink:to="CVM_SeriesLRepricedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesLRepricedMember_doc" xml:lang="en-US">Series L Repriced.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesMModifiedMember" xlink:label="CVM_SeriesMModifiedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesMModifiedMember" xlink:to="CVM_SeriesMModifiedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesMModifiedMember_doc" xml:lang="en-US">Series M Modified.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesMModififedMember" xlink:label="CVM_SeriesMModififedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesMModififedMember" xlink:to="CVM_SeriesMModififedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesMModififedMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesNMember" xlink:to="CVM_SeriesNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesNMember_doc" xml:lang="en-US">Series N.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesOMember" xlink:label="CVM_SeriesOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesOMember" xlink:to="CVM_SeriesOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesOMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesPMember" xlink:to="CVM_SeriesPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesPMember_doc" xml:lang="en-US">Series P.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesQMember" xlink:label="CVM_SeriesQMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQMember" xlink:to="CVM_SeriesQMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesQMember_doc" xml:lang="en-US">Series Q.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesQWarrantsMember" xlink:label="CVM_SeriesQWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQWarrantsMember" xlink:to="CVM_SeriesQWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesQWarrantsMember_doc" xml:lang="en-US">Series Q Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesRMember" xlink:to="CVM_SeriesRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesRMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesSMember" xlink:to="CVM_SeriesSMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesSMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesTMember" xlink:label="CVM_SeriesTMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesTMember" xlink:to="CVM_SeriesTMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesTMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesUMember" xlink:to="CVM_SeriesUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesUMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SharesIssuableUponExerciseOfwarrant" xlink:to="CVM_SharesIssuableUponExerciseOfwarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant_doc" xml:lang="en-US">Shares Issuable Upon Exercise Of warrant.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockBonusPlansMember" xlink:label="CVM_StockBonusPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockBonusPlansMember" xlink:to="CVM_StockBonusPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockBonusPlansMember_doc" xml:lang="en-US">Stock Bonus Plans.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationDetails3Abstract" xlink:label="CVM_StockCompensationDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationDetails3Abstract" xlink:to="CVM_StockCompensationDetails3Abstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockCompensationDetails3Abstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationDetailsAbstract" xlink:to="CVM_StockCompensationDetailsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockCompensationDetailsAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockCompensationNonvestedOptionsDetailsAbstract" xlink:to="CVM_StockCompensationNonvestedOptionsDetailsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockCompensationNonvestedOptionsDetailsAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityDetails1Abstract" xlink:to="CVM_StockholdersEquityDetails1Abstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockholdersEquityDetails1Abstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityTextBlock" xlink:to="CVM_StockholdersEquityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockholdersEquityTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_TotalDeferredRentAsset" xlink:to="CVM_TotalDeferredRentAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_TotalDeferredRentAsset_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_VestedShares" xlink:to="CVM_VestedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_VestedShares_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_Warrants2008SeriesNMember" xlink:label="CVM_Warrants2008SeriesNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Warrants2008SeriesNMember" xlink:to="CVM_Warrants2008SeriesNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Warrants2008SeriesNMember_doc" xml:lang="en-US">Warrants 2008 Series N.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WarrantsHeldbyOfficerAndDirectorMember" xlink:label="CVM_WarrantsHeldbyOfficerAndDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WarrantsHeldbyOfficerAndDirectorMember" xlink:to="CVM_WarrantsHeldbyOfficerAndDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WarrantsHeldbyOfficerAndDirectorMember_doc" xml:lang="en-US">Warrants Held by Officer And Director.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceCancelled" xlink:to="CVM_WeightedAverageExercisePriceCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageExercisePriceCancelled_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceExpired" xlink:to="CVM_WeightedAverageExercisePriceExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageExercisePriceExpired_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageExercisePriceVested" xlink:to="CVM_WeightedAverageExercisePriceVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageExercisePriceVested_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageGrantDateFairValueBeginning" xlink:to="CVM_WeightedAverageGrantDateFairValueBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageGrantDateFairValueBeginning_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageGrantDateFairValueEnding" xlink:to="CVM_WeightedAverageGrantDateFairValueEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageGrantDateFairValueEnding_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:to="CVM_WeightedAverageRemainingContractualLifeInYearsGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsGranted_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:to="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ModificationOfWarrants1" xlink:to="CVM_ModificationOfWarrants1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ModificationOfWarrants1_3_lbl" xml:lang="en-US">Number of unvested shares, Ending [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_3_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CapitalizedLeaseInterest" xlink:to="CVM_CapitalizedLeaseInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_CapitalizedLeaseInterest_2_lbl" xml:lang="en-US">CapitalizedLeaseInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeposits_2_lbl" xml:lang="en-US">Increase (Decrease) in Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_2_lbl" xml:lang="en-US">Increase (Decrease) in Due to Officers and Stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xml:lang="en-US">Repayments of Debt and Capital Lease Obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Deposits2" xlink:to="CVM_Deposits2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_Deposits2_3_lbl" xml:lang="en-US">Deposits2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_2_lbl" xml:lang="en-US">Finite-Lived Patents, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FixedAssetsAndIntangibles" xlink:to="CVM_FixedAssetsAndIntangibles_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FixedAssetsAndIntangibles_2_lbl" xml:lang="en-US">FixedAssetsAndIntangibles</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:to="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds_3_lbl" xml:lang="en-US">Adjustment to Deferreds [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NumberOfOptionsExercised" xlink:to="CVM_NumberOfOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NumberOfOptionsExercised_3_lbl" xml:lang="en-US">NumberOfOptionsExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Next Rolling Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Due in Rolling after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Next Rolling Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_TotalDeferredRentAsset" xlink:to="CVM_TotalDeferredRentAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_TotalDeferredRentAsset_3_lbl" xml:lang="en-US">TotalDeferredRentAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiability" xlink:to="CVM_DeferredRentLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DeferredRentLiability_3_lbl" xml:lang="en-US">DeferredRentLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Instruments Classified in Shareholders' Equity, Settlements</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cvm-20170930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 172274 09302017 10K.xfr; Date: 2017%2D12%2D29T16:05:42Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20170930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20170930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20170930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20170930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20170930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OperationsFinancing" xlink:href="cvm-20170930.xsd#OperationsFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:href="cvm-20170930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:href="cvm-20170930.xsd#ResearchAndOfficeEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/Patents" xlink:href="cvm-20170930.xsd#Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NotesPayable" xlink:href="cvm-20170930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxes" xlink:href="cvm-20170930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensation" xlink:href="cvm-20170930.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:href="cvm-20170930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:href="cvm-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/RelatedPartyTransactions" xlink:href="cvm-20170930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockholdersEquity" xlink:href="cvm-20170930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurements" xlink:href="cvm-20170930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShare" xlink:href="cvm-20170930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SubsequentEvents" xlink:href="cvm-20170930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20170930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:href="cvm-20170930.xsd#DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:href="cvm-20170930.xsd#ResearchAndOfficeEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsTables" xlink:href="cvm-20170930.xsd#PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesTables" xlink:href="cvm-20170930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationTables" xlink:href="cvm-20170930.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:href="cvm-20170930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="cvm-20170930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:href="cvm-20170930.xsd#WarrantsAndNon-employeeOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:href="cvm-20170930.xsd#WarrantsAndNon-employeeOptionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:href="cvm-20170930.xsd#PlantPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20170930.xsd#PlantPropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails" xlink:href="cvm-20170930.xsd#PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetails1" xlink:href="cvm-20170930.xsd#PatentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:href="cvm-20170930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:href="cvm-20170930.xsd#IncomeTaxesNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="cvm-20170930.xsd#IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:href="cvm-20170930.xsd#StockCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:href="cvm-20170930.xsd#StockCompensationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:href="cvm-20170930.xsd#StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:href="cvm-20170930.xsd#StockCompensationNonvestedOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:href="cvm-20170930.xsd#StockCompensationRsuDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:href="cvm-20170930.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20170930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20170930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20170930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:href="cvm-20170930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20170930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DocumentAndEntityInformationAbstract" xlink:label="loc_CVMDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="loc_us-gaapNotesAndLoansPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapNotesAndLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgesLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ModificationOfWarrants1" xlink:label="loc_CVMModificationOfWarrants1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_CVMModificationOfWarrants1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WarrantsIssuedWithNotesPayable" xlink:label="loc_CVMWarrantsIssuedWithNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWarrantsIssuedWithNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:label="loc_CVMAdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMAdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_EquityBasedCompensationNonemployees" xlink:label="loc_CVMEquityBasedCompensationNonemployees" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMEquityBasedCompensationNonemployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CapitalizedLeaseInterest" xlink:label="loc_CVMCapitalizedLeaseInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CVMCapitalizedLeaseInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentOfNotesReceivableFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapConversionOfStockAmountIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:label="loc_CVMLeasePaymentsIncludedInAccountsPayableAtYearEnd" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMLeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:label="loc_CVMIncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncreaseInDirectFinancingCosts" xlink:label="loc_CVMIncreaseInDirectFinancingCosts" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInDirectFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncreaseInPrepaidServices" xlink:label="loc_CVMIncreaseInPrepaidServices" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInPrepaidServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable" xlink:label="loc_CVMConversionOfAccruedSalariesAndFeesToNotesPayable" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMConversionOfAccruedSalariesAndFeesToNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - 1. ORGANIZATION">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OperationsFinancing" xlink:title="00000008 - Disclosure - 2. OPERATIONS AND FINANCING">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_OperationsAndFinancingTextBlock" xlink:label="loc_CVMOperationsAndFinancingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_CVMOperationsAndFinancingTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_CVMSummaryOfSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions" xlink:title="00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipment" xlink:title="00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/Patents" xlink:title="00000012 - Disclosure - 6. PATENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NotesPayable" xlink:title="00000013 - Disclosure - 7. NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxes" xlink:title="00000014 - Disclosure - 8. INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensation" xlink:title="00000015 - Disclosure - 9. STOCK COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - 10. EMPLOYEE BENEFIT PLAN">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - 12. RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - 13. STOCKHOLDERS EQUITY">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockholdersEquityTextBlock" xlink:label="loc_CVMStockholdersEquityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_CVMStockholdersEquityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurements" xlink:title="00000020 - Disclosure - 14. FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShare" xlink:title="00000021 - Disclosure - 15. NET LOSS PER COMMON SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - 16. SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_Deposits2" xlink:label="loc_CVMDeposits2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_CVMDeposits2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaapPropertyPlantAndEquipmentImpairment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:label="loc_us-gaapLessorLeasesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapLessorLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaapDerivativesReportingOfDerivativeActivity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapDerivativesReportingOfDerivativeActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantIncomePolicyTextBlock" xlink:label="loc_CVMGrantIncomePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_CVMGrantIncomePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ResearchAndDevelopmentGrantRevenues" xlink:label="loc_CVMResearchAndDevelopmentGrantRevenues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_CVMResearchAndDevelopmentGrantRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables" xlink:title="00000024 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" xlink:label="loc_CVMDerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_CVMDerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/ResearchAndOfficeEquipmentTables" xlink:title="00000025 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsTables" xlink:title="00000026 - Disclosure - 6. PATENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PatentsTablesAbstract" xlink:label="loc_CVMPatentsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsTablesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsTablesAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - 8. INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationTables" xlink:title="00000028 - Disclosure - 9. STOCK COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:label="loc_CVMScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CVMScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ScheduleOfNonvestedOptionsTableTextBlock" xlink:label="loc_CVMScheduleOfNonvestedOptionsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CVMScheduleOfNonvestedOptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesTables" xlink:title="00000029 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CommitmentsAndContingenciesTablesAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsTables" xlink:title="00000030 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FairValueMeasurementsTablesAbstract" xlink:label="loc_CVMFairValueMeasurementsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsTablesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsTablesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareTables" xlink:title="00000031 - Disclosure - 15. NET LOSS PER COMMON SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NetLossPerCommonShareTablesAbstract" xlink:label="loc_CVMNetLossPerCommonShareTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNetLossPerCommonShareTablesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNetLossPerCommonShareTablesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:label="loc_CVMDisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FullyInsuredAmountOfNoninterestBearingCashBalances" xlink:label="loc_CVMFullyInsuredAmountOfNoninterestBearingCashBalances" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:to="loc_CVMFullyInsuredAmountOfNoninterestBearingCashBalances" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails" xlink:title="00000033 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" xlink:label="loc_CVMDerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesDDMember" xlink:label="loc_CVMSeriesDDMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesDDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesEEMember" xlink:label="loc_CVMSeriesEEMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesEEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesNMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesVMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesWMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesXMember" xlink:label="loc_CVMSeriesXMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesYMember" xlink:label="loc_CVMSeriesYMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesYMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesZZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesBBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesFFMember" xlink:label="loc_CVMSeriesFFMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesFFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesCCMember" xlink:label="loc_CVMSeriesCCMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesCCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesHHMember" xlink:label="loc_CVMSeriesHHMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesHHMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesAAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesJJMember" xlink:label="loc_CVMSeriesJJMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesJJMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesLLMember" xlink:label="loc_CVMSeriesLLMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesLLMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesMMMember" xlink:label="loc_CVMSeriesMMMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesMMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesNNMember" xlink:label="loc_CVMSeriesNNMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesNNMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesOOMember" xlink:label="loc_CVMSeriesOOMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesOOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesQQMember" xlink:label="loc_CVMSeriesQQMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesQQMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesGGMember" xlink:label="loc_CVMSeriesGGMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesGGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesIIMember" xlink:label="loc_CVMSeriesIIMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesIIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesKKMember" xlink:label="loc_CVMSeriesKKMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesKKMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesPPMember" xlink:label="loc_CVMSeriesPPMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMSeriesPPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ConsultantsMember" xlink:label="loc_CVMConsultantsMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CVMConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember_2" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesRMember" xlink:label="loc_CVMSeriesRMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember_2" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesUMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember_2" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember_2" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember_2" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesXMember" xlink:label="loc_CVMSeriesXMember_2" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesXMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesYMember" xlink:label="loc_CVMSeriesYMember_2" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesYMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember_2" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZZMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember_2" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember_2" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAAMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember_2" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBBMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesPMember" xlink:label="loc_CVMSeriesPMember" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ConsultantsMember" xlink:label="loc_CVMConsultantsMember_2" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMConsultantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_Issuedate2" xlink:label="loc_CVMIssuedate2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMIssuedate2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_CVMSharesIssuableUponExerciseOfwarrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMSharesIssuableUponExerciseOfwarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePrice" xlink:label="loc_CVMExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationDate1" xlink:label="loc_CVMExpirationDate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IssueStartDate" xlink:label="loc_CVMIssueStartDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMIssueStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IssueEndDate1" xlink:label="loc_CVMIssueEndDate1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMIssueEndDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationStartDate" xlink:label="loc_CVMExpirationStartDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExpirationStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpirationEndDate" xlink:label="loc_CVMExpirationEndDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExpirationEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePriceMinimum" xlink:label="loc_CVMExercisePriceMinimum" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePriceMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisePriceMaximum" xlink:label="loc_CVMExercisePriceMaximum" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePriceMaximum" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1" xlink:title="00000034 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_EmployeeBenefitPlanDetailsNarrativeAbstract" xlink:label="loc_CVMEmployeeBenefitPlanDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMEmployeeBenefitPlanDetailsNarrativeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesUMember" xlink:label="loc_CVMSeriesUMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesZZMember" xlink:label="loc_CVMSeriesZZMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesAAMember" xlink:label="loc_CVMSeriesAAMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesBBMember" xlink:label="loc_CVMSeriesBBMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesCCMember" xlink:label="loc_CVMSeriesCCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesCCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesDDMember" xlink:label="loc_CVMSeriesDDMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesDDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesEEMember" xlink:label="loc_CVMSeriesEEMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesEEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesFFMember" xlink:label="loc_CVMSeriesFFMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesFFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesGGMember" xlink:label="loc_CVMSeriesGGMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesGGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesHHMember" xlink:label="loc_CVMSeriesHHMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesHHMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesIIMember" xlink:label="loc_CVMSeriesIIMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesIIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesJJMember" xlink:label="loc_CVMSeriesJJMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesJJMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesKKMember" xlink:label="loc_CVMSeriesKKMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesKKMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SeriesLLMember" xlink:label="loc_CVMSeriesLLMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesLLMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetails" xlink:title="00000035 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ResearchAndOfficeEquipmentDetailsAbstract" xlink:label="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="loc_us-gaapCapitalLeasedAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasedAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaapFixturesAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapFixturesAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="00000036 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract" xlink:label="loc_CVMResearchAndOfficeEquipmentDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMResearchAndOfficeEquipmentDetailsNarrativeAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails" xlink:title="00000037 - Disclosure - 6. PATENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetails1" xlink:title="00000038 - Disclosure - 6. PATENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PatentsDetailsAbstract" xlink:label="loc_CVMPatentsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/PatentsDetailsNarrative" xlink:title="00000039 - Disclosure - 6. PATENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_PatentsDetailsNarrativeAbstract" xlink:label="loc_CVMPatentsDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsNarrativeAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails" xlink:title="00000040 - Disclosure - 8. INCOME TAXES Net deferred tax asset (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:label="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="loc_CVMDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_CVMDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_LoanModification" xlink:label="loc_CVMLoanModification" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_CVMLoanModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FixedAssetsAndIntangibles" xlink:label="loc_CVMFixedAssetsAndIntangibles" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_CVMFixedAssetsAndIntangibles" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesNetDeferredTaxAssetDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="00000041 - Disclosure - 8. INCOME TAXES Reconciliation of effective tax rate (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:label="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_EffectiveTaxRateReconciliationExpiredTaxAttributes" xlink:label="loc_CVMEffectiveTaxRateReconciliationExpiredTaxAttributes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_CVMEffectiveTaxRateReconciliationExpiredTaxAttributes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_EffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:label="loc_CVMEffectiveTaxRateReconciliationAdjustmentToDeferreds" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_CVMEffectiveTaxRateReconciliationAdjustmentToDeferreds" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMIncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAwardsDetails" xlink:title="00000042 - Disclosure - 9. STOCK COMPENSATION Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockholdersEquityDetails1Abstract" xlink:label="loc_CVMStockholdersEquityDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityDetails1Abstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NonemployeesShareBasedCompensation" xlink:label="loc_CVMNonemployeesShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityDetails1Abstract" xlink:to="loc_CVMNonemployeesShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationAssumptionsDetails" xlink:title="00000043 - Disclosure - 9. STOCK COMPENSATION Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationDetailsAbstract" xlink:label="loc_CVMStockCompensationDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpectedLifeOfOptionsMin1" xlink:label="loc_CVMExpectedLifeOfOptionsMin1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_CVMExpectedLifeOfOptionsMin1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExpectedLifeOfOptionsMax" xlink:label="loc_CVMExpectedLifeOfOptionsMax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_CVMExpectedLifeOfOptionsMax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails" xlink:title="00000044 - Disclosure - 9. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationDetails3Abstract" xlink:label="loc_CVMStockCompensationDetails3Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetails3Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_OutstandingMember" xlink:label="loc_CVMOutstandingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_CVMOutstandingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ExercisableMember" xlink:label="loc_CVMExercisableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_CVMExercisableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStockVested" xlink:label="loc_CVMNumberOfStockVested" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStockVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfOptionsExercised" xlink:label="loc_CVMNumberOfOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStocksExpired" xlink:label="loc_CVMNumberOfStocksExpired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStocksExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfStocksCancelled" xlink:label="loc_CVMNumberOfStocksCancelled" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfStocksCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceVested" xlink:label="loc_CVMWeightedAverageExercisePriceVested" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceExpired" xlink:label="loc_CVMWeightedAverageExercisePriceExpired" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageExercisePriceCancelled" xlink:label="loc_CVMWeightedAverageExercisePriceCancelled" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageExercisePriceCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_CVMWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageRemainingContractualLifeInYearsGranted" xlink:label="loc_CVMWeightedAverageRemainingContractualLifeInYearsGranted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageRemainingContractualLifeInYearsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails" xlink:title="00000045 - Disclosure - 9. STOCK COMPENSATION Nonvested Options (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationNonvestedOptionsDetailsAbstract" xlink:label="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedOptionsBeginning" xlink:label="loc_CVMNumberOfUnvestedOptionsBeginning" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMNumberOfUnvestedOptionsBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_VestedOptions" xlink:label="loc_CVMVestedOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMVestedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantedOptions" xlink:label="loc_CVMGrantedOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMGrantedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ForfeitedOptions" xlink:label="loc_CVMForfeitedOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMForfeitedOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedOptionsEnding" xlink:label="loc_CVMNumberOfUnvestedOptionsEnding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMNumberOfUnvestedOptionsEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageGrantDateFairValueBeginning" xlink:label="loc_CVMWeightedAverageGrantDateFairValueBeginning" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMWeightedAverageGrantDateFairValueBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantedWeightedAverageGrantDateFairValue" xlink:label="loc_CVMGrantedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMGrantedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageGrantDateFairValueEnding" xlink:label="loc_CVMWeightedAverageGrantDateFairValueEnding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationNonvestedOptionsDetailsAbstract" xlink:to="loc_CVMWeightedAverageGrantDateFairValueEnding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationRsuDetails" xlink:title="00000046 - Disclosure - 9. STOCK COMPENSATION RSU (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationRsuDetailsAbstract" xlink:label="loc_CVMStockCompensationRsuDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationRsuDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_RestrictedStockAwardsMember" xlink:label="loc_CVMRestrictedStockAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedSharesBeginning" xlink:label="loc_CVMNumberOfUnvestedSharesBeginning" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfUnvestedSharesBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_VestedShares" xlink:label="loc_CVMVestedShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMVestedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GrantedShares" xlink:label="loc_CVMGrantedShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMGrantedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_ForfeitedShares" xlink:label="loc_CVMForfeitedShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMForfeitedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_NumberOfUnvestedSharesEnding" xlink:label="loc_CVMNumberOfUnvestedSharesEnding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMNumberOfUnvestedSharesEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_WeightedAverageGrantDateFairValueEnding" xlink:label="loc_CVMWeightedAverageGrantDateFairValueEnding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMWeightedAverageGrantDateFairValueEnding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StockCompensationDetailsNarrative" xlink:title="00000047 - Disclosure - 9. STOCK COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_StockCompensationDetailsNarrativeAbstract" xlink:label="loc_CVMStockCompensationDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsNarrativeAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsNarrativeAbstract" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsNarrativeAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockCompensationDetailsNarrativeAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="00000048 - Disclosure - 10. EMPLOYEE BENEFIT PLAN (Detail Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000050 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000051 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_CommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaapGainContingenciesByNatureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGainContingenciesByNatureAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaapGainContingencyNatureDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGainContingenciesByNatureAxis" xlink:to="loc_us-gaapGainContingencyNatureDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaapCollaborativeArrangementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapCollaborativeArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_SanTomasMember" xlink:label="loc_CVMSanTomasMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CVMSanTomasMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_TotalDeferredRentAsset" xlink:label="loc_CVMTotalDeferredRentAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMTotalDeferredRentAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredRentNetOfCurrentPortion" xlink:label="loc_CVMDeferredRentNetOfCurrentPortion" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMDeferredRentNetOfCurrentPortion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_RDDeferredRentLiability" xlink:label="loc_CVMRDDeferredRentLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMRDDeferredRentLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_DeferredRentLiability" xlink:label="loc_CVMDeferredRentLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMDeferredRentLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails" xlink:title="00000052 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FairValueMeasurementsDetailsAbstract" xlink:label="loc_CVMFairValueMeasurementsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/FairValueMeasurementsDetails1" xlink:title="00000053 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_FairValueMeasurementsDetails1Abstract" xlink:label="loc_CVMFairValueMeasurementsDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails" xlink:title="00000054 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_I.EarningsPerShareDetailsAbstract" xlink:label="loc_CVMI.EarningsPerShareDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_GainOnDerivativeInstruments" xlink:label="loc_CVMGainOnDerivativeInstruments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_CVMGainOnDerivativeInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_IncrementalCommonSharesAttributableToGainOnDerivatives" xlink:label="loc_CVMIncrementalCommonSharesAttributableToGainOnDerivatives" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_CVMIncrementalCommonSharesAttributableToGainOnDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/NetLossPerCommonShareDetails1" xlink:title="00000055 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_I.EarningsPerShareDetailsNarrativeAbstract" xlink:label="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_OptionsAndWarrantsExcludedFromEarningsPerShare" xlink:label="loc_CVMOptionsAndWarrantsExcludedFromEarningsPerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_CVMOptionsAndWarrantsExcludedFromEarningsPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_AntidilutiveConvertibleDebt" xlink:label="loc_CVMAntidilutiveConvertibleDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_CVMAntidilutiveConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170930.xsd#CVM_AntidilutiveUnvestedRestrictedStock" xlink:label="loc_CVMAntidilutiveUnvestedRestrictedStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_CVMAntidilutiveUnvestedRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751805456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 21, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DocumentAndEntityInformationAbstract', window );"><strong>Adjustment to Deferreds</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL SCI CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,206,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,625,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752207616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,369,438<span></span>
</td>
<td class="nump">$ 2,917,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">218,481<span></span>
</td>
<td class="nump">394,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">826,429<span></span>
</td>
<td class="nump">981,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits - current portion</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">154,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory used for R&amp;D and manufacturing</a></td>
<td class="nump">672,522<span></span>
</td>
<td class="nump">1,008,642<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,236,870<span></span>
</td>
<td class="nump">5,457,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant, property and equipment</a></td>
<td class="nump">16,793,220<span></span>
</td>
<td class="nump">17,350,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">223,167<span></span>
</td>
<td class="nump">256,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">1,670,917<span></span>
</td>
<td class="nump">1,820,917<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">22,924,174<span></span>
</td>
<td class="nump">24,886,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,196,334<span></span>
</td>
<td class="nump">3,091,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">936,698<span></span>
</td>
<td class="nump">378,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to employees</a></td>
<td class="nump">693,831<span></span>
</td>
<td class="nump">538,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayableCurrent', window );">Notes payable, net of discounts</a></td>
<td class="nump">994,258<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities', window );">Derivative instruments, current portion</a></td>
<td class="nump">10,984<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">12,449<span></span>
</td>
<td class="nump">3,310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,844,554<span></span>
</td>
<td class="nump">4,011,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent', window );">Derivative instruments, net of current portion</a></td>
<td class="nump">2,042,418<span></span>
</td>
<td class="nump">8,394,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Lease liability</a></td>
<td class="nump">13,211,925<span></span>
</td>
<td class="nump">13,011,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">37,254<span></span>
</td>
<td class="nump">22,609<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">26,261,151<span></span>
</td>
<td class="nump">25,565,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value- 200,000 shares authorized; -0- shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value - 600,000,000 shares authorized; 11,903,133 and 6,248,035 shares issued and outstanding at September 30, 2017 and 2016, respectively</a></td>
<td class="nump">119,031<span></span>
</td>
<td class="nump">62,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">296,298,401<span></span>
</td>
<td class="nump">284,649,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(299,754,409)<span></span>
</td>
<td class="num">(285,391,122)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(3,336,977)<span></span>
</td>
<td class="num">(679,213)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</a></td>
<td class="nump">$ 22,924,174<span></span>
</td>
<td class="nump">$ 24,886,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgesLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability arising from contracts that meet the criteria of being accounted for as derivative instruments, financial instrument or contract used to mitigate a specified risk (hedge), energy marketing activities (trading activities), expected to be settled after one year or beyond the normal operating cycle, if longer. Examples of energy marketing activities include, but are not limited to, trading of electricity, coal, natural gas and oil using financial instruments, including, but not limited to, forward contracts, options and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6751895216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Shares Par Value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Shares Authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Shares Par Value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="nump">11,903,133<span></span>
</td>
<td class="nump">6,248,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock Shares Outstanding</a></td>
<td class="nump">11,903,133<span></span>
</td>
<td class="nump">6,248,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757775424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">GRANT INCOME AND OTHER</a></td>
<td class="nump">$ 69,020<span></span>
</td>
<td class="nump">$ 285,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,606,985<span></span>
</td>
<td class="nump">17,445,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General &amp; administrative</a></td>
<td class="nump">5,800,348<span></span>
</td>
<td class="nump">6,486,501<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,407,333<span></span>
</td>
<td class="nump">23,931,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(21,338,313)<span></span>
</td>
<td class="num">(23,646,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Gain on derivative instruments</a></td>
<td class="nump">11,007,215<span></span>
</td>
<td class="nump">14,013,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest expense, net</a></td>
<td class="num">(4,032,189)<span></span>
</td>
<td class="num">(1,879,390)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,363,287)<span></span>
</td>
<td class="num">(11,512,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ModificationOfWarrants1', window );">Modification of warrants</a></td>
<td class="num">(63,768)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (14,427,055)<span></span>
</td>
<td class="num">$ (11,512,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC</a></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">BASIC</a></td>
<td class="nump">7,891,843<span></span>
</td>
<td class="nump">4,866,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">DILUTED</a></td>
<td class="nump">7,902,647<span></span>
</td>
<td class="nump">4,866,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ModificationOfWarrants1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ModificationOfWarrants1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752409184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Sep. 30, 2015</a></td>
<td class="nump">$ 45,040<span></span>
</td>
<td class="nump">$ 269,071,320<span></span>
</td>
<td class="num">$ (273,878,630)<span></span>
</td>
<td class="num">$ (4,762,270)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">BALANCE, Shares at Sep. 30, 2015</a></td>
<td class="nump">4,503,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock</a></td>
<td class="nump">$ 16,609<span></span>
</td>
<td class="nump">21,357,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,373,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, Shares</a></td>
<td class="nump">1,660,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Issuance of warrants in connection with sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,722,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,722,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WarrantsIssuedWithNotesPayable', window );">Warrants issued with notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">161,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Shares</a></td>
<td class="nump">16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of notes payable to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">689,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, Shares</a></td>
<td class="nump">49,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Ergomed stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation - employees</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">2,012,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,012,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions', window );">Equity based compensation - employees, Shares</a></td>
<td class="nump">16,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_EquityBasedCompensationNonemployees', window );">Equity based compensation - non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,512,492)<span></span>
</td>
<td class="num">(11,512,492)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Sep. 30, 2016</a></td>
<td class="nump">$ 62,480<span></span>
</td>
<td class="nump">284,649,429<span></span>
</td>
<td class="num">(285,391,122)<span></span>
</td>
<td class="num">(679,213)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">BALANCE, Shares at Sep. 30, 2016</a></td>
<td class="nump">6,248,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock</a></td>
<td class="nump">$ 47,389<span></span>
</td>
<td class="nump">10,482,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,530,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, Shares</a></td>
<td class="nump">4,738,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Issuance of warrants in connection with sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,665,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,665,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WarrantsIssuedWithNotesPayable', window );">Warrants issued with notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock</a></td>
<td class="nump">$ 799<span></span>
</td>
<td class="nump">150,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Shares</a></td>
<td class="nump">79,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of notes payable to common stock</a></td>
<td class="nump">$ 2,667<span></span>
</td>
<td class="nump">448,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of notes payable to common stock, Shares</a></td>
<td class="nump">266,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service</a></td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">203,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, Shares</a></td>
<td class="nump">76,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Ergomed stock issuance</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">1,305,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Ergomed stock issuance, Shares</a></td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation - employees</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">1,481,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,481,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions', window );">Equity based compensation - employees, Shares</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_EquityBasedCompensationNonemployees', window );">Equity based compensation - non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,363,287)<span></span>
</td>
<td class="num">(14,363,287)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Sep. 30, 2017</a></td>
<td class="nump">$ 119,031<span></span>
</td>
<td class="nump">$ 296,298,401<span></span>
</td>
<td class="num">$ (299,754,409)<span></span>
</td>
<td class="num">$ (3,336,977)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">BALANCE, Shares at Sep. 30, 2017</a></td>
<td class="nump">11,903,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_AdjustmentAdditionalPaidInCapitalEquityBasedCompensationEmployeesOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_EquityBasedCompensationNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_EquityBasedCompensationNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WarrantsIssuedWithNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WarrantsIssuedWithNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752572304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,363,287)<span></span>
</td>
<td class="num">$ (11,512,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">632,915<span></span>
</td>
<td class="nump">663,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share based payments for services</a></td>
<td class="nump">232,847<span></span>
</td>
<td class="nump">751,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">1,380,500<span></span>
</td>
<td class="nump">2,113,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">151,308<span></span>
</td>
<td class="nump">161,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Ergomed stock issuance</a></td>
<td class="nump">1,310,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on retired equipment</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Gain on derivative instruments</a></td>
<td class="num">(11,007,215)<span></span>
</td>
<td class="num">(14,013,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">917,692<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CapitalizedLeaseInterest', window );">Capitalized lease interest</a></td>
<td class="nump">200,902<span></span>
</td>
<td class="nump">227,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(129,307)<span></span>
</td>
<td class="num">(1,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">151,909<span></span>
</td>
<td class="nump">15,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory used for R&amp;D and manufacturing</a></td>
<td class="nump">336,120<span></span>
</td>
<td class="nump">393,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeposits', window );">Deposits</a></td>
<td class="nump">154,995<span></span>
</td>
<td class="nump">145,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">5,420,816<span></span>
</td>
<td class="num">(2,389,931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">558,026<span></span>
</td>
<td class="nump">290,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders', window );">Due to employees</a></td>
<td class="nump">256,303<span></span>
</td>
<td class="nump">72,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent liability</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,791,894)<span></span>
</td>
<td class="num">(23,082,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(10,525)<span></span>
</td>
<td class="num">(31,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(6,477)<span></span>
</td>
<td class="num">(2,819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(17,002)<span></span>
</td>
<td class="num">(34,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="nump">10,519,306<span></span>
</td>
<td class="nump">21,420,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Payment on related party loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,104,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">2,745,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under capital lease</a></td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(8,213)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">13,260,338<span></span>
</td>
<td class="nump">20,308,031<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(548,558)<span></span>
</td>
<td class="num">(2,808,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">2,917,996<span></span>
</td>
<td class="nump">5,726,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">2,369,438<span></span>
</td>
<td class="nump">2,917,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services</a></td>
<td class="num">(305,341)<span></span>
</td>
<td class="nump">305,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of notes payable to common stock</a></td>
<td class="nump">450,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd', window );">Lease payments included in accounts payable at year end</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants', window );">Fair value of warrant liabilities on the date of issuance reclassed to liabilities</a></td>
<td class="num">(4,665,683)<span></span>
</td>
<td class="num">(8,722,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInDirectFinancingCosts', window );">Financing costs included in accounts payable at year end</a></td>
<td class="nump">35,605<span></span>
</td>
<td class="nump">46,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInPrepaidServices', window );">Prepaid amount under consulting services paid with issuance of common stock</a></td>
<td class="num">(3,339)<span></span>
</td>
<td class="nump">18,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable', window );">Conversion of accrued salaries and fees to notes payable</a></td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">$ 1,888,612<span></span>
</td>
<td class="nump">$ 1,900,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CapitalizedLeaseInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CapitalizedLeaseInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ConversionOfAccruedSalariesAndFeesToNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase In Derivative Liabilities From Issuance Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInDerivativeLiabilitiesFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInDirectFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInDirectFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInPrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInPrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6477933&amp;loc=d3e60009-112784<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747597520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">1. ORGANIZATION</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CEL-SCI Corporation (the Company) was incorporated
on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage
in marketing and selling products.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is focused on finding the best way
to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy, Multikine&#174; (Leukocyte
Interleukin, Injection), is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company
has received Orphan Drug Status from the United States Food and Drug Administration (FDA). If the primary endpoint of this global
study is achieved, the results will be used to support applications to regulatory agencies around the world for worldwide commercial
marketing approvals as a first line cancer therapy.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s immune therapy, Multikine,
is being used in a different way than immune therapy is usually used. It is given before any other therapy has been administered
because that is when the immune system is thought to be strongest.<font style="color: #404040">&#160;</font>It is also administered
locally to treat tumors or infections<font style="color: #404040">.</font> For example, <font style="color: #404040">i</font>n
the Phase 3 clinical trial, Multikine is given locally at the site of the tumor as a first line treatment before surgery, radiation
and/or chemotherapy. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the
cancer. In short, CEL-SCI believes that local administration and administration before weakening of the immune system by chemotherapy
and radiation will result in higher efficacy with less or no toxicity.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Multikine (Leukocyte Interleukin, Injection)
is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this document as Multikine.
Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject
to FDA review in connection with the Company&#8217;s future anticipated regulatory submission for approval. Multikine has not been
licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.
Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational
therapy that is in progress.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Multikine has been cleared by the
regulators in twenty four countries around the world, including the U.S. FDA, for a global Phase 3 clinical trial in advanced
primary (not yet treated) head and neck cancer patients. On September 26, 2016, the Company received verbal notice from the
FDA that the Phase 3 clinical trial has been placed on clinical hold. On August 10, 2017, the Company received a letter from
the FDA stating that the clinical hold that had been imposed on the Phase 3 cancer study with Multikine has been removed and
that all clinical trial activities for the Phase 3 study may resume. On December 7, 2017, the Company announced that the
Independent Data Monitoring Committee (IDMC) has completed its review of the Phase 3 study data. The data from all 928
enrolled patients were provided to the IDMC by the Clinical Research Organization (CRO) responsible for data management of
this Phase 3 study. The IDMC made the following observation and recommendation: a) the IDMC saw no evidence of any
significant safety questions and b) the IDMC recommends continuing the study. On December 11, 2017, the Company announced
that the Phase 3 study was fully enrolled. The activities in the Phase 3 study are now focused on the follow-up of the
patients enrolled to determine if there is a survival benefit in favor of Multikine.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911682160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. OPERATIONS AND FINANCING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_OperationsAndFinancingTextBlock', window );">2. OPERATIONS AND FINANCING</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has incurred significant costs since
its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating
to the human immunological defense system, patent applications, research and development, administrative costs, construction of
laboratory facilities, and clinical trials.&#160; The Company has funded such costs with proceeds from loans and the public and
private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing
in order to continue with its research efforts.&#160; To date, the Company has not generated any revenue from product sales.&#160;
As a result, the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and
capital requirements and anticipates having to do so in the future. During fiscal year 2017 and 2016, the Company raised net proceeds
of approximately $13.3 million and $21.4 million, respectively, through the sale of stock and the issuance of convertible notes.
The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed
on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate
regulatory approvals and obtain sufficient revenues to support its cost structure.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is currently running a large multi-national
Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. To finance the study
beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or
equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently
in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, there can be no assurance that the
Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on
acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations
until such time as it is able to raise the required funding.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements have been
prepared assuming that the Company will continue as a going concern, but due to the Company&#8217;s negative working capital,
stockholders&#8217; deficit, recurring losses from operations and future liquidity needs, there is substantial doubt about
the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the Company launched its Phase 3 clinical
trial for Multikine, the Company has incurred expenses of approximately $45.9 million as of September 30, 2017 on direct costs
for the Phase 3 clinical trial. The Company estimates it will incur additional expenses of approximately $13.0 million for the
remainder of the Phase 3 clinical trial.&#160; It should be noted that this estimate is based only on the information currently
available in the Company&#8217;s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical
trial and does not include other related costs, e.g., the manufacturing of the drug.<font style="color: red">&#160;</font>This
number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot
be foreseen.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nine hundred twenty-eight (928) head and neck
cancer patients have been enrolled and have completed treatment in the Phase 3 study. The study endpoint is a 10% increase in overall
survival of patients between the two main comparator groups in favor of the group receiving the Multikine treatment regimen. The
determination if the study end point is met will occur when there are a total of 298 deaths in those two groups.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 12, 2017, the Company&#8217;s shareholders
approved a reverse split of the Company&#8217;s common stock which became effective on the NYSE American on June 15, 2017. On that
date, every twenty five issued and outstanding shares of the Company&#8217;s common stock automatically converted into one outstanding
share. As a result of the reverse stock split, the number of the Company&#8217;s outstanding shares of common stock decreased from
230,127,331 (pre-split) shares to 9,201,645 (post-split) shares. In addition, by reducing the number of the Company&#8217;s outstanding
shares, the Company&#8217;s loss per share in all prior periods increased by a factor of twenty five. The reverse stock split affected
all stockholders of the Company&#8217;s common stock uniformly, and did not affect any stockholder&#8217;s percentage of ownership
interest. The par value of the Company&#8217;s stock remained unchanged at $0.01 per share and the number of authorized shares
of common stock remained the same after the reverse stock split.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_OperationsAndFinancingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_OperationsAndFinancingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747575520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash and Cash Equivalents</i> &#8211; For
purposes of the statements of cash flows, cash and cash equivalents consist principally of unrestricted cash on deposit and short-term
money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months
as cash and cash equivalents.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Prepaid Expenses</i> &#8211; Prepaid expenses
are payments for future services to be rendered and are expensed over the time period for which the service is rendered. Prepaid
expenses may also include payment for goods to be received within one year of the payment date.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Inventory</i> &#8211; Inventory consists
of manufacturing production advances and bulk purchases of laboratory supplies to be consumed in the manufacturing of the Company&#8217;s
product for clinical studies. Inventories are stated at the lower of cost or market, where cost is determined using the first-in,
first out method applied on a consistent basis.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Deposits</i> &#8211; The deposits are required
by the lease agreement for the manufacturing facility and by the clinical research organization (CRO) agreements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Plant, property and equipment</i>&#8211;
The leased manufacturing facility is recorded at total project costs incurred and is depreciated over the 20-year useful life of
the building. Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful
lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset
or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The plant,
property and equipment are reviewed on a quarterly basis to assess impairment, if any.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Patents</i> &#8211; Patent expenditures are
capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the
patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate
adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted
cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The
amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Leases &#8211;</i> Leases are categorized
as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term
of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of capital leases.
The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset
and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural
improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit
leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.
If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on
the Company's balance sheet. See Note 11.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Deferred Rent</i> &#8211; Certain of the
Company&#8217;s operating leases provide for minimum annual payments that adjust over the life of the lease.&#160; The aggregate
minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent
liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent
liability when the lease payments exceed the straight-line rent expense.&#160; For tenant improvement allowances and rent holidays,
the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Derivative Instruments</i> - The Company
has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features,
specifically, the settlement provisions in the warrant agreements preclude the warrants from being treated as equity. The Company
accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &#8220;Accounting for Derivative
Instruments and Hedging Activities&#8221;. In accordance with accounting principles generally accepted in the United States (U.S.
GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are
measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the
derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based
on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each
instrument. The derivative liabilities are remeasured at fair value at the end of each reporting period as long as they are outstanding.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Grant Income</i> &#8211; The Company's grant
arrangements are handled on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and Development Costs</i> &#8211;
Research and development expenditures are expensed as incurred. Management accrues CRO expenses and clinical trial study expenses
based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a
study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions
to estimated expense in the period in which the facts that give rise to the revision become known.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Net Loss Per Common Share</i> &#8211; The
Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted
net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number
of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common
stock options, restricted stock units, convertible preferred stock and common stock warrants, have not been included in the computation
of diluted net loss per share for all periods as the result would be anti-dilutive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Concentration of Credit Risk</i> &#8211;
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160;
The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may
exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes
it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were
fully insured&#160;up to $250,000 at September 30, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Income Taxes</i> &#8211; The Company uses
the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities
are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets
to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets
as of September 30, 2017 and 2016.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Use of Estimates</i> &#8211; The preparation
of financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of
current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory
obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, deferred tax assets
and the related valuation allowance, and the valuation of derivative liabilities.<font style="color: #444444">&#160;</font>Actual
results could differ from estimates, although management does not generally believe such differences would materially affect the
financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using various
valuation techniques including the Black-Scholes and binomial pricing methodologies, significant fluctuations may materially affect
the financial statements in a given year. The Company considers such valuations to be significant estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fair Value Measurements</i> &#8211; The Company
evaluates financial assets and liabilities subject to fair value measurements in accordance with a fair value hierarchy to prioritize
the inputs used to measure fair value. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest
level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. See Note 14 for
the definition of levels and the classification of assets and liabilities in those levels.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock-Based Compensation</i> &#8211; Compensation
cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &#8220;Compensation
&#8211; Stock Compensation.&#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model.
The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based
compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments issued to non-employees are
accounted for in accordance with ASC 505-50, &#8220;Equity-Based Payments to Non-Employees.&#8221; Accordingly, compensation is
recognized when goods or services are received and may be measured using the Black-Scholes valuation model, based on the type of
award. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the
measurement date and the expected life of the options.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has Incentive Stock Option Plans,
Non-Qualified Stock Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases,
these Plans are collectively referred to as the &#8220;Plans.&#8221; All Plans have been approved by the Company&#8217;s stockholders.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s stock options are not transferable,
and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on
the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of
daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at
date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and
employee termination within the valuation model. The expected term of options represents the period of time that options granted
are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions
used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in
the future from that recorded in the current period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Vesting of restricted stock granted under the
Incentive Stock Bonus Plan is subject to service, performance or market conditions and meets the classification of equity awards.
These awards were measured at fair market value on the grant-dates for issuances where the attainment of performance criteria is
probable and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance
criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Recent Accounting Pronouncements</i> &#8211;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2017, the FASB issued ASU 2017-09,&#160;<i>Compensation
&#8211; Stock Compensation (Topic 718)</i>, which affects any entity that changes the terms or conditions of a share-based payment
award.&#160; This Update amends the definition of modification by qualifying that modification accounting does not apply to changes
to outstanding share-based payment awards that do not affect the total fair value, vesting requirements, or equity/liability classification
of the awards.&#160; The amendments in this Update are effective for all entities for annual periods, and interim periods within
those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period,
for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other
entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in
this Update should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating
the impact the adoption of the standard will have on the Company&#8217;s financial position or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB issued ASU 2017-11,&#160;<i>Earnings
Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging (Topic 815)</i>. The amendments
in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features)
with down-round features. When determining whether certain financial instruments should be classified as liabilities or equity
instruments, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to
an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As
a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as
a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity classified financial
instruments, the amendments require entities that present earnings per share (&#8220;EPS&#8221;) in accordance with Topic 260 to
recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and as a reduction of
income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down-
round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20,&#160;<i>Debt&#8212;Debt
with Conversion and Other Options</i>), including related EPS guidance (in Topic 260). The amendments in Part II of this Update
recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Accounting
Standards Codification, to a scope exception. Those amendments do not have an accounting effect.&#160;For public business entities,
the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning
after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted
for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments
should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part I of this
Update should be applied either retrospectively to outstanding financial instruments with a down-round feature by means of a cumulative-effect
adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the
pending content that links to this paragraph is effective or retrospectively to outstanding financial instruments with a down-round
feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5
through 45-10. The amendments in Part II of this Update do not require any transition guidance because those amendments do not
have an accounting effect.&#160;The Company is currently evaluating the impact the adoption of the standard will have on the Company&#8217;s
financial position or results of operations.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2017, the FASB issued ASU 2017-12,&#160;<i>Derivatives
and Hedging (Topic 850)</i>, the objective of which is to improve the financial reporting of hedging relationships to better portray
the economic results of an entity&#8217;s risk management activities in its financial statements. In addition, the amendments in
this Update make certain targeted improvements to simplify the application and disclosure of the hedge accounting guidance in current
general accepted accounting principles.&#160;&#160;For public business entities, the amendments in&#160;this Update are effective
for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the
amendments are effective for fiscal years beginning after December 15, 2019, and interim periods beginning after December 15, 2020.
Early adoption is permitted in any period after issuance.&#160;&#160;For cash flow and net investment hedges existing at the date
of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate&#160;measurement of ineffectiveness
to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the
beginning of the fiscal year that an entity adopts the amendments in this Update. The amended presentation and disclosure guidance
is required only prospectively.&#160;&#160;The Company is currently evaluating the impact the adoption of the standard will have
on the Company&#8217;s financial position or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases</i>,
which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance
sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases
are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current
standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December
15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning
with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial
statements and related disclosures. Although the Company has not completed its evaluation of the impact of the adoption of ASU
2016-02, because the Company&#8217;s most significant operating lease is currently on its balance sheet (see Note 11), the adoption
of ASU 2016-02 is not expected to have a material impact to the financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the FASB issued ASU No.
2016-09, <i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.</i> ASU
2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including income tax
consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The
new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016
but early adoption is permitted. The Company does not expect the adoption of the new amendment to have a material impact on its financial statements and related
disclosures March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee
Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions,
including income tax consequences, classification of awards as either equity or liabilities and classification on the statement
of cash flows. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after
December 15, 2016 but early adoption is permitted. The Company  does not expect the adoption of the new amendment to have
a material impact on its financial statements and related disclosures. The estimated forfeiture rate is based on historical
information, however, the Company will no longer estimate the forfeiture rate on share based payments, but rather recognize
forfeitures as they occur.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has considered all other recently
issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial
statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911765600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">4. WARRANTS AND NON-EMPLOYEE OPTIONS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following chart represents the warrants
and non-employee options outstanding at September 30, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt"><b>Warrant</b></font></td>
    <td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Issue Date</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Issuable upon Exercise of Warrants</b></font></td>
    <td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Expiration Date</b></font></td>
    <td style="vertical-align: bottom; width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Refer-ence</b></font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td><font style="font-size: 8pt">Series U</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">4/17/2014</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">17,821</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$43.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/17/2017</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series DD</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,360,960</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$4.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/1/2017</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series EE</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,360,960</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$4.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/1/2017</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series N</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/18/2008</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">85,339</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/18/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series S</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">10/11/13- 10/24/14</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,037,120</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$31.25</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/11/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series V</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">5/28/2015</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">810,127</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$19.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5/28/2020</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series W</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">10/28/2015</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">688,930</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$16.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/28/2020</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series X</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1/13/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">120,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$9.25</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1/13/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series Y</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2/15/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">26,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$12.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/15/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series ZZ</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">5/23/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5/18/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series BB</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/26/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/22/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series Z</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">5/23/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">264,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">11/23/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series FF</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">68,048</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.91</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/1/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series CC</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">680,480</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$5.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/8/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series HH</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2/23/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.13</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/16/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series AA</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/26/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">200,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series JJ</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">3/14/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">30,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.13</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/8/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series LL</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">4/30/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">26,398</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.59</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">4/30/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series MM</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">6/22/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">893,491</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$1.86</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">6/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series NN</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">7/24/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">539,300</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.52</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">7/24/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series OO</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">7/31/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">60,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.52</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">7/31/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series QQ</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/22/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">87,500</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series GG</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2/23/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">400,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/23/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series II</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">3/14/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">600,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">9/14/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series KK</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">5/3/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">395,970</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.04</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">11/3/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series PP</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/28/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,750,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.30</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/28/2023</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Consultants</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/28/12- 7/28/17</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">42,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.18- $70.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/27/17- 7/27/27</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following chart represents the warrants
and non-employee options outstanding at September 30, 2016:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 20%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt"><b>Warrant</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Issue Date</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Issuable upon Exercise of Warrants</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Expiration Date</b></font></td>
    <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Refer-ence</b></font></td></tr>
<tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series N</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/18/08</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">113,785</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.18</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/18/17</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series R</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">12/6/12</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">105,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$100.00</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">12/6/16</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series U</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">4/17/14</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">17,821</font></td>
    <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">$43.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/17/17</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series S</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/11/13 -10/24/14</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">1,037,120</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">$31.25</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/11/18</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series V</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/28/15</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">810,127</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$19.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/28/20</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series W</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/28/15</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">688,930</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$16.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/28/20</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series X</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">1/13/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">120,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$9.25</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">1/13/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series Y</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2/15/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">26,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$12.00</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2/15/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series ZZ</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/23/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/18/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series Z</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/23/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">264,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">11/23/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series AA</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/26/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">200,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2/22/22</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series BB</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/26/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/22/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series P</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2/10/12</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">23,600</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$112.50</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">3/6/17</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Consultants</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">12/2/11- 7/1/16</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">25,600</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$9.25- $87.50</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/27/16- 6/30/19</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">3</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: top; width: 24px; padding: 0.75pt"><font style="font-size: 8pt">1.</font></td>
    <td style="padding: 0.75pt; text-align: justify"><font style="font-size: 8pt"><u>Warrant Liabilities</u></font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the warrant liabilities
and their respective balances at September 30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">32,773</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,111,361</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series U warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">72,912</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,620,253</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">83,754</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,799,858</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">77,216</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">970,604</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,753</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">70,609</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">65,087</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">763,661</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,322</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">58,588</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series CC warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">394,220</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series DD warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,492</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series EE warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,492</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series FF warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">47,154</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series GG warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">342,173</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series HH warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,014</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series II warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">511,636</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series JJ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,203</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series KK warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">345,720</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series LL warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">20,481</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total warrant liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2,053,402</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">8,394,934</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The table below presents the gains on the warrant liabilities for
the years ended September 30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,078,588</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">4,252,193</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series U warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">44,552</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,547,341</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,658,228</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,716,104</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">3,260,913</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">893,388</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">997,226</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">65,856</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">75,229</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">698,574</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">672,246</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">54,266</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">53,139</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series CC warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">666,203</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series DD warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">437,780</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series EE warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">685,915</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series FF warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">73,828</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series GG warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">272,464</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series HH warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">13,616</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series II warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">404,823</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series JJ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">20,410</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series KK warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">25,564</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Series LL warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">352,495</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Net gain on warrant liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">11,007,215</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">14,013,726</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews all outstanding warrants
in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether
an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s
contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain
dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#8217;s stock because
future equity offerings or sales of the Company&#8217;s stock are not an input to the fair value of a &#8220;fixed-for-fixed&#8221;
option on equity shares, and equity classification is therefore precluded.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 815, derivative liabilities
must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in
fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuance of Fiscal 2017 Warrant Liabilities</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 30, 2017, the Company entered into
a securities purchase agreement with an institutional investor whereby it sold 527,960 shares of its common stock for net proceeds
of approximately $1.4 million, or $2.875 per share, in a registered direct offering. In a concurrent private placement, the Company
also issued to the purchaser of the Company&#8217;s common stock Series KK warrants to purchase 395,970 shares of common stock.
The warrants can be exercised at a price of $3.04 per share at any time on or after November 3, 2017 and expire on November 3,
2022. In addition, the Company issued 26,398 Series LL warrants to the placement agent as part of its compensation. The Series
LL warrants are exercisable on October 30, 2017 at a price of $3.59 per share and expire on April 30, 2022. The fair value of the
Series KK and LL warrants of approximately $0.7 million on the date of issuance was recorded as a warrant liability.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 14, 2017, the Company sold 600,000
registered shares of common stock and 600,000 Series II warrants to purchase 600,000 unregistered shares of common stock at combined
offering price of $2.50 per share.&#160; The Series II warrants have an exercise price of $3.00 per share and expire September
14, 2022. In addition, the Company issued 30,000 Series JJ warrants to purchase 30,000 shares of unregistered common stock to the
placement agent. The Series JJ warrants have an exercise price $3.13 and expire on March 8, 2022. The&#160;net&#160;proceeds from
this offering&#160;were&#160;approximately $1.3&#160;million. The fair value of the Series II and JJ warrants of approximately
$1.0 million on the date of issuance was recorded as a warrant liability.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 23, 2017, the Company sold 400,000
registered shares of common stock and 400,000 Series GG warrants to purchase 400,000 unregistered shares of common stock at a combined
price of $2.50 per share.&#160; The Series GG warrants have an exercise price of $3.00 per share and expire August 23, 2022. In
addition, the Company issued to the placement agent 20,000 Series HH warrants to purchase 20,000 shares of unregistered common
stock. The Series HH warrants have an exercise price $3.13 and expire on February 16, 2022. The&#160;net&#160;proceeds from this
offering&#160;were&#160;approximately $0.8&#160;million. The fair value of the Series GG and HH warrants of approximately $0.6
million on the date of issuance was recorded as a warrant liability.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 8, 2016, the Company sold 1,360,960
shares of common stock and warrants to purchase common stock at a price of $3.13 in a public offering. The warrants consist of
680,480 Series CC warrants to purchase 680,480 shares of common stock, 1,360,960 Series DD warrants to purchase 1,360,960 shares
of common stock and 1,360,960 Series EE warrants to purchase 1,360,960 shares of common stock. The Series CC warrants were immediately
exercisable, expire in five-years from the offering date and have an exercise price of $5.00 per share. The Series DD warrants
were immediately exercisable and have an exercise price of $4.50 per share. On June 5, 2017 and June 29, 2017, the expiration date
of the Series DD warrants was extended from June 8, 2017 to July 10, 2017 and then to August 10, 2017. On August 29, 2017, the
expiration date of the Series DD warrants was extended to December 1, 2017. The Series EE warrants are immediately exercisable
and have an exercise price of $4.50 per share. On August 29, 2017, the initial expiration date of the Series EE warrants was extended
from September 8, 2017 to December 1, 2017. In addition, the Company issued 68,048 Series FF warrants to purchase 68,048 shares
of common stock to the placement agent. The FF warrants expire on December 1, 2021 and have an exercise price $3.91. Net&#160;proceeds
from this offering&#160;were&#160;approximately $3.7&#160;million. The fair value of the Series CC, DD, EE and FF warrants of approximately
$2.3 million on the date of issuance was recorded as a warrant liability.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series AA and BB Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 26, 2016, the Company closed a registered
direct offering of&#160;400,000 shares of common stock and 200,000 Series AA warrants to purchase 200,000 shares of common stock.
The common stock and warrants were sold at a combined per unit price of $12.50 for proceeds of approximately $4.5 million, net
of placement agent&#8217;s commissions and offering expenses. The Series AA warrants may be exercised at any time after February
22, 2017 and on or before February 22, 2022 at a price of $13.75 per share. The Company also issued 16,000 Series BB warrants to
the placement agent as part of its compensation. The Series BB warrants may be exercised at any time on or after February 22, 2017
and on or before August 22, 2021 at a price of $13.75 per share. The fair value of the Series AA and Series BB warrants of approximately
$1.5 million on the date of issuance was recorded as a warrant liability.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series Z and ZZ Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 23, 2016, the Company closed a registered
direct offering of 400,000 shares of common stock and 264,000 Series Z warrants to purchase shares of common stock. The common
stock and warrants were sold at a combined per unit price of $12.50 for net proceeds of approximately $4.6 million, net of placement
agent&#8217;s commissions and offering expenses. The Series Z warrants may be exercised at any time on or after November 23, 2016
and on or before November 23, 2021 at a price of $13.75 per share. The Company also issued 20,000 Series ZZ warrants to the placement
agent as part of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23, 2016 and on or
before May 18, 2021 at a price of $13.75 per share. The fair value of the Series Z and Series ZZ warrants of approximately $2.1
million on the date of issuance was recorded as a warrant liability.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series W Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 28, 2015, the Company closed an underwritten
public offering of 688,930 shares of common stock and 688,930 Series W warrants to purchase shares of common stock. The common
stock and warrants were sold at a combined per unit price of $16.75 for net proceeds of approximately $10.5 million, net of underwriting
discounts and commissions and offering expenses. The Series W warrants are immediately exercisable at a price of $16.75 and expire
on October 28, 2020. The fair value at issuance of the Series W warrants of approximately $5.1 million was recorded as warrant
liability.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Expiration of Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 16, 2017, 23,600 Series P warrants,
with an exercise price of $112.50, expired. The fair value of the Series P warrants was $0 on the date of expiration.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 6, 2016, 105,000 Series R warrants,
with an exercise price of $100.00, expired. The fair value of the Series R warrants was $0 on the date of expiration.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 22, 2015, 48,000 Series Q warrants,
with an exercise price of $125.00, expired. The fair value of the Series Q warrants was $0 on the date of expiration.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: top; width: 24px; padding: 0.75pt"><font style="font-size: 8pt">2.</font></td>
    <td style="padding: 0.75pt; text-align: justify"><font style="font-size: 8pt"><u>Equity Warrants</u></font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series PP and Series QQ Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 22, 2017, the Company entered into
a securities purchase agreement with institutional investors whereby it sold 1,750,000 shares of its common stock for net proceeds
of approximately $3.2 million, or $2.00 per share, in a registered direct offering. In a concurrent private placement, the Company
also issued to the purchasers of the Company&#8217;s common stock Series PP warrants to purchase 1,750,000 shares of common stock.
The warrants can be exercised at a price of $2.30 per share at any time on or after February 28, 2018 and expire on February 28,
2023. In addition, the Company issued 87,500 Series QQ warrants to the placement agent as part of its compensation. The Series
QQ warrants are exercisable on February 22, 2018 at a price of $2.50 per share and expire on August 22, 2022. The Series PP and
Series QQ warrants qualify for equity treatment in accordance with ASC 815. The relative fair value of the warrants was approximately
$1.4 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series OO Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 26, 2017, the Company entered into a
securities purchase agreement with an investor whereby it sold 100,000 shares of its common stock for gross proceeds of $229,000,
or $2.29 per share, in a registered offering. In a concurrent private placement, the Company also issued to the purchaser of the
common stock Series OO warrants to purchase 60,000 shares of the Company&#8217;s common stock. The warrants can be exercised at
a price of $2.52 per share, commencing six months after the date of issuance and ending five years after the date of issuance.
The Series OO warrants qualify for equity treatment in accordance with ASC 815. The relative fair value of the warrants was approximately
$62,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series NN Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, in connection with the issuances
of convertible notes (See Note 7), the Company issued the note holders Series NN warrants which entitle the purchasers to acquire
up to an aggregate of 539,300 shares of the Company&#8217;s common stock. The warrants are exercisable at a fixed price of $2.52
per share and expire on July 24, 2022. Shares issuable upon the exercise of the notes and warrants were restricted securities unless
registered. The shares were registered effective September 1, 2017. Proceeds from the sale of notes payable and the issuance of
the warrants were approximately $1.2 million. The Company allocated the proceeds received to the notes and the Series NN warrants
on a relative fair value basis. As a result of such allocation, the Company determined the initial carrying value of the Series
NN warrants to be approximately $0.5 million. The Series NN warrants qualify for equity treatment in accordance with ASC 815.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series MM Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 22, 2017, in connection with the issuance
of convertible notes (see Note 7), the Company issued the note holders Series MM warrants, which entitle the purchasers to acquire
up to an aggregate of 893,491 shares of the Company&#8217;s common stock. The Series MM warrants are exercisable at a price of
$1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the notes and warrants were restricted securities
unless registered. The shares were registered effective August 8, 2017. Proceeds from the sale of notes payable and the issuance
of the warrants were $1.5 million. The Company allocated proceeds received to the Notes and the Series MM warrants on a relative
fair value basis. As a result of such allocation, the Company determined the initial carrying value of the Series MM warrants to
be approximately $0.6 million. The Series MM warrants qualify for equity treatment in accordance with ASC 815.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series X Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, the Company sold 120,000 shares
of its common stock and 120,000 Series X warrants to the de Clara Trust for approximately $1.1 million. The de Clara Trust is controlled
by Geert Kersten, the Company's Chief Executive Officer and a director. Each Series X warrant allows the de Clara Trust to purchase
one share of the Company's common stock at a price of $9.25 per share at any time on or before January 13, 2021. The Series X warrants
qualify for equity treatment in accordance with ASC 815. The relative fair value of the warrants was approximately $417,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series Y Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 15, 2016, the Company sold 52,000
shares of its common stock and 26,000 Series Y warrants to a private investor for $624,000. Each Series Y warrant allows the holder
to purchase one share of the Company's common stock at a price of $12.00 per share at any time on or before February 15, 2021.
The Series Y warrants qualify for equity treatment in accordance with ASC 815. The relative fair value on the date of issuance
of the warrants was approximately $144,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series N Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Series N warrants were previously issued in
connection with a financing and were subsequently transferred to the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten,
is a beneficiary.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 17, 2017, the Series N warrants held
in the de Clara Trust were modified. The modification extended the expiration date by one year to expire on August 18, 2018; the
113,785 warrants outstanding were reduced by 25% to 85,339 warrants outstanding; and the exercise price was reduced to $3.00 per
share. The incremental cost of this modification was approximately $64,000, which was recorded as a deemed dividend.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: top; width: 24px; padding: 0.75pt"><font style="font-size: 8pt">3.&#160;</font></td>
    <td style="padding: 0.75pt"><font style="font-size: 8pt"><u>Options and Shares Issued to Consultants</u></font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company typically enters into consulting
arrangements in exchange for common stock or stock options. During the years ended September 30, 2017 and 2016 the Company issued
76,551 and 49,954 shares, respectively, of common stock to consultants of which 68,352 and 31,360 shares, respectively, were restricted
shares. Under these arrangements, the common stock was issued with stock prices ranging between $1.73 and $7.25 per share.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, during the years ended September
30, 2017 and 2016 the Company issued to consultants 20,000 and 16,400 options, respectively, to purchase common stock with an exercise
price of $2.18 per share and a fair value of $1.87 per share. The aggregate values of the issuances of restricted common stock
and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods
of service.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended September 30, 2017 and
2016, the Company recorded total expense of approximately $233,000 and $752,000, respectively, relating to these consulting agreements.
At September 30, 2017 and 2016, approximately $45,000 and $48,000, respectively, are included in prepaid expenses. As of September
30, 2017, 42,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the
Non-Qualified Stock Option plans and are fully vested.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747538944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. PLANT, PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">5. PLANT, PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Plant, property and equipment consisted of the
following at September 30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 23%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2016</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Leased manufacturing facility</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$ 21,183,756</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">$ 21,183,756</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Research equipment</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;3,169,158</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,158,633</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Furniture and equipment</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;124,369</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;133,499</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Leasehold improvements</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;131,910</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;131,910</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24,609,193</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24,607,798</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated depreciation and amortization</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;(7,815,973)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7,256,962)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net plant, property and equipment</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 16,793,220</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 17,350,836</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is not the legal owner of the manufacturing
building, but is deemed to be the owner for accounting purposes, based on the accounting guidance for build-to-suit leases. See
Note 11, Commitments and Contingencies&#8211;Lease Obligations, for additional information.&#160;As of September 30, 2017 and 2016,
accumulated depreciation on the manufacturing building is approximately $4.6 million and $4.1 million, respectively. Depreciation
expense for the years ended September 30, 2017 and 2016 totaled approximately $593,000 and, $626,000, respectively. Depreciation
expense includes depreciation on the leased manufacturing building of approximately $514,000, which is included in research and
development costs on the Statements of Operations. During the year ended September 30, 2017, the Company purchased an asset under
a lease classified as a capital lease. That asset has a net book value of approximately $21,000 on September 30, 2017. Amortization
of the capital lease asset is included in general and administrative expenses on the Statements of Operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911765600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. PATENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">6. PATENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents consisted of the following at September
30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 48%">&#160;</td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2016</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Patents</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 1,535,087</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 1,528,610</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated amortization</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;(1,311,920)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,272,063)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Patents, net</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 223,167</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 256,547</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended September 30, 2017 and
2016,there was no impairment of patent costs. Amortization expense for the years ended September 30, 2017 and 2016 totaled approximately
$40,000 and $38,000, respectively. The total estimated future amortization is as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Years ending September 30,</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 40%"><font style="font-size: 8pt">2018</font></td>
    <td style="width: 60%; text-align: right"><font style="font-size: 8pt">&#160;$ 37,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;35,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;32,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2022</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;66,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 223,000</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911832320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">7. NOTES PAYABLE</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, the Company issued Series
NN convertible notes in the aggregate principal amount of $1.2 million to 12 individual investors. A trust in which Geert Kersten,
the Company&#8217;s Chief Executive Officer, holds a beneficial interest participated in the offering and purchased a note in the
principal amount of $250,000. Patricia B. Prichep, the Company&#8217;s Senior Vice President of Operations, participated in the
offering and purchased a note in the principal amount of $25,000. The Series NN Notes bear interest at 4% per year and are due
on December 22, 2017. At the option of the note holders, the Series NN Notes can be converted into shares of the Company&#8217;s
common stock at a fixed conversion rate of $2.29, the closing price on July 21, 2017. The purchasers of the convertible notes also
received Series NN warrants which entitle the purchasers to acquire up to 539,300 shares of the Company&#8217;s common stock. The
warrants are exercisable at a price of $2.52 per share and expire on July 24, 2022. Shares issuable upon the exercise of the warrants
were restricted securities unless registered. The shares were registered effective September 1, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series NN Notes were issued together with
Series NN warrants, as discussed in the preceding section. Upon issuance of the Series NN Notes and Series NN warrants, the Company
allocated proceeds received to the notes and warrants on a relative fair value basis. As a result of such allocation, the Company
determined the initial carrying value of the Series NN Notes to be approximately $0.7 million, the initial carrying value of the
Series NN warrants to be approximately $0.5 million, and recorded a debt discount in the amount of approximately $0.5 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 22, 2017, CEL-SCI issued Series MM convertible
notes in the aggregate principal amount of $1.5 million to six individual investors. The Series MM Notes bear interest at 4% per
year and are due on December 22, 2017. At the option of the note holders, the Series MM Notes can be converted into shares of the
Company&#8217;s common stock at a fixed conversion rate of $1.69. The number of shares of the Company&#8217;s common stock issued
upon conversion will be determined by dividing the principal amount to be converted by $1.69, which could result in the issuance
of 893,491 shares of the Company&#8217;s common stock. The purchasers of the convertible notes also received Series MM warrants
which entitle the purchasers to acquire up to 893,491 shares of the Company&#8217;s common stock. The warrants are exercisable
at a price of $1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the warrants were restricted securities
unless registered. The shares were registered effective August 8, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series MM Notes were issued together with
Series MM warrants, as discussed in the preceding section. Upon issuance of the Series MM Notes and Series MM warrants, the Company
allocated proceeds received to the notes and warrants on a relative fair value basis. As a result of such allocation, the Company
determined the initial carrying value of the Series MM Notes to be approximately $0.9 million, the initial carrying value of the
Series MM warrants to be approximately $0.6 million, and recorded a debt discount in the amount of approximately $0.6 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended September 30, 2017,
two note holders converted their Series MM notes into shares of common stock. The face value of the converted notes was $450,700.
The unamortized debt discount relating to the converted notes was charged to interest expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the guidance in ASC 815-40, <i>Contracts
in Entity&#8217;s Own Equity</i>, the Company evaluated whether the conversion feature of the note needed to be bifurcated from
the host instrument as a freestanding financial instrument. Under ASC 815-40, to qualify for equity classification (or non-bifurcation,
if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer&#8217;s own stock and (2) meet the requirements
of the equity classification guidance. Based upon the Company&#8217;s analysis, it was determined the conversion option is indexed
to its own stock and also met all the criteria for equity classification. Accordingly, the conversion option is not required to
be bifurcated from the host instrument as a freestanding financial instrument. Since the conversion feature meets the equity scope
exception from derivative accounting, the Company then evaluated whether the conversion feature needed to be separately accounted
for as an equity component under ASC 470-20, <i>Debt with Conversion and Other Options</i>. Based upon the Company&#8217;s analysis,
it was determined that a beneficial conversion feature existed as a result of the reduction in the face value of the Series MM
and NN Notes, due to a portion of proceeds being allocated to the related warrants, and thus the conversion features needed to
be separately accounted for as an equity component. The Company recorded beneficial conversion features relating to the Series
MM and NN notes of approximately $603,000 and $506,000, respectively, which were also recorded as debt discounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total debt discount on both Series MM and
NN notes is being amortized to interest expense using the effective interest method over the expected term of the notes. At September
30, 2017, the remaining debt discount is approximately $1.3 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2017, the
Company recorded approximately $941,000 in interest expense related to the Series MM and NN notes, of which approximately $23,000
was recorded as accrued interest, and approximately $918,000 was recorded as amortization of the debt discount.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series MM and Series NN notes are secured
by a first lien on all of the Company&#8217;s assets.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911621568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">8. INCOME TAXES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2017 and 2016, the Company
had federal net operating loss carryforwards of approximately $187.8 million and $169.7 million, respectively. The NOLs begin to
expire during the fiscal year ending September 30, 2019 and become fully expired by the end of the fiscal year ended 2037. In addition,
the Company has a general business credit as a result of the credit for increasing research activities (&#8220;R&#38;D credit&#8221;)
of approximately $1.2 million at September 30, 2017 and 2016. The R&#38;D credit begins to expire during the fiscal year ending
September 30, 2020 and is fully expired during the fiscal year ended 2029. Deferred taxes consisted of the following at September
30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2017</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2016</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 46%"><font style="font-size: 8pt">Net operating loss carryforwards</font></td>
    <td style="text-align: right; width: 14%"><font style="font-size: 8pt">&#160;$</font></td>
    <td style="text-align: right; width: 14%"><font style="font-size: 8pt">70,752,000</font></td>
    <td style="text-align: right; width: 13%"><font style="font-size: 8pt">&#160;$</font></td>
    <td style="text-align: right; width: 13%"> <font style="font-size: 8pt">64,366,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">R&#38;D credit</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,221,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,221,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock-based compensation</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,292,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,379,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Capitalized R&#38;D</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,160,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;18,508,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Vacation and other</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;121,000</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;179,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total deferred tax assets</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;99,546,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;90,653,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Fixed assets and intangibles</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(523,000)</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(49,000)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total deferred tax liability</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(523,000)</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(49,000)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net deferred tax asset</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;99,023,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;90,604,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Valuation allowance</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(99,023,000)</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(90,604,000)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Ending Balance</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"> <font style="font-size: 8pt">-</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"> <font style="font-size: 8pt">-</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing the realization of deferred tax
assets, management considered whether it was more likely than not that some, or all, of the deferred tax asset will be realized.
The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income. Management has considered
the history of the Company&#8217;s operating losses and believes that the realization of the benefit of the deferred tax assets
cannot be reasonably assured. In addition, under Internal Revenue Code Section 382, the Company&#8217;s ability to utilize these
net operating loss carryforwards may be limited or eliminated in the event of future changes in ownership.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has no federal or state current
or deferred tax expense or benefit. The Company&#8217;s effective tax rate differs from the applicable federal statutory tax rate.
The reconciliation of these rates is as follows at September 30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 46%">&#160;</td>
    <td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2016</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Federal Rate</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">34.00%</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">34.00%</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">State tax rate, net of federal benefit</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">6.44</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3.92</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">State tax rate change</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">(3.91)</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">(22.00)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Other adjustments</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">(3.39)</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">(0.03)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Permanent differences (1)</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">25.49</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">44.90</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Change in valuation allowance</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">(58.63)</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">(60.79)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Effective tax rate</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: center"><font style="font-size: 8pt">0.00%</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: center"><font style="font-size: 8pt">0.00%</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td rowspan="3"><font style="font-size: 8pt">(1) Primarily due to the approximate $11 million and $14 million gain on derivative instruments from the change in fair value of the Company&#8217;s warrant liabilities during the years ended September 30, 2017 and 2016, respectively.</font></td>
    <td>&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the provisions of ASC 740,
<i>&#8220;Accounting for Uncertainty in Income Taxes,&#8221;</i> which requires financial statement benefits to be recognized for
positions taken for tax return purposes when it is more likely than not that the position will be sustained. The Company has elected
to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense.
The Company has generated federal net operating losses in tax years ending September 30, 1998 through 2016. These years remain
open to examination by the major domestic taxing jurisdictions to which the Company is subject.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911681616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">9. STOCK COMPENSATION</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized the following expenses
for options issued or vested and restricted stock awarded during the year:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt double"><font style="font-size: 8pt"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Year Ended September 30,</b></font></td></tr>
<tr>
    <td style="vertical-align: bottom; width: 26%">&#160;</td>
    <td style="width: 36%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Employees</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">$1,380,500</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">$2,113,433</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Non-employees</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">$ 232,847</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">$ 751,651</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock compensation expenses were recorded as
general and administrative expense. During the years ended September 30, 2017 and 2016, non-employee stock compensation excluded
approximately $45,000 and $48,000, respectively, for future services to be performed (Note 12).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended September 30, 2017 and
2016 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the
following assumptions.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 45%">&#160;</td>
    <td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="width: 29%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Expected stock price volatility</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">88.54 &#8211; 90.67%</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">75.58 &#8211; 80.9%</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Risk-free interest rate</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2.18 &#8211; 2.29%</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">0.71 &#8211; 1.56%</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Expected life of options</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">9.69 &#8211; 10 Years</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3.0 &#8211; 9.69 Years</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Expected dividend yield</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Non-Qualified Stock Option Plans</u> &#8211;
At September 30, 2017, the Company has collectively authorized the issuance of 1,187,200 shares of common stock under its Non-Qualified
Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms
of the options were determined by the Company&#8217;s Compensation Committee, which administers the plans. The Company&#8217;s
employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option
Plans.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Incentive Stock Option Plans</u> &#8211;
At September 30, 2017, the Company had collectively authorized the issuance of 138,400 shares of common stock under its Incentive
Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms
of the options were determined by the Company&#8217;s Compensation Committee, which administers the plans. Only the Company&#8217;s
employees are eligible to be granted options under the Incentive Stock Option Plans.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Activity in the Company&#8217;s Non-Qualified
and Incentive Stock Option Plans for the two years ended September 30, 2017 is summarized as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Non-Qualified and Incentive Stock Option
Plans</u></b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Outstanding</b></font></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercisable</b></font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td>&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Ave</b></font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>Aggregate</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Ave</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Aggregate</b></font></td></tr>
<tr>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Number of</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;Average</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Remaining Contractual</b></font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>&#160;Intrinsic</b></font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Number of</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;Average</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Remaining Contractual</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;Intrinsic</b></font></td></tr>
<tr>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Term (Years)</b></font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Value</b></font></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Term (Years)</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Value</b></font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Outstanding at October 1, 2015</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">301,511</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$67.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5.98</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">$50</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">181,102</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$78.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5.01</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$0</font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">56,069</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$31.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Granted (a)</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">48,544</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$12.00</font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,240</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$21.50</font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Expired</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">4,240</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$145.00</font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,240</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$145.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Cancelled</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td><font style="font-size: 8pt">Outstanding at September 30, 2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">343,575</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$59.22</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5.35</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">$0</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">232,931</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$66.28</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">4.76</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$0</font></td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">63,812</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$18.45</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Granted (b)</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">932,825</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.17</font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">15,795</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$9.46</font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Expired</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">20,761</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$88.80</font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">20,761</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$88.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Cancelled</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Outstanding at September 30, 2017</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,239,844</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$16.44</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8.50</font></td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt">$1,400</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">275,982</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$53.53</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">4.91</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$0</font></td></tr>
<tr>
    <td style="vertical-align: top; padding: 0.75pt"><font style="font-size: 8pt">(a)</font></td>
    <td colspan="4" style="padding: 0.75pt; text-align: justify"><font style="font-size: 8pt">Includes 16,400 stock options granted to consultants</font></td>
    <td colspan="6">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="width: 35px">&#160;</td>
    <td style="width: 35px">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: top; width: 48px; padding: 0.75pt"><font style="font-size: 8pt">(b)</font></td>
    <td style="padding: 0.75pt; text-align: justify"><font style="font-size: 8pt">Includes 20,000 stock options granted to consultants</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of the Company&#8217;s
non-vested options for the two years ended September 30, 2017 is presented below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 47%">&#160;</td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Number of Options</b></font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Grant Date Fair Value</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested at October 1, 2015</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;120,409</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 43.09</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Vested</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(56,069)</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Granted</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;48,544</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2,240)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested at September 30, 2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;110,644</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 36.96</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Vested</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(63,812)</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Granted</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;932,825</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(15,795)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested at September 30, 2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;963,862</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 4.91</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Incentive Stock Bonus Plan</u> &#8211; Up
to 640,000 shares are authorized under the 2014 Incentive Stock Bonus Plan. The shares will only be earned upon the achievement
of certain milestones leading to the commercialization of the Company&#8217;s Multikine technology, or specified increases in the
market price of the Company&#8217;s stock. If the performance or market criteria are not met as specified in the Incentive Stock
Bonus Plan, all or a portion of the awarded shares will be forfeited. The fair value of the shares on the grant date was calculated
using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte
Carlo simulation for issuances where the attainment of performance criteria is uncertain. The grant date fair value of shares issued
that remain outstanding as of September 30, 2017 was approximately $8.6 million. The total value of the shares, if earned, is being
expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless
of whether the market conditions are met. No compensation cost is recognized for awards where the requisite service period is not
rendered. During the years ended September 30, 2017 and 2016, the Company recorded expense relating to the issuance of restricted
stock pursuant to the plan of approximately $633,000 and $634,000, respectively. At September 30, 2017, the Company has unrecognized
compensation expense of approximately $2.5 million which is expected to be recognized over a weighted average period of four years.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of the Company&#8217;s
restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2017 is presented below:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 47%">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Number of Shares</font></td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Weighted&#160;Average&#160;Grant&#160;Date&#160;Fair&#160;Value</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Unvested at September 30, 2015</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">604,000</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;Vested</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Unvested at September 30, 2016</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">604,000</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;Vested</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">(136,000)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Unvested at September 30, 2017</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: center"><font style="font-size: 8pt">468,000</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock Bonus Plans</u> &#8211; At September
30, 2017, the Company was authorized to issue up to 383,760 shares of common stock under its Stock Bonus Plans. All employees,
directors, officers, consultants, and advisors are eligible to be granted shares. During the year ended September 30, 2017, 79,941
shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $151,000. During the year ended September 30,
2016, 16,340 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $162,000. As of September 30, 2017,
the Company has issued a total of 206,390 shares of common stock from the Stock Bonus Plans.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock Compensation Plans</u> &#8211; At September
30, 2017, 134,000 shares were authorized for use in the Company&#8217;s Stock Compensation Plans. During the years ended September
30, 2017, and 2016, 23,202 and 18,593 shares, respectively, were issued from the Stock Compensation Plans to consultants for payment
of services at a cost of approximately $60,000 and $234,000, respectively. During the year ended September 30, 2017 and 2016, 13,000
and 3,837 shares, respectively, were issued to employees from the Stock Compensation Plans as part of their compensation at a cost
of approximately $24,000 and $45,000, respectively. As of September 30, 2017, the Company has issued 115,590 shares of common stock
from the Stock Compensation Plans.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911765600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. EMPLOYEE BENEFIT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">10. EMPLOYEE BENEFIT PLAN</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a defined contribution
retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security
Act of 1974, as amended, and covering substantially all Company employees. Each participant&#8217;s contribution is matched by
the Company with shares of common stock that have a value equal to 100% of the participant&#8217;s contribution, not to exceed
the lesser of $10,000 or 6% of the participant&#8217;s total compensation. The Company&#8217;s contribution of common stock is
valued each quarter based upon the closing bid price of the Company&#8217;s common stock. Total expense, including plan maintenance,
for the years ended September 30, 2017 and 2016, in connection with this Plan was approximately $163,000 and $168,000, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747599584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">11. COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i>Clinical Research Agreements</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2013, the Company entered into an agreement
with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will
reimburse Aptiv for costs incurred. The agreement required the Company to make $600,000 in advance payments which are being credited
against future invoices in $150,000 annual increments through December 2017. As of September 30, 2017, the total balance advanced
is $150,000 and is classified as a current asset.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2013, the Company entered into a co-development
and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the study in
the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments,
up to a specific maximum amount. In October 2015, the Company entered into a second <font style="color: #292929">co-development
and revenue sharing agreement with Ergomed</font> for an additional $2 million, for a total of $12 million. The Company accounted
for the co-development and revenue sharing agreement in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;. The Company
determined the payments to Ergomed are within the scope of ASC 730 &#8220;Research and Development.&#8221; Therefore, the Company
records the discount on the clinical services as a credit to research and development expense on its Statements of Operations.
Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development
expenses of approximately $25.0 million related to Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of
approximately $8.4 million. During the years ended September 30, 2017 and 2016, the Company recorded, approximately $5.8 million
and $7.2 million, respectively, as research and development expense related to Ergomed&#8217;s services. These amounts were net
of Ergomed&#8217;s discount of approximately $2.1 million in each of the periods presented.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2013, the Company entered into two
co-development and profit sharing agreements with Ergomed.&#160; One agreement supports the Phase 1 study being conducted at UCSF
for the development of Multikine as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women.&#160; The other
agreement focuses on the development of Multikine as a potential treatment for cervical dysplasia in HIV/HPV co-infected women.
Ergomed will assume up to $3 million in clinical and regulatory costs for each study.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is currently involved in a pending
arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet
AG). The Company initiated the proceedings against inVentiv Health Clinical, LLC, or inVentiv, the former third-party CRO, and
is seeking payment for damages related to inVentiv&#8217;s prior involvement in the ongoing Phase 3 clinical trial of Multikine.
The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract,
(ii) fraud in the inducement, and (iii) common law fraud. Currently, the Company is seeking at least $50 million in damages in
its amended statement of claim.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In an amended statement of claim, the Company
asserted the claims set forth above as well as an additional claim for professional malpractice.&#160;&#160;The arbitrator subsequently
granted inVentiv&#8217;s motion to dismiss the professional malpractice claim based on the &#8220;economic loss doctrine&#8221;
which, under New Jersey law, is a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#160;&#160;The arbitrator denied the remainder of inVentiv&#8217;s motion, which had
sought to dismiss certain other aspects of the amended statement of claim.&#160;&#160;In particular, the arbitrator rejected inVentiv&#8217;s
argument that several aspects of the amended statement of claim were beyond the arbitrator&#8217;s jurisdiction.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the pending arbitration proceedings,
inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in damages for
services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the Company&#8217;s
alleged use of inVentiv&#8217;s name in connection with publications and promotions in violation of the parties&#8217; contract;
(iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits
allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking
at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv&#8217;s counterclaims
are meritless. However, if inVentiv successfully asserts any of its counterclaims, such an adverse determination could have a material
adverse effect on the Company&#8217;s business, results, financial condition and liquidity.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2015 the Company signed an arbitration
funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation
expenses. Pursuant to the agreement, an affiliate of Lake Whillans provides the Company with funding for litigation expenses to
support its arbitration claims against inVentiv. The funding is available to the Company to fund the expenses of the ongoing arbitration
and will only be repaid when the Company receives proceeds from the arbitration. During the year ended September 30, 2016, the
Company recognized a gain of approximately $1.1 million on the derecognition of legal fees to record the transfer of the liability
that existed prior to the execution of the financing agreement from the Company to Lake Whillans. The gain on derecognition of
legal fees is recorded as a reduction of general and administration expenses on the Statement of Operations. All related legal
fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to cap
its fees and expenses for the arbitration at $5 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The arbitration has been going on longer than
expected, but it is finally nearing its end. The hearing (the &#8220;trial&#8221;) started on September 26, 2016. The last witness
in the arbitration hearing testified on Wednesday, November 8, 2017, and no further witnesses or testimony are expected. With that
final witness, the testimony phase of the arbitration concluded. All that remains at the trial level are closing statements and
post-trial submissions.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Lease Agreements</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases a manufacturing facility
near Baltimore, Maryland under an operating lease (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s
specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and
sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each
year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses,
repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase
the building at the end of the 20-year lease. The Company contributed approximately $9.3 million towards the tenant-directed improvements,
of which $3.2 million is being refunded during years six through twenty through reduced rental payments. The landlord paid approximately
$11.9 million towards the purchase of the building, land and the tenant-directed improvements. The asset was placed in service
in October 2008.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because the terms of the original lease agreements
required the Company to be responsible for cost overruns, if there had been any, but of which there were none, the Company was
deemed to be the owner of the building for accounting purposes under the build-to-suit guidance in ASC 840-40-55. In addition to
the tenant improvements the Company incurred and capitalized on its balance sheet, the Company recorded an asset for tenant-directed
improvements and for the costs paid by the lessor to purchase the building and to perform improvements, as well as a corresponding
liability for the landlord costs. Upon completion of the improvements, the Company did not meet the &#8220;sale-leaseback&#8221;
criteria under ASC 840-40-25, <i>Accounting for Leases, Sale-Leaseback Transactions,</i> and therefore, treated the lease as a
financing obligation. Therefore, the asset and corresponding liability were not be derecognized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017 and 2016, the leased
building asset has a net book value of approximately $16.6 million and $17.1 million and the landlord liability as a balance of
$13.2 million and $13.0 million. The leased asset is being depreciated using a straight line method of the 20 year lease term to
a residual value. The landlord liability is being amortized over the 20 years using the effective interest method.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was required to deposit the equivalent
of one year of base rent in accordance with the San Tomas lease. When the Company meets the minimum cash balance required by the
lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets on September
30, 2017 and 2016.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Approximate future minimum lease payments under
the San Tomas lease as of September 30, 2017 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Years ending September 30,</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 64%; text-indent: 0.25in"><font style="font-size: 8pt">2018</font></td>
    <td style="width: 36%; text-align: right"><font style="font-size: 8pt">&#160;$ 1,747,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2019</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,808,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2020</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,872,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2021</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,937,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2022</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,004,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Thereafter</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,758,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total future minimum lease obligation</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,126,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less: imputed interest on financing obligation</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9,914,000)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net present value of lease financing obligation</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 13,212,000</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company subleases a portion of its rental
space on a month to month term lease, which requires a 30 day notice for termination. The sublease rent for the years ended September
30, 2017 and 2016 was approximately $69,000 and $67,000, respectively, and is recorded in grant income and other in the statements
of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases its research and development
laboratory under a 60 month lease which expires February 28, 2017. In September 2016, the lease was extended through February 28,
2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight
line basis over the full 60 month term of the lease at the rate of approximately $13,000 per month. As of September 30, 2017 and
2016, the Company has recorded a deferred rent liability of approximately $5,000 and $2,000, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases its office headquarters under
a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing
the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately $8,000 per
month. As of September 30, 2017 and 2016, the Company has recorded a deferred rent liability of approximately $18,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases office equipment under a
capital lease arrangement. The terms of the capital lease is 60 months and expires on October 31, 2021. The monthly lease payment
is $505. The lease bears interest at approximately 6.25% per annum. The Company&#8217;s previous equipment lease expired on September
30, 2016.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Approximate future minimum annual lease payments
due under non-cancelable operating leases, excluding the San Tomas lease, for the years ending after September 30, 2017 are as
follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 52%"><font style="font-size: 8pt">Years ending September 30,</font></td>
    <td style="width: 48%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2018</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 251,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2019</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;258,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2020</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;238,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2021</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;163,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2022</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;69,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Thereafter</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total future minimum lease obligation</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 979,000</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rent expense, for the years ended September
30, 2017 and 2016, excluding the rent paid on the San Tomas lease, was approximately $245,000 and $234,000, respectively. The Company&#8217;s
three leases expire between June 2020 and October 2028.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Vendor Obligations</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, the Company has contingent obligations
with other vendors for work that will be completed in relation to the Phase 3 trial. The timing of these obligations cannot be
determined at this time. CEL-SCI estimates it will incur additional expenses of approximately $13.0 million for the remainder of
the Phase 3 clinical trial. It should be noted that this estimate is based only on the information currently available in CEL-SCI&#8217;s
contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other
related costs, e.g. the manufacturing of the drug.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6634320832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">12. RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, the Company issued convertible
notes (Series NN Notes) in the aggregate principal amount of $1.2 million to 12 individual investors. A trust in which Geert Kersten,
the Company&#8217;s Chief Executive Officer, holds a beneficial interest participated in the offering and purchased a note in the
principal amount of $250,000. Patricia B. Prichep, the Company&#8217;s Senior Vice President of Operations, participated in the
offering and purchased a note in the principal amount of $25,000. The terms of the trust&#8217;s Note and Ms. Prichep&#8217;s Note
were identical to the other participants. The number of shares of the Company&#8217;s common stock issued upon conversion will
be determined by dividing the principal amount to be converted by $2.29, which would result in the issuance of 109,170 shares to
the trust and 10,917 shares to Ms. Prichep upon conversion. Along with the other purchasers of the convertible notes, the trust
and Ms. Prichep also received Series NN warrants to purchase up to 109,170 and 10,917 shares, respectively, of the Company&#8217;s
common stock. The Series NN warrants are exercisable at a fixed price of $2.52 per share and expire on July 24, 2022. Shares issuable
upon the exercise of the notes and warrants were restricted securities unless registered. The shares were registered effective
September 1, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 22, 2017, CEL-SCI issued convertible
notes (Series MM Notes) in the aggregate principal amount of $1.5 million to six individual investors. Geert Kersten, the Company&#8217;s
Chief Executive Officer, participated in the offering and purchased notes in the principal amount of $250,000. The terms of Mr.
Kersten&#8217;s Note were identical to the other participants. The number of shares of the Company&#8217;s common stock issued
upon conversion will be determined by dividing the principal amount to be converted by $1.69, which would result in the issuance
of 147,929 shares to Mr. Kersten upon conversion. Along with the other purchasers of the convertible notes, Mr. Kersten also received
Series MM warrants to purchase up to 147,929 shares of the Company&#8217;s common stock. The Series MM warrants are exercisable
at a fixed price of $1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the notes and warrants were
restricted securities unless registered. The shares were registered effective August 8, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No interest payments were made to officers during
the year ended September 30, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 31, 2016, the Company issued
Maximilian de Clara, the Company&#8217;s then President and a director, through the de Clara Trust, 26,000 shares of restricted
stock in payment of past services. The de Clara Trust was established by Maximilian de Clara, the Company&#8217;s former President
and a director. The shares were issued as follows; 13,000 shares upon his resignation on August 31, 2016 and 13,000 on August 31,
2017. The total value of the shares issued was approximately $176,000, of which approximately $24,000 was expensed during the year
ended September 30, 2017 and $152,000 was expensed during the year ended September 30, 2016. On September 30, 2016, the fair value
accrued for unissued shares was approximately $101,000.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 13, 2016, the de Clara Trust demanded
payment on a note payable, of which the balance, including accrued and unpaid interest, was approximately $1.1 million. The Company&#8217;s
Chief Executive Officer, Geert Kersten, is a beneficiary of the de Clara Trust. When the de Clara Trust demanded payment on the
note, the Company sold 120,000 shares of its common stock and 120,000 Series X warrants to the de Clara Trust for approximately
$1.1 million. Each warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $9.25 per
share at any time on or before January 13, 2021.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No interest payments were made to Mr. de Clara
or the de Clara Trust during the year ended September 30, 2017. During the year ended September 30, 2016, the Company paid approximately
$43,000 interest expense to Mr. de Clara.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747609888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockholdersEquityTextBlock', window );">13. STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 22, 2017, the Company entered into
a securities purchase agreement with institutional investors whereby it sold 1,750,000 shares of its common stock for net proceeds
of approximately $3.2 million, or $2.00 per share, in a registered direct offering. In a concurrent private placement, the Company
also issued to the purchasers of the Company&#8217;s common stock Series PP warrants to purchase 1,750,000 shares of common stock.
In addition, the Company issued 87,500 Series QQ warrants to the placement agent as part of its compensation. See Note 4 for more
information with respect to the Series PP &#38; QQ warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 15, 2017, the Company entered into
a Securities Purchase Agreement with Ergomed plc, the Company&#8217;s Clinical Research Provider, to facilitate the payment of
some of the accounts payable balances due Ergomed. Under the Agreement, the Company issued Ergomed 480,000 shares, with a fair
market value of approximately $1.3 million, as a forbearance fee in exchange for Ergomed&#8217;s agreement to provisionally forbear
collection of the payables. In an amount equal to the net proceeds from the resales of the shares issued to Ergomed. The Company
recorded the full amount of the expense upon issuance and will credit any amounts realized through reduction of the payables. During
the quarter ended September 30, 2017, 64,792 shares were resold and the Company reduced the expense by approximately $107,000.
The net expense of $1.2 million recorded during the quarter is included in interest expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 26, 2017, the Company entered into a
securities purchase agreement with an investor whereby it sold 100,000 shares of its common stock for gross proceeds of $229,000,
or $2.29 per share, in a registered offering. In a concurrent private placement, the Company also issued to the purchaser of that
common stock Series OO warrants to purchase 60,000 shares of the Company&#8217;s common stock. See Note 4 for more information
with respect to the Series OO warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 30, 2017, the Company entered into
a securities purchase agreement with an institutional investor whereby it sold 527,960 shares of its common stock for net proceeds
of approximately $1.4 million, or $2.875 per share, in a registered direct offering. In a concurrent private placement, the Company
also issued to the purchaser of the Company&#8217;s common stock, Series KK warrants to purchase 395,970 shares of common stock.
In addition, the Company issued 26,398 Series LL warrants to the Placement Agent as part of its compensation. See Note 4 for more
information with respect to the Series KK and LL warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 14, 2017, the Company sold 600,000
registered shares of common stock and 600,000 Series II warrants to purchase 600,000 unregistered shares of common stock at combined
offering price of $2.50 per share.&#160; In addition, the Company issued 30,000 Series JJ warrants to purchase 30,000 shares of
unregistered common stock to the placement agent. The&#160;net&#160;proceeds from this offering&#160;were&#160;approximately $1.3&#160;million.
See Note 4 for more information with respect to the Series II and JJ warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 23, 2017, the Company sold 400,000
registered shares of common stock and 400,000 Series GG warrants to purchase 400,000 unregistered shares of common stock at a combined
price of $2.50 per share.&#160; In addition, the Company issued to the placement agent, 20,000 Series HH warrants to purchase 20,000
shares of unregistered common stock. The&#160;net&#160;proceeds from this offering&#160;were&#160;approximately $0.8&#160;million.
See Note 4 for more information with respect to the Series GG and HH warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 8, 2016, the Company sold 1,360,960
shares of common stock and warrants to purchase common stock at a price of $3.13 in a public offering. The warrants consist of
680,480 Series CC warrants to purchase 680,480 shares of common stock, 1,360,960 Series DD warrants to purchase 1,360,960 shares
of common stock and 1,360,960 Series EE warrants to purchase 1,360,960 shares of common stock. In addition, the Company issued
68,048 Series FF warrants to purchase 68,048 shares of common stock to the placement agent. Net&#160;proceeds from this offering&#160;were&#160;approximately
$3.7&#160;million. See Note 4 for more information with respect to the Series CC, DD, EE and FF warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 26, 2016, the Company closed a registered
direct offering of&#160;400,000 shares of common stock and Series AA warrants to purchase up to 200,000 shares of common stock.
Each share of common stock was sold together with a Series AA warrant to purchase one-half of a share of common stock for the combined
purchase price of $13.75. The Company also issued 16,000 Series BB warrants to the placement agent as part of its compensation.
The Company received proceeds from the sale of Series AA and Series BB shares and warrants of approximately $4.5 million, net of
placement agent&#8217;s commissions and offering expenses. See Note 4 for more information with respect to the Series AA and BB
warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 23, 2016, the Company closed a registered
direct offering of 400,000 shares of common stock and 264,000 Series Z warrants to purchase shares of common stock. The common
stock and warrants were sold at a combined per unit price of $13.75 for net proceeds of approximately $4.6 million, net of placement
agent&#8217;s commissions and offering expenses. The Company also issued 20,000 Series ZZ warrants to the placement agent as part
of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23, 2016 and on or before May 18,
2021 at a price of $13.75 per share. See Note 4 for more information with respect to the Series Z and ZZ warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 28, 2015, the Company closed an underwritten
public offering of 688,930 shares of common stock and 688,930 Series W warrants to purchase shares of common stock. The common
stock and warrants were sold at a combined price of $16.75 for net proceeds of approximately $10.5 million, net of underwriting
commissions and offering expenses. See Note 4 for more information with respect to the Series W warrants.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockholdersEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockholdersEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911824560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">14. FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the provisions of ASC 820,
&#8220;<i>Fair Value Measurements</i>,&#8221; the Company determines fair value as the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company
generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts
to a single present amount. The measurement is based on the value indicated by current market expectations about those future amounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 820 establishes a fair value hierarchy that
prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets
and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies
fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">o</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">o</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">o</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For disclosure purposes, assets and liabilities
are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the
overall fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement
requires judgment and may affect the placement within the fair value hierarchy levels.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth the liabilities measured
at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in Active Markets for Identical Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Derivative Instruments</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">32,773</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2,020,629</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2,053,402</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below sets forth the liabilities measured
at fair value on a recurring basis, by input level, on the balance sheet at September 30, 2016:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in Active Markets for Identical Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Derivative Instruments</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">3,111,361</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">8,394,934</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following sets forth the reconciliation
of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September
30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Beginning balance</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">6,323,032</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;Issuances</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,665,683</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">8,722,073</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160; Net realized and unrealized derivative gain</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,928,627</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(9,761,532</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Ending balance</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2,029,629</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair values of the Company&#8217;s derivative
instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical
price and volatility of the Company&#8217;s stock as well as U.S. Treasury Bill rates are observable in active markets. At September
30, 2017, the Company&#8217;s Level 3 derivative instruments have a weighted average fair value of $0.29 per share and a weighted
average exercise price of $5.41 per share. Fair values were determined using a weighted average risk free interest rate of 1.85%
and 80% volatility. The instruments have a weighted average time to maturity of 4.55 years. At September 30, 2016, the Company&#8217;s
Level 3 derivative instruments have a weighted average fair value of $2.50 per share and a weighted average exercise price of $21.50
per share. Fair values were determined using a weighted average risk free interest rate of 1.04% and 75% volatility.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6646601136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>15. NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">15. NET LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing
net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s
potentially dilutive shares, which include outstanding common stock options, common stock warrants, restricted stock and shares
issuable on convertible debt, have not been included in the computation of diluted net loss per share for all periods presented,
as the result would be anti-dilutive. For the years presented, the gain on derivative instruments is not included in net loss available
to common shareholders for purposes of computing dilutive loss per share because its effect is anti-dilutive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides a reconciliation
of the numerators and denominators of the basic and diluted per-share computations:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Year Ended September 30, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Shares</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>LPS</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%"><font style="font-size: 8pt">Basic loss per share</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(14,427,055</font></td>
    <td style="width: 1%; padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1.5pt double">&#160;</td>
    <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">7,891,843</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(1.83</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less: gain on derivatives(1)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(677,287</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">10,804</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Dilutive loss per share</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(15,104,342</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">7,902,647</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(1.91</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Includes series GG and II warrants</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Year Ended September 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Shares</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>LPS</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Basic and dilutive loss per share</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(11,512,492</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">4,866,204</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(2.37</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The gain on derivative instruments that contain
exercise prices lower than the average market share price during the period is excluded from the numerator and the related shares
are excluded from the denominator in calculating diluted loss per share.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the contingently issuable
shares guidance of FASB ASC Topic 260, <i>Earnings Per Share</i>, the calculation of diluted net loss per share excludes the following
dilutive securities because their inclusion would have been anti-dilutive as of September 30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Options and Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,538,130</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,675,281</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Convertible Debt</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,166,106</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested Restricted Stock</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">604,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">604,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">4,308,236</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">4,279,281</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911827024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>16. SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">16. SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 855, &#8220;<i>Subsequent
Events</i>&#8221;, the Company has reviewed subsequent events through the date of the filing.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 19, 2017 the Company received subscription
agreements for the purchase of 1,289,478 shares of CEL-SCI common stock at a price of $1.90 in the principal amount of $2,450,000
from 19 investors. The common stock will be restricted unless registered. The purchasers of the common stock also received warrants
which entitle the purchasers to acquire up to 1,289,478 shares of the Company&#8217;s common stock. The warrants are exercisable
at a fixed price of $2.09 per share, will not be exercisable for 6 months and one day and will expire on December 18, 2022. Shares
issuable upon the exercise of the warrants will be restricted securities unless registered.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 18, 2017 CEL-SCI Corporation appointed
Robert Watson to its Board of Directors.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 2, 2017, holders of convertible
notes in the principal amount of $1.1 million sold in June 2017 and holders of convertible notes in the principal amount of $1.2
million sold in July 2017 agreed to extend the maturity date of these notes to September 21, 2018. In consideration for the extension
of the maturity date of the convertible notes, the Company issued a total of 716,400 Series RR warrants to the convertible note
holders that agreed to the extension. Each Series RR warrant entitles the holder to purchase one share of the Company&#8217;s common
stock. The Series RR warrants may be exercised at any time on or before October 30, 2022 at an exercise price of $1.65 per share.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752269616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the statements of cash flows,
cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers
all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses are payments for future services
to be rendered and are expensed over the time period for which the service is rendered. Prepaid expenses may also include payment
for goods to be received within one year of the payment date.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventory consists of manufacturing production
advances and bulk purchases of laboratory supplies to be consumed in the manufacturing of the Company&#8217;s product for clinical
studies. Inventories are stated at the lower of cost or market, where cost is determined using the first-in, first out method
applied on a consistent basis.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Deposits2', window );">Deposits</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i>The deposits are required by
the lease agreement for the manufacturing facility and by the clinical research organization (CRO) agreements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Plant, Property and Equipment</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The leased manufacturing facility is recorded
at total project costs incurred and is depreciated over the 20-year useful life of the building. Research and office equipment
is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold
improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and
maintenance which do not extend the life of the asset are expensed when incurred. The plant, property and equipment are reviewed
on a quarterly basis to assess impairment, if any.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Patents</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patent expenditures are capitalized and amortized
using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the
event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset
value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected
to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment
loss would be the difference between the estimated fair value of the asset and its carrying value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Leases are categorized as either operating
or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset
and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease
obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset and liability for
the estimated construction costs incurred to the extent that it is involved in the construction of structural improvements or
takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit leases, the Company
assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance. If a lease does
not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on the Company's
balance sheet. See Note 11.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Rent (Asset)</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of the Company&#8217;s operating leases
provide for minimum annual payments that adjust over the life of the lease.&#160; The aggregate minimum annual payments are expensed
on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when
the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed
the straight-line rent expense.&#160; For tenant improvement allowances and rent holidays, the Company records a deferred rent
liability and amortizes the deferred rent over the lease term as a reduction to rent expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivative Instruments</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into financing arrangements
that consist of freestanding derivative instruments that contain embedded derivative features, specifically, the settlement provisions
in the warrant agreements preclude the warrants from being treated as equity. The Company accounts for these arrangements in accordance
with Accounting Standards Codification (ASC) 815, &#8220;Accounting for Derivative Instruments and Hedging Activities&#8221;.
In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid
instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses
recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company
determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation
models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured
at fair value at the end of each reporting period as long as they are outstanding.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's grant arrangements are handled
on a reimbursement basis. Grant income under the arrangements is recognized when costs are incurred.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ResearchAndDevelopmentGrantRevenues', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenditures are expensed
as incurred. Management accrues CRO expenses and clinical trial study expenses based on services performed and relies on the CROs
to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to
revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the
facts that give rise to the revision become known.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates net loss per common
share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (ASC 260). Basic and diluted net loss per common share was determined
by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the
period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units,
convertible preferred stock and common stock warrants, have not been included in the computation of diluted net loss per share
for all periods as the result would be anti-dilutive.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, which potentially subject
the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash
equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160;
The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant
credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured&#160;up to $250,000
at September 30, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method
of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future
tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that
includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is
more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September
30, 2017 and 2016.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in
conformity U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements
and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions
the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals,
stock options, useful lives for depreciation and amortization of long-lived assets, deferred tax assets and the related valuation
allowance, and the valuation of derivative liabilities.<font style="color: #444444">&#160;</font>Actual results could differ from
estimates, although management does not generally believe such differences would materially affect the financial statements in
any given year. However, in regard to the valuation of derivative liabilities determined using various valuation techniques including
the Black-Scholes and binomial pricing methodologies, significant fluctuations may materially affect the financial statements
in a given year. The Company considers such valuations to be significant estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates financial assets and
liabilities subject to fair value measurements in accordance with a fair value hierarchy to prioritize the inputs used to measure
fair value. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of input significant
to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. See Note 14 for the definition of levels
and the classification of assets and liabilities in those levels.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation cost for all stock-based awards
is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &#8220;Compensation &#8211; Stock
Compensation.&#8221; The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes
model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost
is recognized on the straight line allocation method as expense over the requisite service or vesting period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments issued to non-employees are
accounted for in accordance with ASC 505-50, &#8220;Equity-Based Payments to Non-Employees.&#8221; Accordingly, compensation is
recognized when goods or services are received and may be measured using the Black-Scholes valuation model, based on the type of
award. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the
measurement date and the expected life of the options.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has Incentive Stock Option Plans,
Non-Qualified Stock Options Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases,
these Plans are collectively referred to as the &#8220;Plans.&#8221; All Plans have been approved by the Company&#8217;s stockholders.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s stock options are not transferable,
and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on
the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of
daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at
date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and
employee termination within the valuation model. The expected term of options represents the period of time that options granted
are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions
used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in
the future from that recorded in the current period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Vesting of restricted stock granted under the
Incentive Stock Bonus Plan is subject to service, performance or market conditions and meets the classification of equity awards.
These awards were measured at fair market value on the grant-dates for issuances where the attainment of performance criteria is
probable and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance
criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2017, the FASB issued ASU 2017-09,&#160;<i>Compensation
&#8211; Stock Compensation (Topic 718)</i>, which affects any entity that changes the terms or conditions of a share-based payment
award.&#160; This Update amends the definition of modification by qualifying that modification accounting does not apply to changes
to outstanding share-based payment awards that do not affect the total fair value, vesting requirements, or equity/liability classification
of the awards.&#160; The amendments in this Update are effective for all entities for annual periods, and interim periods within
those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period,
for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other
entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in
this Update should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating
the impact the adoption of the standard will have on the Company&#8217;s financial position or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB issued ASU 2017-11,&#160;<i>Earnings
Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging (Topic 815)</i>. The amendments
in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features)
with down-round features. When determining whether certain financial instruments should be classified as liabilities or equity
instruments, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to
an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As
a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as
a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity classified financial
instruments, the amendments require entities that present earnings per share (&#8220;EPS&#8221;) in accordance with Topic 260 to
recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and as a reduction of
income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down-
round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20,&#160;<i>Debt&#8212;Debt
with Conversion and Other Options</i>), including related EPS guidance (in Topic 260). The amendments in Part II of this Update
recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Accounting
Standards Codification, to a scope exception. Those amendments do not have an accounting effect.&#160;For public business entities,
the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning
after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted
for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments
should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part I of this
Update should be applied either retrospectively to outstanding financial instruments with a down-round feature by means of a cumulative-effect
adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the
pending content that links to this paragraph is effective or retrospectively to outstanding financial instruments with a down-round
feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5
through 45-10. The amendments in Part II of this Update do not require any transition guidance because those amendments do not
have an accounting effect.&#160;The Company is currently evaluating the impact the adoption of the standard will have on the Company&#8217;s
financial position or results of operations.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2017, the FASB issued ASU 2017-12,&#160;<i>Derivatives
and Hedging (Topic 850)</i>, the objective of which is to improve the financial reporting of hedging relationships to better portray
the economic results of an entity&#8217;s risk management activities in its financial statements. In addition, the amendments in
this Update make certain targeted improvements to simplify the application and disclosure of the hedge accounting guidance in current
general accepted accounting principles.&#160;&#160;For public business entities, the amendments in&#160;this Update are effective
for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the
amendments are effective for fiscal years beginning after December 15, 2019, and interim periods beginning after December 15, 2020.
Early adoption is permitted in any period after issuance.&#160;&#160;For cash flow and net investment hedges existing at the date
of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate&#160;measurement of ineffectiveness
to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the
beginning of the fiscal year that an entity adopts the amendments in this Update. The amended presentation and disclosure guidance
is required only prospectively.&#160;&#160;The Company is currently evaluating the impact the adoption of the standard will have
on the Company&#8217;s financial position or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases</i>,
which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance
sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases
are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current
standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December
15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning
with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial
statements and related disclosures. Although the Company has not completed its evaluation of the impact of the adoption of ASU
2016-02, because the Company&#8217;s most significant operating lease is currently on its balance sheet (see Note 11), the adoption
of ASU 2016-02 is not expected to have a material impact to the financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the FASB issued ASU No.
2016-09, <i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.</i> ASU
2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including income tax
consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The
new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016
but early adoption is permitted. The Company does not expect the adoption of the new amendment to have a material impact on its financial statements and related
disclosures March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee
Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions,
including income tax consequences, classification of awards as either equity or liabilities and classification on the statement
of cash flows. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after
December 15, 2016 but early adoption is permitted. The Company  does not expect the adoption of the new amendment to have
a material impact on its financial statements and related disclosures. The estimated forfeiture rate is based on historical
information, however, the Company will no longer estimate the forfeiture rate on share based payments, but rather recognize
forfeitures as they occur.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has considered all other recently
issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_Deposits2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_Deposits2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ResearchAndDevelopmentGrantRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ResearchAndDevelopmentGrantRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_SummaryOfSignificantAccountingPoliciesPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579240-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888428&amp;loc=SL77919352-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6741487312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding', window );">Derivative liabilities, warrants and other options outstanding</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following chart represents the warrants
and non-employee options outstanding at September 30, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt"><b>Warrant</b></font></td>
    <td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Issue Date</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Issuable upon Exercise of Warrants</b></font></td>
    <td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="vertical-align: bottom; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Expiration Date</b></font></td>
    <td style="vertical-align: bottom; width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Refer-ence</b></font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td><font style="font-size: 8pt">Series U</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">4/17/2014</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">17,821</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$43.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/17/2017</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series DD</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,360,960</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$4.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/1/2017</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series EE</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,360,960</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$4.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/1/2017</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series N</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/18/2008</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">85,339</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/18/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series S</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">10/11/13- 10/24/14</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,037,120</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$31.25</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/11/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series V</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">5/28/2015</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">810,127</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$19.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5/28/2020</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series W</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">10/28/2015</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">688,930</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$16.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/28/2020</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series X</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1/13/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">120,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$9.25</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1/13/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series Y</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2/15/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">26,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$12.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/15/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series ZZ</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">5/23/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5/18/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series BB</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/26/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/22/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series Z</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">5/23/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">264,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">11/23/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series FF</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">68,048</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.91</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/1/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series CC</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">680,480</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$5.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/8/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series HH</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2/23/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.13</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/16/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series AA</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/26/2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">200,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series JJ</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">3/14/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">30,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.13</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/8/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series LL</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">4/30/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">26,398</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.59</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">4/30/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series MM</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">6/22/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">893,491</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$1.86</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">6/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series NN</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">7/24/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">539,300</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.52</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">7/24/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series OO</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">7/31/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">60,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.52</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">7/31/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series QQ</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/22/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">87,500</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series GG</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2/23/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">400,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/23/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series II</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">3/14/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">600,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">9/14/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series KK</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">5/3/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">395,970</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$3.04</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">11/3/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series PP</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">8/28/2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,750,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.30</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/28/2023</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Consultants</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">12/28/12- 7/28/17</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">42,000</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.18- $70.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/27/17- 7/27/27</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following chart represents the warrants
and non-employee options outstanding at September 30, 2016:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 20%; border-bottom: black 1.5pt solid"><font style="font-size: 8pt"><b>Warrant</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Issue Date</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Issuable upon Exercise of Warrants</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Expiration Date</b></font></td>
    <td style="width: 12%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Refer-ence</b></font></td></tr>
<tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series N</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/18/08</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">113,785</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.18</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/18/17</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series R</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">12/6/12</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">105,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$100.00</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">12/6/16</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series U</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">4/17/14</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">17,821</font></td>
    <td style="vertical-align: top; text-align: right"><font style="font-size: 8pt">$43.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/17/17</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series S</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/11/13 -10/24/14</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">1,037,120</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">$31.25</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/11/18</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series V</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/28/15</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">810,127</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$19.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/28/20</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series W</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/28/15</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">688,930</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$16.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/28/20</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series X</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">1/13/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">120,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$9.25</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">1/13/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series Y</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2/15/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">26,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$12.00</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2/15/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series ZZ</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/23/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/18/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series Z</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">5/23/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">264,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">11/23/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series AA</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/26/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">200,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2/22/22</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series BB</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/26/16</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$13.75</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">8/22/21</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Series P</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">2/10/12</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">23,600</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$112.50</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">3/6/17</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 8pt">Consultants</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">12/2/11- 7/1/16</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">25,600</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$9.25- $87.50</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 8pt">10/27/16- 6/30/19</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">3</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below presents the warrant liabilities
and their respective balances at September 30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">32,773</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,111,361</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series U warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">72,912</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,620,253</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">83,754</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,799,858</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">77,216</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">970,604</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,753</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">70,609</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">65,087</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">763,661</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,322</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">58,588</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series CC warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">394,220</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series DD warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,492</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series EE warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,492</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series FF warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">47,154</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series GG warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">342,173</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series HH warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,014</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series II warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">511,636</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series JJ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,203</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series KK warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">345,720</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series LL warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">20,481</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total warrant liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2,053,402</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">8,394,934</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The table below presents the gains on the warrant liabilities for
the years ended September 30:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,078,588</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">4,252,193</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series U warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">44,552</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,547,341</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,658,228</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,716,104</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">3,260,913</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">893,388</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">997,226</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">65,856</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">75,229</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">698,574</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">672,246</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">54,266</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">53,139</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series CC warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">666,203</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series DD warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">437,780</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series EE warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">685,915</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series FF warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">73,828</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series GG warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">272,464</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series HH warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">13,616</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series II warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">404,823</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series JJ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">20,410</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series KK warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">25,564</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Series LL warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">352,495</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Net gain on warrant liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">11,007,215</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">14,013,726</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DerivativeLiabilitiesWarrantsAndOtherOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911774928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. PLANT, PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Plant, property and equipment</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 23%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2016</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Leased manufacturing facility</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">$ 21,183,756</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">$ 21,183,756</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Research equipment</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;3,169,158</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3,158,633</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Furniture and equipment</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;124,369</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;133,499</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Leasehold improvements</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;131,910</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;131,910</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24,609,193</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;24,607,798</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated depreciation and amortization</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;(7,815,973)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7,256,962)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net plant, property and equipment</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 16,793,220</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 17,350,836</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6889580928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsTablesAbstract', window );"><strong>Net Loss Per Common Share Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Patents</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 48%">&#160;</td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2016</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Patents</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 1,535,087</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 1,528,610</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Accumulated amortization</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;(1,311,920)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,272,063)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Patents, net</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 223,167</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 256,547</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Years ending September 30,</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 40%"><font style="font-size: 8pt">2018</font></td>
    <td style="width: 60%; text-align: right"><font style="font-size: 8pt">&#160;$ 37,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;35,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;32,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2022</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;66,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 223,000</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747410176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Net deferred tax asset</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2017</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2016</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net operating loss carryforwards</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$</font></td>
    <td style="text-align: right"> <font style="font-size: 8pt">70,752,000</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$</font></td>
    <td style="text-align: right"> <font style="font-size: 8pt">64,366,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">R&#38;D credit</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,221,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,221,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock-based compensation</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,292,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,379,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Capitalized R&#38;D</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,160,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;18,508,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Vacation and other</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;121,000</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;179,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total deferred tax assets</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;99,546,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;90,653,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Fixed assets and intangibles</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(523,000)</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(49,000)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total deferred tax liability</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(523,000)</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(49,000)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net deferred tax asset</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;99,023,000</font></td>
    <td colspan="2" style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;90,604,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Valuation allowance</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(99,023,000)</font></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(90,604,000)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 46%"><font style="font-size: 8pt">Ending Balance</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; width: 14%"><font style="font-size: 8pt">&#160;$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; width: 14%"> <font style="font-size: 8pt">-</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; width: 13%"><font style="font-size: 8pt">&#160;$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right; width: 13%"> <font style="font-size: 8pt">-</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of effective tax rate</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 46%">&#160;</td>
    <td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2017</font></td>
    <td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">2016</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Federal Rate</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">34.00%</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">34.00%</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">State tax rate, net of federal benefit</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">6.44</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3.92</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">State tax rate change</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">(3.91)</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">(22.00)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Other adjustments</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">(3.39)</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">(0.03)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Permanent differences (1)</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">25.49</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">44.90</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Change in valuation allowance</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">(58.63)</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">(60.79)</font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Effective tax rate</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: center"><font style="font-size: 8pt">0.00%</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: center"><font style="font-size: 8pt">0.00%</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6647847088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock', window );">Employees and non-employees stock compensation</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt double"><font style="font-size: 8pt"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Year Ended September 30,</b></font></td></tr>
<tr>
    <td style="vertical-align: bottom; width: 26%">&#160;</td>
    <td style="width: 36%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Employees</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">$1,380,500</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">$2,113,433</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Non-employees</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">$ 232,847</font></td>
    <td style="vertical-align: bottom; text-align: center"><font style="font-size: 8pt">$ 751,651</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Pricing</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 45%">&#160;</td>
    <td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="width: 29%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Expected stock price volatility</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">88.54 &#8211; 90.67%</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">75.58 &#8211; 80.9%</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Risk-free interest rate</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2.18 &#8211; 2.29%</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">0.71 &#8211; 1.56%</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Expected life of options</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">9.69 &#8211; 10 Years</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3.0 &#8211; 9.69 Years</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Expected dividend yield</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Plans</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Outstanding</b></font></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercisable</b></font></td></tr>
<tr>
    <td style="width: 18%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 11%; text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 11%; text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td style="width: 11%">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Ave</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Aggregate</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Weighted</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Ave</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Aggregate</b></font></td></tr>
<tr>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Number of</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;Average</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Remaining Contractual</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;Intrinsic</b></font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Number of</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;Average</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>Remaining Contractual</b></font></td>
    <td style="text-align: center"><font style="font-size: 8pt"><b>&#160;Intrinsic</b></font></td></tr>
<tr>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Term (Years)</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Value</b></font></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Term (Years)</b></font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Value</b></font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Outstanding at October 1, 2015</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">301,511</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$67.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5.98</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$50</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">181,102</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$78.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5.01</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$0</font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">56,069</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$31.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Granted (a)</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">48,544</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$12.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,240</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$21.50</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Expired</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">4,240</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$145.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,240</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$145.00</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Cancelled</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td><font style="font-size: 8pt">Outstanding at September 30, 2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">343,575</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$59.22</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5.35</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$0</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">232,931</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$66.28</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">4.76</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$0</font></td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">63,812</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$18.45</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Granted (b)</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">932,825</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$2.17</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">15,795</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$9.46</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Expired</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">20,761</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$88.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">20,761</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$88.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="text-align: justify"><font style="font-size: 8pt">Cancelled</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Outstanding at September 30, 2017</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td style="text-align: right"><font style="font-size: 8pt">1,239,844</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$16.44</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$1,400</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">275,982</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$53.53</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">4.91</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">$0</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ScheduleOfNonvestedOptionsTableTextBlock', window );">Schedule of non-vested options</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 47%">&#160;</td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Number of Options</b></font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 26%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Grant Date Fair Value</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested at October 1, 2015</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;120,409</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 43.09</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Vested</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(56,069)</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Granted</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;48,544</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2,240)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested at September 30, 2016</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;110,644</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 36.96</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Vested</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(63,812)</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Granted</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;932,825</font></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Forfeited</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(15,795)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested at September 30, 2017</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;963,862</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 4.91</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of restricted stock units</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 47%">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Number of Shares</font></td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Weighted&#160;Average&#160;Grant&#160;Date&#160;Fair&#160;Value</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Unvested at September 30, 2015</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">604,000</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;Vested</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Unvested at September 30, 2016</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">604,000</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;Vested</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">(136,000)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 8pt">Unvested at September 30, 2017</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: center"><font style="font-size: 8pt">468,000</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 8pt">$13.75</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ScheduleEmployeesAndNonemployeesStockCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ScheduleOfNonvestedOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ScheduleOfNonvestedOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747465680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CommitmentsAndContingenciesTablesAbstract', window );"><strong>Commitments And Contingencies Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future minimum lease payments under the San Tomas lease</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt">Years ending September 30,</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 64%; text-indent: 0.25in"><font style="font-size: 8pt">2018</font></td>
    <td style="width: 36%; text-align: right"><font style="font-size: 8pt">&#160;$ 1,747,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2019</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,808,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2020</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,872,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2021</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,937,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2022</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,004,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Thereafter</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,758,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total future minimum lease obligation</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,126,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less: imputed interest on financing obligation</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9,914,000)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Net present value of lease financing obligation</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 13,212,000</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum annual rental payments due under non-cancelable operating leases</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 52%"><font style="font-size: 8pt">Years ending September 30,</font></td>
    <td style="width: 48%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2018</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 251,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2019</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;258,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2020</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;238,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2021</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;163,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">2022</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;69,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: 0.25in"><font style="font-size: 8pt">Thereafter</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total future minimum lease obligation</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">&#160;$ 979,000</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CommitmentsAndContingenciesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CommitmentsAndContingenciesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911639520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueMeasurementsTablesAbstract', window );"><strong>Fair Value Measurements Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in Active Markets for Identical Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Derivative Instruments</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">32,773</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2,020,629</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2,053,402</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in Active Markets for Identical Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Derivative Instruments</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">3,111,361</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">8,394,934</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Beginning balance</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">6,323,032</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;Issuances</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,665,683</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">8,722,073</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160; Net realized and unrealized derivative gain</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,928,627</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(9,761,532</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Ending balance</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2,029,629</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueMeasurementsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueMeasurementsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633488352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>15. NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NetLossPerCommonShareTablesAbstract', window );"><strong>Net Loss Per Common Share Tables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Earnings per share</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Year Ended September 30, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Shares</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>LPS</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 58%"><font style="font-size: 8pt">Basic loss per share</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(14,427,055</font></td>
    <td style="width: 1%; padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1.5pt double">&#160;</td>
    <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">7,891,843</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(1.83</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Less: gain on derivatives(1)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(677,287</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">10,804</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Dilutive loss per share</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(15,104,342</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">7,902,647</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(1.91</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Includes series GG and II warrants</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Year Ended September 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Net Loss</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Shares</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>LPS</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Basic and dilutive loss per share</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(11,512,492</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">4,866,204</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">(2.37</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive securities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Options and Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,538,130</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">3,675,281</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Convertible Debt</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,166,106</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested Restricted Stock</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">604,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">604,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">4,308,236</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">4,279,281</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NetLossPerCommonShareTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NetLossPerCommonShareTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747664128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract', window );"><strong>Summary Of Significant Accounting Policies Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FullyInsuredAmountOfNoninterestBearingCashBalances', window );">Fully Insured Amount of non-interest bearing cash balances</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DisclosureA.OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FullyInsuredAmountOfNoninterestBearingCashBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FullyInsuredAmountOfNoninterestBearingCashBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763597328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 18,  2008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 18,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember', window );">SeriesRMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  06,  2012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  06,  2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember', window );">Series U [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 17,  2014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 17,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember', window );">Series S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 11,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueStartDate', window );">Issue Start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 11,  2013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueEndDate1', window );">Issue End Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 24,  2014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 28,  2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 28,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember', window );">Series W [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 28,  2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 28,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 13,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 13,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 23,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 18,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 23,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 23,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 26,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 22,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 26,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 22,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPMember', window );">Series P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 10,  2012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  06,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueStartDate', window );">Issue Start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  02,  2011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueEndDate1', window );">Issue End Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationStartDate', window );">Expiration start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 27,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationEndDate', window );">Expiration end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePriceMinimum', window );">Exercise Price Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePriceMaximum', window );">Exercise Price Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesUMember', window );">Series U [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Apr. 17,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">17,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 43.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Oct. 17,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesDDMember', window );">Series DD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Dec.  08,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">1,360,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Dec.  01,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesEEMember', window );">Series EE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Dec.  08,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">1,360,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Dec.  01,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Aug. 18,  2008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">85,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Aug. 18,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesSMember', window );">Series S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">1,037,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Oct. 11,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueStartDate', window );">Issue Start date</a></td>
<td class="text">Oct. 11,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueEndDate1', window );">Issue End Date</a></td>
<td class="text">Oct. 24,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesVMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">May 28,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">810,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 19.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">May 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesWMember', window );">Series W [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Oct. 28,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">688,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 16.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Oct. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Jan. 13,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Jan. 13,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Feb. 15,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Feb. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">May 23,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">May 18,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Aug. 26,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Aug. 22,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">May 23,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Nov. 23,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesFFMember', window );">Series FF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Dec.  08,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">68,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Dec.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesCCMember', window );">Series CC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Dec.  08,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">680,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Dec.  08,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesHHMember', window );">Series HH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Feb. 23,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Feb. 16,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Aug. 26,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Feb. 22,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesJJMember', window );">Series JJ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Mar. 14,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Mar.  08,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesLLMember', window );">Series LL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Apr. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">26,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Apr. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Jun. 22,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">893,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Jun. 22,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Jul. 24,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">539,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Jul. 24,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesOOMember', window );">Series OO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Jul. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Jul. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesQQMember', window );">Series QQ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Aug. 22,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Aug. 22,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesGGMember', window );">Series GG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Feb. 23,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Aug. 23,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesIIMember', window );">Series II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Mar. 14,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Sep. 14,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesKKMember', window );">Series KK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">May  03,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">395,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Nov.  03,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesPPMember', window );">Series PP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_Issuedate2', window );">Issue Date</a></td>
<td class="text">Aug. 28,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">Feb. 28,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueStartDate', window );">Issue Start date</a></td>
<td class="text">Dec. 28,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueEndDate1', window );">Issue End Date</a></td>
<td class="text">Jul. 28,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationStartDate', window );">Expiration start date</a></td>
<td class="text">Dec. 27,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationEndDate', window );">Expiration end date</a></td>
<td class="text">Jul. 27,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePriceMinimum', window );">Exercise Price Minimum</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePriceMaximum', window );">Exercise Price Maximum</a></td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePriceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePriceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpirationEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpirationEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpirationStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpirationStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IssueEndDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IssueEndDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IssueStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IssueStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_Issuedate2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_Issuedate2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_SharesIssuableUponExerciseOfwarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issuable Upon Exercise Of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_SharesIssuableUponExerciseOfwarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesDDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesDDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesEEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesEEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesFFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesFFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesHHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesHHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesJJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesJJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesLLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesLLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesOOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesOOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesQQMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesQQMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesGGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesGGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_SeriesPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CVM_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CVM_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759282128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">$ 2,053,402<span></span>
</td>
<td class="nump">$ 8,394,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">11,007,215<span></span>
</td>
<td class="nump">14,013,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember', window );">Series S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">32,773<span></span>
</td>
<td class="nump">3,111,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">3,078,588<span></span>
</td>
<td class="nump">4,252,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember', window );">Series U [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">72,912<span></span>
</td>
<td class="nump">1,620,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">1,547,341<span></span>
</td>
<td class="nump">4,658,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">83,754<span></span>
</td>
<td class="nump">1,799,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">1,716,104<span></span>
</td>
<td class="nump">3,260,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">77,216<span></span>
</td>
<td class="nump">970,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">893,388<span></span>
</td>
<td class="nump">997,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">4,753<span></span>
</td>
<td class="nump">70,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">65,856<span></span>
</td>
<td class="nump">75,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">65,087<span></span>
</td>
<td class="nump">763,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">698,574<span></span>
</td>
<td class="nump">672,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">4,322<span></span>
</td>
<td class="nump">58,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">54,266<span></span>
</td>
<td class="nump">53,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesCCMember', window );">Series CC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">394,220<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">666,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesDDMember', window );">Series DD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">5,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">437,780<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesEEMember', window );">Series EE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">5,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">685,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFFMember', window );">Series FF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">47,154<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">73,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesGGMember', window );">Series GG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">342,173<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">272,464<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHHMember', window );">Series HH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">16,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">13,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesIIMember', window );">Series II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">511,636<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">404,823<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesJJMember', window );">Series JJ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">24,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">20,410<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesKKMember', window );">Series KK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">345,720<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">25,564<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesLLMember', window );">Series LL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total warrant liabilities</a></td>
<td class="nump">20,481<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Net gain on warrant liabilities</a></td>
<td class="nump">$ 352,495<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesDDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesDDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesEEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesEEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesGGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesGGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesJJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesJJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesLLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesLLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6646837408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>5. PLANT, PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ResearchAndOfficeEquipmentDetailsAbstract', window );"><strong>Plant Property And Equipment Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsGross', window );">Leased manufacturing facility</a></td>
<td class="nump">$ 21,183,756<span></span>
</td>
<td class="nump">$ 21,183,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FixturesAndEquipmentGross', window );">Research equipment</a></td>
<td class="nump">3,169,158<span></span>
</td>
<td class="nump">3,158,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and equipment</a></td>
<td class="nump">124,369<span></span>
</td>
<td class="nump">133,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">131,910<span></span>
</td>
<td class="nump">131,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross</a></td>
<td class="nump">24,609,193<span></span>
</td>
<td class="nump">24,607,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(7,815,973)<span></span>
</td>
<td class="num">(7,256,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net research and office equipment</a></td>
<td class="nump">$ 16,793,220<span></span>
</td>
<td class="nump">$ 17,350,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ResearchAndOfficeEquipmentDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ResearchAndOfficeEquipmentDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasedAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45014-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasedAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FixturesAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FixturesAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911683248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract', window );"><strong>Plant Property And Equipment Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 593,000<span></span>
</td>
<td class="nump">$ 626,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ResearchAndOfficeEquipmentDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6666811520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>6. PATENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">$ 1,535,087<span></span>
</td>
<td class="nump">$ 1,528,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,311,920)<span></span>
</td>
<td class="num">(1,272,063)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Patents</a></td>
<td class="nump">$ 223,167<span></span>
</td>
<td class="nump">$ 256,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6645908496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>6. PATENTS (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsDetailsAbstract', window );"><strong>Patents Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2018</a></td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2019</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2020</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2021</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2022</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 223,167<span></span>
</td>
<td class="nump">$ 256,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911662528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsDetailsNarrativeAbstract', window );"><strong>Patents Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patent costs</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745771136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>8. INCOME TAXES Net deferred tax asset (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract', window );"><strong>Income Taxes Net Deferred Tax Asset Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 70,752,000<span></span>
</td>
<td class="nump">$ 64,366,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit</a></td>
<td class="nump">1,221,000<span></span>
</td>
<td class="nump">1,221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,292,000<span></span>
</td>
<td class="nump">6,379,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd', window );">Capitalized R&amp;D</a></td>
<td class="nump">21,160,000<span></span>
</td>
<td class="nump">18,508,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Vacation and other</a></td>
<td class="nump">121,000<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">99,546,000<span></span>
</td>
<td class="nump">90,653,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FixedAssetsAndIntangibles', window );">Fixed assets and intangibles</a></td>
<td class="num">(523,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(523,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">99,023,000<span></span>
</td>
<td class="nump">90,604,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(99,023,000)<span></span>
</td>
<td class="num">(90,604,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">DeferredTaxAssetsLiabilitiesNet</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncomeTaxesNetDeferredTaxAssetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757937632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. INCOME TAXES Reconciliation of effective tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract', window );"><strong>Income Taxes Reconciliation Of Effective Tax Rate Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal Rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">6.44%<span></span>
</td>
<td class="nump">3.92%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">State tax rate change</a></td>
<td class="num">(3.91%)<span></span>
</td>
<td class="num">(22.13%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(3.39%)<span></span>
</td>
<td class="num">(0.03%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">25.49%<span></span>
</td>
<td class="nump">45.08%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(58.63%)<span></span>
</td>
<td class="num">(60.84%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncomeTaxesReconciliationOfEffectiveTaxRateDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747531184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION Awards (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockholdersEquityDetails1Abstract', window );"><strong>Stock Compensation Awards Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Employees</a></td>
<td class="nump">$ 1,380,500<span></span>
</td>
<td class="nump">$ 2,113,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NonemployeesShareBasedCompensation', window );">Non-employees</a></td>
<td class="nump">$ 232,847<span></span>
</td>
<td class="nump">$ 751,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NonemployeesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NonemployeesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockholdersEquityDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockholdersEquityDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911641296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockCompensationDetailsAbstract', window );"><strong>Stock Compensation Assumptions Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, min</a></td>
<td class="nump">88.54%<span></span>
</td>
<td class="nump">75.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, max</a></td>
<td class="nump">90.67%<span></span>
</td>
<td class="nump">80.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, min</a></td>
<td class="nump">2.18%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, max</a></td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">1.056%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpectedLifeOfOptionsMin1', window );">Expected life of options, min</a></td>
<td class="text">9 years 8 months 8 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpectedLifeOfOptionsMax', window );">Expected life of options, max</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">9 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpectedLifeOfOptionsMax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpectedLifeOfOptionsMax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpectedLifeOfOptionsMin1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpectedLifeOfOptionsMin1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockCompensationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockCompensationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745915264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_OutstandingMember', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">343,575<span></span>
</td>
<td class="nump">301,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">932,825<span></span>
</td>
<td class="nump">48,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options Forfeited</a></td>
<td class="nump">15,795<span></span>
</td>
<td class="nump">2,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfStocksExpired', window );">Number of Options Expired</a></td>
<td class="nump">20,761<span></span>
</td>
<td class="nump">4,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">1,239,844<span></span>
</td>
<td class="nump">343,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 59.22<span></span>
</td>
<td class="nump">$ 67.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">2.17<span></span>
</td>
<td class="nump">12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">9.46<span></span>
</td>
<td class="nump">21.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">88.80<span></span>
</td>
<td class="nump">145.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 16.44<span></span>
</td>
<td class="nump">$ 59.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning</a></td>
<td class="text">5 years 4 months 6 days<span></span>
</td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding', window );">Weighted Average Remaining Contractual Life (in years) Outstanding, Ending</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">5 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_ExercisableMember', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">232,931<span></span>
</td>
<td class="nump">181,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfStockVested', window );">Number of Options Vested</a></td>
<td class="nump">63,812<span></span>
</td>
<td class="nump">56,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfStocksExpired', window );">Number of Options Expired</a></td>
<td class="nump">20,761<span></span>
</td>
<td class="nump">4,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">275,982<span></span>
</td>
<td class="nump">232,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 66.28<span></span>
</td>
<td class="nump">$ 78.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageExercisePriceVested', window );">Weighted Average Exercise Price Vested</a></td>
<td class="nump">18.45<span></span>
</td>
<td class="nump">31.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">88.80<span></span>
</td>
<td class="nump">145.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 53.53<span></span>
</td>
<td class="nump">$ 66.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning</a></td>
<td class="text">4 years 9 months 4 days<span></span>
</td>
<td class="text">5 years 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding', window );">Weighted Average Remaining Contractual Life (in years) Outstanding, Ending</a></td>
<td class="text">4 years 10 months 28 days<span></span>
</td>
<td class="text">4 years 9 months 4 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfStocksExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfStocksExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageExercisePriceVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageExercisePriceVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_OutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_OutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_ExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=CVM_ExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745249344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION Nonvested Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockCompensationNonvestedOptionsDetailsAbstract', window );"><strong>Stock Compensation Nonvested Options Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfUnvestedOptionsBeginning', window );">Number of unvested options, Beginning</a></td>
<td class="nump">110,644<span></span>
</td>
<td class="nump">120,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_VestedOptions', window );">Vested options</a></td>
<td class="num">(63,812)<span></span>
</td>
<td class="num">(56,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GrantedOptions', window );">Granted options</a></td>
<td class="nump">932,825<span></span>
</td>
<td class="nump">48,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ForfeitedOptions', window );">Forfeited options</a></td>
<td class="num">(15,795)<span></span>
</td>
<td class="num">(2,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfUnvestedOptionsEnding', window );">Number of unvested options, Ending</a></td>
<td class="nump">963,862<span></span>
</td>
<td class="nump">110,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageGrantDateFairValueBeginning', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 36.96<span></span>
</td>
<td class="nump">$ 43.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageGrantDateFairValueEnding', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="nump">$ 36.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ForfeitedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ForfeitedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GrantedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GrantedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfUnvestedOptionsBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfUnvestedOptionsBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfUnvestedOptionsEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfUnvestedOptionsEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockCompensationNonvestedOptionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockCompensationNonvestedOptionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_VestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_VestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageGrantDateFairValueBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageGrantDateFairValueBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageGrantDateFairValueEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageGrantDateFairValueEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6746466096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION RSU (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageGrantDateFairValueEnding', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="nump">$ 36.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CVM_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfUnvestedSharesBeginning', window );">Number of unvested shares, Beginning</a></td>
<td class="nump">604,000<span></span>
</td>
<td class="nump">604,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_VestedShares', window );">Vested shares</a></td>
<td class="num">(136,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NumberOfUnvestedSharesEnding', window );">Number of unvested shares, Ending</a></td>
<td class="nump">468,000<span></span>
</td>
<td class="nump">604,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_WeightedAverageGrantDateFairValueEnding', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfUnvestedSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfUnvestedSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NumberOfUnvestedSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NumberOfUnvestedSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_VestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_VestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_WeightedAverageGrantDateFairValueEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_WeightedAverageGrantDateFairValueEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CVM_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CVM_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6599238496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockCompensationDetailsNarrativeAbstract', window );"><strong>Stock Compensation Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Expense relating to the restricted stock</a></td>
<td class="nump">$ 633,000<span></span>
</td>
<td class="nump">$ 634,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockCompensationDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockCompensationDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6746552192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. EMPLOYEE BENEFIT PLAN (Detail Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>Employee Benefits and Share-based Compensation, Noncash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Expense for Company's contribution to employee benefit plan</a></td>
<td class="nump">$ 163,000<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6746523328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>11. COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CommitmentsAndContingenciesDetailsAbstract', window );"><strong>Commitments And Contingencies Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths', window );">2018</a></td>
<td class="nump">$ 1,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo', window );">2019</a></td>
<td class="nump">1,808,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree', window );">2020</a></td>
<td class="nump">1,872,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour', window );">2021</a></td>
<td class="nump">1,937,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive', window );">2022</a></td>
<td class="nump">2,004,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">13,758,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Total future minimum lease obligation</a></td>
<td class="nump">23,126,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less imputed interest on financing obligation</a></td>
<td class="num">(9,914,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Net present value of lease financing obligation</a></td>
<td class="nump">$ 13,212,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CommitmentsAndContingenciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CommitmentsAndContingenciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6606199104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>11. COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CommitmentsAndContingenciesDetailsAbstract', window );"><strong>Commitments And Contingencies Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths', window );">2018</a></td>
<td class="nump">$ 251,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo', window );">2019</a></td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree', window );">2020</a></td>
<td class="nump">238,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour', window );">2021</a></td>
<td class="nump">163,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive', window );">2022</a></td>
<td class="nump">69,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments:</a></td>
<td class="nump">$ 979,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CommitmentsAndContingenciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CommitmentsAndContingenciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745139152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 15,606,985<span></span>
</td>
<td class="nump">$ 17,445,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_RDDeferredRentLiability', window );">R &amp; D deferred rent liability</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DeferredRentLiability', window );">Deferred rent liability</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Ergomed Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">5,800,000<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CVM_SanTomasMember', window );">San Tomas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense, including amortization of deferred rent</a></td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="nump">$ 234,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DeferredRentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DeferredRentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_RDDeferredRentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_RDDeferredRentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CVM_SanTomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CVM_SanTomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6887981280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>14. FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">$ 2,053,402<span></span>
</td>
<td class="nump">$ 8,394,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">32,773<span></span>
</td>
<td class="nump">3,111,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">$ 2,020,629<span></span>
</td>
<td class="nump">$ 5,283,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911713232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueMeasurementsDetails1Abstract', window );"><strong>Fair Value Measurements Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 5,283,573<span></span>
</td>
<td class="nump">$ 6,323,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances</a></td>
<td class="nump">4,665,683<span></span>
</td>
<td class="nump">8,722,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Net realized and unrealized derivative (gain)/loss</a></td>
<td class="num">(7,928,627)<span></span>
</td>
<td class="num">(9,761,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 2,029,629<span></span>
</td>
<td class="nump">$ 5,283,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueMeasurementsDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueMeasurementsDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) included in earnings, which have arisen from the use of significant unobservable inputs (level 3) to measure fair value of assets, liabilities, and financial instruments classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745599872">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>15. NET LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_I.EarningsPerShareDetailsAbstract', window );"><strong>Net Loss Per Common Share Details</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss - available to common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14,427,055)<span></span>
</td>
<td class="num">$ (11,512,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainOnDerivativeInstruments', window );">Less: Gain on derivative Instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(677,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss - diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (15,104,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares - basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,891,843<span></span>
</td>
<td class="nump">4,866,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncrementalCommonSharesAttributableToGainOnDerivatives', window );">Less: gain on derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares - diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,902,647<span></span>
</td>
<td class="nump">4,866,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares - basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,866,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.83)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share - diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="num">(2.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">LPS - Basic and Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes series GG and II warrants.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_I.EarningsPerShareDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_I.EarningsPerShareDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncrementalCommonSharesAttributableToGainOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncrementalCommonSharesAttributableToGainOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747625056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>15. NET LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_I.EarningsPerShareDetailsNarrativeAbstract', window );"><strong>Net Loss Per Common Share Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_OptionsAndWarrantsExcludedFromEarningsPerShare', window );">Options and Warrants</a></td>
<td class="nump">2,538,130<span></span>
</td>
<td class="nump">3,675,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_AntidilutiveConvertibleDebt', window );">Convertible Debt</a></td>
<td class="nump">1,166,106<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_AntidilutiveUnvestedRestrictedStock', window );">Unvested Restricted Stock</a></td>
<td class="nump">604,000<span></span>
</td>
<td class="nump">604,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">4,308,236<span></span>
</td>
<td class="nump">4,279,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_AntidilutiveConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_AntidilutiveConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_AntidilutiveUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_AntidilutiveUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_I.EarningsPerShareDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_I.EarningsPerShareDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_OptionsAndWarrantsExcludedFromEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_OptionsAndWarrantsExcludedFromEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'WY783]8MW?_V/@BJ%KX=1?J"U!+ P04    " "H@9U+F5R<(Q &  "<)P
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M0W==GX[T3S=M=1S_KEB>_S.Y^1]02P,$%     @ J(&=2PA$ )FD!0  IAL
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M=3895'/FW RR198I/O\_&8%DR'338LRPB#$<&>2+'*4?0,=R"+_*E1;F?E7
M:&2 1I4TL(;>@F,ACV1(%LAF&,08C@S@Z"0<61,O@:HP+&=V#93#&@HF%_$9
MHY'!T=[) ,LZKUQX%U+8EZZ D(()1<CM.4Q;!K15V1&#HWLZ"\6HMIP6^G0X
M*T(F!##F+0/>JNR(-4B)B^CT! *A<'_YXQ=FK@.9J,O$$8<9Z<#IW,F,WX$,
MDXUGN8370"ATEYXP=!V KI&AQ&F4)I:4"B9 EX&)PZQU@+7RAZV5TR!-.8WR
MHE7!YN8K\X,G(*V3Y'<:H M7%+X(,A-%RE 2F=SIW&'B.D1<&0"<1BG[0L[L
M&LB2^5Q^Y#!Q'2"NER' @1R360:N-9#9=.;)+6K,6@=8ZV4(<.!WU!)$2*#+
M+6K,6 <8JXY6DZBXZ'<(Z:@O[0!A.NWY0F81R[/;C5W=/H\70=WLH7G=]\,]
MPMG;TV73'0VW(^+]REZMCU=&WZLYWF#]7K7/FWTWNV_ZOMF--R1/3=/7R:?Y
ME ;LI:X>3P_;^JD?OI;I>WN\.3H^],UANA5;GJ[F;O\#4$L#!!0    ( *B!
MG4LJ?9KTLP$  -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?5/;
MCILP$/T5RQ^P3H"TJPB0-KNJ6JF5HJW:/CLP@+6^4-N$[=]W; BE+=H7VS.>
M<^;,>)R/QKZX#L"35R6U*VCG?7]DS%4=*.[N3 \:;QIC%?=HVI:YW@*O(TA)
MENQV[YCB0M,RC[ZS+7,S>"DTG"UQ@U+<_CJ!-&-!]_3F>!9MYX.#E7G/6_@*
M_EM_MFBQA:46"K031A,+34$?]L=3%N)CP'<!HUN=2:CD8LQ+,#[5!=T%02"A
M\H&!XW:%1Y R$*&,GS,G75(&X/I\8_\0:\=:+MS!HY$_1.V[@MY34D/#!^F?
MS?@1YGH.E,S%?X8K2 P/2C!'9:2+*ZD&YXV:65"*XJ_3+G3<Q^DFO<&V <D,
M2!; ?02P*5%4_L0]+W-K1F*GWO<\//'^F&!OJN",K8AW*-ZA]UKN#VG.KH%H
MCCE-,<DZ9HE@R+ZD2+92G)+_X,DV/-U4F$9X^I?";)L@VR3((D'V9HE;,8=_
MDK!53Q78-DZ3(Y49=)SDE7<9V(<DOLF?\&G:OW#;"NW(Q7A\V=C_QA@/*&5W
MAR/4X0=;# F-#\?W>+;3F$V&-_W\@]CRC<O?4$L#!!0    ( *B!G4L=:AWM
MM $  -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5/;;MP@$/T5
MQ >$7:]ST<JVE$T4I5(KK1*U?6;ML8T"C -XG?Y] 'M=M[7Z LPPY\R98<@&
M-&^V!7#D0TEM<]HZU^T9LV4+BMLK[$#[FQJ-XLZ;IF&V,\"K"%*2)9O-#5-<
M:%IDT7<T18:]DT+#T1#;*\7-KP-(''*ZI1?'BVA:%QRLR#K>P"NX[]W1>(O-
M+)50H*U 30S4.;W?[@]IB(\!/P0,=G$FH9(3XELPOE0YW01!(*%T@8'[[0P/
M(&4@\C+>)TXZIPS Y?G"_A1K][6<N(4'E#]%Y=J<WE%20<U[Z5YP>(:IGFM*
MIN*_PAFD#P]*?(X2I8TK*7OK4$TL7HKB'^,N=-R'\69W@:T#D@F0S("["&!C
MHJC\D3M>9 8'8L;>=SP\\7:?^-Z4P1E;$>^\>.N]YV)[?9.Q<R":8@YC3+*,
MF2.89Y]3)&LI#LD_\&0=OEM5N(OPW1\*TW6"=)4@C03I?TM<B[G]*PE;]%2!
M:>(T65)BK^,D+[SSP-XG\4U^AX_3_HV;1FA+3NC\R\;^UX@.O)3-E1^AUG^P
MV9!0NW"\]6<SCMEH..RF'\3F;UQ\ E!+ P04    " "H@9U+I,]'%[4!  #2
M P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;'U3;8^4,!#^*TU_P)5E
MN77= ,GM&:.))ILSZN<N#-!<7[ MR_GOG18.48E?VLYTGF>>F4[ST=AGUP%X
M\J*D=@7MO.]/C+FJ \7=G>E!XTUCK.(>3=LRUUO@=00IR=(D.3#%A:9E'GT7
M6^9F\%)HN%CB!J6X_7D&:<:"[NBKXTFTG0\.5N8];^$+^*_]Q:+%%I9:*-!.
M&$TL- 5]V)W.68B/ =\$C&YU)J&2JS'/P?A8%S0)@D!"Y0,#Q^T&CR!E($(9
M/V9.NJ0,P/7YE?U]K!UKN7('CT9^%[7O"GJDI(:&#](_F?$#S/7<4S(7_PEN
M(#$\*,$<E9$NKJ0:G#=J9D$IBK],N]!Q'Z>;[###M@'I#$@7P#'F85.BJ/P=
M][S,K1F)G7K?\_#$NU.*O:F",[8BWJ%XA]Y;N;L_YNP6B.:8\Q23KF.6"(;L
M2XIT*\4Y_0>>;L/WFPKW$;[_0^';;8)LDR"+!-E_2]R(.21_)6&KGBJP;9PF
M1RHSZ#C)*^\RL ]I?)/?X=.T?^:V%=J1J_'XLK'_C3$>4$IRAR/4X0=;# F-
M#\<W>+;3F$V&-_W\@]CRC<M?4$L#!!0    ( *B!G4O0G<P]M $  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;'U386_;(!#]*X@?4&*295%D
M6VHZ3:NT25&GK9^)?;91P><"CKM_/\"NYW;>O@!WW'OW[CC2 <V3;0 <>=&J
MM1EMG.N.C-FB 2WL#7;0^IL*C1;.FZ9FMC,@R@C2BO'-9L^TD"W-T^@[FSS%
MWBG9PMD0VVLMS*\3*!PRFM!7QX.L&Q<<+$\[4<-W<#^ZL_$6FUE*J:&U$EMB
MH,KH;7(\[4)\#/@I8;"+,PF57!"?@G%?9G03!(&"P@4&X;<KW(%2@<C+>)XX
MZ9PR )?G5_;/L79?RT58N$/U*$O79/1 20F5Z)5[P.$+3/5\H&0J_BM<0?GP
MH,3G*%#9N)*BMP[UQ.*E:/$R[K*-^S#>[ \3;!W )P"? 8>8AXV)HO)/PHD\
M-3@0,_:^$^&)DR/WO2F",[8BWGGQUGNO>;)/4G8-1%/,:8SARY@Y@GGV.05?
M2W'B?\'Y.GR[JG ;X=LW"O]!L%LEV$6"W7]+7(O9ODO"%CW58.HX3984V+=Q
MDA?>>6!O>7R3/^'CM'\3II:M)1=T_F5C_RM$!U[*YL:/4.,_V&PHJ%PX?O1G
M,X[9:#CLIA_$YF^<_P902P,$%     @ J(&=2_C6Q;BT 0  T@,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL?5/;;MP@$/T5Q >$7>Q-HY5M*9NJ
M2J166J5J^\S:XXL"C -XG?Y] 3N.U5I] 68XY\R%(1O1O-@6P)$W);7-:>M<
M?V3,EBTH86^P!^UO:C1*.&^:AMG>@*@B24G&=[M;ID2G:9%%W]D4&0Y.=AK.
MAMA!*6%^GT#BF-,]?7<\=TWK@H,562\:^ [N1W\VWF*+2M4IT+9#30S4.;W?
M'T]IP$? SPY&NSJ34,D%\2483U5.=R$AD%"ZH"#\=H4'D#((^31>9TVZA S$
M]?E=_4NLW==R$18>4/[J*M?F](Z2"FHQ2/>,XR/,]1PHF8O_"E>0'AXR\3%*
ME#:NI!RL0S6K^%24>)OV3L=]G&Z29*9M$_A,X OA+L9A4Z"8^6?A1)$9'(F9
M>M^+\,3[(_>]*8,SMB+>^>2M]UZ+_6V:L6L0FC&G"</7F 7!O/H2@F^%./%_
MZ'R;GFQFF$1ZLHY^2+<%TDV!- JD_RUQ"W/X*PA;]52!:>(T65+BH.,DK[S+
MP-[S^"8?\&G:OPG3=-J2"SK_LK'_-:(#G\KNQH]0ZS_88DBH73A^\F<SC=ED
M..SG'\26;US\ 5!+ P04    " "H@9U+Z9G"%+4!  #2 P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q]4]MNVS ,_15!'U#%3I8&@6V@Z3!LP 8$
M+;8^*S9M"]7%D^2X^_M2LNNYG;$72:1X#@\I*AN,?78M@"<O2FJ7T];[[LB8
M*UM0W-V8#C3>U,8J[M&T#7.=!5Y%D)(LW6SV3'&A:9%%W]D6F>F]%!K.EKA>
M*6[_G$":(:<)?7,\B*;UP<&*K.,-/(+_V9TM6FQFJ80"[831Q$*=T[OD>-J%
M^!CP2\#@%F<2*KD8\QR,;U5.-T$02"A]8."X7>$>I Q$*./WQ$GGE &X/+^Q
M?XFU8RT7[N#>R"=1^3:G!THJJ'DO_8,9OL)4SR=*IN*_PQ4DA@<EF*,TTL65
ME+WS1DTL*$7QEW$7.N[#>+--)M@Z()T Z0PXQ#QL3!25?^:>%YDU [%C[SL>
MGC@YIMB;,CAC*^(=BG?HO1;)?I^Q:R":8DYC3+J,F2,8LL\ITK44I_0?>+H.
MWZXJW$;X]IW"VW6"W2K!+A+L_EOB6LSA0Q*VZ*D"V\1I<J0TO8Z3O/#. WN7
MQC?Y&SY.^P]N&Z$=N1B/+QO[7QOC :5L;G"$6OQ@LR&A]N%XBV<[CMEH>---
M/XC-W[AX!5!+ P04    " "H@9U+8A2M+[4!  #2 P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q]4]MNW" 0_17$!P0ON\FF*]M2-E652HVT2M7V
MF;7'-@IX',#KY.\+V'&MQLH+,,,Y9RX,Z8#FV38 CKQJU=J,-LYU!\9LT8 6
M]@H[:/U-A48+YTU3,]L9$&4D:<5XDMPP+61+\S3Z3B9/L7=*MG RQ/9:"_-V
M!(5#1C?TW?$DZ\8%!\O33M3P$]RO[F2\Q6:54FIHK<26&*@R>K<Y''<!'P&_
M)0QV<2:ADC/B<S"^EQE-0D*@H'!!0?CM O>@5!#R:;Q,FG0.&8C+\[OZMUB[
MK^4L+-RC^B-+UV3TEI(2*M$K]X3# TSU7%,R%?\#+J \/&3B8Q2H;%Q)T5N'
M>E+QJ6CQ.NZRC?LPWO#KB;9.X!.!SX3;&(>-@6+F7X43>6IP(&;L?2?"$V\.
MW/>F",[8BGCGD[?>>\DW-U]2=@E"$^8X8O@2,R.85Y]#\+401_Z!SM?IV]4,
MMY&^74;?)^L"NU6!7138?5KB"F;_?Y%LT5,-IH[39$F!?1LG>>&=!_:.QS?Y
M!Q^G_5&86K:6G-'YEXW]KQ =^%22*S]"C?]@LZ&@<N&X]V<SCMEH..RF'\3F
M;YS_!5!+ P04    " "H@9U+U:QG1[,!  #2 P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q]4V%OW" ,_2N('U#N2-96IR12KU7529MTZK3M,Y<X
M"2J$%,BE^_<S),VR+>H7P,;O^=F8;#3VQ;4 GKQIU;F<MM[W!\9<V8(6[LKT
MT.%-;:P6'DW;,-=;$%4$:<7X;G?-M) =+;+H.]DB,X-7LH.3)6[06MA?1U!F
MS.F>OCN>9=/ZX&!%UHL&OH'_WI\L6FQAJ:2&SDG3$0MU3N_VAV,:XF/ #PFC
M6YU)J.1LS$LP/E<YW05!H*#T@4'@=H%[4"H0H8S7F9,N*0-P?7YG?XRU8RUG
MX>#>J)^R\FU.;RFIH!:#\L]F?(*YGD^4S,5_@0LH# ]*,$=IE(LK*0?GC9Y9
M4(H6;],NN[B/TTV2S+!M )\!? '<QCQL2A25/P@OBLR:D=BI][T(3[P_<.Q-
M&9RQ%?$.Q3OT7HK]#<_8)1#-,<<IAJ]CE@B&[$L*OI7BR/^#\VUXLJDPB?#D
M+X7)-D&Z29!&@O3#$K=BTG^2L%5/-=@F3I,CI1FZ.,DK[S*P=SR^R9_P:=J_
M"MO(SI&S\?BRL?^U,1Y0RNX*1ZC%#[88"FH?CC=XMM.8388W_?R#V/*-B]]0
M2P,$%     @ J(&=2TE-;<>T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL?5-A;]L@$/TKB!]0$L=MJLBVU+2J.FF3HE;;/A/[;*,"YP*.
MNW]?P*[G;=:^ '?<>_?N.+(!S:MM 1QY5U+;G+;.=0?&;-F"XO8*.]#^ID:C
MN/.F:9CM#/ J@I1DR69SPQ07FA99])U,D6'OI-!P,L3V2G'SZP@2AYQNZ:?C
M632M"PY69!UOX 7<]^YDO,5FEDHHT%:@)@;JG-YM#\<TQ,> 'P(&NSB34,D9
M\3487ZJ<;H(@D%"ZP,#]=H%[D#(0>1EO$R>=4P;@\OS)_AAK][6<N85[E#]%
MY=J<WE)20<U[Z9YQ>(*IGFM*IN*_P@6D#P]*?(X2I8TK*7OK4$TL7HKB[^,N
M=-R'\6:?3K!U0#(!DAEP&_.P,5%4_L =+S*# S%C[SL>GGA[2'QORN",K8AW
M7KSUWDNQW5]G[!*(IICC&),L8^8(YMGG%,E:BF/R#SQ9A^]6%>XB?/>'PIMU
M@G25((T$Z7]+7(O9_Y6$+7JJP#1QFBPIL==QDA?>>6#ODO@FO\/':?_&32.T
M)6=T_F5C_VM$!U[*YLJ/4.L_V&Q(J%TX[OW9C&,V&@Z[Z0>Q^1L7'U!+ P04
M    " "H@9U+)QWW';4!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q]4V%OW" ,_2N('U"2W&V]G9)(O4[3)FW2J=.ZSUSB)*B ,R"7[M\/
M2)IE:]0O@(W?\[,Q^8CFR78 CCPKJ6U!.^?Z(V.VZD!Q>X,]:'_3H%'<>=.T
MS/8&>!U!2K(L2=XSQ86F91Y]9U/F.#@I-)P-L8-2W/P^@<2QH"E]<3R(MG/!
MP<J\YRU\!_>C/QMOL86E%@JT%:B)@::@=^GQM _Q,>!1P&A79Q(JN2 ^!>-+
M7= D" ()E0L,W&]7N <I Y&7\6OFI$O* %R?7]@_Q=I]+1=NX1[E3U&[KJ '
M2FIH^"#= XZ?8:[G'25S\5_A"M*'!R4^1X72QI54@W6H9A8O1?'G:1<Z[N-T
MLTMGV#8@FP'9 CC$/&Q*%)5_Y(Z7N<&1F*GW/0]/G!XSWYLJ.&,KXIT7;[WW
M6J:WAYQ= ]$<<YIBLG7,$L$\^Y(BVTIQRE[!LVWX;E/A+L)W_RC\L$VPWR38
M1X+]FR5NQ!R2_Y*P54\5F#9.DR45#CI.\LJ[#.Q=%M_D;_@T[=^X:86VY(+.
MOVSL?X/HP$M);OP(=?Z#+8:$QH7CK3^;:<PFPV$__R"V?./R#U!+ P04
M" "H@9U+C 4I!;0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q]4]MNVS ,_15!'U#%2MH%@6V@Z3!TP 8$';8^*S9]077Q)#GN_GZ4[+IN
MY_5%$BF>PT.*2@=CGUP#X,FSDMIEM/&^.S#FB@:4<%>F XTWE;%*>#1MS5QG
M0901I"3CF\T-4Z+5-$^C[V3SU/1>MAI.EKA>*6'_'$&:(:,)?7$\M'7C@X/E
M:2=J^ '^9W>R:+&9I6P5:-<:32Q4&;U-#L==B(\!OUH8W.),0B5G8YZ"\;7,
MZ"8( @F%#PP"MPO<@92!"&7\GCCIG#( E^<7]B^Q=JSE+!S<&?G8EK[)Z)Z2
M$BK12_]@AGN8ZKFF9"K^&UQ 8GA0@CD*(UU<2=$[;]3$@E*4>![W5L=]&&^N
M^01;!_ )P&? /N9A8Z*H_+/P(D^M&8@=>]^)\,3)@6-OBN",K8AW*-ZA]Y(G
M^R1EET TQ1S'&+Z,F2,8LL\I^%J*(_\'SM?AVU6%VPC?OE'X'X+=*L$N$NP^
M+'$M9OLN"5OT5(&MXS0Y4IA>QTE>>.>!O8V/R%[#QVG_+FS=:D?.QN/+QOY7
MQGA *9LK'*$&/]AL2*A\.'["LQW';#2\Z:8?Q.9OG/\%4$L#!!0    ( *B!
MG4OMPX 9M0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;'U3
MVV[<(!#]%<0'A%W625<KVU(V4=5(K;1*U>:9M<<7!1@'\#K]^P)V'">U^@+,
M,.?,F6%(!S3/M@%PY%5);3/:.-<=&+-% TK8*^Q ^YL*C1+.FZ9FMC,@R@A2
MDO'-YH8IT6J:I]%W,GF*O9.MAI,AME=*F#]'D#AD=$O?'(]MW;C@8'G:B1I^
M@OO5G8RWV,Q2M@JT;5$3 U5&;[>'8Q+B8\#O%@:[.)-0R1GQ.1@/948W01!(
M*%Q@$'Z[P!U(&8B\C)>)D\XI W!Y?F/_&FOWM9R%A3N43VWIFHSN*2FA$KUT
MCSA\@ZF>:TJFXK_#!:0/#TI\C@*EC2LI>NM032Q>BA*OX][JN _CS6X_P=8!
M? +P&;"/>=B8*"J_%T[DJ<&!F+'WG0A/O#UPWYLB.&,KXIT7;[WWDF_W2<HN
M@6B*.8XQ?!DS1S#//J?@:RF._!\X7X?O5A7N(GSW0>'U.D&R2I!$@N2_):[%
MW'Q*PA8]56#J.$V6%-CK.,D+[SRPMSR^R7OX..T_A*E;;<D9G7_9V/\*T8&7
MLKGR(]3X#S8;$BH7CE_\V8QC-AH.N^D'L?D;YW\!4$L#!!0    ( *B!G4OU
M'*L+M@$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;&U3[6[;
M(!1]%<0#E,1QURRR+36=IE5JI:C3MM_$OK91@>L!CMNW'V#'\SK_ >[EG',_
MN&0#FE?; CCRIJ2V.6V=ZPZ,V;(%Q>T-=J#]38U&<>=-TS#;&>!5)"G)DLWF
M$U-<:%IDT7<R18:]DT+#R1#;*\7-^Q$D#CG=TJOC132M"PY69!UOX#NX']W)
M>(O-*I50H*U 30S4.;W?'HYIP$? 3P&#79Q)J.2,^!J,QRJGFY 02"A=4.!^
MN\ #2!F$?!J_)TTZAPS$Y?FJ_C76[FLY<PL/*'^)RK4YW5-20<U[Z5YP^ 93
M/;>43,4_P06DAX=,?(P2I8TK*7OK4$TJ/A7%W\9=Z+@/X\WN2ELG)!,AF0G[
M2&!CH)CY%^YXD1D<B!E[W_'PQ-M#XGM3!F=L1;SSR5OOO13;_5W&+D%HPAQ'
M3++$S CFU><0R5J(8_(?/5FG[U8SW$7Z;AG]-ET72%<%TBB0_E/B_D.):YC/
M'X*P14\5F"9.DR4E]CI.\L([#^Q]$M_D+WR<]F=N&J$M.:/S+QO[7R,Z\*EL
M;OP(M?Z#S8:$VH7CG3^;<<Q&PV$W_2 V?^/B#U!+ P04    " "H@9U+0(#^
M_;,!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q]4V%OW" ,
M_2N('U!RN:SK3DFD7J=IDS;IU&GM9RYQ$E3 *9!+]^\')$VS+=L7P,;O^=F8
M?$3S9#L 1UZ4U+:@G7/]@3%;=:"XO<(>M+]IT"CNO&E:9GL#O(X@)5F:)-=,
M<:%IF4??R90Y#DX*#2=#[* 4-S^/('$LZ(Z^.NY%V[G@8&7>\Q:^@_O1GXRW
MV,)2"P7:"M3$0%/0V]WAF(7X&/ @8+2K,PF5G!&?@O&E+F@2!(&$R@4&[K<+
MW(&4@<C+>)XYZ9(R -?G5_9/L79?RYE;N$/Y*&K7%?2&DAH:/DAWC^-GF.MY
M1\E<_%>X@/3A08G/4:&T<2758!VJF<5+4?QEVH6.^SC=[+,9M@U(9T"Z &YB
M'C8EBLH_<L?+W.!(S-3[GH<GWAU2WYLJ.&,KXIT7;[WW4NX^)#F[!*(YYCC%
MI.N8)8)Y]B5%NI7BF/X%3[?A^TV%^PC?_Z;P'_FS38(L$F3_+7$KYD^5;-53
M!::-TV1)A8..D[SR+@-[F\8W>0N?IOT;-ZW0EIS1^9>-_6\0'7@IR94?H<Y_
ML,60T+AP?._/9AJSR7#8SS^(+=^X_ 502P,$%     @ J(&=2VB/BM2T 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL?5/;;MP@$/T5Q >$
M]:5)NK(M95-5K=1*JU1-GUE[;*, XP)>IW]?P(YKM59?@!G..7-A*"8T+[8'
M<.1526U+VCLW'!FS=0^*VQL<0/N;%HWBSINF8W8PP)M(4I*EA\,M4UQH6A71
M=S95@:.30L/9$#LJQ<VO$TB<2IK0-\>3Z'H7'*PJ!M[!-W#?A[/Q%EM5&J%
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M=>%XY\]F'K/9<#@L/XBMW[CZ#5!+ P04    " "H@9U+D"+\S[4!  #2 P
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M\>S&,1N-8+OI!['Y&Q=_ %!+ P04    " "H@9U+K9)(OI<"  "J"@  &0
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M$0HH7(]!D,=D!%<U20"%ZP$(\IB X.(GH++)Y()#()\/</T34-QTX@,$\OD
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MG'*']X#O+8QZM0]<)1<I7YSQJ3Z&D4L(.%3&,3"[W.$).'=$-HV?,V>X2+K
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MUA=#01_B]A[W+M]X-H(=Y\?,EB^J^0]02P,$%     @ J(&=2YGS=R_>#
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ML2 .#7-4G3E&)1Z5 !DJ=IDZ= Q3A5J4&50"9*C()6@M:@@J'MK]Z]YG_Y5
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MIS\A3>!]_\/]BZU=UW*@$G:<_:Y/JMKXF>^=X$RO3+WP_BN,]<2^-Q;_'6[
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M,3QLPT#Q;GRST?3A*/\!4$L#!!0    ( *B!G4OX?6R6W0$  &8$   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;'U4VV[;, S]%4$?4/FV- AL TV&
M80,V(.BP]5FQZ0NJBR<I<??WT\5UG<18'B*1.N>0E$CGHU2ON@,PZ(TSH0O<
M&3/L"-%5!YSJ!SF L">-5)P::ZJ6Z$$!K3V),Y)$T89PV@M<YMYW5&4NSX;U
M HX*Z3/G5/W= Y-C@6/\[GCNV\XX!RGS@;;P$\ROX:BL16:5NN<@="\%4M 4
M^"G>'3*']X#?/8QZL4>NDI.4K\[X5A<X<@D!@\HX!6J7"QR ,2=DT_@S:>(Y
MI",N]^_J7WSMMI83U7"0[*6O35?@+48U-/3,S+,<O\)4SR>,IN*_PP68A;M,
M;(Q*,NW_47761O))Q:;"Z5M8>^'7,9QD\41;)R03(9D)\>:_A'0BI!\$?YLD
M9.9+_4P-+7,E1Z3"8PW4]42\2^UE5L[I[\Z?V6JU]5[*+-KDY.*$)LP^8)(%
M)IX1Q*K/(9*U$/ODCIY<!SC<(])H/4*Z6D3J^>E5$8_K MFJ0.8%LBN![<TM
M!,S&8\2$L;^;4NY1Z7:)"LF0Q?-P4*WO9(TJ>1;&7<3".P_+4^*>]\:_MT,4
M>OY#)DS@#ZK:7FATDL8VCW_B1DH#-LGHP;9U9X=^-A@TQFT?[5Z%U@^&D<,T
MU63^M)3_ %!+ P04    " "H@9U+.$$@EXT"  "/"0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6R-EMN.FS 0AE\%<=_%!XZK)%*3JFJE5HJVVO;:
MFS@)6L#4=I+MV]<V+")X2'L#MOEGYILQ&GMQ%?)5G3C7P5M=-6H9GK1N'Z-(
M[4Z\9NI!M+PQ7PY"UDR;J3Q&JI6<[9U1744$H32J6=F$JX5;V\K50IQU539\
M*P-UKFLF_ZQY):[+$(?O"T_E\:3M0K1:M.S(?W#]W&ZEF46#EWU9\T:5H@DD
M/RS#C_AQ@ZDU<(J?);^JT3BPJ;P(\6HG7_?+$%DB7O&=MBZ8>5WXAE>5]60X
M?O=.PR&F-1R/W[U_=LF;9%Z8XAM1_2KW^K0,\S#8\P,[5_I)7+_P/J$D#/KL
MO_$+KXS<DI@8.U$I]PQV9Z5%W7LQ*#5[Z]YEX][7[DM2]&:P >D-R&" X[L&
MM#>@$X.H(W.I?F*:K1927 /9[5;+[$^!'ZDIYLXNNMJY;R9;958OJQ@5B^AB
M'?6:=:<A(PVY56Q\!46#)#(  P4!*8BSIV,*/.. @@ZH<Q#?.,"3-#I-ZC2-
MTV0H2\P?CR;9^,(TIFDZ%MX@Q2!2#"!-ZK;N-,DH$B8$^T3_UMT )2!0 @#1
M"5#B!4I) 90(T-&LF 5*0: 4 (HG0*D7B&!LMV)*Y MQGJ!\%BD#D3( *9D@
M9<!F 'L&R.Y4* =Q<@ GG>#D7IRB2.+4!P*$*$WH+%(!(A4 4C9!*KQ('Q)"
M?2) %\^7"".X@R& *)^V,/2?2)#P'M-,5\4>$XD])@SL' *A "5*43R/!;=9
M3(!2>=V>^!68XX*D]\'@]HV!_DW0%,SORQ[0/4D'$HU.1GM5^<[DL6Q4\"*T
M.63=47@00G/C#CV8S$[F=C1,*G[0=IB9L>RN"-U$B[:__D3#'6SU%U!+ P04
M    " "H@9U+\.Q$*D4"  "=!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6R%5=MNVS ,_17#'U#Y%N<"QT#C8MB #0@ZK'M6'"8V*EN>I,3=WT^2
M72=1N/8EDJC#PT/1(;.>BU=9 2COK6&M7/N54MV*$%E6T%#YP#MH]<V!BX8J
M?11'(CL!=&^=&D:B($A)0^O6SS-KVXH\XR?%ZA:VPI.GIJ'B[P88[]=^Z+\;
MGNMCI8R!Y%E'C_ 3U*]N*_2)3"S[NH%6UKSU!!S6_F.X*L+ .%C$2PV]O-I[
M)I4=YZ_F\&V_]@.C"!B4RE!0O9RA ,8,D];Q9R3UIYC&\7K_SO[%)J^3V5$)
M!6>_Z[VJUO["]_9PH">FGGG_%<:$9KXW9O\=SL TW"C1,4K.I/WURI-4O!E9
MM)2&O@UKW=JU'V[2>'3#':+1(9H<PO1#AWATB"\.B4U^4&93?:**YIG@O2>&
M:G74?!3A*M:/61JC?3M[I[.5VGK.DRC,R-D0C9C-@(FN,!<$T>Q3B @+L8GN
MW*/; ,4](@[P"#&:1&S]XYLD(IP@00D22Y#<$,3.*V"8Q$GD8\R-D!DJ9(80
MS!PA&"9UA&"8.2XD186D",'"$8)AEHX0!/._VLY1(7.$P/U ,8S[C6&8&!>R
M0(4L$ *G_AL,XY2OP# I+F2)"EDB!'-'"(9QRE=@F"4N1#=JM'D$]Q1)X'8/
M#.14L/@$-(@A5TVM 7&T_5]Z)3^URK2/*^LT8QXCTQ0=^\;,'MLL+S3#X/I!
MQ;%NI;?C2K=<VQ@/G"O0&H,'_:>J]*R<#@P.RFSG>B^&@3$<%._&84BFB9S_
M U!+ P04    " "H@9U+]G6X0?P!  #Y!   &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q]5-N.FS 0_17$!ZP!0Y)&@+1)5;52*T5;M7UV8+AH;4QM
M)VS_OKZP+ NT+]@S/N?,&6,[';AXE@V \EX8[63F-TKU1X1DT0 C\H'WT.F5
MB@M&E Y%C60O@)26Q"B*@F"'&&D[/T]M[B+RE-\4;3NX"$_>&"/BSPDH'S(_
M]%\33VW=*)- >=J3&KZ#^M%?A([0I%*V##K9\LX34&7^8W@\)P9O 3];&.1L
M[IE.KIP_F^!+F?F!,004"F44B![N< 9*C9"V\7O4]*>2ACB?OZI_LKWK7JY$
MPIG37VVIFLP_^%X)%;E1]<2'SS#VD_C>V/Q7N /5<.-$UR@XE?;K%3>I.!M5
MM!5&7MS8=G8<W$K\8:1M$Z*1$$V$</=? AX)^(T0V^:=,]OJ1Z)(G@H^>,+]
MK)Z8,Q$>L=[,PB3MWMDUW:W4V7L>QU&*[D9HQ)P<)IIAP@F!M/I4(MHJ<8I6
M]$6!\QJ!@^T*>+,);/GX71-X6R#>%(BM0/Q.(%[L@L/L+*9SNX /01($BV;6
MN"@,<8S_82C9-)1L&$H6AI)U(1P=XOW"SQJV3\)=LOR%:'9B&(C:7B[I%?S6
M*?-O9MGI_CY&YL0M\B=]K]TU?)-QC\(W(NJVD]Z5*WV>[:FK.%>@708/VF:C
MWZ$IH% I,]WKN7"WT06*]^-#@Z;7+O\+4$L#!!0    ( *B!G4L%V+>00@(
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MX^B^<*94@(3T5O*T*GE3C L"9Z&FJ9PSTR_-0M!NN K0>!\5_P!02P,$%
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M99JI;HOA)ATZBG?C7R*8?E7E7U!+ P04    " "H@9U+CQDJ/?P!  #,!0
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MQ*'E8[' @G#M!\VF0P/\8@:I<$IV;:7^'\ZBTZQ^Q'JZ+.([-<.'D?M.,UP
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MTO?9WKH3YPJT9O"@#Z;4[_!8,#@I,TWU7/2O45\HW@X/+1I?^^(?4$L#!!0
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M;M"=$)J;O**)R>M@NK!A4/&=MJ^9>9==*](-M&C[-@L-O=[B/U!+ P04
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MCW^9'[][#Y\'LY_A'M_-O8D!Z#Y> 0B>OH'[W0V:/J%B\M0-I"X6["# YTB
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M2A/5?7S<1Q C-Z ) G@<M!)_5)QRE U K%@[WK!X%(H3S(5_PPY \,'MP!(
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M HJ8Q&/,5;FA,^Z#%FN5+E 0X"^!5] T+,,;^Y0>O2PR)OS\_#Z=8,LRN:L
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MD??)V(M2T3ISYU4T;R]P%#&]AKD8FI2NAV]VO24JV+&5]DU[&]31-TLV3,9
M3Z-X'"9)%.P#6SZDM0[TKV'3TQ#N+AP-AO ]H*\_ ,B9E?)"M*8!MFX7&EZ?
MO5N^BJH=>BC(ZP%-GA2"A7(E0"[H#1A;0WEJE<%&,G2G:$'8""K9YV5\;KG:
M("5  CT()W;%@V>]^7:=(UU>B4]EF2^)!/*DQ(Z=*<T4L/,%; U$4URD^"*"
MN-).=MZM333IV EO@;E/AM:?Q1W&:BQ17MSK4ZZ*N3FMDMIGL8DJ\J"J#B]F
MYHT)][C92*A(RU4V+6D)2!(?/WR87?Q*,=;'[TZ/WQX?8=3^[.CH["/E"P7G
M9R?'+2E#?[O<WI/#X Q$ ,=P)MED"&;G!?K:&D$:'?$#.C.0_IC;S,! QV+,
M-=NW:7LFU6]GIEW J7550&$L54 /%/U@TH6!TZ(5W,;P']L8_N =Q:A(VH.7
MB?#&4:6/R+*%$4\4^G>.&:42A$[/>X22XEJ[LS&P =8%Z+[(JT]Z\JOT=]C<
MQXK@:6[$( J:H222X /L?ZOM,105?/B:$.O(#9Z5X$8G$<&/';9QM<A1E(3%
M9#J.A.)DRB4I7224S"Z/@F%_>#@$\0ZO+N[_P$O(XB9$#*8_A>GG>OH>C8:+
MGM&, !*(AUZ@;UXIM'L#^""<$Z^[+9!H.,&;Q/>L\X82,U'/!4Y)UP&856FJ
M]GJ5PJ5<+@"AX8>(G;S.?;',5J&1VYCA/S[@5:OT2UJ*'=S_.?U(:U$X6TEQ
M&O_<+F_QP"A7H8[TH.6RV[0TCK@;+]0)/\F:SR(:[;U]5HY\TL0 !5VD?:#-
MW)AY"EZO:6D])A!#^.6 \3.V5R-J5*'"E_EIF\),N4EJ.I.M\Q"@S?RQ!TWX
M72A?O"[66QDMYL#&HG8(\9\* 7N!6!>B@@6P+;]&+1]E/['6>:[XE!WJ FOT
M PM*P 5X"BM&UCW/K718N$9[D 532;E9\7:@!Q36@6U1WJK2CX(B,3R]][;^
M[]FIMS8!\.*LH\C=$"4_6#ID&8_-N!HBL]_1.J GY0@29*9HH5R3@JH#X[+?
MT1J(I.*S$'SS"8UO0@>#/M)*"[0<$T%[YU4^%^AQ8(,G;PF!7DRD()KE*#@!
MS^<@*4+.7;Q/N#K0N,.;,K/AR@&9N)Q]?$DK'S?)CWU5$F(\RG"6#:T,CG29
MM2:TV0-ZH2)7/(4XO>!]7J&CD[PGZ";$Q74LD%'R>+"]532+F_=T!7G<0:[O
MRB,W?'JS%=HEBA.&7A#S8S- )M(2[17-.@1#>BB=%46@TIV/[,1>7BII4<9!
M(%ZWI;W9%/^3KA[)^G43W-F+,.>\SM"N7Y1DS"*3%U^>0^F4#C=J$ERFF"SF
MN.XTI/L$$8<MR1ZBSA,PKK,O ='CBI"&PYD"?!'48REN35DO@[:6I!ORGI9+
MNR^3G4W7V@M^ELAM. Y"()QZ8[(TY'IMH*WJIFI.  [9N'7F#:Q#!@!"E5+C
M+B@9+'\SO42O2R6Q!7"A7CZ?L <^//D>$.KX*LA';K@=G):XBZPAA&AML>)P
M28(#L7/Q<%!L5LDFHW2#9B3M 7 WOBASNFADRT!2KSE*=FV7[%HK%!9,802
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M]66 73.Q MK-G.AYB*EYTA)ARQ;0P<$B]FM1-5[-[5L23WM#J^"#9(! 60-
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M&/2C_4\'&O):+20A9HC^$\M_B=9IFIT[QQ(=ZY)]W8]J1M7"@F@Z'H3L R&
M"Z7RX&>.]\/44R1J.>4+H@_#%%K2NH,D%9NP0:^\J#TR@BT(N8L[,KM[)G3.
MDVNO\T@F*&F#SF)TAE=%\9RH?\N]/+5ZR(8]M&RC;YN61T\_X\Q>Q-0=<'"T
M<TIV#38K>#4C'YR#UX^45TIZ69$ZH'V]K(H:VY\.'KS.G;(WSXBR<%/%W*YL
M"&8,EQDF&&>A>F$<=$<1DUP(6%N.],A)2XM&K3'2#8R->JC@?SB^PA0I[EA_
M='9Z=7SZ;GYZ=-ST@NW,9/D#CK&C%8BE"\(T\<S,;.NY8UV#,L96@%[TLE^
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M"^(OD$L+'AC9#V!;<>0?XTU%]=Y,&3MGQE 2 4AK1/IK\FR$QU.FC%A]T)J
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MYU,^H"!3WI22_5IC?ZX*I>-;I$J\[4\L"IF=!+;._]AB9RV/Q>#JZ:>L\G]
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M%S!'0]RC'6&@UC18MVW5F8>N')2'R<GTJF4D6U[>9&S(S:'!;>$V,5[8?FD
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M5D;2:?S$NE.PYY?#T 98]'!%81D,<-U4FF4B9G]6-3=@'9I!%N9]&X%#")I
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M- I' !/Q,+&@:H9, !>'B GCZ32<#"<62NPLXS"&FP<:"5<_< #.C!C '$E
MWT\=V#'?CP"-)^-@/((''[D@X\R0 #0-)^%P8K;@=J?!@J,Q8) YY1NGX\R0
MBDJ9K]SV,;6OW(XO \!\./FAPV_L<D"L([AT\Z7;OPCA.W)^Z';@&L(+C9*1
M_=+M?A7#&?K.I&Y#M&0P#,?N =T^9C%*)1%\QV646D#.+87K5FAM%"+V8%=B
MX-==@&QRXSBBI=GDL15V?W%@-^R/Z4WA;SC\$&YUFK2"[V 0#H=Q"PQ'X1!>
M*AE$6'D5 "2.)RU@#/ ;856J 2R)U:^F4=("R2C[)+"9Z11 .AZU@3* ZF0X
M"K#Z5=P.RU,XT'@0C "YXL&H#9B'<-31"&2G,$JF;= \HMIG23LT#X EC2?]
M=G@>@>(Q!0[3"M'C!'C@I!VB8]CN8#3H@&C RVC4#M&#_@!F33H@&@ SZK=#
M-%#JH;N@"]#)$ O!X3$P_E@7?6N'ZPB[JR,)&N(_@&.A^!"/&@1^V O.3T!!
M#X/SB[/S^<75KZ2I8^OG<^SHT*F>6Q ^V5DE80\+ $5$,$?>/Y0)G;=)]?#V
MHRD0F G^!6 [2A+U=ENN*8R^EH ? 6%(1E-X!A3-I\H4(_ S1:,D@K?OZ_]7
M\"N@MXA1 ?T)8#.=J-EBL;T7]_/ND)1]$)DBE'V3 _P['HY _XT/Z$EV5PS8
M0QHX!F1"DKR'LE<"0O$D&=6O=@1O,KO""FZ=M]\9@![P#QKA!XN[;+GEKD?M
ME0:<!Y4!N,=PF# 7HK^Q C-<H7M9_MT HP7 F\9]K*,8(O;T1\F!GI#[F  ,
MQ/C.."?>'A"J7;ME\V\CX]Y=M_[S7S7=I9PP5X979#4 "DO=</%?(/0,Y6]X
ME236?T?8BT;^CA$KJ1X?6K*YI<Z(Q#7%AX&_ZGO <E>G1V<?YL'5[!_SW0_9
MC&?J?AL<[R2\-F(WX7 @48R'HC9A(^%$]GI!+;3?Z*!K>)\XHE'F+W79Y;4!
MRCOE*4%K'E/_7'7D5)O0<R-ZBSX; <7O\QW^G"XL-K')+M)KRV3,H]LBNT#"
M&@Y8.)Z"K#2DZU9OJ2*=$XV#D>#K6XS0KX+](3\*0.& IC]HF]^&_[:,;W\7
MW$R?Q])FI$[CSRTQE/MV*%8L-X--Q?+7IF(Y5HH_;'%(.!5=R6=$48@ZI!>]
MI-U@\I9CU(,+5"N3 2@_W\G_J4MN3RY3F-Y"$M4. L\ZNP'P&/4&(!;TIG'M
M!]K?MX^F(3A9C)K5@6([ORW 4>& 9 H#0 =%$I"AIX=B'IQ 7BRV&@][@RE(
M,KTI@)0)O&T+2]T?3GHC)+NC?F\\A8ML7$C0IY/2_]8O9]H++J_.CG[$8M'G
M\]/+&9J?._%R;J-F:L8"'3^PZ([B^EM7=5A'\+,+[ '5G/3%K!.BGC\ MG?J
M+0ET!FC3A"K5CH<@+0^C^IHS)SH%'7 Z((2CI;I!9:Y=S!VA 9-)#P1^[;B:
M]GNC\7>PAQXP:?WAI-^;?J<N.CS_:+HQ0['?-C[0V+;RB7K#T7=V&]J)KVTR
MTQXP>3.V'S!U3WI]NR<<01_;62A;"8,M'O,,1(+#)H(UPV;J(\X<:]#<*8EI
MBOKJ/Y1;YC>8_;_M7=U/'#<0?PY_Q3Y0]4Z"S>W'[>WF >D2C@0"=PE'JC9Y
M D*BDRA4$*K\^?7X:[T[,[87JK:1^L2QMF?'8X_M&?]VQH8+H!]O+>W73R8J
M\*F,KP#O$5:\#,@*\(9#\5.8&IO+9'"++>V3ZCF<S@"5,)*B&FLL:VS%K577
M-V:""ZKHCE,QNR%2<99L5S/I0$G!MPI>AEIL"6!>S6KU?"+JB"53A< 5^_^D
M:J0C:3;=>JVOYD?GXZ04VX=8@93G9LNP]WGKX/;NRY7\:AHLB8F)2R]=:>)A
MJ1YFI?1%=_X3&Y981:[A:]-5R,\G%DO(&R$.S],F!1L[+<3OB=3"IH!>5JDP
M&LIT5CF]$99ZG8FN9G5:.KVY&"<-:&\^E7[,&=D;<::<B;/]=I.6E>V-L!1F
MD$Q$Z*"P;3K_#>@-^%_SHA'+1RF=:^)/#0X@L?! >,Q<F&U-+=B>%NFT$'T"
M/S<ZT+AG,E@.=0QCK:7H6&,GK+GZ19&PU7>]TN_90JO;X,C$% .O7SF!O!ZE
M4/_&2'VD)M'8"EQ-'4>V(SE5QAWBQ)AGF=BE049)4:5-9>FK86WIZ\%T7Z!&
M+_"&6=( J0I\#2!EGXCI+Q%Y,6LU?H24$9M3&X=:.2.-''9#\J.;C;*B4@>?
M@'#*JG::HPC762K3/!R>R42#TDI]M9*11Q=+%7:4V<K!/-KH0\D< H>:^. R
MSBAM+QTH*Z,;J,7&.&F_0E^?WR1GM[_#Q_109;@EDNW,2L<8R7;J2=W:(^+?
MF6.2"-/*6BY@E8B?9=\P 3M_6CMGZB]45YS846",*3>Y#K._T2DP["X.B!X;
MC\1I.6J$15VVYV7M)6O!DNI=9-MM8#3/<LIV<O6@Q[T.O'.G +EV0#X_F-
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MGU!+ 0(4 Q0    ( *B!G4L?(\\#P    !,"   +              "  0
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *B!G4MF\PM@@@   +$    0
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M965T,RYX;6Q02P$"% ,4    " "H@9U+TJFW^T@#  "B#   &
M    @ ':$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MJ(&=2X2;"K,?!0  /QD  !@              ( !6!8  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( *B!G4L(1 "9I 4  *8;   8
M          "  :T;  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " "H@9U+*GV:]+,!  #2 P  &               @ &'(0  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ J(&=2QUJ'>VT 0  T@,
M !@              ( !<",  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( *B!G4NDST<7M0$  -(#   8              "  5HE  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "H@9U+T)W,/;0!
M  #2 P  &0              @ %%)P  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( *B!G4OXUL6XM $  -(#   9              "
M 3 I  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ J(&=
M2^F9PA2U 0  T@,  !D              ( !&RL  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " "H@9U+8A2M+[4!  #2 P  &0
M        @ $'+0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( *B!G4O5K&='LP$  -(#   9              "  ?,N  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ J(&=2TE-;<>T 0  T@,
M !D              ( !W3   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " "H@9U+)QWW';4!  #2 P  &0              @ '(,@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( *B!G4N,!2D%
MM $  -(#   9              "  ;0T  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ J(&=2^W#@!FU 0  T@,  !D
M ( !GS8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "H
M@9U+]1RK"[8!  #2 P  &0              @ &+.   >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( *B!G4M @/[]LP$  -(#   9
M          "  7@Z  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#
M%     @ J(&=2VB/BM2T 0  T@,  !D              ( !8CP  'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "H@9U+D"+\S[4!  #2
M P  &0              @ %-/@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+ 0(4 Q0    ( *B!G4NMDDB^EP(  *H*   9              "  3E
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ J(&=2SP9
MQG#& 0  -P0  !D              ( !!T,  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " "H@9U+&[RG"+@!  #1 P  &0
M    @ $$10  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M *B!G4M02\XYQ $  #<$   9              "  ?-&  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ J(&=2WHHT>G' 0  -P0  !D
M             ( ![D@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " "H@9U+M.-+$>T!  !F!0  &0              @ 'L2@  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *B!G4ND$HU5P0$
M #<$   9              "  1!-  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ J(&=2_6IY+/! 0  -P0  !D              ( !
M"$\  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "H@9U+
MHE M;<4!   W!   &0              @ $ 40  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( *B!G4N(3G/+G@$  %T#   9
M      "  ?Q2  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ J(&=2YGS=R_>#   %V$  !D              ( !T50  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "H@9U+9I;D[5P%  ")'0
M&0              @ 'F80  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( *B!G4M7V4MX4@(  $('   9              "  7EG  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ J(&=2_<S6S/A
M 0  : 0  !D              ( ! FH  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " "H@9U+ANR76O(!  #Z!   &0
M@ $:;   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *B!
MG4N:R!P>%0(  $0&   9              "  4-N  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ J(&=2_A];);= 0  9@0  !D
M         ( !CW   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " "H@9U+.$$@EXT"  "/"0  &0              @ &C<@  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( *B!G4OP[$0J10(  )T'
M   9              "  6=U  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ J(&=2_9UN$'\ 0  ^00  !D              ( !XW<
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "H@9U+!=BW
MD$("  "=!P  &0              @ $6>@  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( *B!G4NG(\#-VP,  (D1   9
M  "  8]\  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MJ(&=2Q"%A/-V @  P <  !D              ( !H8   'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " "H@9U+ (ZM#3D"  ";!@  &0
M            @ %.@P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( *B!G4LB3!9O[P$  -$$   9              "  ;Z%  !X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ J(&=2S.6+]S> 0
M: 0  !D              ( !Y(<  'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " "H@9U+2:UKX2D"  "V!@  &0              @ 'Y
MB0  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( *B!G4N/
M&2H]_ $  ,P%   9              "  5F,  !X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ J(&=2U9> )1$ @  Y08  !D
M     ( !C(X  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *B!G4M=H.10B7<  "?& 0 4              "
M 1Z;  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( *B!G4MO8_J0
M0P(  ( *   -              "  =D2 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ J(&=2R3D'0J!!   ^2,   \              ( !1Q4! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( *B!G4LMGDXW^0$  'HA   :
M      "  ?49 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( *B!G4MWOQ-;U@$  #4A   3              "  28< 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !  $  <A$  "T> 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>182</ContextCount>
  <ElementCount>278</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - 1. ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>1. ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 2. OPERATIONS AND FINANCING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/OperationsFinancing</Role>
      <ShortName>2. OPERATIONS AND FINANCING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/ResearchAndOfficeEquipment</Role>
      <ShortName>5. PLANT, PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 6. PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/Patents</Role>
      <ShortName>6. PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 7. NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cel-sci.com/role/NotesPayable</Role>
      <ShortName>7. NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 8. INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/IncomeTaxes</Role>
      <ShortName>8. INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 9. STOCK COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensation</Role>
      <ShortName>9. STOCK COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 10. EMPLOYEE BENEFIT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/EmployeeBenefitPlan</Role>
      <ShortName>10. EMPLOYEE BENEFIT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingencies</Role>
      <ShortName>11. COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 12. RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/RelatedPartyTransactions</Role>
      <ShortName>12. RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 13. STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockholdersEquity</Role>
      <ShortName>13. STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 14. FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/FairValueMeasurements</Role>
      <ShortName>14. FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 15. NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/NetLossPerCommonShare</Role>
      <ShortName>15. NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 16. SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/SubsequentEvents</Role>
      <ShortName>16. SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/ResearchAndOfficeEquipmentTables</Role>
      <ShortName>5. PLANT, PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/ResearchAndOfficeEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - 6. PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PatentsTables</Role>
      <ShortName>6. PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/Patents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - 8. INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/IncomeTaxesTables</Role>
      <ShortName>8. INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - 9. STOCK COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationTables</Role>
      <ShortName>9. STOCK COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/StockCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>11. COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/FairValueMeasurementsTables</Role>
      <ShortName>14. FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - 15. NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>15. NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/NetLossPerCommonShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - 4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/WarrantsAndNon-employeeOptionsDetails1</Role>
      <ShortName>4. WARRANTS AND NON-EMPLOYEE OPTIONS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/DerivativesLiabilitiesWarrantsAndOtherOptionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PlantPropertyAndEquipmentDetails</Role>
      <ShortName>5. PLANT, PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/ResearchAndOfficeEquipmentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - 5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PlantPropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>5. PLANT, PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/ResearchAndOfficeEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - 6. PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PatentsDetails</Role>
      <ShortName>6. PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/PatentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - 6. PATENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PatentsDetails1</Role>
      <ShortName>6. PATENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/PatentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - 6. PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/PatentsDetailsNarrative</Role>
      <ShortName>6. PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/PatentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - 8. INCOME TAXES Net deferred tax asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/IncomeTaxesNetDeferredTaxAssetDetails</Role>
      <ShortName>8. INCOME TAXES Net deferred tax asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - 8. INCOME TAXES Reconciliation of effective tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateDetails</Role>
      <ShortName>8. INCOME TAXES Reconciliation of effective tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - 9. STOCK COMPENSATION Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationAwardsDetails</Role>
      <ShortName>9. STOCK COMPENSATION Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - 9. STOCK COMPENSATION Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationAssumptionsDetails</Role>
      <ShortName>9. STOCK COMPENSATION Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - 9. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationNon-qualifiedAndIncentiveStockOptionPlansDetails</Role>
      <ShortName>9. STOCK COMPENSATION Non-Qualified and Incentive Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - 9. STOCK COMPENSATION Nonvested Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationNonvestedOptionsDetails</Role>
      <ShortName>9. STOCK COMPENSATION Nonvested Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - 9. STOCK COMPENSATION RSU (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationRsuDetails</Role>
      <ShortName>9. STOCK COMPENSATION RSU (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/StockCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - 9. STOCK COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StockCompensationDetailsNarrative</Role>
      <ShortName>9. STOCK COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/StockCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - 10. EMPLOYEE BENEFIT PLAN (Detail Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/EmployeeBenefitPlanDetailNarrative</Role>
      <ShortName>10. EMPLOYEE BENEFIT PLAN (Detail Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>11. COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>11. COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - 11. COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>11. COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>14. FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - 14. FAIR VALUE MEASUREMENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>14. FAIR VALUE MEASUREMENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/NetLossPerCommonShareDetails</Role>
      <ShortName>15. NET LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cvm-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - 15. NET LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/NetLossPerCommonShareDetails1</Role>
      <ShortName>15. NET LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20170930.xml</File>
    <File>cvm-20170930.xsd</File>
    <File>cvm-20170930_cal.xml</File>
    <File>cvm-20170930_def.xml</File>
    <File>cvm-20170930_lab.xml</File>
    <File>cvm-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001654954-17-011928-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-17-011928-xbrl.zip
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M%FX..7Y&%(KOT "Y=WVD'#\L+UKDS9C00WWH#!4Y6 >"IJ&OK1SM_M"VA\T
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MH#1QHT< =GP7A'YX^TAO_16$#R=WX8,6,6S]'MP2$$E(T]S-8>&:-YW.Z0L
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MX,W/(Z[7U(P<\@+)_N+)IA59NXSWQ"W=>=:+!'?=NCEFY/3GX+TT!IS]OZ7
M XUU3ZT;R*GE8;HL(0Z]?I[8[$7C^10##6A&<$Z@KX7['.6XDT_66T@]R0[*
MY-DBYV,^"&)&F)_H."L)N11S="<8\0D4-N2Q#"%!P(G\C]P%V=84QC >%/-L
M7B9SI*2WE>$2#YD+QW68%J#N.!Z+H,<P(&E&"MO@-E(]'<P B*)'I&TNOD"#
M9/%6?F N'Q87]B"/;NATPKNY87A P')1866E2)'%R;@,1\\Q!]!Q[5R2]+&Z
M795-+!ZZE+:1L%L>K9$>*O.(_\71-!J]49H#XXLODRP_]52[2M_DEA%7J5S.
MIEQ*DC:_XT4Z1^J,25<]KS/. H6L:+Y&_-R,@I9^VIQ&&F$Y2+7P&G#$-Q1I
MCABS/[P8#U_3#\C<OBDL,4ND6SH@'G"D4BU=A2H4Q K>P4QD')PDX4D\]Q(Q
M1_Y(-X,-]:.B3G'=B^O,MD$N<;9@S@B90RHU25.,, 4ON _]^\S-*63?IJEN
MXN Q9RX@!.Y?O#P_^RCRXK]$4%7,2GE_P"8R7T]!R:^8!XI'*;#T,<5SLOQ>
M%%VL@#%NVY1@C2MJ^ BD(+$M_ >-<ZS;O17P@GX'JG#440:KY$N"F\\F,QI/
M:))K%T/T:6A.NYU[$]0#G"LN;S#UC=@A/8:E'%5:=.0!(WMX(I2;V"T.#ULA
MB-TQEZ:"HBES9AR?49Y'3&4NDX*$_\;C;)\,*?@8I>UGQC1,F=<,X[C$GKRM
M6ON4\QER9LNYR)173(724X:\5*-4TWMO(H[JP8^;SJ= H6".SH2,1M$.XSI_
ME4@H)(R[M^#RW4J38=G8^1#66G$JA^&,BL(U'_!,93.>*$TDWC#M03@2JL2A
M7E<,,Z-%[H(\ -4RA9Z'AG_QE2=Y9UZS7 TW*^C@A\4BN7<Y".EL^4'$^"7&
M9)0:IGELHR@FIR-1/2 ,^88/6;R(O@8W"3;]8]PK;C?AO2V@3=FJJL5;LCJ%
M-5+B\)0L0@B))3+-U$4<US:6700UI8V@LI]/5%8FH# CBM%1ESA$S;)D<\J
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MH[W',ZDQ1$1)U@(4)>XVG<UY8IC$BJ!3GD4X<2B0A+F+(FN16Q0RAI]&S[%
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MGAKK7-B5&NQ#+JI2DS>#O"B$-H2Z$A2CE6LK'Z[< S'UE1Y(ZE:H[M%RMZ0
MD0@ 2T^89?/$)=A:^+Q7O/&'%TVE9D3$;GP>Q\X2,K+EBA_4:Q6+*=+TKSS
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M;V2U*#<-IV6/_;DSY[]:8TY0[>WZ1"9=N=,>;XY:5>D<G2U&R]HV//]HBU'
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MGC,X)3;&A(GP5@L/P4WX.2PE4<C[!=%A5\Z9>4-3_A)!4KI4DU\5<JI]=+'
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MZ]4#_$QMPVDM]%WA8D@D- FWASLN?S,"D<ESPUQ*#%$MO0"$8%H(=.W=@!G
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M'DA>;MOC13KSX5>W08KI'>A+PTP/>*5,'R*2B:-';Y8^2K)G%R2#UA,9;F/
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MJFH4M(<O?_,G\)N)]ZAK[\"$IU</U<3:$(5=3+8:?S_2?,S><A^ANA7[L@U
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M5"59-HH*-JM.Q<C;5/!+B=#/2P)(EI'*LM;,B\G<1>Q:)3M0ADSD++$QT%G
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MV ]V$%P(Q #;\O8U)(R45]"7:#/C'M;(&: -W(:Z@U62(%C6D 7N0+28X$0
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MKX@5.TZVBUQMD)1EZJV:9T^(*;8L>VS_ZPXNH'RG&^%Q?Y.YQ<3L%='>B2O
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MQ8HD:H(2BGM<@/@B&:HR]:S,VI0D.5]F?HC9!>1("3G5%2\:HJ[L4A5*J#-
M%69<#RH0,G9P@Y+;+O%2<R;R%]"OPGS#-F4E9L%)>:)#"'&SGFU)&0ZN@)P%
M^19,'U(@S1A^RXH12L64/Y"<8? ''Q0!\X!Z.V*1L1GE*\+_N,@+BL8YB"3!
MLM?.MD B]+,,1T%F3>[L6B$$YQ3%.45N#HJ^JR(JU\P-\'DT)PZ01_RYC/V+
MF1V"PWOETY]P8!^*A$R.53['VTK'H"P!$I.PNLZF6I(X*(0 ULJ;(M7CZS*<
M-/WOPD^Q!D&QPL_!_"RA$+E0=9GR) 0;Q30"LH3(%W+^6QU85UFAB<>4Y$P*
M@Y% -!,@]9U6[]]&P"AK!A>J]K0T-")?VA9).Y^!_\[!4@K(1GC.:-I41>+J
M#H\I-&N,S]U/7;1:#AU2U[:KRW7(% ^8;+@^,"7R"3K(7.6<-95WVEC."W _
M6 W"<DY\B$ :24Z]+.%<=00NESNU6%(6]P\J19: !$)AF;J>O0#<K0Q"*W@N
M)9@$TN5%5GG%- X\8N:VF* O]'O$R7 %)Q*250ZAC9@HJQ!D M?*+%+-3(T$
M_SP%B1 C$)]CO=RK\<U"XB4%Q;0&,X#03?$&1*L9@)&A/EB<-:T5N7'"4;BB
MPP1".:<X$"H2P"N8(RECV"0!&45@1B@],T&]#O14 LLC3!RO9"[%NQ@66W&*
MDL!^G _"@IQW]^K=RU.: BQ:H.;#&(R!3P=S75O4V?-@.*ZC\!-K':=YXUP3
M:16E<1# 0,:FH%A)<<T6/\#JB)(=#HJD36Q^:23TFXF9']*)C/S_Z,7?R]\^
MG*)($JAI\<Q4$AQ1!R>&X$WY,1YKL4.(JW',S!*]$/(CYV]@,9Y1_33*5/I0
MU5M@4KA^BSSZZ;F0IQ6[F9QA,:1P(KK.,XO>#"(%':B)Y3*GC7\7&(IQ'8GC
MCJQQ2AK<._.CPCB]9MA6>[^_5N^5K2VK"MM*6*G@2IF5PK*P3' AK?!]$,Y@
MGC.[^U$)[:Q([ *WU'*I=U"P!Y:4AE29T)4I50T2*_4''[(X>$RDQCZ5GF/Y
M$%.Y8U4W?ZZ<T42VZGMNW]%<[(E^@EK?*P+U8?R&2BK]Q@BUDS_*.7I'!@L[
MW6FFG[-[?".G78\4:Q\(HRH(LD2Z8+G8S:7OB?0\\[TFQ[[SN"!GOI=/X=)>
M[\=GE6*07FH&HS.3(4X8(8_B/(_#ZFJ4"MV!)\@C=]'/SYR2E5&<0F%]QC?!
MS9!TOHA^]Q)8R^+ ]^H*A$H2;)C'7E@'X^>SS/^/(@.A2_X7PA:Z &7O*G\.
M>IW: IF^Y%[U,=U]IOH.+;ZKBQ_U/'R*_F"87>?2CS:="#[*NY+EM90'5S_6
M)9ABVW-3NI6/_$WT.\.+8:?7ZQU+=KO)ZV9+>>U!1G_=3_W.=>_ZN[$-9S6;
M3[9Q"-L8.M^/;?2?;..8MG$S^'YRBN,\V<;Q/F',N/A.;.,>%U-R#*7IEA:R
M7?7[9$/K8LF@,[P\2A&RJ5'01K[NIX<:IR# =9Z(1X'N!C]%E -%CT&G[UQ]
M0];P5F79<VQE%M3.,P^N\2,L,G*YZ]72+)["R-X^G=QT;OJ4=TZ_$<MYKW*1
M<,=)/,B@H XGQY'#FHX7%Z- [:M],.@X_:W7 >?4UJJWYG9OK&W8JOL->WR!
M->2'1*6T;_'7Z-;5.TF7SH\'[+NM)7UQ_6-3R_:;*P-;M.GVXEO.9?\[*92?
M&G/?^B?G.#7T4R/O+_#)&7Q'MO34^/NF/_6O!M^/+3TU"K^[3U<WWXEY/?4:
MGSYM_NGL&VEB'*(9>JS6Q<UPZ]BP1=]BNR[#8NNBUN6HC6M&?(\]B9C>#[R?
MJ>!!O8,I3%N_H]H?7@QK;XBVYF#[J;PJU%VD1\(>P_TL;CV-Z][UEM-HH+Z'
M*4Q3M>Z\VD<F,71VG032WWT:;_@IZG:SN!EL:U%-Y/<P"?^AM2I #Q>[3@+(
M[S:)6ZP*=IU)?S"\W,4U:DQL/Q_];.4_L=']8?Q>Y0M_;ZV@05^?Y[0_7K:?
MG<$1N*.7"I1W%^TZKYN;_K:&MYJ)5N;7WM"<?HOPM<CC0KH\1@YT+OLUOG=@
MH<UL]I@&G057;TE^+[/8)1,Z@SW,HRD5MAEHIV1X-=AY(DW9L-4X.V21JYO=
MI]&0/[8=9R\9<8=YK$V&&P[6.C,,6^G QMOY5?K1A^B52A%' V9P%V5Y6BSG
MJ\TA=WP/KH[C_*P'5RXB\%P-A\ZU1E=;0[J&$A6Y*;UI) .-:$1@1K=YGOJC
M@E9A]_'B6"V8-\A*-O_]AB-1KWL&UZH58ZMWIM_']!*I\GZ#_U/?A4\$WH1P
M'=DMOSHT_U/L2.=QLL%V],5PW9[PVEO[^$[$(=\[>5_0?G<\%JST=KO>-ZTG
MZ%P?>(*_*^RE**_B[1:TB/!$Y0^_XCE"U5>$6:N^O9%^6GVC^GH_?:H5MK.I
M'(]WW3YFU;1[4'O#[7%%?M9!!7$^:@]JX,N-ESOL8FQG3U>//.G;3OJ[\_6W
M_J [7"V&;T2)VW>%_TE*/^C^P7:"7MVFWDWU"SS_LLCSOAXK^H,\].K)0Y\\
M]#@>>M(?7*U_*O;)4]=XZO"P>UO;Z?+B:OUS.=^/,Z_?9VNQ9EI<@,'"YM8E
M>!A8 GU,8\9WX.XPF*4[Y_^_(5S3.P0HG5O@%&]N/_TB?(0[]L3MI\]"<]&I
MZ]3'>Q''0D59A=;&UUP[_?X+0:(3]B7BY#Y.?%<,^]<<%F@0#:XEY!@1[S+"
M85*$.<QH*.Y4(@8?8V.I-"0T,Q";YS,N!^)WB P73F<CF1%D"34G&"]M)E.O
M6[$N[A%9Y'/B(<ZG9/0.'-A38S^B 7&\,/8(!H3!VA $! 0WGI<(-+6_RU+?
MX&J*P:P0@))@_33S!F,KMA":&U@6Q*X&D_-B'HK$PK/G37%8#/&#_1U!.%$P
MEH:F(COK$-05?,_GYX'&X)T+-Y!95C)-_&A@&*99EY&6#7=N"%W$DEJJ$$D+
MP<$>&,0%@6-(8P8.1T812$PD8(2QEW4T7"HHSP_-CX3 XQNLP3A32S>-%)@N
MH>/1TRL6ELHEA\BN>(T87$)Z,0%N(#I)@H@E>:YJ0$S5!1%95YT5QJE$MD_Z
MIR(AQ&TQTG@>]7FE"N%%"3E7SZ("4-7O5B F+T*ALNBF\D$) ][$X$3L6"B1
M$^>41$=(9AIU9[_$""E'/D@_D 9P!^DC$%)W6<L5\H[6=#:-BP!!E1A0%>TT
MC;.$-<_V+2.V'^T2##.#%D J(_,RPL<AF:H%S5O!V2HT:>HWELA//ERF3;\<
M11LM>1'2)0A$FKG&MVD$J2O%E<29]O*TA&F#(6/N=4(X.01LS7:@,D<@"S'_
MOXO@T:#?[S<%?7 Z]$J.:1]!R]2T,K'=N>J==L0KG^)2X6=3-& ;9YR@IEY3
M>#+W7%SC/80:7+8VZ>M_*6^"]^OKKON75MY8M&#B!SS\HTQS<5>"Z6E;YD"L
ML</L4 B$9##/?+(#%ZH_"6-P^#P+_.@+H@.6YN-;#>T3#+,0D#S$PQHKB>WQ
MC/$E"5W,BV?1&</#F;]VQ>^(/&N E7!JLZDBH$%#N9E6Y8F&>8PAF0@LP991
M7PNBO+N#F+M+S" &5H#HMBF^+48[NYD>8%%"!)<+OT \M%EFQ%5#AD$)/?65
MP*,X^48ZD=><$3@!FX;:8"D$$4@NT 8SAGCPE6T(P;7=(,Z093O-4333>K*$
M8LV[*V[9**1V=13$.%6J3,&/J[FN91<+Q)3@+#D<G5I2G)7!D@L" RMI>/ J
MVZ[2,N3Y*I\S2*[&<]6!CL10XI0UZ+%+<+\-T[)-I9S:LFWD=1UH$5=YCVH1
M\SZATKZ/*8D+&'%BE.OT7KS^^*G\UG]Q2OD6A)%Z!&E/7E%&"6,D"*,VB:"N
MY^ERM:,GWV"U9(L^61N4Z),) J&B(0&3^E[Z"\$DLCP]GY#>..=J"2/J/6<3
M+1 W#NU,B94;[<+P)!%D4#$,)-1KP#],M N9)J+5(MY@.RO-<[7-9 :N\$%/
MD,50"Q0E>)O&:#5X>YA\?3YG0D!T9;F.N1Y&9V$\941E(SNV:)<CG\ D/A6C
MG"/OL'?F])JB_"LURDNW=?AK&=I>5N.B4#]0./B0E'#5'*!/[1HL50&I!"17
M<8Z\5&FCH231P7PQFAO# =U @0!^I:T'XP_5\530JS1E4%436PF],#.+AC+W
ML#Y0VI(@#LG4V7H299VFPH<O()UJB4><?-+%2 :"J18&=)P#K$Q<*"[ C5U%
M\L%)4K5;35,7^F00LK:>8(NV2G-T]545:J>LFYI$N)@/EZOX,<19D-<<7\9<
M5[(++M?KEY?%.@>[QH+]FD-56?)6G"\&H99<;\3%S=JY-0_7O )Q>FM7(.6R
MPEX>K5Z6+'!$QR24"931AOF.K$%:2[=W:*$C/:SZJNJH*B-2-0Z4JZU<1]MJ
MNOH'2Q@:=SC2=8+^5F=XE?<:)1(+*Y<6&K4Y5?GB&L->-#>71Q24&HL<6+R'
M2IHN@5N$B.@+(Y^Q%;&=E%(JPZQ95.%M#8N'M3)#B'M;<LO6=I)1:BP/WB N
M%D,- \I#99(Q5VA:$.XFJ4P(C;IR@WA?4F.+U9*C\DH"@PFPO+P:M>)D0Y9'
M2911OMXC,>T<C,=F/IEP+NGL[8O+LTL=QE(\B$%<X!E1FR<&$TM-%8-.D*>@
M?]9;R5)U($1C+"86-HG'&ZQFQ3Y7LJRA;5:S?\P"\X];UVJDZ<=6MDYSS5,^
M6*/7+\M+T,M>K76)%&(JT<@3Q]JI^5P*T#JBU^NX8)16>1)</M7#4WF$&IOZ
M2<:GCQ 2-EZ:FB.*L#Z&\!"'P(BE[N9E5NIG7VQDY3I<,.)#-S61Z(P+?(!'
M5S"/]HA"^465!58.*F+X:9XYWX4'\]"9"6,&BK9.Y^'3K:H%GO8)E(JR':]T
M7#R9@)V,.(&"5Z4$QXWE%6:SZAZ(6S"[)% U+]BLE&J8>'GCRGJD3/C;%!']
MZRUKK;5%%)NMM:+>L%Y:P=N*6NGQNHCX6%,;F4ZLSB4\3-F:7*4N5V93,0ZP
M4"?D^UR?E$#V33:356T#C:5=+A?0430K':NPTH4(-^P;*@2KABK7,'BZ6N"'
MX#YE@,\4)C/[F24H.]"D314!!F;T@*9F-@3 7IDB=DZY$011'U:<"G+6@Q)Z
M9:I3-219!E#7]>-BW0*!G]0RDH'4+0.H#, SE5<MW<OBA7AXO.BK9+6R_+1<
MPLK5JBP2&GW=^#2OP*OC-2#]@2IJG>9&BSA([F53>>HD;Y%QWZA16N I%=49
M$PTY]^JLUYAS^>%B*Z5REX&RJ#[>B$NY,,:CH^AJ<5(6F>6ZN@2YTG6MWBD<
M\_E'=,A8'"DRZU-]NE?9>2JQ\;7?Z+624G1>C^3>9\[](_T2:MG!ZXJWABJ?
M15=OT")9\QRU>7\UI9.P#!(7_=@5'^I7Z0($P_?7A(_#*;+J?(%4X@.59W22
M5J@@27C8&$N5S!9'KA@S33'(Q7Y H9GZ$RZ_1*.9*^C8(NJ26VG6^ D[=P3V
M4O><T=*.(._E-22/SD9=A(7$0DQ4^7)4Y/:">#&Y-'!I3N*I%BV5-,N=J]HB
MRHBUWE*H[ [(^WR2;$B1'V]97!EMM-O5T/:LL1XO%&M&(6;7CX^[X Q215=L
M?@=\F-W2"5*X0*J?%&*XJ2*C#IIFB]B*F^#/Q(+Q:6LMU1PRR7'MDS46':(F
M&#U=D\'8"T\RI<3[& JN?O^T4V/)Y'8KS." .$?T'%?G:U[,"3P>E4_:T4DA
M7BC.K4KX+Q*^]>FT*V/W^[AKZ?N&#Q1<>OI#G#WRO,=S<;>P)G@-%AC/0;&T
M?WCV"ST(H5\LL3JLW2HW+-C>C5E6X)HF4P^\$B '+OLSUGJ SFY;]<P%=PDD
MG[AH-^ET 9;+KT09EE\9)"3<D('+%O;)L,3D!SC RW0_2^_% &U[KPZ==O%F
MZU1@4S26!6]&H80X.'[T-:N!*RX8-PF^)MR4#\2P+S8683BALIQ<XZN+@5 T
M!T%BT@J$FQBX*(U[3S;-VP+K[=H*68>S9+.]M63-XGB6;$+T@C4?KXX@!I:L
M>;,RPEAR>U/6V[\MS;F>TY$C?.0KE'I[>0S*H9UQ[$;@6;M2'_4$*S(\*<PM
MMWSAXE#O2TWC&=I8_2PJ4D"UFVVHZ#.CZH3,OJBHV5_&E1E<P8U\75V;MH@>
M@4P*K@!+@K5O^I=(L_<+%1CZGN_1&9Y5(P>/P<,22*^'^3$QNYUE/TS*BVEC
MDOH4VB6;S KJW]=NK-K,C]OD0JUIZ:IZ?';;)U[-$[.XM?%\',<Y3$"]A2_B
M*_V4SQ.0/EQ-'81G^M<T1IU,\SQY?GX^F\VZ7T=IT(W3R;G3ZPW.\<_G>.$S
M/;PA !1KX^()O> 79MAIBL_=_F"]8<J_!Q)$6KZY^7]PUS-QOM/0_6V&-F*Y
M3>LD().98>#C(S+15YR/0;-G9D1S.SZ%M<"$)A3SSWCQ60^XI@?+?W[67\UE
MC45P\+A(7;6-XA:9LT14LO$U#.!W?*U416>?/SW[QYW9B\P4G<3YZZ_D$W=W
M A(7ODR8=?]^7N/36-[YDNG!7_Y^CHSYS_%_^/K_4$L#!!0    ( *F!G4N;
M3,9 G1,  !KB   0    8W9M+3(P,3<P.3,P+GAS9.U=6W/;.I)^WJW:_\!U
MU=:<K1G)IIR;/<E,T1)E:Z);1-FYO$S1)&1Q0I$ZO#CR^?7; "\B"1"D%&>(
M+).'E PTP*^[<>EN@,VW?]]M;.D1>;[E.N].Y.[9B80<PS4MY^'=R:W64;3^
M:'0B_?UO__6?$OQ[^]^=CC2TD&U>2@/7Z(R<E?M7::IOT*5TC1SDZ8'K_56Z
MT^T0E[A#RT:>U'<W6QL%""JB)UU*+[H]69<ZG1K]WB''=+W;Q2CM=QT$V\O3
MTV_?OG4=]U'_YGI?_:[AUNM.<T//0&E?\NM>[_4+Z>SB_*QW)K^6Y+/WW=T*
M>!CH 53CLO_I#>0>_->[6,JO+L]>7K[H?:GYK$ /0C]]UMGN+/Y7K_G$\HVT
M\<7O%U_\U[N%]6D=.F_"OGXS\6?ZGP?O]7FP^_+R]?O/7]?^]9<_WWS8O%H^
M??7_]:9__>%)V:TGYQMCX<^C1[[UC37:Z!*HW?'?G60D^>V\ZWH/I[VS,_GT
MTV2L$;J3B/!R9UO.5Q:Y?'%Q<4IJ$U**<G?OV4G7YZ>X^E[W4=HSU%H<>LOQ
M ]TQ<O1FD#;($K\\C2ISI!:3]%5$:B6D)BK0^<CH/KB/IU !]/*+SIG<.9<3
M\M#O/.CZ-FVRTOU[TG5<@9N\IIIXKHU\9AM2PVCDN(X3;MC2,0/O-'C:HE,@
MZ@ 5\BPC;5?=*-\ ,.!B-CI2PT#7OYND] :R.[YAP2S<$$H\GV IL=$&.<'0
M]38#M-)#&Q3W>ZC;ULI"YHD4Z-X#"O!8][>Z@?B=)?-%=QP7IA6L(G$)+MMN
M+9@W4/ ?;_$ N\0"70)L"?^ I8/9-:X[A3D78HR*8ZI.8 5/> )Z&_* $\DR
MWYUP*? C 0!YJ(E6EF,19/$TEZ6.E#3/_M0=4XKZDC*=O3TM=I/I//21.7/^
M1GYO/>1#-Z31& KBAC%)22-#MXW0/JS-'@JS25R0"/L8\5_I-I[=VAJAP(_D
MG2_B"[@'4L6++(HE?*6,E6E?E;0;55UJK1?H7/> K34*+ #+D&Z^GB_J<ZZH
MI=]R??UO&T6?2L>?K69;; O!P^)!75+'%_F+@LBUI;)4)^H4Q#T;2K.YNE"6
MH]FTE>,\*U M<(VO:]<VP;I4?P]A6:6%SJ#A"_\E5_C:<M9_?S,;#]2%]B=)
M_7 [6GYNNQKZNK\>VNXWQI#?5_&%_HHK]+ZBW4C#\>QC*T?\S'O0'>L/ @ML
M$2W<;'3O"4:V]>" 067H8*(8AAN"7>$\S%W;,BP4J^*XIGQ5O<8&#3@HMNN'
M'H(_Y*XT6UPKT]$7LBJU4D7IRCZT'-AF09JQ A@5?/&^*8JWU\VL^)(R'4C#
MT11VX-'TNHVB/F3X/\MXOR@JY+PK:;>3B;+X3#:$T?5T-!SUE>E24OK]V>UT
M"9J1YK/QJ#]26[E@#<##? 10C\@?6_J]9</3D/]1]SR0OP_KT S,16^VS9A)
MAS7A*DP^*RKL15?ZJ"P6"MY-\/R9SJ8==3(?SSZK*LRMUII2"^!$]XPU%N\*
M9@?"]M$6[\"14CCU? W(10V\[$IS\!J6?Y'F"[R8+3\316#S:8YW^39*?P[6
MCI/XOLD??+GVBG)]!7(%0VG:3I=WZ@8(7-DG_=Y&D1AS)7Q9GA=E^;H+"\-2
MU4"BGY6KL=I&B8X<^(F6^B[90;,%?'F^*,KS35<:3?NSB2HME4_MW B)[XD/
M09#C9P*+=#%?M"^+HKWH1GZH!.*=JU.MM7:WNMG:[A-"5\B!9P5S6X]%S*K@
M"_D5Y=:<=:742KA2I^IPM"2[6!L%#:-U8P7$J0=KH.\2 QHY>U.;1\ 7/.U/
M@D,) WLR6D8! &PI]&?$K%:G;;6I%P@@(7.N>\'3$HQB7S<RYG-I+5_TE*\I
M@[.Y4,=@4@Q@&\1FVA+,9DWIM]9&+@\Q'A96E"DW4C[OYJ*)+0XF#G7+(Z?=
M$Z1CZ6SVAC&[BBOJ'N4 RN !#I710KI3QK>J-%$5[781A1?;*.XI"L:N[\^1
MAU=MU]'6NI<8T,PJOK@I;T\&=V^J+J7Q3 -K6EV0U7PVE;0;9=%*LUH+[WWT
M>PC<J(_[H4V5\L5,.7_R*QR(NM)@W8"1+*EW;1W/1T6YGR%07B^ V*,\S8,"
MB-)OR:]6GJT>%!A<8K__F(ABW)"O1\K#K1-7E'Z+^FZE\LH#B%E-55+QU4)Y
MQU7!QE:K) XT9N6?+^(+F_*2]Q'(5HLU$R?+BI8NYHN7\H4+0;16RY@*FV4E
M75;)ES?E #,C:ZV6.B>PDY5_-1E?$[1[7!4%:K56F&YQ5A\\ JXFS@_QGENM
M Z:OG-4!CX"O@\-<ZE9KH9ZK-D"!;MD'70M)FO U17GE!SIW\5-:J;J,,S9U
MG0Z*SVQBGRRGLGJD?%51?G@]_^V7ABK$+A^@(KE"1T?ZV''ODMQ*+>'3S6#N
MN5OD!4_X;97$?\Y-H4HJOF:.<+/;/'.JI#W%LP5'I^HI9T_.UQ+EG]?6DI0^
MHIWZBH(@^1F3+^-+GG+=LY&15L^$G!1EEFBK=@7*36?(MJUK?TZ0Q56EI)(O
M;<H59TF[W:M%)JX'3MX K9#G(1/^5GP?Y;?=>J1<C;R@7/)B6!!ZELRX:RG0
M=Y*..V_WNI,1_ (9KF-8MD4PSE;J:H4,/'BA=@%SI$QA==OQM4<Y\T7MY1\C
MN2L))0\BRH2)AMJM2RJZJWS3/;/@U?-I^#JBW'AV(#CJ\I<N\G+V_7##\-GK
M$/*U0GGL)5K9]_M+-3F)8T<\S;L ;@6L;< JK"N$,G+-L>M1H;B#N^&KE7+R
MV6K%3_V0/)6D3DB?*Y$'2]&3)?+H7YHOJNP1^0$\HL[,+*/FZ['>O70I[3S6
MUR]5Y86_\$.^=C($?(50WC];(0OM]I<*<A)FNT_59'QU4"&!DM/E7SY5R;L<
MD6 *6JE!QU<+?>N][$V/1#4MUPSG;#^W<-6@XVOFF$L ;5['J@4NU]5,10CN
M)7TKH+9J6AJ9JY9Y86$[I %?6?3U@?K*:O=2Q[PVDUODN!1\M= W^'DW:]J\
ML/&$+%?KH6HQH^(*=131TF6,>8DI-R.X%'Q%4)& BGM.;9X3/#'+U9JHFA.4
M,U]/%?^O9@7^#^>H7:"51'+;7N(4J.].? OG,3Z)R]8>6KT[,1XWG21'Z3^!
ML^YN8R<4N&=.:ENBSJ(PXN<F7>B>0?5"I=Z%3LB- ; 03A/L20>!%>#F\\QC
M)/P<F+2GS\"QK=\?RC$T0?8/9'6,^W].'F'H'<IC8;3^($[[^Z<\)[\P;0[E
M-S_3?A"[@_0A66[C%,"G^QS \=_%/,%O@6_7"R2'RC?,RSH=Y<L>NP;IBM,$
M_]5)VG5P44?N=<[E[LXW]T@/ ;$7PV$@DG9'@.#FOBY!P6R#?W3VC>L^GYM(
MF_=\9L-39 =^4M+9=W4,&CH)]O%P2%]'X*F1_[O.2,FVG$8-\5"YP$-%?O6=
M8(X#4H4B3B0>^<=WDW]&J1:N8)";A?.+Y+XIK X8\[N3>J26;>.[\^]. B_$
MZP[.2G\)ZY'EFDNR:IIAE, QJ;N/\BC#TNDATPI.I&AQC2K!Y@*SR'L:!6B#
MFX,XPGL?EK$0=W'MN>$V(;6 A,/H&+P:-->?B%LS<@P[-)$Y<N)KZDF.*R7X
MC'1/=<R$Z<.;'2\ $]W_./X!NX=Y&3G[%WDS[_$./7<S\OT0(YFMDJO'B12.
M;2SJ8,CP8WG("(9)+M&^ZS.Y9E,)KVHP5K>Z96K(>[0,Q&",)A"4I^(]KZ&U
M0R;Y!;,2+(4'"[^P@\-\^M8*=-OZ YF+=!8?W;I2&I&=$OQ[A9%=<HE+2BW*
M">.U* 55N;K;PJ1#YMA:(9SKG1QU3RQ'3C<D#L$!/&71)Z4_"KV^XX,G]8UC
M_XBLAS5@4QZ1IS^@:[R<XZ_XI"%"V.E(1N:(E?KD!W,&]@RN)T/W^_E:#)*%
M8 '%R0;VE/!17GWT,O!CMS$N-S\9+XKYK] GAS6*:1+?5+?GL#6-G'A-+C$_
MD]-K/TU_'+'_C/T=.1]]/&C]9YB-L3V%+2QD?K2"=3Y/:SP)JZA$M<7Z^#83
M^9C9; 5F-8 S-7BR9Y$->0B:6+HLAH]H)ZH(]DGM,?+$RERB77!EN\;7A.-J
MLL/75_)=K,L@Z>/[>:'S^%%\\$D$X&& MJYO!7YOOY;N"P3 1W;8Z%H]>;F:
M%C&70@ .,BF*!N@1V2YY-X^@7L#?3KAW5NJ1"L 3TS4NR8\U"P.\R6:MJ..;
M"\ [_LBA&=HHW3VCEY;WO@<SFPR],GQW-P+)8K8JW@+F,UV#7@#NAJ%M/XT<
M?*9I*AL<!".X+2= 8.T$5S!7<81$]]?Q!]+2B7Q42S$=\$S\@-S>3T,(*:\<
M D$-\&FXN8<%)OJ^EP_NJ>6A-(!25MFT:9SW/-4=\@S+1W,/)[W+<U"/M&$'
MM0!R@3:ZY9" HQ-XNA&$NHWC!2,'AYNSNP#7(3^BF\9#$+D!=T<61>983*L$
M'HEY^+4H&QZ'B8AO\_M1?I15$36LD:'KK9"UQY4NS71YPTB)+4OAI$H;1GF7
M57("LEC8,,:2(7F%'BS'J1ZZ63JQUA,ZIDKQ=% +P=87TFVUFF@R(>9$!"L_
M)=(RP69$A(N_D!=H&N9 <0++M.P0>\8)P@7\#_LEQAID/*EZI +Q$\4P ^P9
M#-!]P.*#)FD8?[Q6@EN3!"?4770M E\#4'4/3TU\93;^"D(2NSRP5<-<3ER3
M)#(,2'PYP9P>/997"WJ8&AT+P':0QC1S)<?:^]#\.8Y*,R;P_GPT7UC?:_X1
M&U:T))([+@#B=NLZ";[9ZEND_32<4XOT4':>=W3GA#L!WW 3;IB"W]<U*_\\
M*'U7#CBM:QKPUHIF#+;!LE<6"L4-S[P$C@;+##$7::39*D'0@FW"QKJO:!0I
M65LID5*ES6.,Y27G(&8*&T68N8PUCJZK19'B] 2XO%[4D]YKW7)FF4N4(UB#
MO##^/%?L]W-)1&6,7"G$);J=>57*5P(PON_#@!QDN$76\A<2CVG=L)6H(7S=
M8#I!V(%*#8!"X;&'-J:+P[;/,(TT8VVC$!O8$30ECY=3WS3T"$^?)=^^8"!5
M%DA5,)!#%LBA8""O62"O!0-YPP)Y(QC(#RR0'P0#.6:!'(L&<H&VV+TPF6"I
M2C% 3Z(H!1LT72D&Z#D+[%P8D'-B?8!1AJ.+KN?GT9;6-@T[B5#=(-N\?XJ^
M"N?A&U7DQ1;7R[-1F[IIMOJNXX<V]N(+BF!5- TV&LKOXQB0SQKG=&73H--K
MICY^I3 9&+&=N'0+5D]MZJ;92J !S#=,(YY'T#3XV&R#"7G]D3.8V 1B@/_
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MUUQ>,XJ+NL0_54;S..=Q"8^U&S>>O9R:[L4O.]1= 2O;B;9JQ$JH3$:<<'P
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MLWAU<8?.%$HEWQJV6!LIR'=<\3DEC\05/:-D&BJ4-W)YRM5-.0[B_?ID2'!
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MGPB1#APBF) OI\2&BJ06B_YUBP,"W_P?4$L#!!0    ( *F!G4O!,ZAY11D
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MXNC<P<)<+, ,40J_'4&%427,7::^*R'>NN8O-)"V'PL,M0?V(&\<X-GUEX_
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M)0<K>B=!0SYF#A.I(/CYR0AO<!CB]1R3@:[PJK&&GNVA(M<-U8BQI 2??7S
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M.ZX_\P__+8]65?JW=] V<C2P\@[L/1!A>LR[88BZ>,ITMMF0!BO/Q:P^--%
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M>2J--/>*JR&ZRF87Z)HX5%ZMT]$$0\=&<&LK+TSYG&FC@SI*],\0[>I_S6P
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MH27K/.T$OO2\4-DDFFU0;I0='Z)F89T>RO'E!4,QEOT8Q%=XC4/'6\1.O"=
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M;?VW?12S*520.5'KB%J8 #)K/P9Y;2J02].=C%P>TEGW2R?"ZV+^QP$]RO_
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M="?UF0JQS]2.Z70[$$T#_X'052[SIF[G#QC0T.J=R#IF\+&IO*70I794SIY
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MQIB9QM(7Z'9"BOT*M16P(X!2P00A/]M"R!X0 >I5 3V'ZIDQ;&7V[]UE&68
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MXN" _3WW@'V^F/1_^32Y&@QG\W^UAK_>C!9?S;BDT"R@'U0=]9I")N&";>\
MFF3E1-VV9-U:^JX4/:5K"8<:Y7?@)A!"NR89T1\Y3L"JLH81<V!6=0SDQ,]G
M-3.!A=24^O[FP?>2%!%/#H20ZFK'R$VU)KFX#LPMYZ%L W]C.QYGPUE=W#!6
M>!97W'A6*Y0[>38C/O*:L,50/3$51;$#BYK04:NQ&1O#FG0#(G($U;##BIH0
M!4+"#-**R09$;-65QPXD:D(37W<S^.DHN8+^[E-:;NK/J?"0O =.)0@B? \(
M[(Z%:7<$H>3Q;U$<,VW,+%/%!G% 1XGTD?GD#M:8?$O^A;M@!U7'#A"3ZZ50
M. P:0<LBIR;;G,)2?>P8LK8<U@!B!HF]U?_$89I$<>'7+*\$X64236 'G8&I
ME(:E+9N5@4S;0)[4IKXXT7WRL$7VH$5U/).H#G; F9@"@!(F]: !N8WVR=#[
MOO=(@HB] WE!O"2KF.VFOPPIPI?$CF+>?>MFK6''JH'[51NPS*";-U$/-P^N
M_TPR92+V>&NS%4QE0^B1:$H6,QR,C"8XG<55,,QI"3WP3,U:QWB.]V-,=O[4
MV["G]E)]J@*%=XY"?CWTZ#0P?S $#&4KORN68:M0#SU<K3E;E0B8P19O\$]_
M?>D'<Q(\.LNF&_R*9M CU91,CK7X&$UMWAC;<%O;#GJ,FIII\3C930Q3X (
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M.YTS"@*%_9X]YKA>.TM2E)T?02-1'?,PVGYP(MN](G9(5KTP)%'X,?!#7I1
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M=DCH;_X_4$L! A0#%     @ J8&=2\DU374O_   S;@* !
M ( !     &-V;2TR,#$W,#DS,"YX;6Q02P$"% ,4    " "I@9U+FTS&0)T3
M   :X@  $               @ %=_   8W9M+3(P,3<P.3,P+GAS9%!+ 0(4
M Q0    ( *F!G4L9DU^.NA   /W    4              "  2@0 0!C=FTM
M,C Q-S Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( *F!G4O!,ZAY11D  ,1I 0 4
M              "  10A 0!C=FTM,C Q-S Y,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( *F!G4M\+!P?]5D  )I0!0 4              "  8LZ 0!C=FTM,C Q
M-S Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( *F!G4MORK4X-3@  )>> P 4
M          "  ;*4 0!C=FTM,C Q-S Y,S!?<')E+GAM;%!+!08     !@ &
+ (0!   9S0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
